0001708599 2023-01-01 2023-12-31 0001708599 dei:BusinessContactMember 2023-01-01 2023-12-31 0001708599 2023-12-31 0001708599 2022-12-31 0001708599 us-gaap:RelatedPartyMember 2023-12-31 0001708599 us-gaap:RelatedPartyMember 2022-12-31 0001708599 SER:AgeXTherapeuticsIncMember 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember 2022-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:RelatedPartyMember 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:RelatedPartyMember 2022-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:SeriesAPreferredStockMember 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:SeriesAPreferredStockMember 2022-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:SeriesBPreferredStockMember 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:SeriesBPreferredStockMember 2022-12-31 0001708599 us-gaap:RedeemableConvertiblePreferredStockMember 2023-12-31 0001708599 us-gaap:RedeemableConvertiblePreferredStockMember 2022-12-31 0001708599 2022-01-01 2022-12-31 0001708599 SER:ContractRevenueMember 2023-01-01 2023-12-31 0001708599 SER:ContractRevenueMember 2022-01-01 2022-12-31 0001708599 SER:GrantRevenueMember 2023-01-01 2023-12-31 0001708599 SER:GrantRevenueMember 2022-01-01 2022-12-31 0001708599 SER:OtherRevenuesMember 2023-01-01 2023-12-31 0001708599 SER:OtherRevenuesMember 2022-01-01 2022-12-31 0001708599 SER:AgeXTherapeuticsIncMember 2023-01-01 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember 2022-01-01 2022-12-31 0001708599 SER:GrantRevenuesMember SER:AgeXTherapeuticsIncMember 2023-01-01 2023-12-31 0001708599 SER:GrantRevenuesMember SER:AgeXTherapeuticsIncMember 2022-01-01 2022-12-31 0001708599 SER:OtherRevenuesMember SER:AgeXTherapeuticsIncMember 2023-01-01 2023-12-31 0001708599 SER:OtherRevenuesMember SER:AgeXTherapeuticsIncMember 2022-01-01 2022-12-31 0001708599 SER:RedeemableConvertiblePreferredStockSeriesAMember us-gaap:PreferredStockMember 2021-12-31 0001708599 SER:RedeemableConvertiblePreferredStockSeriesAOneMember us-gaap:PreferredStockMember 2021-12-31 0001708599 SER:RedeemableConvertiblePreferredStockSeriesATwoMember us-gaap:PreferredStockMember 2021-12-31 0001708599 SER:RedeemableConvertiblePreferredStockSeriesAThreeMember us-gaap:PreferredStockMember 2021-12-31 0001708599 SER:RedeemableConvertiblePreferredStockSeriesAMember us-gaap:PreferredStockMember 2022-12-31 0001708599 SER:RedeemableConvertiblePreferredStockSeriesAOneMember us-gaap:PreferredStockMember 2022-12-31 0001708599 SER:RedeemableConvertiblePreferredStockSeriesATwoMember us-gaap:PreferredStockMember 2022-12-31 0001708599 SER:RedeemableConvertiblePreferredStockSeriesAThreeMember us-gaap:PreferredStockMember 2022-12-31 0001708599 SER:RedeemableConvertiblePreferredStockSeriesAFourMember us-gaap:PreferredStockMember 2021-12-31 0001708599 SER:RedeemableConvertiblePreferredStockSeriesAFiveMember us-gaap:PreferredStockMember 2021-12-31 0001708599 us-gaap:RedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001708599 SER:RedeemableConvertiblePreferredStockSeriesAFourMember us-gaap:PreferredStockMember 2022-12-31 0001708599 SER:RedeemableConvertiblePreferredStockSeriesAFiveMember us-gaap:PreferredStockMember 2022-12-31 0001708599 us-gaap:RedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001708599 us-gaap:CommonStockMember 2021-12-31 0001708599 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001708599 us-gaap:RetainedEarningsMember 2021-12-31 0001708599 us-gaap:NoncontrollingInterestMember 2021-12-31 0001708599 2021-12-31 0001708599 us-gaap:CommonStockMember 2022-12-31 0001708599 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001708599 us-gaap:RetainedEarningsMember 2022-12-31 0001708599 us-gaap:NoncontrollingInterestMember 2022-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:CommonStockMember 2021-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:RetainedEarningsMember 2021-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:NoncontrollingInterestMember 2021-12-31 0001708599 SER:AgeXTherapeuticsIncMember 2021-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:CommonStockMember 2022-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:RetainedEarningsMember 2022-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:NoncontrollingInterestMember 2022-12-31 0001708599 SER:RedeemableConvertiblePreferredStockSeriesAMember us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001708599 SER:RedeemableConvertiblePreferredStockSeriesAOneMember us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001708599 SER:RedeemableConvertiblePreferredStockSeriesATwoMember us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001708599 SER:RedeemableConvertiblePreferredStockSeriesAThreeMember us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001708599 SER:RedeemableConvertiblePreferredStockSeriesAFourMember us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001708599 SER:RedeemableConvertiblePreferredStockSeriesAFiveMember us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001708599 us-gaap:RedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001708599 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001708599 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001708599 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001708599 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-12-31 0001708599 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001708599 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001708599 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001708599 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:NoncontrollingInterestMember 2022-01-01 2022-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:NoncontrollingInterestMember 2023-01-01 2023-12-31 0001708599 SER:RedeemableConvertiblePreferredStockSeriesAMember us-gaap:PreferredStockMember 2023-12-31 0001708599 SER:RedeemableConvertiblePreferredStockSeriesAOneMember us-gaap:PreferredStockMember 2023-12-31 0001708599 SER:RedeemableConvertiblePreferredStockSeriesATwoMember us-gaap:PreferredStockMember 2023-12-31 0001708599 SER:RedeemableConvertiblePreferredStockSeriesAThreeMember us-gaap:PreferredStockMember 2023-12-31 0001708599 SER:RedeemableConvertiblePreferredStockSeriesAFourMember us-gaap:PreferredStockMember 2023-12-31 0001708599 SER:RedeemableConvertiblePreferredStockSeriesAFiveMember us-gaap:PreferredStockMember 2023-12-31 0001708599 us-gaap:RedeemableConvertiblePreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0001708599 us-gaap:CommonStockMember 2023-12-31 0001708599 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001708599 us-gaap:RetainedEarningsMember 2023-12-31 0001708599 us-gaap:NoncontrollingInterestMember 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:CommonStockMember 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:RetainedEarningsMember 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:NoncontrollingInterestMember 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember 2023-08-29 0001708599 us-gaap:SubsequentEventMember 2024-02-29 0001708599 2023-11-01 2023-11-30 0001708599 srt:MinimumMember 2023-12-31 0001708599 srt:MaximumMember 2023-12-31 0001708599 SER:CustomerOneMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001708599 SER:CustomerOneMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001708599 SER:AgeXTherapeuticsIncMember SER:LeaseAgreementMember 2022-01-01 2022-12-31 0001708599 SER:AgeXTherapeuticsIncMember SER:LeaseAgreementMember 2023-01-01 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember SER:NationalInstitutesOfHealthMember 2023-08-01 2023-08-31 0001708599 SER:AgeXTherapeuticsIncMember SER:NationalInstitutesOfHealthMember 2023-01-01 2023-12-31 0001708599 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001708599 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001708599 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001708599 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001708599 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001708599 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001708599 SER:AgeXSerinaNoteMember 2021-12-31 0001708599 SER:SerinaConvertibleNotesMember 2021-12-31 0001708599 SER:AgeXSerinaNoteMember 2022-01-01 2022-12-31 0001708599 SER:SerinaConvertibleNotesMember 2022-01-01 2022-12-31 0001708599 SER:AgeXSerinaNoteMember 2022-12-31 0001708599 SER:SerinaConvertibleNotesMember 2022-12-31 0001708599 SER:AgeXSerinaNoteMember 2023-01-01 2023-12-31 0001708599 SER:SerinaConvertibleNotesMember 2023-01-01 2023-12-31 0001708599 SER:AgeXSerinaNoteMember 2023-12-31 0001708599 SER:SerinaConvertibleNotesMember 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:SeriesAPreferredStockMember SER:JuvenescenceLimitedMember 2023-07-24 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:SeriesBPreferredStockMember SER:JuvenescenceLimitedMember 2023-07-24 0001708599 SER:AgeXTherapeuticsIncMember SER:JuvenescenceLimitedMember 2023-07-23 2023-07-24 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:SubsequentEventMember SER:ExchangeAgreementMember 2024-02-01 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:SeriesBPreferredStockMember 2023-07-24 0001708599 SER:AgeXTherapeuticsIncMember SER:JuvenescenceMember 2023-01-01 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember SER:IssuanceAndSaleOfWarrantsMember SER:JuvenescenceMember 2023-12-31 0001708599 SER:SeriesAPreferredStockSeriesAOnePreferredStockAndSeriesATwoPreferredStockMember 2019-06-01 2019-06-30 0001708599 us-gaap:SeriesAPreferredStockMember 2023-12-31 0001708599 SER:SeriesAOnePreferredStockMember 2023-12-31 0001708599 SER:SeriesATwoPreferredStockMember 2023-12-31 0001708599 SER:SeriesAThreePreferredStockMember 2023-12-31 0001708599 SER:SeriesAFourPreferredStockMember 2023-12-31 0001708599 SER:SeriesAFivePreferredStockMember 2023-12-31 0001708599 us-gaap:SeriesAPreferredStockMember 2022-12-31 0001708599 SER:SeriesAOnePreferredStockMember 2022-12-31 0001708599 SER:SeriesATwoPreferredStockMember 2022-12-31 0001708599 SER:SeriesAThreePreferredStockMember 2022-12-31 0001708599 SER:SeriesAFourPreferredStockMember 2022-12-31 0001708599 SER:SeriesAFivePreferredStockMember 2022-12-31 0001708599 SER:CaliforniaPurposesMember SER:AgeXTherapeuticsIncMember 2023-12-31 0001708599 SER:CaliforniaPurposesMember SER:AgeXTherapeuticsIncMember 2023-01-01 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:DomesticCountryMember 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:StateAndLocalJurisdictionMember 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:DomesticCountryMember 2023-01-01 2023-12-31 0001708599 country:US SER:AgeXTherapeuticsIncMember 2023-01-01 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember SER:OtherIncomeTaxMattersMember 2023-01-01 2023-12-31 0001708599 us-gaap:ComputerEquipmentMember 2023-12-31 0001708599 us-gaap:ComputerEquipmentMember 2022-12-31 0001708599 us-gaap:EquipmentMember 2023-12-31 0001708599 us-gaap:EquipmentMember 2022-12-31 0001708599 us-gaap:SoftwareDevelopmentMember 2023-12-31 0001708599 us-gaap:SoftwareDevelopmentMember 2022-12-31 0001708599 SER:TwoThousandAndSevenPlanMember 2007-12-31 0001708599 SER:TwoThousandAndSevenPlanMember 2007-01-01 2007-12-31 0001708599 SER:TwoThousandAndSeventeenPlanMember 2017-12-31 0001708599 SER:TwoThousandAndSeventeenPlanMember 2021-12-31 0001708599 SER:TwoThousandAndSeventeenPlanMember 2017-01-01 2017-12-31 0001708599 2021-01-01 2021-12-31 0001708599 SER:RedeemableConvertiblePreferredStockSeriesAFiveMember 2023-01-01 2023-12-31 0001708599 SER:RedeemableConvertiblePreferredStockSeriesAFiveMember 2022-01-01 2022-12-31 0001708599 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2023-12-31 0001708599 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2023-12-31 0001708599 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2023-12-31 0001708599 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2022-12-31 0001708599 us-gaap:MeasurementInputExpectedTermMember us-gaap:WarrantMember 2023-12-31 0001708599 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember us-gaap:WarrantMember 2022-12-31 0001708599 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember us-gaap:WarrantMember 2023-12-31 0001708599 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2023-12-31 0001708599 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2023-12-31 0001708599 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2023-12-31 0001708599 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2022-12-31 0001708599 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2022-12-31 0001708599 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:WarrantMember 2023-12-31 0001708599 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:WarrantMember 2022-12-31 0001708599 2022-08-01 2022-08-31 0001708599 SER:ConvertiblePromissoryNoteMember 2023-03-15 0001708599 SER:ConvertiblePromissoryNoteMember 2023-03-15 2023-03-15 0001708599 srt:MinimumMember SER:ConvertiblePromissoryNoteMember 2023-03-15 2023-03-15 0001708599 SER:ConvertiblePromissoryNoteMember 2023-03-15 2023-12-31 0001708599 SER:IssuedInterestBearingConvertiblePromissoryNotesMember 2022-12-31 0001708599 SER:IssuedInterestBearingConvertiblePromissoryNotesMember 2023-02-28 0001708599 SER:IssuedInterestBearingConvertiblePromissoryNotesMember 2022-11-10 0001708599 SER:IssuedInterestBearingConvertiblePromissoryNotesMember 2023-11-10 0001708599 srt:MinimumMember SER:IssuedInterestBearingConvertiblePromissoryNotesMember 2022-06-01 2022-12-31 0001708599 SER:IssuedInterestBearingConvertiblePromissoryNotesMember 2022-06-01 2022-12-31 0001708599 srt:MaximumMember SER:IssuedInterestBearingConvertiblePromissoryNotesMember 2022-06-01 2022-12-31 0001708599 us-gaap:MeasurementInputEntityCreditRiskMember 2022-07-19 0001708599 us-gaap:MeasurementInputExpectedTermMember 2022-07-19 2022-07-19 0001708599 us-gaap:MeasurementInputPriceVolatilityMember 2022-07-19 0001708599 SER:MeasurementInputProbabilityMember 2022-07-19 0001708599 SER:NonQualifiedFinancingMember SER:MeasurementInputProbabilityMember 2022-07-19 0001708599 SER:NonQualifiedFinancingMember SER:ConvertibleNotesMember 2022-07-19 0001708599 SER:ConvertibleNotesMember 2023-01-01 2023-12-31 0001708599 SER:ConvertibleNotesMember 2023-07-26 2023-07-26 0001708599 SER:ConvertibleNotesMember SER:SeriesAFivePreferredStockMember 2023-07-26 0001708599 us-gaap:RedeemableConvertiblePreferredStockMember 2023-01-01 2023-12-31 0001708599 us-gaap:RedeemableConvertiblePreferredStockMember 2022-01-01 2022-12-31 0001708599 us-gaap:ConvertibleDebtSecuritiesMember 2023-01-01 2023-12-31 0001708599 us-gaap:ConvertibleDebtSecuritiesMember 2022-01-01 2022-12-31 0001708599 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001708599 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001708599 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001708599 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001708599 SER:MergerAgreementMember 2023-08-29 2023-08-29 0001708599 SER:PostMergerWarrantsMember SER:MergerAgreementMember 2023-08-29 2023-08-29 0001708599 2023-08-29 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:SubsequentEventMember 2024-03-14 2024-03-14 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:SubsequentEventMember 2024-03-14 0001708599 SER:AgeXTherapeuticsIncMember SER:JuvenescenceLimitedMember 2023-03-31 0001708599 SER:AgeXTherapeuticsIncMember SER:SerinaTherapeuticsIncMember 2023-03-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:SubsequentEventMember 2024-03-19 2024-03-19 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:SubsequentEventMember 2024-01-01 2024-03-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:SubsequentEventMember 2024-03-31 0001708599 SER:JuvenescenceMember SER:AgeXTherapeuticsIncMember 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:SubsequentEventMember SER:LoanFacilityAgreementMember SER:JuvenescenceMember 2024-03-22 0001708599 SER:ReCyteTherapeuticsIncMember SER:AgeXTherapeuticsIncMember 2023-12-31 0001708599 SER:AgeXMember SER:AgeXTherapeuticsIncMember SER:MergerAgreementMember SER:ReCyteTherapeuticsIncMember 2023-12-31 0001708599 SER:NeuroAirmidMember SER:AgeXTherapeuticsIncMember 2023-12-31 0001708599 country:US SER:AgeXTherapeuticsIncMember 2022-01-01 2022-12-31 0001708599 SER:ForeignMember SER:AgeXTherapeuticsIncMember 2023-01-01 2023-12-31 0001708599 SER:ForeignMember SER:AgeXTherapeuticsIncMember 2022-01-01 2022-12-31 0001708599 us-gaap:StockOptionMember SER:AgeXTherapeuticsIncMember 2023-01-01 2023-12-31 0001708599 us-gaap:StockOptionMember SER:AgeXTherapeuticsIncMember 2022-01-01 2022-12-31 0001708599 us-gaap:WarrantMember SER:AgeXTherapeuticsIncMember 2023-01-01 2023-12-31 0001708599 us-gaap:WarrantMember SER:AgeXTherapeuticsIncMember 2022-01-01 2022-12-31 0001708599 us-gaap:RestrictedStockUnitsRSUMember SER:AgeXTherapeuticsIncMember 2023-01-01 2023-12-31 0001708599 us-gaap:RestrictedStockUnitsRSUMember SER:AgeXTherapeuticsIncMember 2022-01-01 2022-12-31 0001708599 SER:AgeXTherapeuticsIncMember SER:LoanAgreementsMember 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember SER:LoanAgreementsMember 2022-12-31 0001708599 SER:AgeXTherapeuticsIncMember SER:AssetPurchaseAgreementMember 2018-08-12 2018-08-13 0001708599 us-gaap:AccountsPayableAndAccruedLiabilitiesMember SER:AgeXTherapeuticsIncMember 2023-12-31 0001708599 us-gaap:AccountsPayableAndAccruedLiabilitiesMember SER:AgeXTherapeuticsIncMember 2022-12-31 0001708599 SER:AgeXTherapeuticsIncMember SER:ConvertibleNotePurchaseAgreementMember SER:JuvenescenceMember 2023-03-15 0001708599 SER:AgeXTherapeuticsIncMember SER:SecuredConvertiblePromissoryNoteMember 2023-03-15 0001708599 SER:AgeXTherapeuticsIncMember 2023-03-15 0001708599 SER:AgeXTherapeuticsIncMember SER:SecuredConvertiblePromissoryNoteMember SER:JuvenescenceLimitedMember 2023-03-15 0001708599 SER:AgeXTherapeuticsIncMember SER:SecuredConvertiblePromissoryNoteMember SER:SubordinationAgreementMember 2023-03-15 0001708599 SER:AgeXTherapeuticsIncMember SER:JuvenescenceLimitedMember 2023-07-01 2023-07-31 0001708599 SER:AgeXTherapeuticsIncMember SER:TwoThousandNineteenLoanAgreementMember SER:JuvenescenceMember 2019-08-13 0001708599 SER:AgeXTherapeuticsIncMember SER:TwoThousandNineteenLoanAgreementMember SER:JuvenescenceMember 2019-08-12 2019-08-13 0001708599 SER:AgeXTherapeuticsIncMember SER:TwoThousandNineteenLoanAgreementMember SER:JuvenescenceMember 2021-02-09 2021-02-10 0001708599 SER:AgeXTherapeuticsIncMember SER:TwoThousandNineteenLoanAgreementMember SER:JuvenescenceMember 2021-11-07 2021-11-08 0001708599 SER:AgeXTherapeuticsIncMember SER:TwoThousandNineteenLoanAgreementMember SER:JuvenescenceMember 2021-12-31 0001708599 SER:AgeXTherapeuticsIncMember SER:TwoThousandNineteenLoanAgreementMember SER:JuvenescenceMember 2022-02-14 2022-02-14 0001708599 SER:AgeXTherapeuticsIncMember SER:TwoThousandNineteenLoanAgreementMember SER:JuvenescenceMember 2022-02-14 0001708599 SER:AgeXTherapeuticsIncMember SER:TwoThousandAndTwentyLoanAgreementMember 2020-03-30 0001708599 SER:AgeXTherapeuticsIncMember SER:TwoThousandAndTwentyLoanAgreementMember 2020-03-29 2020-03-30 0001708599 SER:AgeXTherapeuticsIncMember SER:TwoThousandAndTwentyLoanAgreementMember 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:ExtendedMaturityMember SER:TwoThousandAndTwentyLoanAgreementMember 2020-03-29 2020-03-30 0001708599 SER:AgeXTherapeuticsIncMember SER:TwentyTwentyLoanAgreementMember 2023-07-01 2023-07-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:WarrantMember SER:TwoThousandAndTwentyLoanAgreementMember 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember SER:TwentyTwentyWarrantMember SER:TwoThousandAndTwentyLoanAgreementMember 2023-01-01 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember SER:TwoThousandAndTwentyTwoSecuredConvertiblePromissoryNoteandSecurityAgreementMember 2022-02-14 0001708599 SER:AgeXTherapeuticsIncMember SER:TwoThousandAndTwentyTwoSecuredConvertiblePromissoryNoteandSecurityAgreementMember 2022-02-14 2022-02-14 0001708599 SER:AgeXTherapeuticsIncMember SER:SecuredConvertiblePromissoryNoteMember SER:TwoThousandAndTwentyTwoSecuredConvertiblePromissoryNoteandSecurityAgreementMember 2023-02-08 2023-02-09 0001708599 SER:AgeXTherapeuticsIncMember SER:SecuredConvertiblePromissoryNoteMember SER:TwoThousandAndTwentyTwoSecuredConvertiblePromissoryNoteandSecurityAgreementMember 2023-05-09 2023-05-09 0001708599 SER:AgeXTherapeuticsIncMember SER:FourthAmendmentMember 2023-07-31 2023-07-31 0001708599 SER:AgeXTherapeuticsIncMember SER:TwoThousandAndTwentyTwoSecuredNoteMember 2023-10-03 0001708599 SER:AgeXTherapeuticsIncMember SER:TwoThousandAndTwentyTwoSecuredNoteMember 2023-10-31 0001708599 SER:AgeXTherapeuticsIncMember SER:TwoThousandAndTwentyTwoSecuredNoteMember 2023-11-09 0001708599 SER:AgeXTherapeuticsIncMember SER:TwoThousandAndTwentyTwoSecuredNoteMember 2023-11-15 0001708599 SER:AgeXTherapeuticsIncMember SER:TwoThousandAndTwentyTwoSecuredNoteMember 2023-12-05 0001708599 SER:AgeXTherapeuticsIncMember SER:SecuredConvertiblePromissoryNoteMember 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember SER:SecuredConvertiblePromissoryNoteMember 2023-01-01 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember SER:SecuredConvertiblePromissoryNoteMember 2023-07-01 2023-07-31 0001708599 SER:AgeXTherapeuticsIncMember SER:SecuredConvertiblePromissoryNoteMember 2023-07-31 0001708599 SER:AgeXTherapeuticsIncMember SER:JuvenescenceMember 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember SER:TwoThousandTwentyTwoWarrantsMember 2023-01-01 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember SER:SecurityAgreementMember 2023-01-01 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember SER:SecuredConvertiblePromissoryNoteMember SER:JuvenescenceMember 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember SER:SecuredConvertiblePromissoryNoteMember SER:JuvenescenceMember 2023-03-13 0001708599 SER:AgeXTherapeuticsIncMember SER:SecuredConvertiblePromissoryNoteMember SER:JuvenescenceLimitedMember 2023-03-13 0001708599 SER:AgeXTherapeuticsIncMember SER:SecuredConvertiblePromissoryNoteMember SER:JuvenescenceLimitedMember 2023-03-13 2023-03-13 0001708599 SER:AgeXTherapeuticsIncMember SER:SecuredConvertiblePromissoryNoteMember SER:JuvenescenceMember 2023-07-31 2023-07-31 0001708599 srt:MinimumMember SER:AgeXTherapeuticsIncMember SER:JuvenescenceLimitedMember 2023-07-31 2023-07-31 0001708599 SER:AgeXTherapeuticsIncMember SER:JuvenescenceLimitedMember 2023-07-31 2023-07-31 0001708599 srt:MinimumMember SER:AgeXTherapeuticsIncMember 2023-07-31 2023-07-31 0001708599 SER:AgeXTherapeuticsIncMember SER:DerivativesAndHedgingMember SER:JuvenescenceLimitedMember 2023-07-31 2023-07-31 0001708599 SER:AgeXTherapeuticsIncMember SER:RegistrationRightsAgreementsMember 2023-01-01 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember SER:JuvenescenceMember 2022-12-31 0001708599 SER:AgeXTherapeuticsIncMember SER:RegistrationRightsAgreementsMember 2023-12-21 2023-12-21 0001708599 SER:AgeXTherapeuticsIncMember SER:TwoThousandAndTwentyLoanAgreementMember 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember SER:TwentyTwentyTwoSecuredNoteMember 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:DebtMember 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember SER:TwentyTwentyThreeSecuredNoteMember 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember SER:TotalDebtNetMember 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:WarrantMember 2023-12-31 0001708599 SER:InceptionDateMember SER:AgeXTherapeuticsIncMember 2022-02-14 0001708599 SER:InceptionDateMember SER:AgeXTherapeuticsIncMember 2022-02-14 2022-02-14 0001708599 SER:IssuanceDateMember SER:AgeXTherapeuticsIncMember 2022-02-14 0001708599 SER:IssuanceDateMember SER:AgeXTherapeuticsIncMember 2022-02-14 2022-02-14 0001708599 SER:IssuanceDateMember SER:AgeXTherapeuticsIncMember 2022-02-15 0001708599 SER:IssuanceDateMember SER:AgeXTherapeuticsIncMember 2022-02-15 2022-02-15 0001708599 SER:PeriodEndingMember SER:AgeXTherapeuticsIncMember 2022-03-31 0001708599 SER:PeriodEndingMember SER:AgeXTherapeuticsIncMember 2022-03-31 2022-03-31 0001708599 SER:IssuanceDateMember SER:AgeXTherapeuticsIncMember 2022-04-04 0001708599 SER:IssuanceDateMember SER:AgeXTherapeuticsIncMember 2022-04-04 2022-04-04 0001708599 SER:IssuanceDateMember SER:AgeXTherapeuticsIncMember 2022-06-06 0001708599 SER:IssuanceDateMember SER:AgeXTherapeuticsIncMember 2022-06-06 2022-06-06 0001708599 SER:PeriodEndingMember SER:AgeXTherapeuticsIncMember 2022-06-30 0001708599 SER:PeriodEndingMember SER:AgeXTherapeuticsIncMember 2022-06-30 2022-06-30 0001708599 SER:IssuanceDateMember SER:AgeXTherapeuticsIncMember 2022-08-16 0001708599 SER:IssuanceDateMember SER:AgeXTherapeuticsIncMember 2022-08-15 2022-08-15 0001708599 SER:IssuanceDateMember SER:AgeXTherapeuticsIncMember 2022-08-15 2022-08-16 0001708599 SER:PeriodEndingMember SER:AgeXTherapeuticsIncMember 2022-09-30 0001708599 SER:PeriodEndingMember SER:AgeXTherapeuticsIncMember 2022-09-29 2022-09-30 0001708599 SER:IssuanceDateMember SER:AgeXTherapeuticsIncMember 2022-10-21 0001708599 SER:IssuanceDateMember SER:AgeXTherapeuticsIncMember 2022-10-20 2022-10-21 0001708599 SER:IssuanceDateMember SER:AgeXTherapeuticsIncMember 2022-12-14 0001708599 SER:IssuanceDateMember SER:AgeXTherapeuticsIncMember 2022-12-13 2022-12-14 0001708599 SER:PeriodEndingMember SER:AgeXTherapeuticsIncMember 2022-12-31 0001708599 SER:PeriodEndingMember SER:AgeXTherapeuticsIncMember 2022-12-30 2022-12-31 0001708599 SER:IssuanceDateMember SER:AgeXTherapeuticsIncMember 2023-01-25 0001708599 SER:IssuanceDateMember SER:AgeXTherapeuticsIncMember 2023-01-24 2023-01-25 0001708599 SER:InceptionDateMember SER:AgeXTherapeuticsIncMember 2023-02-09 0001708599 SER:InceptionDateMember SER:AgeXTherapeuticsIncMember 2023-02-08 2023-02-09 0001708599 SER:IssuanceDateMember SER:AgeXTherapeuticsIncMember 2023-02-15 0001708599 SER:IssuanceDateMember SER:AgeXTherapeuticsIncMember 2023-02-14 2023-02-15 0001708599 SER:PeriodEndingMember SER:AgeXTherapeuticsIncMember 2023-03-31 0001708599 SER:PeriodEndingMember SER:AgeXTherapeuticsIncMember 2023-03-30 2023-03-31 0001708599 SER:IssuanceDateMember SER:AgeXTherapeuticsIncMember 2023-04-04 0001708599 SER:IssuanceDateMember SER:AgeXTherapeuticsIncMember 2023-04-03 2023-04-04 0001708599 SER:InitialMeasurementDateOfFourteenFebruaryTwoThousandAndTwentyTwoMember SER:AgeXTherapeuticsIncMember 2022-01-01 2022-12-31 0001708599 SER:FourteenFebruaryTwoThousandAndTwentyTwoOneMember SER:AgeXTherapeuticsIncMember 2022-01-01 2022-12-31 0001708599 SER:FifteenFebruaryTwentyThousandAndTwentyTwoMember SER:AgeXTherapeuticsIncMember 2022-01-01 2022-12-31 0001708599 SER:FourAprilTwentyThousandAndTwentyTwoMember SER:AgeXTherapeuticsIncMember 2022-01-01 2022-12-31 0001708599 SER:SixJuneTwentyThousandAndTwentyTwoMember SER:AgeXTherapeuticsIncMember 2022-01-01 2022-12-31 0001708599 SER:SixteenAugustTwentyThousandAndTwentyTwoMember SER:AgeXTherapeuticsIncMember 2022-01-01 2022-12-31 0001708599 SER:TwentyFirstOctoberTwoThousandAndTwentyTwoMember SER:AgeXTherapeuticsIncMember 2022-01-01 2022-12-31 0001708599 SER:FourteenDecemberTwoThousandAndTwentyTwoMember SER:AgeXTherapeuticsIncMember 2022-01-01 2022-12-31 0001708599 SER:TwentyFiveJanuaryTwoThousandAndTwentyThreeMember SER:AgeXTherapeuticsIncMember 2023-01-01 2023-12-31 0001708599 SER:NineFebruaryTwoThousandAndTwentyThreeMember SER:AgeXTherapeuticsIncMember 2023-01-01 2023-12-31 0001708599 SER:FifteenFebruaryTwentyThousandAndTwentyThreeMember SER:AgeXTherapeuticsIncMember 2023-01-01 2023-12-31 0001708599 SER:FourthAprilTwentyThousandAndTwentyThreeMember SER:AgeXTherapeuticsIncMember 2023-01-01 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember SER:TwentyTwentyTwoSecuredNoteMember 2023-01-01 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember SER:TwoThousandSeventeenEquityIncentivePlanMember 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember SER:TwoThousandSeventeenEquityIncentivePlanMember 2023-01-01 2023-12-31 0001708599 srt:MaximumMember SER:AgeXTherapeuticsIncMember SER:TwoThousandSeventeenEquityIncentivePlanMember 2023-01-01 2023-12-31 0001708599 srt:MaximumMember us-gaap:RestrictedStockMember SER:AgeXTherapeuticsIncMember SER:TwoThousandSeventeenEquityIncentivePlanMember 2023-01-01 2023-12-31 0001708599 us-gaap:EmployeeStockOptionMember SER:AgeXTherapeuticsIncMember 2023-01-01 2023-12-31 0001708599 srt:MaximumMember SER:StockOptionsMember SER:AgeXTherapeuticsIncMember 2023-12-31 0001708599 srt:MaximumMember SER:RestrictedStockAndRestrictedStockUnitsMember SER:AgeXTherapeuticsIncMember 2023-01-01 2023-12-31 0001708599 us-gaap:StockAppreciationRightsSARSMember SER:AgeXTherapeuticsIncMember 2023-01-01 2023-12-31 0001708599 us-gaap:EmployeeStockOptionMember SER:AgeXTherapeuticsIncMember 2023-01-01 2023-12-31 0001708599 us-gaap:EmployeeStockOptionMember SER:AgeXTherapeuticsIncMember 2022-01-01 2022-12-31 0001708599 SER:AgeXTherapeuticsIncMember SER:EquityIncentivePlanMember us-gaap:EmployeeStockMember 2021-12-31 0001708599 SER:AgeXTherapeuticsIncMember SER:EquityIncentivePlanMember us-gaap:EmployeeStockMember 2022-01-01 2022-12-31 0001708599 SER:AgeXTherapeuticsIncMember SER:EquityIncentivePlanMember us-gaap:EmployeeStockMember 2022-12-31 0001708599 SER:AgeXTherapeuticsIncMember SER:EquityIncentivePlanMember us-gaap:EmployeeStockMember 2023-01-01 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember SER:EquityIncentivePlanMember us-gaap:EmployeeStockMember 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:SegmentContinuingOperationsMember 2023-04-19 2023-04-20 0001708599 SER:AgeXTherapeuticsIncMember SER:SegmentContinuingOperationsOneMember 2023-04-19 2023-04-20 0001708599 SER:AgeXTherapeuticsIncMember SER:SegmentContinuingOperationsTwoMember 2023-04-19 2023-04-20 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:SegmentContinuingOperationsMember 2023-05-16 2023-05-17 0001708599 SER:AgeXTherapeuticsIncMember SER:SegmentContinuingOperationsOneMember 2023-05-16 2023-05-17 0001708599 SER:AgeXTherapeuticsIncMember SER:SegmentContinuingOperationsTwoMember 2023-05-16 2023-05-17 0001708599 SER:AgeXTherapeuticsIncMember SER:JuvenescenceLimitedMember 2023-07-24 2023-07-24 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:SubsequentEventMember SER:TwentyTwentyTwoSecuredNoteMember 2024-01-01 2024-03-20 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:SubsequentEventMember SER:JuvenescenceLimitedMember 2024-02-01 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:SubsequentEventMember SER:JuvenescenceLimitedMember 2024-03-14 0001708599 SER:AgeXTherapeuticsIncMember us-gaap:SubsequentEventMember SER:JuvenescenceLimitedMember 2024-03-14 2024-03-14 iso4217:USD shares iso4217:USD shares pure utr:sqft SER:Integer false 0001708599

-2477037

S-1 SERINA THERAPEUTICS, INC. DE 82-1436829 601 Genome Way Suite 2001 Huntsville AL 35806 Steven Ledger 601 Genome Way Suite 2001 Huntsville AL 35806 (256) 327-9630 Non-accelerated Filer true true true

7618405

532229

16346

7618405

548575

573321

91569

666088

84752

109798

133146

8967612

858042

579534

143337

11935 5520

558082

13138

6925

153500

213526

80696

36344

47708

1412559

437686

1076766

2983400

1617000

460636

26283

624

36968

4857219

3194703

0.01

10000000

3520128

3402225

36404084

35441500

0.01

15000000

2467434

2218500

24674

22185

858263

646136

-33176628

-38446482

-32293691

-37778161

8967612

858042

3000000

500000

153500

91500

3153500

591500

2387270

1573085

3893881

1288783

6281151

2861868

-3127651

-2270368

-7585

558082

15878

283160

1757

2240000 -179000 5355661 -88000

-1076766

124118

1084

8397505

-411740

5269854

-2682108

2.30

-1.25

1.46

-1.25

2288377

2145002

4005072

2145002

400000

2000000

300000

1998000

1117013

11085291

499200

6240000

400000

2000000

300000

1998000

1117013

11085291

499200

6240000

400000

2000000

300000

1998000

1117013

11085291

499200

6240000

718997

9346961

367015

4771248

3402225

35441500

718997

9346961

367015

4771248

3402225

35441500

718997

9346961

367015

4771248

3402225

35441500

718997

9346961

367015

4771248

3402225

35441500

117903

962584

117903

962584

718997

9346961

484918

5733832

3520128

36404084

718997

9346961

484918

5733832

3520128

36404084

2144800

21448

635341

-35764374

-35107585

73700

737

3685

4422

7110

-2682108

2218500

22185

646136

-38446482

-37778161

2218500

22185

646136

-38446482

-37778161

248934

2489

12447

14936

175355

24325

5269854

2467434

24674

858263

-33176628

-32293691

2467434

24674

858263

-33176628

-32293691

5269854

-2682108

88747

61272

-839

-3083

24325

7110

-7585

1757

-1076766

124118

173624

150012

2240000 -179000 5355661 -88000

-1109

-16346

-1507

392222

-2131

6415 1213

558082

6213

-2973

-187777

-164164

-153500

153500

-2477037

-2075624

990619

504015

9682

-504015

980937

10100000

5000000

3650000

4422

14936

47708

42352

10067228

1312070

7086176

217383

532229

314846

7618405

532229

15878

43975

754960 1137939

Note 1 - Summary of Significant Accounting Policies Nature of Business Serina Therapeutics, Inc. (the “Company” or “Serina”) is a privately-held clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and pain. Serina’s POZ drug delivery technology is designed to enable certain existing drugs and novel drug candidates to be modified in a way that may provide an increase in efficacy and safety of the resulting polymeric drug conjugate. Serina’s proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Serina’s POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. Serina is headquartered in Huntsville, Alabama. Basis of Accounting The accompanying financial statements reflect the operations of the Company and have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). Plan of Merger As described in Note 17, on August 29, 2023, the Company entered into the Agreement and Plan of Merger and Reorganization with AgeX Therapeutics, Inc. and Canaria Transaction Corporation (the “Plan of Merger”). Pursuant to the Plan of Merger, AgeX Therapeutics, Inc. will merge with and into the Company, Canaria Transaction Corporation will cease to exists, and the Company will become a direct, wholly owned subsidiary of AgeX Therapeutics, Inc. (“AgeX”). Subject to the Plan of Merger, at the effective time of the Merger, AgeX will issue shares of its common stock to the Company’s former shareholders, representing approximately <span id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20230829__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AgexTherapeuticsIncMember_zK9zvarij4E9" title="Ownership percent">75% of fully diluted ownership of the combined company. Accordingly, the Plan of Merger is anticipated to be accounted for as a reverse acquisition, with the Company treated as the acquirer for financial accounting purposes. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Liquidity The Company recognized net income of approximately $5,300,000 for the year ended December 31, 2023. The Company used approximately $2,400,000 in net cash from operating activities for the year ended December 31, 2023 and has historically incurred losses from operations and expects to continue to generate negative cash flows as the Company implements its business plan. The Company had cash on hand of approximately $6,900,000 as of February 29, 2024. As discussed in Note 15, during the year ended December 31, 2023, the Company raised $10,100,000 of additional capital. Additionally, the Company received an upfront payment of $3,000,000 from a licensing agreement in November 2023 as described in Note 2. Management believes that the cash on hand, along with the approximately $15 million of cash proceeds expected to be received from Juvenescence through the exercise of all the post-merger warrants it holds pursuant to the terms of the Side Letter if the Merger is consummated, will fund operations through calendar year 2025 based on the current plan. Management has based this estimate on assumptions that may prove to be wrong, and available capital resources could be exhausted sooner than expected. As such, there is substantial doubt about the Company’s ability to continue as a going concern. SERINA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 2023 AND 2022 The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, technical risks associated with the successful research, development and manufacturing of therapeutic candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, and the ability to secure additional capital to fund operations. Therapeutic candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts will require significant amounts of additional capital, adequate personnel, and infrastructure. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. The Company largely relies on raising capital from equity investors for funding its operations. Some funding is obtained through licensing agreements or other arrangements with commercial entities. As a result of recurring losses from operations and recurring negative cash flows from operations, there is substantial doubt regarding the Company’s ability to maintain liquidity sufficient to operate its business effectively. If sufficient capital is not available, the Company would be required to delay, limit, reduce, or terminate its product development or future commercialization efforts or grant rights to develop and market therapeutic candidates to other entities. There can be no assurance that the Company will be able to raise additional funds or that the terms and conditions of any future financings will be workable or acceptable to the Company or its shareholders. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern. Cash and Cash Equivalents Cash and cash equivalents includes funds held in readily available checking and money market type accounts. Contract Liabilities Contract liabilities include billings in excess of revenue recognized. Contract liabilities are classified as current based on the Company’s contract operating cycle and reported on a contract-by-contract basis, net of revenue recognized, at the end of each reporting period. Property and Equipment Property and equipment are carried at cost less accumulated depreciation. The costs of additions and betterments are capitalized and expenditures for repairs and maintenance are expensed as incurred. When items of property and equipment are sold or retired, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is included in the statements of operations. Depreciation of property and equipment is provided utilizing the straight-line method over the range of lives used of the respective assets, which is 3 - 10 years. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if its carrying amount exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposal of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell. No impairment loss was recognized during the years ended December 31, 2023 and 2022, respectively. Revenue Recognition The Company recognizes revenue under a grant contract with a commercial entity under federal funding in accordance with ASC 606, Revenue from Contracts with Customers. Under the commercial grant, the Company received substantially all funding upon award of the grant, and recognizes revenue as eligible expenses under the grant are incurred. The Company has concluded that it is a principal in the grant contract and, accordingly, recognizes revenue in the gross amount of consideration to which it is entitled from the agency in exchange for the services provided. The Company also recognizes revenue under licensing agreements with commercial entities in accordance with ASC 606, Revenue from Contracts with Customers. Under revenue sharing licensing agreements, the Company receives reimbursement for eligible costs as well as payments upon the achievement of certain milestones as defined by the contract. These licensing agreements provide for the Company to receive a certain percentage of revenue from sales of their product. The Company accounts for a contract after it has been approved by all parties to the arrangement, the rights of the parties are identified, payment terms are identified, the contract has commercial substance, and collection is probable. Each contract is assessed at inception to determine whether it should be combined with other contracts. When making this determination, factors such as whether two or more contracts were negotiated or executed at or near the same time or were negotiated with an overall profit objective. If combined, the Company treats the combined contracts as a single contract for revenue recognition purposes. SERINA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 2023 AND 2022 The Company evaluates the services promised in each contract at inception to determine whether the contract should be accounted for as having one or more performance obligations. The services in the contracts are typically not distinct from one another due to the requirements to perform under the contract. Accordingly, the contracts are typically accounted for as one performance obligation. The Company determines the transaction price for each contract based on the consideration expected to be received for the services being provided under the contract. For contracts where a portion of the price may vary, the Company estimates variable consideration at the most likely amount, which is included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur. The Company analyzes the risk of a significant reversal and if necessary, constrains the amount of variable consideration recognized in order to mitigate the risk. At inception of a contract, the transaction price is estimated based on current rights and do not contemplate future modifications (including unexercised options) or follow-on contracts until they become legally enforceable. Depending on the nature of the modification, the Company considers whether to account for the modification as an adjustment to the existing contract or as a separate contract. For contracts with multiple performance obligations, the transaction price is allocated to each performance obligation based on the estimated standalone selling price of the service underlying each performance obligation. Revenue is recognized as performance obligations are satisfied and the customer obtains control of the service. For performance obligations in which control does not continuously transfer to the customer, revenue is recognized at the point in time that each performance obligation is fully satisfied. Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not probable at the inception of the agreement; and (ii) the Company has a right to payment. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue. Various economic factors affect revenues and cash flows. Services are primarily provided under grants from U.S. Government agencies and a licensing agreement with a commercial entity, with amounts invoiced quarterly or upon the achievement of a milestone and typically being collected within one month. Research and Development Research and development costs are expensed as they are incurred and include compensation for scientists, support personnel, outside contracted services, and material costs associated with product development. The Company continually evaluates new product opportunities and engages in intensive research and product development efforts. Research and development expenses include both direct costs tied to a specific contract or grant, and indirect costs. Concentrations of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, and accounts receivable. The Company maintains cash and cash equivalents in accounts with high quality, federally insured financial institutions. At times, the balances in these accounts may be in excess of federally insured limits, including the Federal Deposit Insurance Corporation (FDIC) and the Securities Investor Protection Corporation (SIPC). At December 31, 2023 and 2022, cash and cash equivalents in excess of FDIC limits was $0 and $282,000, respectively. At December 31, 2023 and 2022, cash and cash equivalents in excess of SIPC limits was $7,300,000 and $0, respectively. For the year ended December 31, 2023, <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__srt--MajorCustomersAxis__custom--CustomerOneMember_z87x3asXTYEj" title="Concentration risk">95% of the Company’s revenue was related to a single contract with a customer. For the year ended December 31, 2022, <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zJC9DbHEvXuh" title="Concentration risk">85% of the Company’s revenue was related to a single contract (with a different customer than for the year ended December 31, 2023). Fair Value of Financial Instruments The Company has adopted ASC Topic 820 for certain financial instruments measured as fair value on a recurring basis. ASC Topic 820 defines fair value, establishes a framework for measuring fair value in accordance with accounting principles generally accepted in the United States, and expands disclosures about fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. SERINA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 2023 AND 2022 The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). The three levels of inputs that may be used to measure fair value are as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">● </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1: Quoted prices in active markets for identical assets or liabilities.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">● </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets with insufficient volume or infrequent transactions (less active markets), or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated with observable market data for substantially the full term of the assets or liabilities. Level 2 inputs also include non-binding market consensus prices that can be corroborated with observable market data, as well as quoted prices that were adjusted for security-specific restrictions.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">● </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3: Unobservable inputs to the valuation methodology are significant to the measurement of the fair value of assets or liabilities. Level 3 inputs also include non-binding market consensus prices or non-binding broker quotes that we were unable to corroborate with observable market data.</td></tr> </table> The Company has elected to measure the convertible promissory notes at fair value on a recurring basis. Redeemable Convertible Preferred Stock The Company recorded redeemable convertible preferred stock at fair value upon issuance, net of any issuance costs. The Company classified stock that was redeemable in circumstances outside of the Company’s control outside of permanent equity. Income Taxes Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due plus deferred taxes related primarily to differences between the basis of loss carryovers and depreciation differences for financial and income tax reporting. Deferred taxes represent the future tax return consequences of those differences, which will either be taxable or deductible when the assets and liabilities are recovered or settled. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which the differences are expected to be recovered or settled. The Company only recognizes tax benefits from an uncertain tax position if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statement from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. To date, the Company has not recognized such tax benefits in its financial statements. Earnings (Loss) Per Share Basic earnings (loss) per share (“EPS”) of common stock is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS give effect to all dilutive potential common shares outstanding during the period using the treasury stock method for stock options and warrants and the if-converted method for redeemable, convertible preferred stock and convertible promissory notes. In computing diluted EPS, the average stock price for the period is used to determine the number of shares assumed to be purchased from the exercise of stock options and/or warrants. Diluted EPS excluded all dilutive potential shares if their effect is anti-dilutive. Basic loss per common share is computed based on the weighted average number of shares outstanding during the period. Diluted loss per share is computed in a manner similar to the basic loss per share, except the weighted-average number of shares outstanding is increased to include all common shares, including those with the potential to be issued by virtue of convertible debt and other such convertible instruments. Diluted loss per share contemplates a complete conversion to common shares of all convertible instruments only if they are dilutive in nature with regards to earnings per share. SERINA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 2023 AND 2022 Segment Reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment in the United States of America.

Nature of Business Serina Therapeutics, Inc. (the “Company” or “Serina”) is a privately-held clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and pain. Serina’s POZ drug delivery technology is designed to enable certain existing drugs and novel drug candidates to be modified in a way that may provide an increase in efficacy and safety of the resulting polymeric drug conjugate. Serina’s proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Serina’s POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. Serina is headquartered in Huntsville, Alabama.

Basis of Accounting The accompanying financial statements reflect the operations of the Company and have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).

Plan of Merger As described in Note 17, on August 29, 2023, the Company entered into the Agreement and Plan of Merger and Reorganization with AgeX Therapeutics, Inc. and Canaria Transaction Corporation (the “Plan of Merger”). Pursuant to the Plan of Merger, AgeX Therapeutics, Inc. will merge with and into the Company, Canaria Transaction Corporation will cease to exists, and the Company will become a direct, wholly owned subsidiary of AgeX Therapeutics, Inc. (“AgeX”). Subject to the Plan of Merger, at the effective time of the Merger, AgeX will issue shares of its common stock to the Company’s former shareholders, representing approximately <span id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20230829__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AgexTherapeuticsIncMember_zK9zvarij4E9" title="Ownership percent">75% of fully diluted ownership of the combined company. Accordingly, the Plan of Merger is anticipated to be accounted for as a reverse acquisition, with the Company treated as the acquirer for financial accounting purposes.

0.75

Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Liquidity The Company recognized net income of approximately $5,300,000 for the year ended December 31, 2023. The Company used approximately $2,400,000 in net cash from operating activities for the year ended December 31, 2023 and has historically incurred losses from operations and expects to continue to generate negative cash flows as the Company implements its business plan. The Company had cash on hand of approximately $6,900,000 as of February 29, 2024. As discussed in Note 15, during the year ended December 31, 2023, the Company raised $10,100,000 of additional capital. Additionally, the Company received an upfront payment of $3,000,000 from a licensing agreement in November 2023 as described in Note 2. Management believes that the cash on hand, along with the approximately $15 million of cash proceeds expected to be received from Juvenescence through the exercise of all the post-merger warrants it holds pursuant to the terms of the Side Letter if the Merger is consummated, will fund operations through calendar year 2025 based on the current plan. Management has based this estimate on assumptions that may prove to be wrong, and available capital resources could be exhausted sooner than expected. As such, there is substantial doubt about the Company’s ability to continue as a going concern. SERINA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 2023 AND 2022 The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, technical risks associated with the successful research, development and manufacturing of therapeutic candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, and the ability to secure additional capital to fund operations. Therapeutic candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts will require significant amounts of additional capital, adequate personnel, and infrastructure. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. The Company largely relies on raising capital from equity investors for funding its operations. Some funding is obtained through licensing agreements or other arrangements with commercial entities. As a result of recurring losses from operations and recurring negative cash flows from operations, there is substantial doubt regarding the Company’s ability to maintain liquidity sufficient to operate its business effectively. If sufficient capital is not available, the Company would be required to delay, limit, reduce, or terminate its product development or future commercialization efforts or grant rights to develop and market therapeutic candidates to other entities. There can be no assurance that the Company will be able to raise additional funds or that the terms and conditions of any future financings will be workable or acceptable to the Company or its shareholders. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

5300000

6900000

10100000

3000000

15000000

Cash and Cash Equivalents Cash and cash equivalents includes funds held in readily available checking and money market type accounts.

Contract Liabilities Contract liabilities include billings in excess of revenue recognized. Contract liabilities are classified as current based on the Company’s contract operating cycle and reported on a contract-by-contract basis, net of revenue recognized, at the end of each reporting period.

Property and Equipment Property and equipment are carried at cost less accumulated depreciation. The costs of additions and betterments are capitalized and expenditures for repairs and maintenance are expensed as incurred. When items of property and equipment are sold or retired, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is included in the statements of operations. Depreciation of property and equipment is provided utilizing the straight-line method over the range of lives used of the respective assets, which is 3 - 10 years. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if its carrying amount exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposal of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell. No impairment loss was recognized during the years ended December 31, 2023 and 2022, respectively.

P3Y

P10Y

Revenue Recognition The Company recognizes revenue under a grant contract with a commercial entity under federal funding in accordance with ASC 606, Revenue from Contracts with Customers. Under the commercial grant, the Company received substantially all funding upon award of the grant, and recognizes revenue as eligible expenses under the grant are incurred. The Company has concluded that it is a principal in the grant contract and, accordingly, recognizes revenue in the gross amount of consideration to which it is entitled from the agency in exchange for the services provided. The Company also recognizes revenue under licensing agreements with commercial entities in accordance with ASC 606, Revenue from Contracts with Customers. Under revenue sharing licensing agreements, the Company receives reimbursement for eligible costs as well as payments upon the achievement of certain milestones as defined by the contract. These licensing agreements provide for the Company to receive a certain percentage of revenue from sales of their product. The Company accounts for a contract after it has been approved by all parties to the arrangement, the rights of the parties are identified, payment terms are identified, the contract has commercial substance, and collection is probable. Each contract is assessed at inception to determine whether it should be combined with other contracts. When making this determination, factors such as whether two or more contracts were negotiated or executed at or near the same time or were negotiated with an overall profit objective. If combined, the Company treats the combined contracts as a single contract for revenue recognition purposes. SERINA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 2023 AND 2022 The Company evaluates the services promised in each contract at inception to determine whether the contract should be accounted for as having one or more performance obligations. The services in the contracts are typically not distinct from one another due to the requirements to perform under the contract. Accordingly, the contracts are typically accounted for as one performance obligation. The Company determines the transaction price for each contract based on the consideration expected to be received for the services being provided under the contract. For contracts where a portion of the price may vary, the Company estimates variable consideration at the most likely amount, which is included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur. The Company analyzes the risk of a significant reversal and if necessary, constrains the amount of variable consideration recognized in order to mitigate the risk. At inception of a contract, the transaction price is estimated based on current rights and do not contemplate future modifications (including unexercised options) or follow-on contracts until they become legally enforceable. Depending on the nature of the modification, the Company considers whether to account for the modification as an adjustment to the existing contract or as a separate contract. For contracts with multiple performance obligations, the transaction price is allocated to each performance obligation based on the estimated standalone selling price of the service underlying each performance obligation. Revenue is recognized as performance obligations are satisfied and the customer obtains control of the service. For performance obligations in which control does not continuously transfer to the customer, revenue is recognized at the point in time that each performance obligation is fully satisfied. Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not probable at the inception of the agreement; and (ii) the Company has a right to payment. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue. Various economic factors affect revenues and cash flows. Services are primarily provided under grants from U.S. Government agencies and a licensing agreement with a commercial entity, with amounts invoiced quarterly or upon the achievement of a milestone and typically being collected within one month.

Research and Development Research and development costs are expensed as they are incurred and include compensation for scientists, support personnel, outside contracted services, and material costs associated with product development. The Company continually evaluates new product opportunities and engages in intensive research and product development efforts. Research and development expenses include both direct costs tied to a specific contract or grant, and indirect costs.

Concentrations of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, and accounts receivable. The Company maintains cash and cash equivalents in accounts with high quality, federally insured financial institutions. At times, the balances in these accounts may be in excess of federally insured limits, including the Federal Deposit Insurance Corporation (FDIC) and the Securities Investor Protection Corporation (SIPC). At December 31, 2023 and 2022, cash and cash equivalents in excess of FDIC limits was $0 and $282,000, respectively. At December 31, 2023 and 2022, cash and cash equivalents in excess of SIPC limits was $7,300,000 and $0, respectively. For the year ended December 31, 2023, <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__srt--MajorCustomersAxis__custom--CustomerOneMember_z87x3asXTYEj" title="Concentration risk">95% of the Company’s revenue was related to a single contract with a customer. For the year ended December 31, 2022, <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zJC9DbHEvXuh" title="Concentration risk">85% of the Company’s revenue was related to a single contract (with a different customer than for the year ended December 31, 2023).

282000

7300000 0

0.95

0.85

Fair Value of Financial Instruments The Company has adopted ASC Topic 820 for certain financial instruments measured as fair value on a recurring basis. ASC Topic 820 defines fair value, establishes a framework for measuring fair value in accordance with accounting principles generally accepted in the United States, and expands disclosures about fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. SERINA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 2023 AND 2022 The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). The three levels of inputs that may be used to measure fair value are as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">● </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1: Quoted prices in active markets for identical assets or liabilities.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">● </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets with insufficient volume or infrequent transactions (less active markets), or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated with observable market data for substantially the full term of the assets or liabilities. Level 2 inputs also include non-binding market consensus prices that can be corroborated with observable market data, as well as quoted prices that were adjusted for security-specific restrictions.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">● </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3: Unobservable inputs to the valuation methodology are significant to the measurement of the fair value of assets or liabilities. Level 3 inputs also include non-binding market consensus prices or non-binding broker quotes that we were unable to corroborate with observable market data.</td></tr> </table> The Company has elected to measure the convertible promissory notes at fair value on a recurring basis.

Redeemable Convertible Preferred Stock The Company recorded redeemable convertible preferred stock at fair value upon issuance, net of any issuance costs. The Company classified stock that was redeemable in circumstances outside of the Company’s control outside of permanent equity.

Income Taxes Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due plus deferred taxes related primarily to differences between the basis of loss carryovers and depreciation differences for financial and income tax reporting. Deferred taxes represent the future tax return consequences of those differences, which will either be taxable or deductible when the assets and liabilities are recovered or settled. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which the differences are expected to be recovered or settled. The Company only recognizes tax benefits from an uncertain tax position if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statement from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. To date, the Company has not recognized such tax benefits in its financial statements.

Earnings (Loss) Per Share Basic earnings (loss) per share (“EPS”) of common stock is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS give effect to all dilutive potential common shares outstanding during the period using the treasury stock method for stock options and warrants and the if-converted method for redeemable, convertible preferred stock and convertible promissory notes. In computing diluted EPS, the average stock price for the period is used to determine the number of shares assumed to be purchased from the exercise of stock options and/or warrants. Diluted EPS excluded all dilutive potential shares if their effect is anti-dilutive. Basic loss per common share is computed based on the weighted average number of shares outstanding during the period. Diluted loss per share is computed in a manner similar to the basic loss per share, except the weighted-average number of shares outstanding is increased to include all common shares, including those with the potential to be issued by virtue of convertible debt and other such convertible instruments. Diluted loss per share contemplates a complete conversion to common shares of all convertible instruments only if they are dilutive in nature with regards to earnings per share. SERINA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 2023 AND 2022

Segment Reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment in the United States of America.

Note 2 - Contracts with Customers Commercial Grant The Company was performing under a commercial grant during the period August 2022 - December 2023. All of the grant revenue is recognized over time using the input method as the Company performs under the contract because control of the work in process transfers continuously to the customer. At December 31, 2023, the Company has substantially completed its obligation under a grant to continue its research and development related to the treatment of neurological disorders and stroke. There were no remaining contract liabilities at December 31, 2023 related to this grant. Licensing Agreement In October 2023, the Company entered into a non-exclusive license agreement with Pfizer, Inc. to use the Company’s POZ polymer technology for use in lipid nanoparticle drug delivery formulations. The agreement grants Pfizer non-exclusive rights to certain intellectual property, know-how, and proprietary technologies. Under the terms of the agreement, Pfizer is authorized to develop, manufacture, market, and commercialize products incorporating the licensed technology with respect to a specific POZ polymer structure in one field. The agreement outlines the protection and enforcement of intellectual property rights related to the licensed technology. Pfizer is obligated to use commercially reasonable diligent efforts to develop and commercialize licensed products, and to use such efforts to accomplish specified development and commercial objectives. The Company is not considered the principal under this licensing arrangement. The agreement includes a one-time upfront payment of $3,000,000 which was received in November 2023, milestone payments payable to the Company upon the achievement of specific development, regulatory, and commercial milestones, and a royalty on net sales of products incorporating the licensed technology in accordance with the terms outlined in the license agreement. In accordance with the Company’s revenue recognition policy as described in Note 1, the upfront payment was recognized upon execution of the contract as the performance obligation related to the payment was substantially satisfied. No other milestones or product sales have been achieved as of December 31, 2023.

3000000

Note 3 - Fair Value Measurements <p id="xdx_893_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zTd7AJ3nrGKd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company had the following liabilities measured at fair value on a recurring basis at December 31, 2023. Schedule of Liabilities Measured at Fair Value on Recurring Basis <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_492_20231231_zuDu8DTNnTvg" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Total</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_49A_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zijpouC5WEwk" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_499_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zQRrrlUfpDql" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_493_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zyyihbkeF6O" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_zYK3q5tOywF8" style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-bottom: 1.5pt">Convertible promissory notes</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">2,983,400</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"> -</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"> -</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">2,983,400</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--WarrantLiabilityNonCurrent_iI_zXvK5e8dU77k" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Warrant liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_z41RwH8R9kUc" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,983,400</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,983,400</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The Company had the following liabilities measured at fair value on a recurring basis at December 31, 2022. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_497_20221231_zb4ogDqhWAX2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Total</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_495_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zK65ZMm8Od85" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_490_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zSlA9FpWzmc1" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_49C_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zm0UW2P0Tsgg" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_zTvSF2tdH5B8" style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left">Convertible promissory notes</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,617,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"> -</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"> -</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,617,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--WarrantLiabilityNonCurrent_iI_zkuxbS19HVcg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Warrant liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,076,766</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,076,766</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_zBAFEkn8fVg6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,693,766</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,693,766</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> SERINA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 2023 AND 2022 The following is a reconciliation of the beginning and ending balances for the convertible promissory note liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the years ended December 31, 2023 and 2022: <p id="xdx_892_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zcgd6HC48sC5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> Schedule of Convertible Promissory Note Liabilities Measured at Fair Value on Recurring Basis <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_4BF_us-gaap--DebtInstrumentAxis_custom--AgeXSerinaNoteMember_zhBkbdPXNDXh" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">AgeX-Serina Note</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_4BB_us-gaap--DebtInstrumentAxis_custom--SerinaConvertibleNotesMember_zjgaFWcpX4Yc" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Serina Convertible Notes</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr id="xdx_43C_c20220101__20221231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_zX0tD0txjAq2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance as of December 31, 2021</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_zPQFXv5rQIyb" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Convertible debt issuance</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,350,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_zgP9n19rbjg7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Inception adjustment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">179,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_zGhxuPC3SjG6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">88,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_431_c20230101__20231231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_z9dAyavmH71a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance as of December 31, 2022</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,617,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_43A_c20230101__20231231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_ztQJlxPbfuf8" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Beginning balance</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,617,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_zmoP3iiIBC3a" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Convertible debt issuance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_zZYzbyhsoNOj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Inception adjustment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,240,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityNotesConvertedToSeriesAFivePreferredStock_zstHbYjIpU6j" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Notes converted to Series A-5 pref. stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(962,584</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_ecustom--ChangeInFairValueOfPromissoryNotesConvertedToWarrants_zcHmjqn6zEi1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Notes converted to warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(175,355</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_zWyv0Jk0Hhyl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,776,600</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(579,061</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_437_c20230101__20231231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_zjGnZdaZOChj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,983,400</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_436_c20230101__20231231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_z1NMnNC8s39f" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Ending balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,983,400</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_89E_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zaKyz5pMhHv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following is a reconciliation of the beginning and ending balances for the warrant liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the years ended December 31, 2023 and 2022: Schedule of Warrant Liability Measured at Fair Value on Recurring Basis <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%">Balance as of December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstanding_iS_c20220101__20221231_zQGZqgbQS30j" style="width: 26%; text-align: right" title="Balance">952,648</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231_znpiNBt3eH6k" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">124,118</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance as of December 31, 2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--WarrantsAndRightsOutstanding_iS_c20230101__20231231_zWrCPbDBquMf" style="text-align: right" title="Balance">1,076,766</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231_z4x2uNVqtWld" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">(1,076,766</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--WarrantsAndRightsOutstanding_iE_c20230101__20231231_zNhCnCsQ7knh" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> See Note 14 for further information regarding valuation of the warrant liability.

<p id="xdx_893_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zTd7AJ3nrGKd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company had the following liabilities measured at fair value on a recurring basis at December 31, 2023. Schedule of Liabilities Measured at Fair Value on Recurring Basis <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_492_20231231_zuDu8DTNnTvg" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Total</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_49A_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zijpouC5WEwk" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_499_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zQRrrlUfpDql" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_493_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zyyihbkeF6O" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_zYK3q5tOywF8" style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-bottom: 1.5pt">Convertible promissory notes</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">2,983,400</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"> -</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right"> -</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right">2,983,400</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--WarrantLiabilityNonCurrent_iI_zXvK5e8dU77k" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Warrant liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_z41RwH8R9kUc" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,983,400</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,983,400</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The Company had the following liabilities measured at fair value on a recurring basis at December 31, 2022. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_497_20221231_zb4ogDqhWAX2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Total</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_495_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zK65ZMm8Od85" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_490_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zSlA9FpWzmc1" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_49C_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zm0UW2P0Tsgg" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_zTvSF2tdH5B8" style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left">Convertible promissory notes</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,617,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"> -</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"> -</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,617,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--WarrantLiabilityNonCurrent_iI_zkuxbS19HVcg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Warrant liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,076,766</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,076,766</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_zBAFEkn8fVg6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,693,766</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,693,766</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

2983400

1617000

1076766 1076766

2693766

<p id="xdx_892_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zcgd6HC48sC5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> Schedule of Convertible Promissory Note Liabilities Measured at Fair Value on Recurring Basis <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_4BF_us-gaap--DebtInstrumentAxis_custom--AgeXSerinaNoteMember_zhBkbdPXNDXh" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">AgeX-Serina Note</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_4BB_us-gaap--DebtInstrumentAxis_custom--SerinaConvertibleNotesMember_zjgaFWcpX4Yc" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Serina Convertible Notes</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr id="xdx_43C_c20220101__20221231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_zX0tD0txjAq2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance as of December 31, 2021</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_zPQFXv5rQIyb" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Convertible debt issuance</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,350,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_zgP9n19rbjg7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Inception adjustment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">179,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_zGhxuPC3SjG6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">88,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_431_c20230101__20231231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_z9dAyavmH71a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance as of December 31, 2022</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,617,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_43A_c20230101__20231231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_ztQJlxPbfuf8" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Beginning balance</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,617,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_zmoP3iiIBC3a" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Convertible debt issuance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_zZYzbyhsoNOj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Inception adjustment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,240,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityNotesConvertedToSeriesAFivePreferredStock_zstHbYjIpU6j" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Notes converted to Series A-5 pref. stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(962,584</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_ecustom--ChangeInFairValueOfPromissoryNotesConvertedToWarrants_zcHmjqn6zEi1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Notes converted to warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(175,355</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_zWyv0Jk0Hhyl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,776,600</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(579,061</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_437_c20230101__20231231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_zjGnZdaZOChj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,983,400</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_436_c20230101__20231231_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_z1NMnNC8s39f" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Ending balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,983,400</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1350000

179000

88000

1617000

10000000

100000

-2240000

-962584 -175355

-4776600

-579061

2983400

<p id="xdx_89E_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zaKyz5pMhHv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following is a reconciliation of the beginning and ending balances for the warrant liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the years ended December 31, 2023 and 2022: Schedule of Warrant Liability Measured at Fair Value on Recurring Basis <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%">Balance as of December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstanding_iS_c20220101__20221231_zQGZqgbQS30j" style="width: 26%; text-align: right" title="Balance">952,648</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231_znpiNBt3eH6k" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">124,118</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance as of December 31, 2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--WarrantsAndRightsOutstanding_iS_c20230101__20231231_zWrCPbDBquMf" style="text-align: right" title="Balance">1,076,766</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231_z4x2uNVqtWld" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">(1,076,766</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--WarrantsAndRightsOutstanding_iE_c20230101__20231231_zNhCnCsQ7knh" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

952648

124118

1076766

-1076766

Note 4 - Contract Balances The beginning and ending contract balances were as follows: Schedule of Contract Balances <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left; padding-bottom: 2.5pt">Deferred revenue</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--DeferredRevenue_iI_c20231231_z0TXKJZFIVsj" style="border-bottom: Black 2.5pt double; width: 14%; text-align: right" title="Deferred revenue"> -</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--DeferredRevenue_iI_c20221231_zqTiImOLB0ib" style="border-bottom: Black 2.5pt double; width: 14%; text-align: right" title="Deferred revenue">153,500</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DeferredRevenue_iI_c20211231_ziWjIcF2rTWd" style="border-bottom: Black 2.5pt double; width: 14%; text-align: right" title="Deferred revenue"> -</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

The beginning and ending contract balances were as follows: Schedule of Contract Balances <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left; padding-bottom: 2.5pt">Deferred revenue</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--DeferredRevenue_iI_c20231231_z0TXKJZFIVsj" style="border-bottom: Black 2.5pt double; width: 14%; text-align: right" title="Deferred revenue"> -</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--DeferredRevenue_iI_c20221231_zqTiImOLB0ib" style="border-bottom: Black 2.5pt double; width: 14%; text-align: right" title="Deferred revenue">153,500</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DeferredRevenue_iI_c20211231_ziWjIcF2rTWd" style="border-bottom: Black 2.5pt double; width: 14%; text-align: right" title="Deferred revenue"> -</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

153500

Note 5 - Profit Sharing Plan Serina has established a 401(k) profit sharing plan (the PSP) for all eligible employees of Serina. The PSP provides for eligible employee contributions subject to certain annual Internal Revenue Code limits. For participants who are age 50 or older during any calendar year, additional employee contributions are allowed under the PSP, subject to Internal Revenue Code limits. Employer contributions, if any, may include matching contributions and profit sharing contributions, both of which are made on a discretionary basis and are subject to service and employment requirements. Employer matching contributions and employer profit sharing contributions vest based on a graded vesting schedule. Serina made no discretionary employer matching or employer profit sharing contributions for the years ended December 31, 2023 and 2022. SERINA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 2023 AND 2022

Note 6 - Common Stock Stockholders’ Equity/(Deficit) The holders of the common stock are entitled to one vote for each share of common stock on all matters that may be submitted to the holders of common stock of Serina. The holders of common stock shall vote together with the holders of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, and Series A-5 Preferred Stock as a single class. Serina shall not plan a merger or conversion, sale or dispose of property, or dissolve the Company without the written consent or affirmative vote of the entire single class.

common stock are entitled to one vote for each share of common stock

Note 7 - Redeemable Convertible Preferred Stock Serina has authority to issue <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zUQSAXM7RpXb" title="Preferred stock, shares authorized"><span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_z7UwDtp33PLl" title="Preferred stock, shares authorized">10,000,000 shares of preferred stock with a par value of $<span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zzAa8TxJtSMj" title="Preferred stock, par value per share"><span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zoU5iIjvmSCi" title="Preferred stock, par value per share">0.01 per share. All outstanding preferred stock is redeemable upon a Deemed Liquidation Event and convertible and has been classified as temporary stockholders’ equity at December 31, 2023 and 2022, as the shares are redeemable for cash or other assets upon the occurrence of an event that is not solely within the control of the Company. As of December 31, 2023 and 2022, all outstanding preferred stock was not initially redeemable and was not considered probable of being redeemed upon consideration of the events that would constitute a Deemed Liquidation Event. As such, accrued dividends are not included in the redeemable convertible preferred stock balances. Redeemable convertible preferred stock was as follows as of December 31, 2023: Schedule of Redeemable Convertible Preferred Stock <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Preference Order</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Designation</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_481_eus-gaap--TemporaryEquitySharesAuthorized_iI_pid_zMbEcWiCOTK9" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Shares Designated</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_488_eus-gaap--TemporaryEquitySharesIssued_iI_pid_zkqnI0phx9Dj" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Shares Issued</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_488_eus-gaap--TemporaryEquitySharesOutstanding_iI_pid_zmjjvkyTpBD8" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Shares Outstanding</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_485_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_pid_zsKpnyI6wtzj" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Issue Price per Share</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_488_eus-gaap--TemporaryEquityLiquidationPreference_iI_zx0auhZoIISf" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Liquidation Preference</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr id="xdx_41A_20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zpYRYv9HzNzi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 9%; text-align: center">#1</td><td style="width: 2%"> </td> <td style="width: 24%; text-align: left">Series A Preferred Stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">400,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">400,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">400,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_414_20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zmr123YSMtrj" style="vertical-align: bottom; background-color: White"> <td style="text-align: center">#2</td><td> </td> <td style="text-align: left">Series A-1 Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6.66</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,998,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_415_20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_zuZwLswWWkD2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">#3</td><td> </td> <td style="text-align: left">Series A-2 Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,117,013</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,117,013</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,117,013</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">9.93793</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">11,085,291</td><td style="text-align: left"> </td></tr> <tr id="xdx_417_20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAThreePreferredStockMember_z4ECGzZBvii4" style="vertical-align: bottom; background-color: White"> <td style="text-align: center">#4</td><td> </td> <td style="text-align: left">Series A-3 Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">499,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">499,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">499,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">12.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,240,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_418_20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAFourPreferredStockMember_zUPd5x0mZCzg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">#5</td><td> </td> <td style="text-align: left">Series A-4 Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">718,997</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">718,997</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">718,997</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">9,346,961</td><td style="text-align: left"> </td></tr> <tr id="xdx_411_20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAFivePreferredStockMember_z5EC6vU7YfK8" style="vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-bottom: 1.5pt">#6</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left; padding-bottom: 1.5pt">Series A-5 Preferred Stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,000,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">484,918</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">484,918</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">13.00</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,733,832</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--TemporaryEquitySharesAuthorized_iI_pid_c20231231_zhx1U9Fjjmw4" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares Designated">5,035,210</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--TemporaryEquitySharesIssued_iI_pid_c20231231_zv7TzyhZvHPg" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares Issued">3,520,128</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--TemporaryEquitySharesOutstanding_iI_pid_c20231231_z230AnNvgY45" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares Outstanding">3,520,128</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_984_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_pid_c20231231_zS8ADIls39h" style="padding-bottom: 2.5pt; text-align: right" title="Issue Price per Share">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--TemporaryEquityLiquidationPreference_iI_c20231231_zRka6NfAqOtg" style="border-bottom: Black 2.5pt double; text-align: right" title="Liquidation Preference">36,404,084</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Redeemable convertible preferred stock was as follows as of December 31, 2022: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Preference Order</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Designation</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_481_eus-gaap--TemporaryEquitySharesAuthorized_iI_pid_z3w2LcfrZ04f" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Shares Designated</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_488_eus-gaap--TemporaryEquitySharesIssued_iI_pid_zhcC9VtWALZh" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Shares Issued</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_488_eus-gaap--TemporaryEquitySharesOutstanding_iI_pid_zoNwQUxi72l5" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Shares Outstanding</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_485_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_pid_zUcVtnhCCmy6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Issue Price per Share</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_488_eus-gaap--TemporaryEquityLiquidationPreference_iI_zBq0VLOADfHg" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Liquidation Preference</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr id="xdx_410_20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z5xxMIJBLTng" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 9%; text-align: center">#1</td><td style="width: 2%"> </td> <td style="width: 24%; text-align: left">Series A Preferred Stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">400,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">400,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">400,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_41B_20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zGqcWufSQTQj" style="vertical-align: bottom; background-color: White"> <td style="text-align: center">#2</td><td> </td> <td style="text-align: left">Series A-1 Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6.66</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,998,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_41E_20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_zCxMXkqReD5c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">#3</td><td> </td> <td style="text-align: left">Series A-2 Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,122,077</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,117,013</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,117,013</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">9.94</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">11,085,291</td><td style="text-align: left"> </td></tr> <tr id="xdx_417_20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAThreePreferredStockMember_zXL313wUZEyb" style="vertical-align: bottom; background-color: White"> <td style="text-align: center">#4</td><td> </td> <td style="text-align: left">Series A-3 Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">499,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">499,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">499,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">12.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,240,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_41C_20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAFourPreferredStockMember_zzbTQ48LBIw4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">#5</td><td> </td> <td style="text-align: left">Series A-4 Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">718,997</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">718,997</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">718,997</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">9,346,961</td><td style="text-align: left"> </td></tr> <tr id="xdx_410_20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAFivePreferredStockMember_zpXnS8rqrHG6" style="vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-bottom: 1.5pt">#6</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left; padding-bottom: 1.5pt">Series A-5 Preferred Stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,000,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">367,015</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">367,015</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">13.00</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,771,248</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--TemporaryEquitySharesAuthorized_iI_pid_c20221231_z8qPyCF1dKpk" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares Designated">5,040,274</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--TemporaryEquitySharesIssued_iI_pid_c20221231_zqo1C6A5055d" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares Issued">3,402,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--TemporaryEquitySharesOutstanding_iI_pid_c20221231_zGDQlzWD0Lek" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares Outstanding">3,402,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_98E_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_pid_c20221231_zKkbTLYIt1il" style="padding-bottom: 2.5pt; text-align: right" title="Issue Price per Share">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--TemporaryEquityLiquidationPreference_iI_c20221231_zfOnXFcRnMha" style="border-bottom: Black 2.5pt double; text-align: right" title="Liquidation Preference">35,441,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, and Series A-5 Preferred Stock all have the same rights, preferences, powers, privileges, restrictions, qualifications, and limitations. Dividends From and after the date of the issuance of any shares of Series A Preferred Stock, Series A-1 Preferred Stock, and Series A-2 Preferred Stock, they accrued dividends at the rate per annum of <span id="xdx_903_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_c20190601__20190630__us-gaap--StatementClassOfStockAxis__custom--SeriesAPreferredStockSeriesAOnePreferredStockAndSeriesATwoPreferredStockMember_zPCHpI5V0cB" title="Accrued dividends rate per annum">6% of the original issue price until June 30, 2019. The dividends accrued from day to day, whether or not declared, compounded annually, were calculated on the basis of a 365-day year, and were cumulative. Effective June 30, 2019, Series A Preferred Stock, Series A-1 Preferred Stock, and Series A-2 Preferred Stock no longer accrued dividends. The holders of the Series A Preferred Stock, Series A-1 Preferred Stock, and Series A-2 Preferred Stock were entitled to receive dividends when and if declared by the Board of Directors. The Series A-3 Preferred Stock, Series A-4 Preferred Stock, and Series A-5 Preferred Stock shall not accrue dividends. Dividends on Preferred Stock are in preference to and prior to any payment of any dividends on common stock. As of December 31, 2023 and 2022, $10,276,653 in Preferred Stock dividends have been accrued, but not declared. As such, these dividends are not currently an obligation of the Company and are not included in the redeemable convertible preferred stock balances. SERINA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 2023 AND 2022 Convertibility Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, and Series A-5 Preferred Stock shall be convertible, at the option of the holder, at any time and from time to time, and without the payment of additional consideration by the holder into common stock. The number of shares will be determined by dividing the original issue price by the conversion price of the Preferred Stock. The conversion price initially is the same as the issue price of the Preferred Stock, but may be adjusted based on certain events as provided in the amended Articles of Incorporation. Liquidation Preference In the event of Deemed Liquidation Event for Serina (described below), the holders of the various series of Preferred Stock are entitled to receive prior to, and in preference to, any distribution to the holders of common stock or any other class or series of stock ranking on liquidation junior to the series of Preferred Stock they hold, an amount equal to the original issue price plus any accrued dividends (excepting Series A-3 Preferred Stock, Series A-4 Preferred Stock, and Series A-5 Preferred Stock) together with any other dividends declared that have not yet been paid. The preference order is noted above. The following events will constitute a Deemed Liquidation Event: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">a) </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The consummation of a plan of merger or conversion in accordance with various sections of Alabama Business Corporation Law (“ABCL”), with some exceptions as provided in the amended Articles of Incorporation;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">b) </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The sale, lease, exchange, license, or other disposal, in a single transaction or series of related transactions, of all, or substantially all, of the corporation’s property (with or without goodwill), other than in the usual course of business in accordance with Section 10A-2A-12.02 of the ABCL;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">c) </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Dissolution of the corporation in accordance with Section 10A-2A-14.02 of the ABCLE, or liquidation or winding-up of the business and affairs of the corporation; or</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">d) </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The sale, lease, exchange, license, or other disposal, other than in the usual and regular course of business, of all, or substantially all, of the intellectual property of the corporation in a single transaction or a series of related transactions.</td></tr> </table> The holders of at least 60% of the Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, and Series A-5 Preferred Stock, acting as a single class of stock, may elect that any such events described above shall not be a Deemed Liquidation Event as provided in the amended Articles of Incorporation. The Series A Preferred Stock liquidation preference, the Series A-1 Preferred Stock liquidation preference, the Series A-2 liquidation preference, the Series A-3 liquidation preference, the Series A-4 liquidation preference, and the Series A-5 liquidation preference shall be on parity with one another. In the event that upon liquidation or dissolution, the assets and funds of the Company are insufficient to permit the payment to holders of shares of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, and Series A-5 Preferred Stock the full amount to which they shall be entitled, the holders of shares of Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, and Series A-5 Preferred Stock then outstanding and any class or series of stock ranking on liquidation on a parity with the Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, and Series A-5 Preferred Stock shall share in any distribution of the remaining assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full. After the distributions described above have been paid in full, the remaining assets of the Company available for distribution shall be distributed pro-rata to the holders of the shares of common stock. SERINA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 2023 AND 2022

10000000

0.01

Redeemable convertible preferred stock was as follows as of December 31, 2023: Schedule of Redeemable Convertible Preferred Stock <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Preference Order</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Designation</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_481_eus-gaap--TemporaryEquitySharesAuthorized_iI_pid_zMbEcWiCOTK9" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Shares Designated</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_488_eus-gaap--TemporaryEquitySharesIssued_iI_pid_zkqnI0phx9Dj" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Shares Issued</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_488_eus-gaap--TemporaryEquitySharesOutstanding_iI_pid_zmjjvkyTpBD8" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Shares Outstanding</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_485_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_pid_zsKpnyI6wtzj" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Issue Price per Share</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_488_eus-gaap--TemporaryEquityLiquidationPreference_iI_zx0auhZoIISf" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Liquidation Preference</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr id="xdx_41A_20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zpYRYv9HzNzi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 9%; text-align: center">#1</td><td style="width: 2%"> </td> <td style="width: 24%; text-align: left">Series A Preferred Stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">400,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">400,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">400,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_414_20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zmr123YSMtrj" style="vertical-align: bottom; background-color: White"> <td style="text-align: center">#2</td><td> </td> <td style="text-align: left">Series A-1 Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6.66</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,998,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_415_20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_zuZwLswWWkD2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">#3</td><td> </td> <td style="text-align: left">Series A-2 Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,117,013</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,117,013</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,117,013</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">9.93793</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">11,085,291</td><td style="text-align: left"> </td></tr> <tr id="xdx_417_20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAThreePreferredStockMember_z4ECGzZBvii4" style="vertical-align: bottom; background-color: White"> <td style="text-align: center">#4</td><td> </td> <td style="text-align: left">Series A-3 Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">499,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">499,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">499,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">12.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,240,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_418_20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAFourPreferredStockMember_zUPd5x0mZCzg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">#5</td><td> </td> <td style="text-align: left">Series A-4 Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">718,997</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">718,997</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">718,997</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">9,346,961</td><td style="text-align: left"> </td></tr> <tr id="xdx_411_20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAFivePreferredStockMember_z5EC6vU7YfK8" style="vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-bottom: 1.5pt">#6</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left; padding-bottom: 1.5pt">Series A-5 Preferred Stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,000,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">484,918</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">484,918</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">13.00</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,733,832</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--TemporaryEquitySharesAuthorized_iI_pid_c20231231_zhx1U9Fjjmw4" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares Designated">5,035,210</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--TemporaryEquitySharesIssued_iI_pid_c20231231_zv7TzyhZvHPg" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares Issued">3,520,128</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--TemporaryEquitySharesOutstanding_iI_pid_c20231231_z230AnNvgY45" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares Outstanding">3,520,128</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_984_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_pid_c20231231_zS8ADIls39h" style="padding-bottom: 2.5pt; text-align: right" title="Issue Price per Share">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--TemporaryEquityLiquidationPreference_iI_c20231231_zRka6NfAqOtg" style="border-bottom: Black 2.5pt double; text-align: right" title="Liquidation Preference">36,404,084</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Redeemable convertible preferred stock was as follows as of December 31, 2022: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Preference Order</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Designation</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_481_eus-gaap--TemporaryEquitySharesAuthorized_iI_pid_z3w2LcfrZ04f" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Shares Designated</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_488_eus-gaap--TemporaryEquitySharesIssued_iI_pid_zhcC9VtWALZh" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Shares Issued</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_488_eus-gaap--TemporaryEquitySharesOutstanding_iI_pid_zoNwQUxi72l5" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Shares Outstanding</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_485_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_pid_zUcVtnhCCmy6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Issue Price per Share</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_488_eus-gaap--TemporaryEquityLiquidationPreference_iI_zBq0VLOADfHg" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Liquidation Preference</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr id="xdx_410_20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z5xxMIJBLTng" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 9%; text-align: center">#1</td><td style="width: 2%"> </td> <td style="width: 24%; text-align: left">Series A Preferred Stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">400,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">400,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">400,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_41B_20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAOnePreferredStockMember_zGqcWufSQTQj" style="vertical-align: bottom; background-color: White"> <td style="text-align: center">#2</td><td> </td> <td style="text-align: left">Series A-1 Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6.66</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,998,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_41E_20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_zCxMXkqReD5c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">#3</td><td> </td> <td style="text-align: left">Series A-2 Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,122,077</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,117,013</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,117,013</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">9.94</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">11,085,291</td><td style="text-align: left"> </td></tr> <tr id="xdx_417_20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAThreePreferredStockMember_zXL313wUZEyb" style="vertical-align: bottom; background-color: White"> <td style="text-align: center">#4</td><td> </td> <td style="text-align: left">Series A-3 Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">499,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">499,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">499,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">12.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,240,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_41C_20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAFourPreferredStockMember_zzbTQ48LBIw4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">#5</td><td> </td> <td style="text-align: left">Series A-4 Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">718,997</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">718,997</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">718,997</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">9,346,961</td><td style="text-align: left"> </td></tr> <tr id="xdx_410_20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesAFivePreferredStockMember_zpXnS8rqrHG6" style="vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-bottom: 1.5pt">#6</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left; padding-bottom: 1.5pt">Series A-5 Preferred Stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,000,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">367,015</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">367,015</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">13.00</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,771,248</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--TemporaryEquitySharesAuthorized_iI_pid_c20221231_z8qPyCF1dKpk" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares Designated">5,040,274</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--TemporaryEquitySharesIssued_iI_pid_c20221231_zqo1C6A5055d" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares Issued">3,402,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--TemporaryEquitySharesOutstanding_iI_pid_c20221231_zGDQlzWD0Lek" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares Outstanding">3,402,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_98E_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_pid_c20221231_zKkbTLYIt1il" style="padding-bottom: 2.5pt; text-align: right" title="Issue Price per Share">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--TemporaryEquityLiquidationPreference_iI_c20221231_zfOnXFcRnMha" style="border-bottom: Black 2.5pt double; text-align: right" title="Liquidation Preference">35,441,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

400000

5.00

2000000

300000

6.66

1998000

1117013

9.93793

11085291

499200

12.50

6240000

718997

13.00

9346961

2000000

484918

13.00

5733832

5035210

3520128

36404084

400000

5.00

2000000

300000

6.66

1998000

1122077

1117013

9.94

11085291

499200

12.50

6240000

718997

13.00

9346961

2000000

367015

13.00

4771248

5040274

3402225

35441500

Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, and Series A-5 Preferred Stock all have the same rights, preferences, powers, privileges, restrictions, qualifications, and limitations.

0.06

10276653

The holders of at least 60% of the Series A Preferred Stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, and Series A-5 Preferred Stock, acting as a single class of stock, may elect that any such events

Note 8 - Income Taxes Deferred tax assets and liabilities reflect the effects of tax losses, credits, and the future income tax effects of temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and are measured using enacted tax rates that apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. <p id="xdx_89D_ecustom--ScheduleOfDeferredTaxAssetsAndLiabilitiesSubjectToExpirationTableTextBlock_zfwNLw432YM6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">At December 31, 2023, the Company had the following carryovers subject to expiration: Schedule of Deferred Tax Assets and Liabilities of Carryovers Subject to Expiration <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: center">Carryover</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20231231_zcM1PjQMm2g1" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Begin to Expire In</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_405_ecustom--DeferredTaxAssetsOneTwoThreeOneLossCarryOver_iI_zdRY8oZZktQ7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; text-align: left">1231 loss carryover</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">798</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 16%; text-align: center">2024</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--DeferredTaxAssetsCapitalLossCarryforwardsOfCarryovers_iI_zM34D1wHQ2f3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net capital loss carryover</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">29,402</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">2026</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--DeferredTaxAssetsOperatingLossCarryforwardsForeignIndefiniteLife_iI_zOIa21uYgfCe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">NOL carryover – Federal – indefinite life</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13,925,183</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">N/A</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_iI_zk8pzHUZDgi7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">NOL carryover – Federal – subject to expiration</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">23,207,997</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">2027</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--DeferredTaxAssetsOperatingLossCarryforwardsState_iI_zfM7jYLpKbyb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">NOL carryover - state</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">36,494,174</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">2024</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--DeferredTaxAssetsCharitableContributionCarryover_iI_zVE16xxC4N19" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Charitable contributions carryover</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">25,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">2027</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_zIu34CtRFOed" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">General business credit carryover ESB*</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">129,310</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">2030</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusinessNonEsb_iI_zh1YziGeQahl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">General business credit carryover NonESB*</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,920,911</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">2026</td><td style="text-align: left"> </td></tr> </table> The Company’s effective tax rate is 0% for the years ended December 31, 2023 and 2022. The Company’s effective tax rate is different than what would be expected if the federal statutory rate was applied to income before income taxes primarily because certain expenses are deductible for financial reporting purposes that are not deductible for tax purposes and valuation allowances applied to the Company’s net deferred tax assets. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The major temporary differences that give rise to the deferred tax assets and liabilities are as follows: NOL carryovers, general business credit carryovers, charitable contribution carryovers, operating and finance lease assets and liabilities, depreciation and amortization, and capitalization of research & development expenses. Section 174 of the Internal Revenue Code became effective on January 1, 2022. Under this section, research and development expenses are no longer deducted in the year expended, but are required to be capitalized and expensed over five years for tax purposes. The Company evaluates the recoverability of these future tax deductions and credits by assessing the adequacy of future expected taxable income from all sources, including reversal of taxable temporary differences, forecasted operating earnings and available tax planning strategies. To the extent that management does not consider it more likely than not that a deferred tax asset will be recovered, a valuation allowance is established. The Company has provided a valuation allowance against the deferred income taxes at December 31, 2023 and 2022. The valuation allowance increased by $752,330 during the year ended December 31, 2023. <p id="xdx_893_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zGNCr4GrImu4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -0.35pt">The components of the deferred income tax asset and liability as of December 31, 2023 and 2022 are as follows: Schedule of Deferred Tax Assets and Liabilities <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_49D_20231231_zCVDoEMtTkqe" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">December 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_490_20221231_zlyRhUDNQEQj" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsNetAbstract_iB_zBTI7HmKbiJc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred Tax Assets (Liabilities):</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_maDTAGzYms_zKuvXTyEapGj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">General business credit carryover ESB</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">129,310</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">129,310</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusinessNonEsb_iI_maDTAGzYms_zifStsJabix5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">General business credit carryover NonESB</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,920,911</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,824,263</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--DeferredTaxAssetsOneTwoThreeOneLossCarryOvers_iI_maDTAGzYms_zL91XmVWQswi" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">1231 loss carryover</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">219</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">219</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_maDTAGzYms_zAqMXRlLmPV2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Net capital loss carryover </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,086</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,805</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_maDTAGzYms_zXcnwzg26G8j" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">NOL carryover - Federal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,797,968</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,399,496</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_maDTAGzYms_za8OE7arGphc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">NOL carryover - State </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,372,121</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,308,126</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_maDTAGzYms_zK61JWpjUUE1" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">580,578</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">389,339</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsCharitableContributionCarryforwards_iI_maDTAGzYms_zpMgxz0z2zmi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Charitable contributions carryover</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,875</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,875</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--DeferredTaxLiabilitiesRightOfUseAssetOperatingLeases_iNI_di_msDTAGzYms_zWh8tQg2LoE2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Right of use assets - operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(183,174</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(23,307</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_ecustom--DeferredTaxAssetsOperationLeaseLiabilities_iI_maDTAGzYms_z55JFwtys4Xb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Operating lease liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">185,395</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,419</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTAGzYms_zzsteEiFKmzh" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Depreciation of property and equipment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">23,362</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,776</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzYms_maDTANzK5A_zogVvCk2Q42a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Total deferred tax asset</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,841,651</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,089,321</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzK5A_zLmJykuaD1L" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">Valuation allowance </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12,841,651</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12,089,321</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzK5A_zIxhvniT3Ci6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; text-align: left; padding-bottom: 2.5pt">Net Deferred Tax Asset</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> SERINA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 2023 AND 2022

<p id="xdx_89D_ecustom--ScheduleOfDeferredTaxAssetsAndLiabilitiesSubjectToExpirationTableTextBlock_zfwNLw432YM6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">At December 31, 2023, the Company had the following carryovers subject to expiration: Schedule of Deferred Tax Assets and Liabilities of Carryovers Subject to Expiration <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: center">Carryover</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20231231_zcM1PjQMm2g1" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Begin to Expire In</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_405_ecustom--DeferredTaxAssetsOneTwoThreeOneLossCarryOver_iI_zdRY8oZZktQ7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; text-align: left">1231 loss carryover</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">798</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 16%; text-align: center">2024</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--DeferredTaxAssetsCapitalLossCarryforwardsOfCarryovers_iI_zM34D1wHQ2f3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net capital loss carryover</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">29,402</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">2026</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--DeferredTaxAssetsOperatingLossCarryforwardsForeignIndefiniteLife_iI_zOIa21uYgfCe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">NOL carryover – Federal – indefinite life</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13,925,183</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">N/A</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_iI_zk8pzHUZDgi7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">NOL carryover – Federal – subject to expiration</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">23,207,997</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">2027</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--DeferredTaxAssetsOperatingLossCarryforwardsState_iI_zfM7jYLpKbyb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">NOL carryover - state</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">36,494,174</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">2024</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--DeferredTaxAssetsCharitableContributionCarryover_iI_zVE16xxC4N19" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Charitable contributions carryover</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">25,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">2027</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_zIu34CtRFOed" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">General business credit carryover ESB*</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">129,310</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">2030</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusinessNonEsb_iI_zh1YziGeQahl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">General business credit carryover NonESB*</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,920,911</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">2026</td><td style="text-align: left"> </td></tr> </table> 798 2024 29402 2026 13925183

23207997

2027 36494174 2024 25000 2027

129310

2030 1920911 2026

752330

<p id="xdx_893_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zGNCr4GrImu4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -0.35pt">The components of the deferred income tax asset and liability as of December 31, 2023 and 2022 are as follows: Schedule of Deferred Tax Assets and Liabilities <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_49D_20231231_zCVDoEMtTkqe" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">December 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_490_20221231_zlyRhUDNQEQj" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsNetAbstract_iB_zBTI7HmKbiJc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred Tax Assets (Liabilities):</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_iI_maDTAGzYms_zKuvXTyEapGj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">General business credit carryover ESB</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">129,310</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">129,310</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusinessNonEsb_iI_maDTAGzYms_zifStsJabix5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">General business credit carryover NonESB</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,920,911</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,824,263</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--DeferredTaxAssetsOneTwoThreeOneLossCarryOvers_iI_maDTAGzYms_zL91XmVWQswi" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">1231 loss carryover</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">219</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">219</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_maDTAGzYms_zAqMXRlLmPV2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Net capital loss carryover </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,086</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,805</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_maDTAGzYms_zXcnwzg26G8j" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">NOL carryover - Federal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,797,968</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,399,496</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_maDTAGzYms_za8OE7arGphc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">NOL carryover - State </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,372,121</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,308,126</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_maDTAGzYms_zK61JWpjUUE1" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">580,578</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">389,339</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsCharitableContributionCarryforwards_iI_maDTAGzYms_zpMgxz0z2zmi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Charitable contributions carryover</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,875</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,875</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--DeferredTaxLiabilitiesRightOfUseAssetOperatingLeases_iNI_di_msDTAGzYms_zWh8tQg2LoE2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Right of use assets - operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(183,174</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(23,307</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_ecustom--DeferredTaxAssetsOperationLeaseLiabilities_iI_maDTAGzYms_z55JFwtys4Xb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Operating lease liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">185,395</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,419</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_maDTAGzYms_zzsteEiFKmzh" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Depreciation of property and equipment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">23,362</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,776</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzYms_maDTANzK5A_zogVvCk2Q42a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Total deferred tax asset</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,841,651</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,089,321</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzK5A_zLmJykuaD1L" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">Valuation allowance </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12,841,651</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12,089,321</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzK5A_zIxhvniT3Ci6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; text-align: left; padding-bottom: 2.5pt">Net Deferred Tax Asset</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

129310

1920911 1824263 219 219

8086

4805

7797968

7399496

2372121

2308126

580578

389339

6875

183174 23307 185395 29419

23362

20776

12841651

12089321

12841651

12089321

Note 9 - Leases The Company leases many of its operating and office facilities for various terms under long-term, non-cancelable operating lease agreements. The leases expire at various dates through 2028. In the normal course of business, it is expected that these leases will be renewed or replaced by leases on other properties. The Company also leases equipment for various terms under long-term, non-cancelable finance lease agreements. These leases expire at various dates through 2025. The following represents information on leases as of and for the years ended December 31: Schedule of Information on Leases <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_49C_20230101__20231231_zAgbpBooDv9f" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_49B_20220101__20221231_zksuBA91Dz5" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr id="xdx_40D_ecustom--FinanceLeaseCost_maLCzawp_zDazVTEE1dv4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Finance lease cost (including amortization of right-of use assets of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGluZm9ybWF0aW9uIG9uIGxlYXNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_c20230101__20231231_zEUp4GYi3Tmc" title="Amortization of right-of use assets">23,349 and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGluZm9ybWF0aW9uIG9uIGxlYXNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_c20220101__20221231_zc9erRJvOHVi" title="Amortization of right-of use assets">23,349 and interest on lease liabilities of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGluZm9ybWF0aW9uIG9uIGxlYXNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_eus-gaap--FinanceLeaseInterestExpense_c20230101__20231231_zpX1XdZQvXo5" title="Interest on lease liabilities">7,083 and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGluZm9ybWF0aW9uIG9uIGxlYXNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--FinanceLeaseInterestExpense_c20220101__20221231_zKc5puDaYyF6" title="Interest on lease liabilities">12,843 in 2023 and 2022, respectively)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">30,432</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">36,192</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OperatingLeaseCost_maLCzawp_zXqYwqd6SWQ8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Operating lease expense</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">208,856</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">101,399</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LeaseCost_iT_mtLCzawp_zmkEMcqMWT7k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total lease cost</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">239,288</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">137,591</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Other information</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted average remaining lease term (years) – finance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.64</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.71</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted average remaining lease term (years) – operating</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.32</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.30</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted average discount rate - finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11.90</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11.90</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted average discount rate - operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6.67</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6.67</td><td style="text-align: left">%</td></tr> </table> The following is a maturity analysis of the annual undiscounted cash flows of the lease liabilities as of December 31, 2023: Schedule of Annual Undiscounted Cash Flows of The Lease Liabilities <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Operating Leases</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Finance Leases</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Year ending December 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20231231_zz15u6S13ERe" style="width: 16%; text-align: right" title="Year ending December 31, 2024 - Operating leases">258,395</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20231231_zggksq51kLpk" style="width: 16%; text-align: right" title="Year ending December 31, 2024 - Finance leases">38,055</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Year ending December 31, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20231231_zCzJIns0RdP3" style="text-align: right" title="Year ending December 31, 2025 - Operating leases">212,512</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_c20231231_zYl6ga41np9l" style="text-align: right" title="Year ending December 31, 2025 - Finance leases">629</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Year ending December 31, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_c20231231_zcFkkF8fgOUa" style="text-align: right" title="Year ending December 31, 2026 - Operating leases">158,282</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_c20231231_zaJ3z0X6fO08" style="text-align: right" title="Year ending December 31, 2026 - Finance leases">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Year ending December 31, 2027</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_c20231231_zC6ULDxG6l44" style="text-align: right" title="Year ending December 31, 2027 - Operating leases">116,592</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_c20231231_zMZEwP2Wfauk" style="text-align: right" title="Year ending December 31, 2027 - Finance leases">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Thereafter </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_c20231231_zTOwUj6L9jD7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Thereafter - Operating leases">9,716</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_ecustom--FinanceLeaseLiabilityPaymentsDueAfterYearFour_iI_c20231231_ziTLU470qleg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Thereafter - Finance Leases">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Total undiscounted lease payments</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_c20231231_zOiCaeh7tjcc" style="text-align: right" title="Total undiscounted lease payments - Operating leases">755,497</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iI_c20231231_zlP6qykeV7Na" style="text-align: right" title="Total undiscounted lease payments - Finance leases">38,684</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_c20231231_zibxvm10eP0k" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: imputed interest- Operating leases">(81,335</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_c20231231_z4pChv2bTmR2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: imputed interest - Finance leases">(1,716</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Total lease obligations</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--LesseeOperatingLeaseTotalObligations_iI_c20231231_zGG5kao22qKa" style="text-align: right" title="Total lease obligations - Operating leases">674,162</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--FinanceLeaseTotalObligations_iI_c20231231_zOPgTFalfGqk" style="text-align: right" title="Total lease obligations - Finance leases">36,968</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_c20231231_zsqenRNiRde8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: current portion - Operating leases">(213,526</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_di_c20231231_zQ9FrjjWCAE4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: current portion - Finance leases">(36,344</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Long-term lease obligations</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--OperatingLeaseLiability_iI_c20231231_zbpCKiRgqWbc" style="border-bottom: Black 2.5pt double; text-align: right" title="Long-term lease obligations - Operating leases">460,636</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FinanceLeaseLiability_iI_c20231231_zB3pBrohIhL1" style="border-bottom: Black 2.5pt double; text-align: right" title="Long-term lease obligations - Finance leases">624</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Right of use assets - operating leases obtained in exchange for new operating lease liabilities was $<span id="xdx_90F_ecustom--AcquisitionOfRightOfUseAssetsInExchangeForOperatingLeaseLiabilities_c20230101__20231231_zCVpS4WyLVQa" title="Operating leases obtained in exchange for new operating lease liabilities">754,960 for the year ended December 31, 2023. SERINA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 2023 AND 2022

The following represents information on leases as of and for the years ended December 31: Schedule of Information on Leases <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_49C_20230101__20231231_zAgbpBooDv9f" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_49B_20220101__20221231_zksuBA91Dz5" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr id="xdx_40D_ecustom--FinanceLeaseCost_maLCzawp_zDazVTEE1dv4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Finance lease cost (including amortization of right-of use assets of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGluZm9ybWF0aW9uIG9uIGxlYXNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_c20230101__20231231_zEUp4GYi3Tmc" title="Amortization of right-of use assets">23,349 and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGluZm9ybWF0aW9uIG9uIGxlYXNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_c20220101__20221231_zc9erRJvOHVi" title="Amortization of right-of use assets">23,349 and interest on lease liabilities of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGluZm9ybWF0aW9uIG9uIGxlYXNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_eus-gaap--FinanceLeaseInterestExpense_c20230101__20231231_zpX1XdZQvXo5" title="Interest on lease liabilities">7,083 and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIGluZm9ybWF0aW9uIG9uIGxlYXNlcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--FinanceLeaseInterestExpense_c20220101__20221231_zKc5puDaYyF6" title="Interest on lease liabilities">12,843 in 2023 and 2022, respectively)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">30,432</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">36,192</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OperatingLeaseCost_maLCzawp_zXqYwqd6SWQ8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Operating lease expense</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">208,856</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">101,399</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LeaseCost_iT_mtLCzawp_zmkEMcqMWT7k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total lease cost</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">239,288</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">137,591</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Other information</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted average remaining lease term (years) – finance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.64</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.71</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted average remaining lease term (years) – operating</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.32</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.30</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted average discount rate - finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11.90</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11.90</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted average discount rate - operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6.67</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6.67</td><td style="text-align: left">%</td></tr> </table>

23349

7083

12843

30432 36192

208856

101399

239288

137591

P0Y7M20D

P1Y8M15D

P3Y3M25D

P1Y3M18D

0.1190

0.0667

The following is a maturity analysis of the annual undiscounted cash flows of the lease liabilities as of December 31, 2023: Schedule of Annual Undiscounted Cash Flows of The Lease Liabilities <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Operating Leases</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Finance Leases</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Year ending December 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20231231_zz15u6S13ERe" style="width: 16%; text-align: right" title="Year ending December 31, 2024 - Operating leases">258,395</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_c20231231_zggksq51kLpk" style="width: 16%; text-align: right" title="Year ending December 31, 2024 - Finance leases">38,055</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Year ending December 31, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_c20231231_zCzJIns0RdP3" style="text-align: right" title="Year ending December 31, 2025 - Operating leases">212,512</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_c20231231_zYl6ga41np9l" style="text-align: right" title="Year ending December 31, 2025 - Finance leases">629</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Year ending December 31, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_c20231231_zcFkkF8fgOUa" style="text-align: right" title="Year ending December 31, 2026 - Operating leases">158,282</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_c20231231_zaJ3z0X6fO08" style="text-align: right" title="Year ending December 31, 2026 - Finance leases">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Year ending December 31, 2027</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_c20231231_zC6ULDxG6l44" style="text-align: right" title="Year ending December 31, 2027 - Operating leases">116,592</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_c20231231_zMZEwP2Wfauk" style="text-align: right" title="Year ending December 31, 2027 - Finance leases">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Thereafter </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_iI_c20231231_zTOwUj6L9jD7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Thereafter - Operating leases">9,716</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_ecustom--FinanceLeaseLiabilityPaymentsDueAfterYearFour_iI_c20231231_ziTLU470qleg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Thereafter - Finance Leases">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Total undiscounted lease payments</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_c20231231_zOiCaeh7tjcc" style="text-align: right" title="Total undiscounted lease payments - Operating leases">755,497</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iI_c20231231_zlP6qykeV7Na" style="text-align: right" title="Total undiscounted lease payments - Finance leases">38,684</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_c20231231_zibxvm10eP0k" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: imputed interest- Operating leases">(81,335</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_di_c20231231_z4pChv2bTmR2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: imputed interest - Finance leases">(1,716</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Total lease obligations</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--LesseeOperatingLeaseTotalObligations_iI_c20231231_zGG5kao22qKa" style="text-align: right" title="Total lease obligations - Operating leases">674,162</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--FinanceLeaseTotalObligations_iI_c20231231_zOPgTFalfGqk" style="text-align: right" title="Total lease obligations - Finance leases">36,968</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_c20231231_zsqenRNiRde8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: current portion - Operating leases">(213,526</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_di_c20231231_zQ9FrjjWCAE4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: current portion - Finance leases">(36,344</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Long-term lease obligations</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--OperatingLeaseLiability_iI_c20231231_zbpCKiRgqWbc" style="border-bottom: Black 2.5pt double; text-align: right" title="Long-term lease obligations - Operating leases">460,636</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FinanceLeaseLiability_iI_c20231231_zB3pBrohIhL1" style="border-bottom: Black 2.5pt double; text-align: right" title="Long-term lease obligations - Finance leases">624</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

258395

38055

212512

629

158282

116592

9716

755497

38684

81335

1716

674162 36968

213526

36344

460636

624

754960

Note 10 - Property and Equipment Property and equipment at December 31, 2023 and 2022 consists of: Schedule of Property and Equipment <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20231231_zQTUg9N0Oo4b" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20221231_zrkcLWxIixx" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zkrUwMVZLYqj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Computer </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">29,581</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">24,061</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zAXYqt5NTNl3" style="vertical-align: bottom; background-color: White"> <td>Equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">836,771</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">353,343</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareDevelopmentMember_zXMPQzVj0Lyk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Software </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">96,517</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">81,676</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzLw3_zNQJzT8w1vl6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total property and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">962,869</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">459,080</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzLw3_zhQ5vanFLa2k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(389,548</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(367,511</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzLw3_z8hnq0mVs6Hk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">573,321</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">91,569</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Depreciation expense for the years ended December 31, 2023 and 2022 totaled $65,399 and $37,923, respectively.

Property and equipment at December 31, 2023 and 2022 consists of: Schedule of Property and Equipment <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20231231_zQTUg9N0Oo4b" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20221231_zrkcLWxIixx" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zkrUwMVZLYqj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Computer </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">29,581</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">24,061</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zAXYqt5NTNl3" style="vertical-align: bottom; background-color: White"> <td>Equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">836,771</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">353,343</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareDevelopmentMember_zXMPQzVj0Lyk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Software </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">96,517</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">81,676</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzLw3_zNQJzT8w1vl6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total property and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">962,869</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">459,080</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzLw3_zhQ5vanFLa2k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(389,548</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(367,511</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzLw3_z8hnq0mVs6Hk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">573,321</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">91,569</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

29581

24061

836771

353343

96517

81676

962869

459080

389548

367511

573321

91569

65399

37923

Note 11 - Stock Option Plan Stock Option Plan Description In 2007, the Company’s Board of Directors (“the Board”) adopted the Serina Therapeutics, Inc. 2007 Stock Option Plan (the 2007 Plan) that provides for the granting of stock options to employees. The 2007 Plan as amended in March 2014 reserved <span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20071231__us-gaap--PlanNameAxis__custom--TwoThousandAndSevenPlanMember_zBtSas4Gyaxj" title="Number of shares reserved for grant">2,000,000 shares of common stock for grant. Options are granted at the discretion of the Board. <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20070101__20071231__us-gaap--PlanNameAxis__custom--TwoThousandAndSevenPlanMember_zJV8OYjI1Y7i" title="Stock option plan description">Options granted under the 2007 Plan shall be either incentive stock options (ISOs) or nonstatutory stock options (NSOs), as designated by the Board. The options will be granted at an exercise price set by the Board at the time of grant, but in no event will the price for ISOs be less than 100% of the fair market value of the common stock on the date of the grant, or in the case of an option holder who owns more than 10% of the total combined voting power of all classes of stock of Serina, not less than 110%; and not less than the par value of the common stock at grant, in the case of NSOs. In 2017, the Serina Therapeutics, Inc. 2007 Plan by its terms expired, except with respect to unexercised stock options outstanding under the 2007 Plan. No future stock options shall be awarded under the 2007 Plan. In 2017, the Company’s Board adopted the Serina Therapeutics, Inc. 2017 Stock Option Plan (the 2017 Plan) that provides for the granting of stock options to employees. The 2017 Plan reserved <span id="xdx_90F_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20171231__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenPlanMember_zIachkDlnNwk" title="Number of shares reserved for grant">1,000,000 shares of common stock for grant. In 2021, the 2017 Plan was amended to increase the reserved shares to <span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20211231__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenPlanMember_zvVDSbfsrmyg" title="Number of shares reserved for grant">2,000,000, and then later in 2021 further amended to increase the reserved shares to <span id="xdx_903_ecustom--CommonStockIncreaseInCapitalSharesReservedForFutureIssuance_iI_c20211231__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenPlanMember_zrj1qTrtqwUh" title="Number of shares reserved for grant">2,100,000. Options are granted at the discretion of the Board. <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20170101__20171231__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenPlanMember_zJjc0OSM3IP9" title="Stock option plan description">Options granted under the 2017 Plan shall be either incentive stock options (ISOs) or nonstatutory stock options (NSOs), as designated by the Board. The options will be granted at an exercise price set by the Board at the time of grant, but in no event will the price for ISOs be less than 100% of the fair market value of the common stock on the date of the grant or in the case of an option holder who owns more than 10% of the total combined voting power of all classes of stock of Serina, not less than 110%; and not less than the par value of the common stock at grant, in the case of NSOs. Vesting and Exercisability Stock options are exercisable at such time or times and subject to such terms and conditions as determined by the Board at or after grant. If the Board provides, in its sole discretion, that any stock option is exercisable only in installments, the Board may waive such installment exercise provisions at any time at or after the grant, in whole or in part, based on such factors as the Board shall determine, in its sole discretion. The terms of the grants are generally for ten years (or in the case of an option holder who owns more than 10% of the total combined voting power of all classes of stock of Serina, the term shall be five years) and vest over a period of time as determined on the date of the grant. Stock-Based Compensation The Company follows the provisions of the FASB ASC 718, Compensation - Stock Compensation (“FASB ASC 718”). FASB ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized as compensation expense in the financial statements based on their fair value at the grant date. SERINA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 2023 AND 2022 Valuation and Expense The Company recognizes compensation expense related to stock options on a straight-line basis over the requisite service period of the awards, which is generally three to four years. The Company estimates the fair value of options on the date of grant using the Black-Scholes-Merton option pricing model. There were no options issued during the years ended December 31, 2023 or 2022. The Company recorded stock-based compensation expense related to the stock options of $24,325 and $7,110 during the years ended December 31, 2023 and 2022, respectively. In 2021, all options outstanding as of December 31, 2020 were canceled and replaced, with the exception of 3,300 options, which were not replaced due to termination of the grantee. Total replacement options issued were 1,294,042. Incremental compensation cost of $113 and $878 was recognized during the years ended December 31, 2023 and 2022, respectively, as a result of the accounting for the modification required by FASB ASC 718. In February 2023, by vote of the Board all remaining unvested options became fully vested. Therefore as of December 31, 2023, the Company had no unrecognized compensation cost related to nonvested stock options. Details of stock option activity for the years ended December 31, 2023 and 2022 are as follows: Schedule of Stock Option Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Options</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding at December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231_zU2nZdGdPoff" style="width: 16%; text-align: right" title="Number of Options, beginning balance (in shares)">2,012,750</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231_zjRoodbmhN5g" title="Weighted Average Exercise Price, beginning balance">0.06</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230101__20231231_zcn9lgdARHbh" style="text-align: right" title="Number of Options, forfeited">(7,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20231231_zh9QBaNIhjX3" title="Weighted Average Exercise Price, forfeited">0.06</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Exercised </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20230101__20231231_zd7mUkHhzdhb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, exercised">(248,934</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20231231_zaSbO7EQj0w1" title="Weighted Average Exercise Price, forfeited">0.06</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Granted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_z4Xtu5pFaKPh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, granted">50,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_ztqpVqv6kTrk" title="Weighted Average Exercise Price, granted">0.06</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20231231_zC0rwLcT8Jdf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, ending balance (in shares)">1,756,816</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231_zBEHLg70YUnc" title="Weighted Average Exercise Price, ending balance">0.06</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Options</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding at December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zbbJE32l0h5c" style="width: 16%; text-align: right" title="Number of Options, beginning balance (in shares)">2,036,450</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231_zADhkHJ7nY1d" title="Weighted Average Exercise Price, beginning balance">0.06</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20220101__20221231_zGEsjdQbYoh5" style="text-align: right" title="Number of Options, exercised">(73,700</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zEgRSnPNoAE4" title="Weighted Average Exercise Price, forfeited">0.06</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Granted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zMCcA29fsOf1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, granted">50,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_z1us2bur3VF" title="Weighted Average Exercise Price, granted">0.06</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_z5KaTpAjTsZ5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, ending balance (in shares)">2,012,750</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231_zdARaUC3wqyi" title="Weighted Average Exercise Price, ending balance">0.06</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_znRh3tkTBwmk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes information about stock options exercisable at December 31, 2023: Schedule of Stock Options Exercisable <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Shares Exercisable</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Remaining Contractual Life in Years</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td style="width: 22%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231_zyTEarQOmhX9" title="Weighted Average Exercise Price, beginning balance">0.06</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231_zmps8KMdwgl5" style="width: 21%; text-align: right" title="Number of Shares Exercisable">1,756,816</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 21%; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zsOdFo0b8bV" title="Weighted average remaining contractual term">7.46</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 22%; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231_ztU9BqPQipKg" title="Weighted Average Exercise Price, beginning balance">0.06</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p id="xdx_897_eus-gaap--ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_ztBXJKDq9rI" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes information about nonvested stock options for the years ended December 31, 2023 and 2022: Schedule of Nonvested Stock Options Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Nonvested Options</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Weighted Average Grant Date Fair Value</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%">Nonvested options at December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20230101__20231231_zmzlKl8AKpB6" style="width: 16%; text-align: right" title="Nonvested options, beginning balance">548,807</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230101__20231231_zLL1lpY9o7f9" title="Weighted Average Grant Date Fair Value, Nonvested options beginning balance">0.05</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Forfeited/cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_di_c20230101__20231231_z1LWtL0OtIec" style="text-align: right" title="Nonvested options, forfeited/cancelled">(1,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_c20230101__20231231_za3PKTEOA656" title="Weighted Average Grant Date Fair Value, forfeited/cancelled">0.03</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Vested </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20230101__20231231_zQjkNmhYFod6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Nonvested options, vested">(547,807</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20230101__20231231_zQU51rgoOUwg" title="Weighted Average Grant Date Fair Value, vested">0.04</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_z4nBVHqtB43" style="text-align: right" title="Nonvested options, granted">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231_zGDyVXPqTsT1" title="Weighted Average Grant Date Fair Value, granted">0.05</td><td style="text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedNumberOfShares_iN_di_c20220101__20221231_zVmunm4leJsg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Nonvested options, exercised">(73,700</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue_c20220101__20221231_zUY0fuE8d561" title="Weighted Average Grant Date Fair Value, vested">0.03</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Nonvested options at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20230101__20231231_zTRq6Onrne4b" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested options, ending balance">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230101__20231231_zCeupfRiduQ2" title="Weighted Average Grant Date Fair Value, Nonvested optionsending balance">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Nonvested Options</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Weighted Average Grant Date Fair Value</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%">Nonvested options at December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20220101__20221231_zs2kP4ybJVZk" style="width: 16%; text-align: right" title="Nonvested options, beginning balance">656,742</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20221231_zC4U4ehk35h9" title="Weighted Average Grant Date Fair Value, Nonvested options beginning balance">0.04</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zWPKdf2UNwxj" style="text-align: right" title="Nonvested options, granted">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231_zC6bjIBJzR4g" title="Weighted Average Grant Date Fair Value, granted">0.05</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20220101__20221231_zX8ksqLH7wn5" style="text-align: right" title="Nonvested options, vested">(84,235</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20220101__20221231_zadecr7JB1Lb" title="Weighted Average Grant Date Fair Value, vested">0.04</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedNumberOfShares_iN_di_c20220101__20221231_zO8gLuRvRid" style="border-bottom: Black 1.5pt solid; text-align: right" title="Nonvested options, exercised">(73,700</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue_c20220101__20221231_zlF5U37rIyoj" title="Weighted Average Grant Date Fair Value, vested">0.03</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Nonvested options at December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20220101__20221231_zAgYPb9F5ujj" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested options, ending balance">548,807</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20220101__20221231_zkVjjdG7v2Id" title="Weighted Average Grant Date Fair Value, Nonvested optionsending balance">0.05</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> SERINA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 2023 AND 2022

2000000

Options granted under the 2007 Plan shall be either incentive stock options (ISOs) or nonstatutory stock options (NSOs), as designated by the Board. The options will be granted at an exercise price set by the Board at the time of grant, but in no event will the price for ISOs be less than 100% of the fair market value of the common stock on the date of the grant, or in the case of an option holder who owns more than 10% of the total combined voting power of all classes of stock of Serina, not less than 110%; and not less than the par value of the common stock at grant, in the case of NSOs

1000000

2000000

2100000

Options granted under the 2017 Plan shall be either incentive stock options (ISOs) or nonstatutory stock options (NSOs), as designated by the Board. The options will be granted at an exercise price set by the Board at the time of grant, but in no event will the price for ISOs be less than 100% of the fair market value of the common stock on the date of the grant or in the case of an option holder who owns more than 10% of the total combined voting power of all classes of stock of Serina, not less than 110%; and not less than the par value of the common stock at grant, in the case of NSOs

24325

7110

3300

1294042

113

878

Details of stock option activity for the years ended December 31, 2023 and 2022 are as follows: Schedule of Stock Option Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Options</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding at December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231_zU2nZdGdPoff" style="width: 16%; text-align: right" title="Number of Options, beginning balance (in shares)">2,012,750</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231_zjRoodbmhN5g" title="Weighted Average Exercise Price, beginning balance">0.06</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230101__20231231_zcn9lgdARHbh" style="text-align: right" title="Number of Options, forfeited">(7,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20231231_zh9QBaNIhjX3" title="Weighted Average Exercise Price, forfeited">0.06</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Exercised </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20230101__20231231_zd7mUkHhzdhb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, exercised">(248,934</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20231231_zaSbO7EQj0w1" title="Weighted Average Exercise Price, forfeited">0.06</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Granted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_z4Xtu5pFaKPh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, granted">50,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_ztqpVqv6kTrk" title="Weighted Average Exercise Price, granted">0.06</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20231231_zC0rwLcT8Jdf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, ending balance (in shares)">1,756,816</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231_zBEHLg70YUnc" title="Weighted Average Exercise Price, ending balance">0.06</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Options</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding at December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zbbJE32l0h5c" style="width: 16%; text-align: right" title="Number of Options, beginning balance (in shares)">2,036,450</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231_zADhkHJ7nY1d" title="Weighted Average Exercise Price, beginning balance">0.06</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20220101__20221231_zGEsjdQbYoh5" style="text-align: right" title="Number of Options, exercised">(73,700</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zEgRSnPNoAE4" title="Weighted Average Exercise Price, forfeited">0.06</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Granted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zMCcA29fsOf1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, granted">50,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_z1us2bur3VF" title="Weighted Average Exercise Price, granted">0.06</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_z5KaTpAjTsZ5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options, ending balance (in shares)">2,012,750</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20220101__20221231_zdARaUC3wqyi" title="Weighted Average Exercise Price, ending balance">0.06</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

2012750

0.06

7000

0.06

248934

0.06

50000

0.06

1756816

0.06

2036450

0.06

73700

0.06

50000

0.06

2012750

0.06

<p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_znRh3tkTBwmk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes information about stock options exercisable at December 31, 2023: Schedule of Stock Options Exercisable <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Shares Exercisable</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Remaining Contractual Life in Years</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td style="width: 22%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231_zyTEarQOmhX9" title="Weighted Average Exercise Price, beginning balance">0.06</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231_zmps8KMdwgl5" style="width: 21%; text-align: right" title="Number of Shares Exercisable">1,756,816</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 21%; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zsOdFo0b8bV" title="Weighted average remaining contractual term">7.46</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 22%; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231_ztU9BqPQipKg" title="Weighted Average Exercise Price, beginning balance">0.06</td><td style="width: 1%; text-align: left"> </td></tr> </table>

0.06

1756816

P7Y5M15D

0.06

<p id="xdx_897_eus-gaap--ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_ztBXJKDq9rI" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes information about nonvested stock options for the years ended December 31, 2023 and 2022: Schedule of Nonvested Stock Options Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Nonvested Options</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Weighted Average Grant Date Fair Value</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%">Nonvested options at December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20230101__20231231_zmzlKl8AKpB6" style="width: 16%; text-align: right" title="Nonvested options, beginning balance">548,807</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230101__20231231_zLL1lpY9o7f9" title="Weighted Average Grant Date Fair Value, Nonvested options beginning balance">0.05</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Forfeited/cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_di_c20230101__20231231_z1LWtL0OtIec" style="text-align: right" title="Nonvested options, forfeited/cancelled">(1,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_c20230101__20231231_za3PKTEOA656" title="Weighted Average Grant Date Fair Value, forfeited/cancelled">0.03</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Vested </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20230101__20231231_zQjkNmhYFod6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Nonvested options, vested">(547,807</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20230101__20231231_zQU51rgoOUwg" title="Weighted Average Grant Date Fair Value, vested">0.04</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_z4nBVHqtB43" style="text-align: right" title="Nonvested options, granted">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231_zGDyVXPqTsT1" title="Weighted Average Grant Date Fair Value, granted">0.05</td><td style="text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedNumberOfShares_iN_di_c20220101__20221231_zVmunm4leJsg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Nonvested options, exercised">(73,700</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue_c20220101__20221231_zUY0fuE8d561" title="Weighted Average Grant Date Fair Value, vested">0.03</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Nonvested options at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20230101__20231231_zTRq6Onrne4b" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested options, ending balance">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230101__20231231_zCeupfRiduQ2" title="Weighted Average Grant Date Fair Value, Nonvested optionsending balance">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Nonvested Options</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Weighted Average Grant Date Fair Value</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%">Nonvested options at December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20220101__20221231_zs2kP4ybJVZk" style="width: 16%; text-align: right" title="Nonvested options, beginning balance">656,742</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20221231_zC4U4ehk35h9" title="Weighted Average Grant Date Fair Value, Nonvested options beginning balance">0.04</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zWPKdf2UNwxj" style="text-align: right" title="Nonvested options, granted">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231_zC6bjIBJzR4g" title="Weighted Average Grant Date Fair Value, granted">0.05</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20220101__20221231_zX8ksqLH7wn5" style="text-align: right" title="Nonvested options, vested">(84,235</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20220101__20221231_zadecr7JB1Lb" title="Weighted Average Grant Date Fair Value, vested">0.04</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedNumberOfShares_iN_di_c20220101__20221231_zO8gLuRvRid" style="border-bottom: Black 1.5pt solid; text-align: right" title="Nonvested options, exercised">(73,700</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue_c20220101__20221231_zlF5U37rIyoj" title="Weighted Average Grant Date Fair Value, vested">0.03</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Nonvested options at December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20220101__20221231_zAgYPb9F5ujj" style="border-bottom: Black 2.5pt double; text-align: right" title="Nonvested options, ending balance">548,807</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20220101__20221231_zkVjjdG7v2Id" title="Weighted Average Grant Date Fair Value, Nonvested optionsending balance">0.05</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

548807

0.05

1000

0.03

547807

0.04

50000

0.05

73700 0.03

656742

0.04

50000

0.05

84235

0.04

73700 0.03

548807

0.05

Note 12 - Stock Warrants Grants Warrants for <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--RedeemableConvertiblePreferredStockSeriesAFiveMember_zhKryRdCtr2f" title="Warrants granted">117,903 Series A-5 Preferred Stock were granted during the year ended December 31, 2023 pursuant to the conversion of the promissory notes as described in Note 15. <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_do_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--RedeemableConvertiblePreferredStockSeriesAFiveMember_zzyhQwecM4s1" title="Warrants granted">No warrants were granted during the year ended December 31, 2022. The warrants contain both put and call options. The Company may call the warrants at any time following the date the warrants become exercisable. Warrants issued prior to 2023 are accounted for as a liability and remeasured to fair value at each reporting period. The liability as of December 31, 2023 and 2022 was $0 and $1,076,766, respectively. The warrants issued in 2023 with a fair value of $175,355 are accounted for as equity pursuant to FASB ASC 815 as they were issued in connection with the conversion of promissory notes to equity. Vesting and Exercisability The warrants vest immediately upon grant. All outstanding warrants at December 31, 2023 are exercisable at any time prior to close of business on December 31, 2024. Valuation and Expense <p id="xdx_892_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z8V2HTZp4sda" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company estimates the fair value of warrants using the Black-Scholes-Merton pricing model with the following assumptions at the reporting date: Schedule of Fair Value of Warrants <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">December 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"> </td><td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Liability Classified</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"> </td><td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Equity Classified</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"> </td><td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Liability Classified</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Expected volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zzAG2sIkAaS3" title="Liability classified measurement input, minimum">97-<span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zCoOdvgj9fg3" title="Liability classified measurement input, maximum">98</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFRsX145Arwk" title="Equity classified measurement input">99</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBn9t3BZYgm5" title="Derivative liability measurement input">89</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_ecustom--DerivativeLiabilityMeasurementTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ze4GayqUOYva" title="Liability classified measurement input term">0.3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaKPnYgFkU4i" title="Equity classified measurement input term">1.5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_ecustom--DerivativeLiabilityMeasurementTerm_iI_dtY_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zZHQcrsfUQWa" title="Liability classified measurement input, term minimum">1.0 - <span id="xdx_907_ecustom--DerivativeLiabilityMeasurementTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zEYZe2yeelde" title="Liability classified measurement input, term maximum">1.5</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zP9lBye4JzIc" title="Liability classified measurement input, minimum">5.26-<span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zxiZzWcoTwAc" title="Liability classified measurement input, maximum">5.60</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dt_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHvKgUudcdt4" title="Equity classified measurement input">5.09</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z004UjTKJaQ7" title="Liability classified measurement input, minimum">4.41% - <span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z6i9k42bk0Y1" title="Liability classified measurement input, maximum">4.73</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zS8bIf0gW9Bc" title="Liability classified measurement input">0.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dt_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRCvXSm3WM73" title="Equity classified measurement input">0.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7M0UDGuBKj9" title="Liability classified measurement input">0.00</td><td style="text-align: left">%</td></tr> </table> Expected volatility is estimated using the historical volatility of comparable public entities. The Company estimates the expected term using historical option exercise data to determine the expected employee exercise behavior. The risk-free interest rate is the yield on a U.S. Treasury zero-coupon issue with a remaining term equal to or approximating the expected term of the option at the grant date. Related to the warrants, the Company recorded a benefit of $1,076,766 due to the decrease in the liability and an expense of $124,118 due to the increase in the liability during the years ended December 31, 2023 and 2022, respectively. Details of stock warrant activity for the years ended December 31, 2023 and 2022, are as follows: Schedule of Stock Warrant Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Number of Warrants – Liability Classified</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Number of Warrants – Equity Classified</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Weighted Average Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; padding-bottom: 1.5pt">Outstanding at December 31, 2021</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_986_ecustom--ClassOfWarrantLiabilityClassified_iS_c20220101__20221231_zO50lgJV3hQb" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Number of Warrants - Liability Classified Outstanding">367,015</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20220101__20221231_zFQAtJltnM6j" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Number of Warrants - Equity Classified Outstanding">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20220101__20221231_zCvM8m4VUEY" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Weighted Average Exercise Price Outstanding">20.00</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Granted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--WarrantsLiabilityClassifiedGranted_c20220101__20221231_zU01L2FLt6k" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants - Liability Classified Granted">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--WarrantsEquityClassifiedGranted_c20220101__20221231_zyTn6BBLEjrk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants - Liability Classified Granted">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted_c20220101__20221231_zbis5Vb9shO7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Outstanding">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Outstanding at December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--ClassOfWarrantLiabilityClassified_iS_c20230101__20231231_zqqQ23aw7CQc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants - Liability Classified Outstanding">367,015</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20230101__20231231_zuznBwIM0RC8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants - Equity Classified Outstanding">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20230101__20231231_zELQHAg32Ih8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Outstanding">20.00</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Granted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_ecustom--WarrantsLiabilityClassifiedGranted_c20230101__20231231_zO8ZACMzjWHi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants - Liability Classified Granted">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_ecustom--WarrantsEquityClassifiedGranted_c20230101__20231231_zTDfh0t8mecl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants - Liability Classified Granted">117,903</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted_c20230101__20231231_zPej9vVlam6l" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Outstanding">20.00</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_ecustom--ClassOfWarrantLiabilityClassified_iE_c20230101__20231231_zI0iYfkwazr" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants - Liability Classified Outstanding">367,015</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20230101__20231231_zG0gCrgk7Eq6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants - Equity Classified Outstanding">117,903</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20230101__20231231_zTMTyKxJrHai" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding">20.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> All warrants expire on December 31, 2024. Remaining weighted average contractual life at December 31, 2023 was one year. SERINA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 2023 AND 2022

117903

1076766

175355

<p id="xdx_892_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z8V2HTZp4sda" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company estimates the fair value of warrants using the Black-Scholes-Merton pricing model with the following assumptions at the reporting date: Schedule of Fair Value of Warrants <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">December 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"> </td><td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Liability Classified</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"> </td><td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Equity Classified</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"> </td><td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Liability Classified</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Expected volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zzAG2sIkAaS3" title="Liability classified measurement input, minimum">97-<span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zCoOdvgj9fg3" title="Liability classified measurement input, maximum">98</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFRsX145Arwk" title="Equity classified measurement input">99</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBn9t3BZYgm5" title="Derivative liability measurement input">89</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_ecustom--DerivativeLiabilityMeasurementTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ze4GayqUOYva" title="Liability classified measurement input term">0.3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaKPnYgFkU4i" title="Equity classified measurement input term">1.5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_ecustom--DerivativeLiabilityMeasurementTerm_iI_dtY_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zZHQcrsfUQWa" title="Liability classified measurement input, term minimum">1.0 - <span id="xdx_907_ecustom--DerivativeLiabilityMeasurementTerm_iI_dtY_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zEYZe2yeelde" title="Liability classified measurement input, term maximum">1.5</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zP9lBye4JzIc" title="Liability classified measurement input, minimum">5.26-<span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zxiZzWcoTwAc" title="Liability classified measurement input, maximum">5.60</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dt_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHvKgUudcdt4" title="Equity classified measurement input">5.09</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z004UjTKJaQ7" title="Liability classified measurement input, minimum">4.41% - <span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z6i9k42bk0Y1" title="Liability classified measurement input, maximum">4.73</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zS8bIf0gW9Bc" title="Liability classified measurement input">0.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dt_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRCvXSm3WM73" title="Equity classified measurement input">0.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7M0UDGuBKj9" title="Liability classified measurement input">0.00</td><td style="text-align: left">%</td></tr> </table>

P0Y3M18D

P1Y6M

P1Y P1Y6M

5.26

5.60

5.09

4.41

4.73

0.00

-1076766

124118

Details of stock warrant activity for the years ended December 31, 2023 and 2022, are as follows: Schedule of Stock Warrant Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Number of Warrants – Liability Classified</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Number of Warrants – Equity Classified</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">Weighted Average Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; padding-bottom: 1.5pt">Outstanding at December 31, 2021</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_986_ecustom--ClassOfWarrantLiabilityClassified_iS_c20220101__20221231_zO50lgJV3hQb" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Number of Warrants - Liability Classified Outstanding">367,015</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20220101__20221231_zFQAtJltnM6j" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Number of Warrants - Equity Classified Outstanding">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20220101__20221231_zCvM8m4VUEY" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Weighted Average Exercise Price Outstanding">20.00</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Granted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--WarrantsLiabilityClassifiedGranted_c20220101__20221231_zU01L2FLt6k" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants - Liability Classified Granted">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--WarrantsEquityClassifiedGranted_c20220101__20221231_zyTn6BBLEjrk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants - Liability Classified Granted">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted_c20220101__20221231_zbis5Vb9shO7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Outstanding">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Outstanding at December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--ClassOfWarrantLiabilityClassified_iS_c20230101__20231231_zqqQ23aw7CQc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants - Liability Classified Outstanding">367,015</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20230101__20231231_zuznBwIM0RC8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants - Equity Classified Outstanding">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20230101__20231231_zELQHAg32Ih8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Outstanding">20.00</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Granted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_ecustom--WarrantsLiabilityClassifiedGranted_c20230101__20231231_zO8ZACMzjWHi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants - Liability Classified Granted">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_ecustom--WarrantsEquityClassifiedGranted_c20230101__20231231_zTDfh0t8mecl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants - Liability Classified Granted">117,903</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted_c20230101__20231231_zPej9vVlam6l" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Outstanding">20.00</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_ecustom--ClassOfWarrantLiabilityClassified_iE_c20230101__20231231_zI0iYfkwazr" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants - Liability Classified Outstanding">367,015</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20230101__20231231_zG0gCrgk7Eq6" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants - Equity Classified Outstanding">117,903</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20230101__20231231_zTMTyKxJrHai" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding">20.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

367015

20.00

367015

20.00

117903 20.00 367015

117903

20.00

2024-12-31

P1Y

Note 13 - Research and Development During the year ended December 31, 2023, the Company performed under a grant provided by a corporation via funding provided by a federal government agency to continue its research and development related to treatment of neurological disorders and strokes. The grant is structured such that the Company received $245,000 upon execution of the award in August 2022 which is recognized as revenue as eligible costs are incurred. The Company has recognized all $245,000 of eligible costs and substantially completed the grant performance as of December 31, 2023.

245000

Note 14 - Commitments and Contingencies The Company is subject to legal proceedings, claims, and litigation arising in the ordinary course of business. In the opinion of management, all such matters would be adequately covered by insurance or accruals or would be such that disposition would not have a material adverse effect on the financial position, results of operations, or cash flows of the Company.

Note 15 - Convertible Promissory Notes On March 15, 2023, The Company issued a convertible promissory note (the “AgeX-Serina Note”) in the amount of $10,000,000 to AgeX Therapeutics (“AgeX”). The AgeX-Serina Note bears interest at <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230315__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zjGqZBAMqLS3" title="Debt instrument, interest rate">7% per annum and matures on March 15, 2026. The Company issued the AgeX-Serina Note to provide for general working capital needs. As described in Note 17, the Company and AgeX have entered into a merger agreement. In connection with the issuance of the AgeX-Serina Note, AgeX is entitled to elect one member to the board of directors of the Company and receive certain information and inspection rights as well as participation rights for subsequent equity issuances. The AgeX-Serina Note has various conversion options. <span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleTermsOfConversionFeature_c20230315__20230315__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zCzJLV5sghM4" title="Debt instrument, convertible terms of conversion feature">The principal balance of the AgeX-Serina Note with accrued interest will automatically convert into the Company’s preferred stock if the Company raises at least $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20230315__20230315__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zKTi3QYuPUzb" title="Proceeds from issuance of preferred Stock">25,000,000 through the sale of shares of the Company’s preferred stock. The conversion price per share shall be the lower of (a) <span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionRatio1_pid_dp_uPure_c20230315__20230315__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zYPfkQsUldo5" title="Debt instrument, conversion percentage">80% of the lowest price at which the shares of preferred stock were sold, and (b) a “capped price” equal to $105,000,000 divided by the Company’s then fully diluted capitalization. AgeX has the option to convert the AgeX-Serina Note into the Company’s preferred stock after a sale of the Company’s preferred stock regardless of the amount sold by the Company. AgeX may (i) at its election, upon a change of control (as defined in the AgeX-Serina Note), convert the AgeX-Serina Note in whole or in part into either (a) cash in an amount equal to 100% of the outstanding principal amount of the AgeX-Serina Note, plus interest, or (b) into the highest ranking shares of the Company then issued at a conversion price equal to the lowest price per share at which the most senior series of the Company’s shares has been sold in a single transaction or a series of related transactions through which the Company raised at least $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20230315__20230315__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__srt--RangeAxis__srt--MinimumMember_zC1TE2MQA3jf" title="Proceeds from issuance of preferred Stock">5,000,000 or (ii) if the AgeX-Serina Note remains outstanding as of the maturity date, AgeX may convert the AgeX-Serina Note into the most senior shares of the Company issued at the time of conversion at a conversion price equal to the capped price. Upon the consummation of a merger between the Company and AgeX, the AgeX-Serina Note would remain outstanding and become an intercompany asset of AgeX and an intercompany liability of the Company. The Company evaluated the AgeX-Serina Note in accordance with ASC Topic 815, Derivatives and Hedging, and determined it contains certain variable share settlement features tied to the price of a future financing which were not considered clearly and closely related to the host instruments. These provisions included automatic conversion upon the event of a Qualified Financing, the Holder’s option to convert the AgeX-Serina Note upon a Non-Qualified Financing, and the Holder’s option to convert or request repayment upon sale of the Company. The AgeX-Serina Note also contains a Change in Control Put and a Default Put which were not clearly and closely related to the host instrument. The Company elected to initially and subsequently measure the AgeX-Serina Note in its entirety at fair value, with changes in fair value recognized in earnings. The fair value inception date adjustment on the instrument is recorded as a component of other income in the Company’s statements of operations. SERINA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 2023 AND 2022 The change in fair value of the instrument since inception date is recorded on a separate line item as a component of other income in the Company’s statements of operations. FASB ASC 825-10-25 allows the Company to elect the fair value option for recording financial instruments when they are initially recognized or if there is an event that requires re-measurement of the instruments at fair value, such as a significant modification of the debt. The Company elected the fair value option because they believed it to be the most appropriate method of encompassing the credit risk and exercise behavior that a market participant would consider when valuing the hybrid financial instrument. As of March 15, 2023 (inception), the outstanding principal on the AgeX-Serina Note was approximately $10,000,000 and the fair value recorded on the balance sheet was $7,760,000. From March 15, 2023 to December 31, 2023, the change in value was approximately $<span id="xdx_904_ecustom--ChangeInFairValueOfConvertiblePromissoryNotes_c20230315__20231231__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zjJSCPJH9ILg" title="Proceeds from issuance of preferred Stock">4,780,000 and was recorded as a component of other income in the Company’s statements of operations. From June through December 2022, the Company issued interest-bearing Convertible Promissory Notes (the “Serina Convertible Notes”) to various investors in the principal amount of $1,350,000. In February 2023, the Company issued a Serina Convertible Note to an investor in the principal amount of $100,000. In addition, on November 10, 2022, The Company issued a Convertible Promissory Note to a related party investor in the principal amount of $3,650,000 which was repaid in full on December 14, 2022. The Serina Convertible Notes incur interest at <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20231110__us-gaap--DebtInstrumentAxis__custom--IssuedInterestBearingConvertiblePromissoryNotesMember_zN9RoDdvmsRf" title="Debt instrument, interest rate">6% per annum and are payable by the Company two years from their issuance date. The Company may not voluntarily prepay the Serina Convertible Notes. Upon a Qualified Equity Financing event in which the Company sells shares of Preferred Stock for aggregate proceeds of at least $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20220601__20221231__us-gaap--DebtInstrumentAxis__custom--IssuedInterestBearingConvertiblePromissoryNotesMember__srt--RangeAxis__srt--MinimumMember_zYyjnNR7lWC6" title="Proceeds from issuance of preferred Stock">15 million, the principal and outstanding interest on the Serina Convertible Notes will automatically convert into shares of the Company’s <span id="xdx_905_eus-gaap--DebtInstrumentConvertibleTermsOfConversionFeature_uPure_c20220601__20221231__us-gaap--DebtInstrumentAxis__custom--IssuedInterestBearingConvertiblePromissoryNotesMember_z8Ufuo1isxDd" title="Debt instrument, convertible terms of conversion feature">Preferred Stock issued in the Qualified Financing at a conversion price of the lesser of i) a <span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionRatio1_pid_dp_uPure_c20220601__20221231__us-gaap--DebtInstrumentAxis__custom--IssuedInterestBearingConvertiblePromissoryNotesMember_z5APqSL0fF2c" title="Debt conversion percentage">20% discount to the price paid by purchasers in the Qualified Financing and ii) the quotient resulted from dividing $100 million by the fully diluted capitalization of the Company immediately prior to the Qualified Financing. If the Company enters into a Non-Qualified Equity Financing (less than $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pn6n6_c20220601__20221231__us-gaap--DebtInstrumentAxis__custom--IssuedInterestBearingConvertiblePromissoryNotesMember__srt--RangeAxis__srt--MaximumMember_zQKZFenPOse7" title="Proceeds from issuance of preferred Stock">15 million in proceeds), the Holder has the option to convert the Serina Convertible Notes into shares of the Company’s Preferred Stock issued in the Non-Qualified Financing at the price paid per share. The Company may also choose to optionally convert the Serina Convertible Notes into Series A-5 Preferred Stock at a price of $13 per share, and a warrant to purchase shares of Series A-5 Preferred Stock with an exercise price of $<span id="xdx_909_eus-gaap--DebtInstrumentConvertibleStockPriceTrigger_pid_uUSDPShares_c20220601__20221231__us-gaap--DebtInstrumentAxis__custom--IssuedInterestBearingConvertiblePromissoryNotesMember_zFV1zwrHUqYb" title="Debt instrument, stock price">20.00, and an expiration date of December 31, 2024. If a Change in Control or an IPO occurs prior to a Qualified Financing, then the Holder has the option to convert outstanding principal and interest into common stock at a price per share equal to an amount obtained by dividing i) the Post-Money Valuation Cap ($100,000,000) by ii) the Fully Diluted Capitalization immediately prior to the conversion. Upon a change in control, the Holder may also elect to require the Company to repay the outstanding principal and accrued but unpaid interest in cash. The Company evaluated the Serina Convertible Notes in accordance with ASC Topic 815, Derivatives and Hedging, and determined they contained certain variable share settlement features tied to the price of a future financing which were not considered clearly and closely related to the host instruments. These provisions included mandatory conversion upon the event of a Qualified Financing and the Holder’s option to convert the Serina Convertible Notes upon a Non-Qualified Financing. The Serina Convertible Notes also contained a Change in Control Put and a Default Put which were not clearly and closely related to the host instrument. The Company elected to initially and subsequently measure the Serina Convertible Notes in their entirety at fair value, with changes in fair value recognized in earnings. The fair value inception date adjustment on the instrument is recorded as a component of other income in the Company’s statements of operations. The change in fair value of the instrument since inception date is recorded on a separate line item as a component of other income in the Company’s statements of operations. Because the Serina Convertible Notes are carried in their entirety at fair value, the value of the compound embedded conversion features and the redemption features are embodied in that fair value. The Company estimated the fair value of the hybrid instrument based on a probability weighted cash flow analysis. A Monte Carlo model, which considered the present value of the cash flows under the different scenarios using a credit risk adjusted rate, was considered by management to be the most appropriate method of encompassing credit risk and exercise behavior. Inputs used to value the hybrid instrument at inception (July 19, 2022) included, (i) present value of future cash flows using a credit risk adjusted rate of <span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20220719__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputEntityCreditRiskMember_zUl3WVFX9CR6" title="Debt instrument, measurement input">16%, (ii) remaining term of approximately 2 years, (iii) volatility of <span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20220719__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z2gkc7qSpEP5" title="Debt instrument, measurement input">90% based on the volatility of comparable guideline public companies, (iv) closing stock price on the valuation date, and (v) <span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20220719__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityMember_zGf4y861YZNc" title="Debt instrument, measurement input">70% probability the Serina Convertible Notes will be converted upon a Non-Qualified Financing, at the expected price of the Non-Qualified Financing, and <span id="xdx_905_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20220719__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityMember__us-gaap--AwardTypeAxis__custom--NonQualifiedFinancingMember_zz0T4ooBGi6j" title="Debt instrument, measurement input">30% probability the Serina Convertible Notes will be optionally converted at their stated conversion price ($<span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20220719__us-gaap--AwardTypeAxis__custom--NonQualifiedFinancingMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember_ziWTNQz6o50a" title="Debt instrument, conversion price">13 per share plus one warrant). SERINA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 2023 AND 2022 Management expects the probability of a change in control, default, or Qualified Financing event occurring over the remaining term of the Serina Convertible Notes to be minimal. However, this assumption will be considered each reporting period. Material changes due to instrument-specific credit risk are recorded in Other Comprehensive Income with all other changes in value being recorded in net income. For the year ended December 31, 2023, interest expense associated with the convertible notes was approximately $558,082. On July 26, 2023, all of the Convertible Promissory Notes described in this Note (excluding the AgeX-Serina Note) previously issued for a total principal amount of $1,450,000 and accrued interest of $82,695 were converted to <span id="xdx_90E_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20230726__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAFivePreferredStockMember_zCkpGIeySJM6" title="Conversion of preferred stock">117,903 shares of Series A-5 Preferred Stock. In accordance with FASB ASC 470, upon conversion, the carrying value of the debt, $<span id="xdx_908_eus-gaap--DebtInstrumentCarryingAmount_iI_c20230726__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAFivePreferredStockMember_zJaRkcSt8lSd" title="Carrying value of debt">962,584, was recognized in the Series A-5 Preferred Stock balance. As provided for in the note agreements, the holders of the notes also received warrants to purchase an additional <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230726__us-gaap--DebtInstrumentAxis__custom--ConvertibleNotesMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAFivePreferredStockMember_zNLtMTiy14Sj" title="Warrants to purchase preferred stock">117,903 shares of Series A-5 Preferred Stock (See Note 12).

10000000

0.07

The principal balance of the AgeX-Serina Note with accrued interest will automatically convert into the Company’s preferred stock if the Company raises at least $25,000,000 through the sale of shares of the Company’s preferred stock. The conversion price per share shall be the lower of (a) 80% of the lowest price at which the shares of preferred stock were sold, and (b) a “capped price” equal to $105,000,000 divided by the Company’s then fully diluted capitalization. AgeX has the option to convert the AgeX-Serina Note into the Company’s preferred stock after a sale of the Company’s preferred stock regardless of the amount sold by the Company. AgeX may (i) at its election, upon a change of control (as defined in the AgeX-Serina Note), convert the AgeX-Serina Note in whole or in part into either (a) cash in an amount equal to 100% of the outstanding principal amount of the AgeX-Serina Note, plus interest, or (b) into the highest ranking shares of the Company then issued at a conversion price equal to the lowest price per share at which the most senior series of the Company’s shares has been sold in a single transaction or a series of related transactions through which the Company raised at least $5,000,000 or (ii) if the AgeX-Serina Note remains outstanding as of the maturity date, AgeX may convert the AgeX-Serina Note into the most senior shares of the Company issued at the time of conversion at a conversion price equal to the capped price.

25000000

0.80

105000000

5000000

10000000

7760000

4780000

1350000

100000

3650000

0.06

Preferred Stock issued in the Qualified Financing at a conversion price of the lesser of i) a 20% discount to the price paid by purchasers in the Qualified Financing and ii) the quotient resulted from dividing $100 million by the fully diluted capitalization of the Company immediately prior to the Qualified Financing. If the Company enters into a Non-Qualified Equity Financing (less than $15 million in proceeds), the Holder has the option to convert the Serina Convertible Notes into shares of the Company’s Preferred Stock issued in the Non-Qualified Financing at the price paid per share. The Company may also choose to optionally convert the Serina Convertible Notes into Series A-5 Preferred Stock at a price of $13 per share, and a warrant to purchase shares of Series A-5 Preferred Stock with an exercise price of $20.00, and an expiration date of December 31, 2024. If a Change in Control or an IPO occurs prior to a Qualified Financing, then the Holder has the option to convert outstanding principal and interest into common stock at a price per share equal to an amount obtained by dividing i) the Post-Money Valuation Cap ($100,000,000) by ii) the Fully Diluted Capitalization immediately prior to the conversion.

0.20

100000000

15000000

20.00

100000000

P2Y

558082

1450000

82695

117903

962584

117903

Note 16 - Net Earnings (Loss) Per Common Share Net earnings (loss) per common share is calculated in accordance with ASC 260, Earnings Per Share. Basic and diluted net earnings (loss) per common share attributable to common shareholders is calculated as follows for the years ended December 31, 2023 and 2022: Schedule of Basic and Diluted Net Earnings (Loss) Per Common Share Attributable to Common Shareholders <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_498_20230101__20231231_zxbMV40rbYs7" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_49D_20220101__20221231_zDBNlYZJViBl" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Basic net earnings (loss) per common share allocable to common shareholders</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>NUMERATOR</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--NetIncomeLoss_maNILATzEYV_zvMRHoEG2Z8i" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Net income (loss)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,269,854</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(2,682,108</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_msNILATzEYV_ziBhdSXpORu5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less: net earnings allocable to participating securities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_mtNILATzEYV_zMqzuXSRc4jj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Net earnings (loss) allocable to common shareholders</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,269,854</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,682,108</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>DENOMINATOR</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zzA2QoW1FCB4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Weighted-average shares of common stock outstanding used to calculate basic net earnings (loss) per common share</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,288,377</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,145,002</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--EarningsPerShareBasic_z3MMBBrvAUt9" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Basic net earnings (loss) per common share allocable to common shareholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2.30</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.25</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Diluted net earnings (loss) per common share allocable to common shareholders</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>NUMERATOR </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_maNILATz77l_zqodzOcfFyik" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Net earnings (loss) allocable to common shareholders</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5,269,854</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(2,682,108</td><td style="text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--InterestOnConvertibleDebtNetOfTax_maNILATz77l_zT3822ffzzfc" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Add back: interest on convertible promissory notes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">558,082</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_iT_mtNILATz77l_zdZY7wV54sr7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 30pt; text-align: left; padding-bottom: 1.5pt">Net earnings (loss) allocable to common shareholders</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,827,936</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,682,108</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>DENOMINATOR</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zv4JcoF9V5Ge" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt">Weighted-average shares of common stock outstanding used to calculate basic net earnings (loss) per common share </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,288,377</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,145,002</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_zIHJwwGpc5u" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Add: dilutive effect of stock options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,716,695</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_zqdYWBZps7E9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Add: dilutive effect of warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--IncrementalCommonSharesAttributableToConversionOfDebtSecurities_zcjSpWBHj0D" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Add: dilutive effect of common stock issued for convertible promissory notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--IncrementalCommonSharesAttributableToConversionOfPreferredStock_zvokutEtXN9e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 30pt; text-align: left">Add: dilutive effect of redeemable convertible preferred stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zkKX0VldHc48" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 30pt; text-align: left; padding-bottom: 1.5pt">Weighted-average shares of common stock outstanding used to calculate diluted net earnings (loss) per common share</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,005,072</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,145,002</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--EarningsPerShareDiluted_zRJQFWPcHkT" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 30pt; padding-bottom: 2.5pt">Diluted net earnings (loss) per common share attributable to common shareholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1.46</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.25</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> SERINA THERAPEUTICS, INC. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 2023 AND 2022 <p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zWSoFRtKbOCc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net earnings (loss) per common share for the years ended December 31, 2023 and 2022 because to do so would be anti-dilutive: Schedule of Diluted Net Earnings (loss) Per Common Share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 65%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20230101__20231231_z2YnU75hFXil" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20220101__20221231_z86r0x4sEQfi" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zUilnBbbwkL" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Redeemable convertible preferred stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">3,402,225</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zdDvwEcMaEw9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Convertible promissory notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">220,008</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z5yW0IzLsFDf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Stock options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,012,750</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zp0lsHMxwAzj" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">484,918</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">367,015</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zJtgMvJ1uiU8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total anti-dilutive securities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">484,918</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">6,001,998</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

Net earnings (loss) per common share is calculated in accordance with ASC 260, Earnings Per Share. Basic and diluted net earnings (loss) per common share attributable to common shareholders is calculated as follows for the years ended December 31, 2023 and 2022: Schedule of Basic and Diluted Net Earnings (Loss) Per Common Share Attributable to Common Shareholders <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_498_20230101__20231231_zxbMV40rbYs7" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td> <td colspan="2" id="xdx_49D_20220101__20221231_zDBNlYZJViBl" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Basic net earnings (loss) per common share allocable to common shareholders</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>NUMERATOR</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--NetIncomeLoss_maNILATzEYV_zvMRHoEG2Z8i" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Net income (loss)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,269,854</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(2,682,108</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_msNILATzEYV_ziBhdSXpORu5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less: net earnings allocable to participating securities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_mtNILATzEYV_zMqzuXSRc4jj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Net earnings (loss) allocable to common shareholders</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,269,854</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,682,108</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>DENOMINATOR</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zzA2QoW1FCB4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Weighted-average shares of common stock outstanding used to calculate basic net earnings (loss) per common share</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,288,377</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,145,002</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--EarningsPerShareBasic_z3MMBBrvAUt9" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Basic net earnings (loss) per common share allocable to common shareholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2.30</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.25</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Diluted net earnings (loss) per common share allocable to common shareholders</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>NUMERATOR </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_maNILATz77l_zqodzOcfFyik" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Net earnings (loss) allocable to common shareholders</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5,269,854</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(2,682,108</td><td style="text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--InterestOnConvertibleDebtNetOfTax_maNILATz77l_zT3822ffzzfc" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Add back: interest on convertible promissory notes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">558,082</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_iT_mtNILATz77l_zdZY7wV54sr7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 30pt; text-align: left; padding-bottom: 1.5pt">Net earnings (loss) allocable to common shareholders</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,827,936</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,682,108</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>DENOMINATOR</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zv4JcoF9V5Ge" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt">Weighted-average shares of common stock outstanding used to calculate basic net earnings (loss) per common share </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,288,377</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,145,002</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_zIHJwwGpc5u" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Add: dilutive effect of stock options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,716,695</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_zqdYWBZps7E9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Add: dilutive effect of warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--IncrementalCommonSharesAttributableToConversionOfDebtSecurities_zcjSpWBHj0D" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Add: dilutive effect of common stock issued for convertible promissory notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--IncrementalCommonSharesAttributableToConversionOfPreferredStock_zvokutEtXN9e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 30pt; text-align: left">Add: dilutive effect of redeemable convertible preferred stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zkKX0VldHc48" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 30pt; text-align: left; padding-bottom: 1.5pt">Weighted-average shares of common stock outstanding used to calculate diluted net earnings (loss) per common share</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,005,072</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,145,002</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--EarningsPerShareDiluted_zRJQFWPcHkT" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 30pt; padding-bottom: 2.5pt">Diluted net earnings (loss) per common share attributable to common shareholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1.46</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1.25</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

5269854

-2682108

5269854

-2682108

2288377

2145002

2.30

-1.25

5269854

-2682108

558082

5827936

-2682108

2288377

2145002

1716695

4005072

2145002

1.46

-1.25

<p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zWSoFRtKbOCc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net earnings (loss) per common share for the years ended December 31, 2023 and 2022 because to do so would be anti-dilutive: Schedule of Diluted Net Earnings (loss) Per Common Share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 65%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20230101__20231231_z2YnU75hFXil" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20220101__20221231_z86r0x4sEQfi" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RedeemableConvertiblePreferredStockMember_zUilnBbbwkL" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Redeemable convertible preferred stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">3,402,225</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zdDvwEcMaEw9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Convertible promissory notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">220,008</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z5yW0IzLsFDf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Stock options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,012,750</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zp0lsHMxwAzj" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">484,918</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">367,015</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zJtgMvJ1uiU8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total anti-dilutive securities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">484,918</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">6,001,998</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

3402225

220008

2012750

484918

367015

484918

6001998

Note 17 - Merger Agreement On August 29, 2023, the Company entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with AgeX Therapeutics, Inc. and Canaria Transaction Corporation, an Alabama corporation and wholly owned subsidiary of AgeX (“Merger Sub”). Upon the terms and subject to the satisfaction of the conditions described in the Merger Agreement, including that the Merger is approved by the stockholders of AgeX and the stockholders of Serina, Merger Sub will be merged with and into Serina, with Serina surviving as a wholly owned subsidiary of AgeX (the “Merger”). There is no assurance the necessary approvals by AgeX stockholders and Serina stockholders will be obtained or that the other conditions to the Merger as provided in the Merger Agreement will be met. Immediately following the Merger, equity holders of Serina immediately prior to the closing of the Merger are expected to own approximately <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_uPure_c20230829__20230829__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_zlSLjckogHvk" title="Common stock percentage">75% of the outstanding shares of common stock of the combined company, and stockholders of AgeX immediately prior to the closing of the Merger are expected to own, excluding the impact of the exercise of any of the Post-Merger Warrants or Incentive Warrants described below, approximately <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_uPure_c20230829__20230829__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__srt--ConsolidatedEntitiesAxis__custom--PostMergerWarrantsMember_zsvopr4jXzj7" title="Common stock percentage">25% of the outstanding shares of common stock of the combined company, in each case, on a fully diluted basis, subject to certain assumptions, including giving effect to a planned reverse stock split and the conversion of AgeX Preferred Stock into shares of AgeX common stock. Prior to the closing of the Merger, AgeX will issue to each holder of AgeX common stock three warrants (“Post-Merger Warrants”) for each five shares of AgeX common stock held by such stockholder. Each Post-Merger Warrant will be exercisable for one unit of AgeX (“AgeX Unit”) at a price equal to $13.20 (post-reverse split) and will expire on July 31, 2025. Each AgeX Unit will consist of (i) one share of AgeX common stock and (ii) one warrant (“Incentive Warrant”). Each Incentive Warrant will be exercisable for one share of AgeX common stock at a price equal to $18.00 (post reverse split) and will expire on the four-year anniversary of the closing date of the Merger. The terms of each Post-Merger Warrant and Incentive Warrant will be further detailed in the forms of warrant agreements that will be negotiated between the parties prior to the closing of the Merger.

0.75

0.25

13.20

18.00

Note 18 – Subsequent Events Management has evaluated subsequent events through March 21, 2024, the date the financial statements were issued. In February 2024, the U.S. Securities and Exchange Commission accepted the S-4/S-1 registration statement filing related to the proposed merger described in Note 17.

345000

645000

57000

4000

352000

1804000

754000

2453000

50000

607000

738000

10554000

11965000

3241000

2176000

1034000

3672000

7646000

66000

141000

180000 1077000

5914000

10078000

693000

10478000

6607000

20556000

0.0001

5000000

100

212000

100

148000

0.0001

200000000

1079000

136482000

98998000

-131013000

-116210000

5469000

-17212000

-111000

-103000

5358000

-17315000

11965000

3241000

77000

65000

34000

142000

34000

40000

13000

102000

21000

734000

1025000

9328000

5971000

10062000

6996000

73000

-9887000

-6975000

4900000

3335000

35000

225000

11000

13000

-4924000

-3547000

-14811000

-10522000

-8000

-60000

-14803000

-10462000

-13.72

-9.70

1079

93916000

-105748000

-43000

-11875000

-4000

178000

4148000

760000

-10462000

-60000

-10522000

1079

98998000

-116210000

-103000

-17315000

1079

98998000

-116210000

-103000

-17315000

212

148

35958000

-1000

879000

648000

-14803000

-8000

-14811000

212

148

1079

136482000

-131013000

-111000

5358000

212

148

1079

136482000

-131013000

-111000

5358000

-14803000

-10462000

-8000

-60000

35000

225000

131000

132000

5285000

3137000

648000

760000

73000

360000

53000

-21000

-1092000

-896000

554000

1150000

144000

69000

255000

-1075000

-983000

-4000

-7800000

-5939000

10000000

-10000000

17500000

6000000

17500000

6000000

-300000

61000

695000

634000

395000

695000

27000

14000

36000000

2000

8000

178000 663000 4148000 7160000

<p id="xdx_809_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z5SH9cbZtKa3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">1. Organization, Basis of Presentation and Liquidity AgeX Therapeutics, Inc. (“AgeX,” “we,” “our,” or “us”) was incorporated in January 2017 in the state of Delaware. AgeX is a biotechnology company focused on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. AgeX’s mission is to apply its comprehensive experience in fundamental biological processes of human aging to a broad range of age-associated medical conditions. AgeX’s proprietary technology, based on telomerase-mediated cellular immortality and regenerative biology, allows AgeX to utilize telomerase-expressing regenerative pluripotent stem cells (“PSCs”) for the manufacture of cell-based therapies to regenerate tissues afflicted with age-related chronic degenerative disease. AgeX’s main technology platforms and product candidates are as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">PureStem® PSC-derived clonal embryonic progenitor cell lines that may be capable of generating a broad range of cell types for use in cell-based therapies;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">UniverCyte™ which uses the HLA-G gene to suppress rejection of transplanted cells and tissues to confer low immune observability to cells;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">AGEX-BAT1 using adipose brown fat cells for metabolic diseases such as Type II diabetes;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">AGEX-VASC1 using vascular progenitor cells to treat tissue ischemia; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Induced tissue regeneration or iTR technology to regenerate or rejuvenate cells to treat a variety of degenerative diseases including those associated with aging, as well as other potential tissue regeneration applications such as scarless wound repair.</td></tr> </table> AgeX is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012. Reverse Stock Split On March 14, 2024 AgeX effected a reverse stock split of its common stock at a ratio of 1 for 35.17 (the “Reverse Stock Split”) resulting in approximately 2,500,000 shares of AgeX common stock being outstanding immediately upon the Reverse Stock Split. Except for the number of authorized but unissued shares of AgeX common stock, and except as may be otherwise stated in these notes to financial statements, numbers of shares of AgeX common stock issued and outstanding, or issuable upon the exercise of options or warrants or upon conversion of convertible indebtedness, and AgeX common stock prices, shown in the consolidated financial statements and these notes thereto have been retroactively adjusted to reflect the effect of the Reverse Stock Split. See Note 11, Subsequent Events. Merger Agreement and Certain Transactions with Serina Therapeutics, Inc. During March 2023, AgeX borrowed $10,000,000 from Juvenescence Limited (“Juvenescence”) under the terms of a Secured Convertible Promissory Note (the “2023 Secured Note”) and used the loan proceeds to make a $10,000,000 loan to Serina Therapeutics, Inc. (“Serina”) under the terms of a Convertible Promissory Note to Serina (the “Serina Note”), in order to provide Serina with financing in advance of corporate restructuring plans that include a merger through which AgeX would acquire Serina. On August 29, 2023, AgeX entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Serina Therapeutics, Inc. (“Serina”), and Canaria Transaction Corporation, a wholly owned subsidiary of AgeX (“Merger Sub”). Upon the terms and subject to the satisfaction of the conditions described in the Merger Agreement, Merger Sub will be merged with and into Serina, with Serina surviving as a wholly owned subsidiary of AgeX (the “Merger”). At a special meeting of AgeX stockholders on March 14, 2024 (the “Special Meeting”), AgeX stockholders approved certain proposals required for consummation of the Merger pursuant to the terms of the Merger Agreement. Serina stockholders have also approved the Merger. There is no assurance that all conditions to the Merger will be met or waiver and that the Merger will be consummated. See Note 11, Subsequent Events. On March 19, 2024, AgeX issued to each holder of AgeX common stock as of the dividend record date, March 18, 2024, three warrants (“Post-Merger Warrants”) for each five shares of AgeX common stock held by such stockholder. Each Post-Merger Warrant will be exercisable for one unit of AgeX (“AgeX Unit”) at a price equal to $13.20 per unit and will expire on July 31, 2025. Each AgeX Unit will consist of (i) one share of AgeX common stock and (ii) one warrant (“Incentive Warrant”). Each Incentive Warrant will be exercisable for one share of AgeX common stock at a price equal to $18.00 per warrant and will expire on the four-year anniversary of the closing date of the Merger. See Note 11, Subsequent Events. <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20240101__20240331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zAx8jcRAjGO4" title="Share based compensation arrangement, description">Immediately following the Merger, equity holders of Serina immediately prior to the closing of the Merger are expected to own approximately 75% of the outstanding shares of common stock of AgeX, and stockholders of AgeX immediately prior to the closing of the Merger are expected to own approximately 25% of the outstanding shares of common stock of AgeX, with Serina as a wholly-owned subsidiary, in each case, on a pro forma fully diluted basis, subject to certain assumptions and exclusions, including the Actual Closing Price (as defined in the Merger Agreement) of AgeX common stock being equal to or greater than $12.00 per share excluding the impact of any Post-Merger Warrant, Incentive Warrant or the issuance of any shares of AgeX common stock upon exercise of any Post-Merger Warrants or Incentive Warrants. Concurrently with the execution of the Merger Agreement, AgeX, Serina, and AgeX’s controlling stockholder Juvenescence entered into a Side Letter, which will become effective immediately prior to the closing of the Merger. The Side Letter provides, among other things, that (i) effective immediately before the consummation of the Merger, Juvenescence will cancel all out of the money AgeX warrants held by Juvenescence; (ii) Juvenescence will exercise all Post-Merger Warrants it holds to provide the Combined Company an additional $15 million in capital according to the following schedule: (x) at least one-third on or before May 31, 2024, (y) at least one-third on or before November 30, 2024, and (z) at least one-third on or before June 30, 2025; (iii) Juvenescence will not sell any shares of AgeX Series A Preferred Stock or AgeX Series B Preferred Stock and will take all actions necessary to convert all of such Preferred Stock into AgeX common stock before a Reverse Stock Split that will occur before the Merger; (iv) Juvenescence will release all security interests, guarantees, pledges, assignments and other forms of collateral that it may have in AgeX’s assets pursuant to the terms of Juvenescence loans to AgeX; and (v) Juvenescence will consent to a newly formed subsidiary of AgeX assuming AgeX’s obligations with respect to loan agreements and promissory notes governing loans payable to Juvenescence, including obligations for amounts currently owed and future advances of loan funds, and Juvenescence shall release AgeX from those loan obligations. Juvenescence’s covenant regarding retaining ownership of and converting the Series A Preferred Stock and Series B Preferred Stock into AgeX common stock has been satisfied through the conversion of such preferred stock into AgeX common stock on February 1, 2024. Prior to the closing of the Merger, any assets of AgeX other than certain “Legacy Assets” will be transferred into a recently formed subsidiary of AgeX “UniverXome Bioengineering, Inc. (“UniverXome”). UniverXome will assume (i) any indebtedness of AgeX issued to Juvenescence that has not been previously converted into AgeX Series A Preferred Stock or AgeX Series B Preferred Stock, which will be secured by the Legacy Assets (ii) most of AgeX’s contracts with third parties, other than certain designated contracts and any contracts that are terminated before the Merger, and (iii) all other liabilities of AgeX in existence as of the effective time of the Merger (other than certain transaction expenses related to the Merger). See Note 11, Subsequent Events. Serina currently has a pipeline of small molecule candidates targeting central nervous system (“CNS”) indications, enabled by the company’s proprietary POZ PlatformTM delivery technology. In addition to advancing Serina’s wholly owned pipeline assets, Serina is working with pharma partners currently advancing pre-clinical studies exploring POZ polymer lipid-nanoparticles (“LNPs”) in next generation LNP delivered RNA vaccines. In addition, Serina is advancing a lead drug candidate, SER-252 (POZ-apomorphine) for the treatment of advanced Parkinson’s Disease through pre-clinical studies toward the goal of an investigational new drug submission or “IND” to the Food and Drug Administration for the initiation of a Phase I clinical trial during the fourth quarter of 2024. Serina has two other pipeline assets that are positioned to enter IND enabling studies, SER-227 (POZ-buprenorphine) for certain post-operative pain indications, and SER-228 (POZ-cannabidiol) for treatment refractory epilepsy indications. Serina is also focused on expanding its LNP and anti-body drug conjugate partnering collaborations. If the Merger is completed, the Combined Company will primarily focus on developing Serina’s product candidates and it is anticipated that the Combined Company will not continue to develop AgeX product candidates, other than potentially the development program of NeuroAirmid. If the Merger is not completed, AgeX expects to continue to execute on its current business strategies below while seeking out and evaluating potential strategic alternatives with respect to its assets and development programs, which may include a merger, business combination, investment into AgeX, sale or other disposition of assets or other strategic transaction. In such case, AgeX may not be successful in executing such strategies or identifying or implementing any such strategic alternatives, and there is a risk that Juvenescence may decide to stop funding AgeX’s operations, which would likely result in the delisting of AgeX common stock from the NYSE America and the dissolution of AgeX. Liquidity and Going Concern In addition to general economic and capital market trends and conditions, AgeX’s ability to raise sufficient additional capital to finance its operations from time to time will depend on a number of factors specific to AgeX’s operations such as operating expenses and progress in out-licensing its technologies and development of its product candidates. Although AgeX has been able to reduce its operating expenses, with the exception of certain non-recurring expenses incurred related to the possible Merger between AgeX and Serina, by eliminating internal research and development activities and focusing instead on outsourcing research and development and seeking licensing arrangements for AgeX technologies, this approach has also made it more difficult for AgeX to make progress in developing its target product candidates and technologies, which in turn, along with the amount of indebtedness to Juvenescence and Juvenescence’s ownership of approximately <span id="xdx_90F_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--JuvenescenceMember_zVy695o7FA8k" title="Ownership percentage">75.6% of the outstanding shares of AgeX common stock, may make it more difficult for AgeX to raise capital. The unavailability or inadequacy of financing to meet future capital needs could force AgeX to modify, curtail, delay, or suspend some or all aspects of planned operations. Sales of additional equity securities could result in the dilution of the interests of its stockholders. AgeX cannot assure that adequate financing will be available on favorable terms, if at all. AgeX primarily finances its operations through loans from Juvenescence. A subsidiary of Juvenescence is the largest stockholder of AgeX. AgeX has incurred operating losses and negative cash flows since inception and had an accumulated deficit of $131.0 million as of December 31, 2023. AgeX expects to continue to incur operating losses and negative cash flows. Based on a strategic review of its operations, giving consideration to the status of its product development programs, human resources, capital needs and resources, and current conditions in the capital markets, AgeX’s board of directors and management have adopted operating plans and budgets to extend the period over which AgeX can continue its operations with its available cash resources. Notwithstanding those operating plans and budgets, based on AgeX’s most recent projected cash flows AgeX believes that its cash and cash equivalents of $0.3 million as of December 31, 2023, plus cash on hand remaining from the drawdown of the $<span id="xdx_900_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn5n6_c20240322__dei--LegalEntityAxis__custom--JuvenescenceMember__us-gaap--TypeOfArrangementAxis__custom--LoanFacilityAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zI0E0bENupVj">4.4 million loan facility from Juvenescence, would not be sufficient to satisfy AgeX’s anticipated operating and other funding requirements for the next twelve months from the issuance of these consolidated financial statements. These conditions raise substantial doubt about AgeX’s ability to continue as a going concern. AgeX will need to obtain substantial additional funding in connection with its continuing operations. The financial statements do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should AgeX not continue as a going concern. Principles of Consolidation The consolidated financial statements of AgeX are presented in accordance with accounting principles generally accepted in the United States of American (“U.S. GAAP”). AgeX’s consolidated financial statements include the accounts of AgeX and its subsidiaries in which AgeX has a controlling financial interest. The consolidated financial statements also include certain variable interest entities in which AgeX is the primary beneficiary (as described in more detail below). For consolidated entities where AgeX has less than <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ReCyteTherapeuticsIncMember_zIZK1ZpnvMaa" title="Ownership, percentage">100% of ownership, AgeX records net loss attributable to noncontrolling interest on the consolidated statement of operations equal to the percentage of the ownership interest retained in such entities by the respective noncontrolling parties. The noncontrolling interest is reflected as a separate element of stockholders’ equity/(deficit) on AgeX’s consolidated balance sheets. AgeX assesses whether it is the primary beneficiary of a variable interest entity (“VIE”) at the inception of the arrangement and at each reporting date. This assessment is based on its power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and AgeX’s obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. If the entity is within the scope of the variable interest model and meets the definition of a VIE, AgeX considers whether it must consolidate the VIE or provide additional disclosures regarding its involvement with the VIE. If AgeX determines that it is the primary beneficiary of the VIE, AgeX will consolidate the VIE. This analysis is performed at the initial investment in the entity or upon any reconsideration event. For entities AgeX holds as an equity investment that are not consolidated under the VIE model, AgeX will consider whether its investment constitutes a controlling financial interest in the entity and therefore should be considered for consolidation under the voting interest model. AgeX has four subsidiaries, Reverse Bioengineering, Inc. (“Reverse Bio”), ReCyte Therapeutics, Inc. (“ReCyte”), NeuroAirmid Therapeutics, Inc. (“NeuroAirmid”), and Canaria Transaction Corporation (“Merger Sub”), and has incorporated but not yet capitalized a fifth subsidiary UniverXome. See Note 11, Subsequent Events. Reverse Bio is a wholly owned subsidiary of AgeX through which AgeX plans to finance its iTRTM research and development efforts. AgeX has been seeking equity financing for Reverse Bio and to the extent that such Reverse Bio Financing is obtained through the sale of capital stock or other equity securities by Reverse Bio, AgeX’s equity interest in Reverse Bio and its iTRTM business would be diluted. ReCyte is an early stage pre-clinical research and development company involved in stem cell-derived endothelial and cardiovascular related progenitor cells for the treatment of vascular disorders and ischemic conditions. AgeX owns <span id="xdx_90F_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20231231__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__dei--LegalEntityAxis__custom--ReCyteTherapeuticsIncMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AgeXMember_zcxT70bInoR9" title="Ownership, percentage">94.8% of the outstanding capital stock of ReCyte. NeuroAirmid is jointly owned by AgeX with the University of California – Irvine and certain researchers and was recently organized to pursue clinical development and commercialization of cell therapies, focusing initially on Huntington’s Disease. AgeX owns <span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NeuroAirmidMember_zyg6ocmI5arc" title="Ownership, percentage">50% of the outstanding capital stock of NeuroAirmid. AgeX consolidates NeuroAirmid despite not having majority ownership interest as it has the ability to influence decision making and financial results through contractual rights and obligations as per Accounting Standards Codification (“ASC”) 810, Consolidation. Merger Sub was incorporated for the purpose of merging with Serina to implement the Merger. UniverXome is expected, in connection with the planned Merger, to hold certain AgeX assets and assume AgeX liabilities, including but not limited to indebtedness obligations to Juvenescence. See Note 11, Subsequent Events. All material intercompany accounts and transactions between AgeX and its subsidiaries have been eliminated in consolidation.

1 for 35.17

2500000

10000000

AgeX issued to each holder of AgeX common stock as of the dividend record date, March 18, 2024, three warrants (“Post-Merger Warrants”) for each five shares of AgeX common stock held by such stockholder. Each Post-Merger Warrant will be exercisable for one unit of AgeX (“AgeX Unit”) at a price equal to $13.20 per unit and will expire on July 31, 2025. Each AgeX Unit will consist of (i) one share of AgeX common stock and (ii) one warrant (“Incentive Warrant”). Each Incentive Warrant will be exercisable for one share of AgeX common stock at a price equal to $18.00 per warrant and will expire on the four-year anniversary of the closing date of the Merger

Immediately following the Merger, equity holders of Serina immediately prior to the closing of the Merger are expected to own approximately 75% of the outstanding shares of common stock of AgeX, and stockholders of AgeX immediately prior to the closing of the Merger are expected to own approximately 25% of the outstanding shares of common stock of AgeX, with Serina as a wholly-owned subsidiary, in each case, on a pro forma fully diluted basis, subject to certain assumptions and exclusions, including the Actual Closing Price (as defined in the Merger Agreement) of AgeX common stock being equal to or greater than $12.00 per share excluding the impact of any Post-Merger Warrant, Incentive Warrant or the issuance of any shares of AgeX common stock upon exercise of any Post-Merger Warrants or Incentive Warrants.

15000000

0.756

-131000000.0

300000

4400000

0.948

0.50

2. Summary of Significant Accounting Policies Going Concern Assessment AgeX assesses going concern uncertainty for its consolidated financial statements to determine if AgeX has sufficient cash and cash equivalents on hand and working capital to operate for a period of at least one year from the date the consolidated financial statements are issued or are available to be issued, which is referred to as the “look-forward period” as defined by Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2014-15. As part of this assessment, based on conditions that are known and reasonably knowable to AgeX, AgeX will consider various scenarios, forecasts, projections, and estimates, and AgeX will make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and its ability to delay or curtail those expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, AgeX makes certain assumptions concerning its ability to curtail or delay research and development programs and expenditures within the look-forward period in accordance with ASU No. 2014-15 (see Note 1, Organization, Basis of Presentation and Liquidity). Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and (ii) the reported amounts of revenues and expenses during the reporting period with consideration given to materiality. Significant estimates and assumptions which are subject to significant judgment include those related to going concern assessment of consolidated financial statements, allocations and adjustments necessary for carve-out basis of presentation, including the separate return method for income taxes, useful lives associated with long-lived assets, including evaluation of asset impairment, allowances for uncollectible accounts receivables, loss contingencies, deferred income taxes and tax reserves, including valuation allowances related to deferred income taxes, and assumptions used to value stock-based awards or other equity instruments and liability classified warrants. Actual results could differ materially from those estimates. To the extent there are material differences between the estimates and actual results, AgeX’s future results of operations will be affected. See Note 6, Warrant Liability, for discussion on estimated change in fair value of warrant liability. See Note 6, Warrant Liability, for discussion on estimated change in fair value of warrant liability. Transactions with Noncontrolling Interests of Subsidiaries AgeX accounts for a change in ownership interests in its subsidiaries that does not result in a change of control of the subsidiary under the provisions of ASC 810-10-45-23, Consolidation – Other Presentation Matters, which prescribes the accounting for changes in ownership interest that do not result in a change in control of the subsidiary, as defined by U.S. GAAP, before and after the transaction. Under this guidance, changes in a controlling stockholder’s ownership interest that do not result in a change of control, as defined by U.S. GAAP, in the subsidiary are accounted for as equity transactions. Accordingly, if the controlling stockholder retains control, no gain or loss is recognized in the statements of operations of the controlling stockholder. Similarly, the controlling stockholder will not record any additional acquisition adjustments to reflect its subsequent purchases of additional shares in the subsidiary if there is no change of control. Only a proportional and immediate transfer of carrying value between the controlling and the noncontrolling stockholders occurs based on the respective ownership percentages. Fair Value Measurements of Financial Instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of the financial statement presentation date. The carrying values of cash equivalents, accounts receivable and accounts payable are carried at, or approximate, fair value as of the reporting date because of their short-term nature. Fair values for AgeX’s warrant liabilities are estimated by utilizing valuation models that consider current and expected stock prices, volatility, dividends, market interest rates, forward yield curves and discount rates. Such amounts and the recognition of such amounts are subject to significant estimates that may change in the future. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value (ASC 820-10-50, Fair Value Measurements and Disclosures): <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 – Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2 – Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets, and inputs that are observable for the assets or liabilities, either directly or indirectly, for substantially the full term of the financial instruments.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3 – Inputs to the valuation methodology are unobservable; that reflect management’s own assumptions about the assumptions market participants would make and significant to the fair value.</td></tr> </table> In determining fair value, AgeX utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented, AgeX has no financial assets recorded at fair value on a recurring basis, except for cash and cash equivalents primarily consisting of money market funds. These assets are measured at fair value using the period-end quoted market prices as a Level 1 input. The carrying amounts of accounts receivable, net, prepaid expenses and other current assets, related party amounts due to affiliates, accounts payable, accrued liabilities and other current liabilities approximate fair values because of the short-term nature of these items. The discounted conversion prices triggered by certain qualified events in the Serina Note and the 2023 Secured Note are Level 3 on the fair value hierarchy and subject to fair valuation at inception and remeasurement at each reporting period. The fair value of the discounted conversion prices under both notes were determined to have an immaterial value at inception and life to date of the notes, as the probability of a future qualifying event is remote. The likelihood of the future qualifying event will be evaluated at the end of each reporting period. For additional information regarding the convertible notes and derivatives, see Notes 4, Convertible Note Receivable, and 5, Related Party Transactions. The accounting guidance establishes a hierarchy which requires an entity to maximize the use of quoted market prices and minimize the use of unobservable inputs. An asset or liability’s level is based on the lowest level of input that is significant to the fair value measurement. Fair value estimates are reviewed at the origination date and again at each applicable measurement date and interim or annual financial reporting dates, as applicable for the financial instrument, and are based upon certain market assumptions and pertinent information available to management at those times. The methods and significant inputs and assumptions utilized in estimating the fair value of the warrant liabilities, as well as the respective hierarchy designations are discussed further in Note 6, Warrant Liability. The warrant liability measurement is considered a Level 3 measurement based on the availability of market data and inputs and the significance of any unobservable inputs as of the measurement date. As of December 31, 2023, AgeX has utilized the full credit subject to warrants, and accordingly, the warrants were fully issued for each of the advances of loan funds under the 2022 Secured Note. See Note 6, Warrant Liability, for additional information on accounting for liability classified warrants and certain Level 3 warrant valuation tables. Cash and Cash Equivalents AgeX considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of December 31, 2023 and 2022, AgeX’s cash balances totaled $0.3 million and $0.6 million, respectively, and consist entirely of bank account deposits and amounts held in money market funds. Concentrations of Credit Risk Financial instruments that potentially subject AgeX to significant concentrations of credit risk consist primarily of cash and cash equivalents. AgeX limits the amount of credit exposure of cash balances by maintaining its accounts in high credit quality financial institutions. Cash equivalent deposits with financial institutions may occasionally exceed the limits of insurance on bank deposits; however, AgeX has not experienced any losses on such accounts. Restricted Cash In accordance with ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, a reconciliation of AgeX’s cash and cash equivalents in the consolidated balance sheets to cash, cash equivalents and restricted cash in the consolidated statements of cash flows for all periods presented is as follows (in thousands): Schedule of Cash, Cash Equivalents and Restricted Cash <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20231231_zJwHuxtUjdW" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20221231_zAdoAAk17wrg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maRCACEzuPR_zD8HvlDjPRSl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Cash and cash equivalents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">345</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">645</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--RestrictedCashEquivalents_iI_pn3n3_maRCACEzuPR_zQzk7OblT8lj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Restricted cash (1)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">50</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">50</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iTI_pn3n3_mtRCACEzuPR_zN69HgOkHkZ1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Cash, cash equivalents, and restricted cash as shown in the consolidated statements of cash flows</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">395</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">695</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(1)</td><td id="xdx_F15_zZI0Kj9Ymc0a" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Restricted cash entirely represents the deposit required to maintain AgeX’s corporate credit card program.</td></tr></table> Accounts Receivable, Net AgeX establishes an allowance for doubtful accounts based on the evaluation of the collectability of its receivables after considering a variety of factors, including the length of time receivables are past due, significant events that may impair the customer’s ability to pay, such as a bankruptcy filing or deterioration in the customer’s operating results or financial position, and historical experience. If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted. There were no amounts reserved for doubtful accounts as of December 31, 2023 and 2022. Long-Lived Intangible Assets, Net Long-lived intangible assets, consisting primarily of acquired in-process research and development (“IPR&D”) and patents, are stated at acquired cost, less accumulated amortization. Amortization expense is computed using the straight-line method over the estimated useful life of 10 years. See Note 3, Selected Balance Sheet Components. Impairment of Long-Lived Assets AgeX assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not be recoverable. AgeX’s long-lived assets consist entirely of intangible assets. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss, equal to the excess of the carrying value of the asset over its fair value, is recorded. As of December 31, 2023, there has been no impairment of long-lived assets. Leases AgeX accounts for leases in accordance with ASU 2016-02, Leases (Topic 842) (“ASC 842”), and its subsequent amendments affecting AgeX: (i) ASU 2018-10, Codification Improvements to Topic 842, Leases, and (ii) ASU 2018-11, Leases (Topic 842): Targeted improvements, using the modified retrospective method. AgeX management determines if an arrangement is a lease at inception. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the consolidated statements of operations. When determining whether a lease is a financing lease or an operating lease, ASC 842 does not specifically define criteria to determine “major part of remaining economic life of the underlying asset” and “substantially all of the fair value of the underlying asset.” For lease classification determination, AgeX continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset. Under the available practical expedients, and as applicable, AgeX accounts for the lease and non-lease components as a single lease component. AgeX recognizes right-of-use (“ROU”) assets and lease liabilities for leases with terms greater than twelve months in the consolidated balance sheets. ROU assets represent an entity’s right to use an underlying asset during the lease term and lease liabilities represent an entity’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. If the lease agreement does not provide an implicit rate in the contract, an entity uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the entity will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. AgeX does not capitalize leases that have terms of twelve months or less. AgeX leased office space in Alameda, California. For 2022 base monthly rent was $1,074 and for 2023 base monthly rent is $844 for slightly less space at the same building. AgeX has elected to not apply the recognition requirements under ASC 842 for the lease agreements and instead recognizes the lease payments as lease cost on a straight-line basis over the lease term as lease payments are not deemed material. Accounting for Warrants AgeX determines the accounting classification of warrants it issues, as either liability or equity, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, then in accordance with ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock. Under ASC 480-10, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate AgeX to settle the warrants or the underlying shares by paying cash or other assets, or warrants that must or may require settlement by issuing a variable number of shares. If warrants do not meet liability classification under ASC 480-10, AgeX assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, and in order to conclude equity classification, AgeX also assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable provisions of U.S. GAAP. After all relevant assessments, AgeX concludes whether the warrants are classified as liability or equity. Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance with all changes in fair value after the issuance date recorded in the consolidated statements of operations. Equity classified warrants only require fair value accounting at issuance with no changes recognized subsequent to the issuance date. AgeX has liability classified warrants as of December 31, 2023. See Notes 5, Related Party Transactions, and 6, Warrant Liability, for additional information regarding AgeX warrants. Stock-Based Compensation AgeX recognizes compensation expense related to employee option grants and restricted stock grants, if any, in accordance with ASC 718, Compensation – Stock Compensation (“ASC 718”). AgeX estimates the fair value of employee stock-based payment awards on the grant-date and recognizes the resulting fair value, net of estimated forfeitures for grants prior to 2017, over the requisite service period. Upon adoption of ASU 2016-09 on January 1, 2017 as further discussed below, forfeitures are accounted for as they occur instead of based on the number of awards that were expected to vest prior to adoption of ASU 2016-09. AgeX uses the Black-Scholes option pricing model for estimating the fair value of options granted under AgeX’s 2017 Equity Incentive Plan (the “Incentive Plan”). The fair value of each restricted stock grant, if any, is determined based on the value of the common stock granted or sold. AgeX has elected to treat stock-based payment awards with time-based service conditions as a single award and recognizes stock-based compensation on a straight-line basis over the requisite service period. Compensation expense for non-employee stock-based awards is recognized in accordance with ASC 718. Stock option awards issued to non-employees, principally consultants or outside contractors, as applicable, are accounted for at fair value using the Black-Scholes option pricing model. Management believes that the fair value of the stock options and restricted stock units can more reliably be measured than the fair value of services received. AgeX records compensation expense based on the then-current fair values of the stock options and restricted stock units at the grant date. Compensation expense for non-employee grants is recorded on a straight-line basis in the consolidated statements of operations. The Black-Scholes option pricing model requires AgeX to make certain assumptions including the fair value of the underlying common stock, the expected term, the expected volatility, the risk-free interest rate and the dividend yield (see Note 8, Stock-Based Awards). The fair value of the shares of common stock underlying the stock options is determined in accordance with the Incentive Plan and is based on prevailing market prices on the NYSE American where AgeX common stock is traded. The expected term of employee stock options represents the weighted-average period that the stock options are expected to remain outstanding. AgeX estimates the expected term of options granted using the “simplified method” provided under Staff Accounting Bulletin Topic 14, or SAB Topic 14. Because AgeX’s common stock has public trading history of fewer than five years, AgeX has estimated the expected volatility using its own stock price volatility to the extent applicable or a combination of its stock price volatility and the stock price volatility of peer companies, for a period equal to the expected term of the options, which may exceed five years. The peer companies used include selected public companies within the biotechnology industry with comparable characteristics to AgeX, including similarity in size, lines of business, market capitalization, revenue and financial leverage. The risk-free interest rate assumption is based upon observed interest rates on the United States government securities appropriate for the expected term of AgeX’s stock options. The dividend yield assumption is based on AgeX’s history and expectation of dividend payouts. AgeX has never declared or paid any cash dividends on its common stock, and AgeX does not anticipate paying any cash dividends in the foreseeable future. All excess tax benefits and tax deficiencies from stock-based compensation awards accounted for under ASC 718 are recognized as an income tax benefit or expense, respectively, in the consolidated statements of operations. An excess income tax benefit arises when the tax deduction of a share-based award for income tax purposes exceeds the compensation cost recognized for financial reporting purposes and, a tax deficiency arises when the compensation cost exceeds the tax deduction. Stock-based compensation expense for the years ended December 31, 2023 and 2022 consists of stock-based compensation under the AgeX Incentive Plan (see Note 8, Stock-Based Awards). Certain of AgeX’s consolidated subsidiaries have had their own share-based compensation plans; however, there are no awards granted and outstanding under those plans as of December 31, 2023 and 2022. For share-based compensation awards granted by privately held consolidated subsidiaries under their respective equity plans, AgeX determines the fair value of the options granted under those plans using similar methodologies and assumptions AgeX used for its stock options discussed above. Although the fair value of stock options and restricted stock units is determined in accordance with FASB guidance, changes in the assumptions and allocations can materially affect the estimated value and therefore the amount of compensation expense recognized in the consolidated financial statements. Income Taxes AgeX accounts for income taxes in accordance with ASC 740, which prescribes the use of the asset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and enacted rates in effect. Valuation allowances are established when necessary to reduce deferred tax assets when it is more likely than not that a portion or all of the deferred tax assets will not be realized. AgeX’s judgments, estimates and projections regarding future taxable income may change over time due to changes, among other factors, in market conditions, changes in tax laws, and tax planning strategies. If AgeX’s assumptions and consequently its estimates change in the future, the valuation allowance may be increased or decreased, which may have a material impact on AgeX’s consolidated financial statements. The guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities. AgeX recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No unrecognized tax benefits have been recorded and no amounts were accrued for the payment of interest and penalties as of December 31, 2023 and 2022. AgeX does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. AgeX is currently unaware of any tax issues under review. Revenue Recognition AgeX recognizes revenue in a manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the consideration it expects to receive in exchange for such product or service. In doing so, AgeX follows a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) the customer obtains control of the product or service. AgeX considers the terms of a contract and all relevant facts and circumstances when applying the revenue recognition standard. AgeX applies the revenue recognition standard, including the use of any practical expedients, consistently to contracts with similar characteristics and in similar circumstances. In the applicable paragraphs below, AgeX has summarized its revenue recognition policies for its various revenue sources in accordance with Topic 606. Revenue recognition by source and geography – Revenues are recognized when control of the promised goods or services is transferred to customers, or in the case of governmental entities funding a grant, when allowable expenses are incurred, in an amount that reflects the consideration AgeX or a subsidiary, depending on which company has the customer or the grant, expects to be entitled to in exchange for those goods or services. The following table presents AgeX’s consolidated revenues disaggregated by source for operations (in thousands): Schedule of Disaggregated of Revenues <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">REVENUES:</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20230101__20231231_zS6OVWWDdZsd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20220101__20221231_zaemvQoXIaee" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">REVENUES:</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--GrantRevenuesMember_zXMEKMi9uZAf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Grant revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">77</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--OtherRevenuesMember_zMkFTWBBH1od" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Other revenues</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">65</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">34</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zuW5xB1rwPof" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total revenues</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">142</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">34</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The following table presents consolidated revenues for operations (in thousands), disaggregated by geography, based on the billing addresses of customers: Schedule of Disaggregated Geographical Revenue <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">REVENUES:</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20230101__20231231_zEwqOMG13Jd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20220101__20221231_zUj9cYQ3hdY5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">REVENUES:</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__country--US_zLRF1yU43Nv" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">United States</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">90</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">10</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__custom--ForeignMember_zudc5O7nzrKk" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">52</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">24</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zoqFVmBXwzM9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total revenues</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">142</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">34</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Grant revenues – AgeX accounts for grants received to perform research and development services in accordance with ASC 730-20, Research and Development Arrangements. At the inception of the grant, we perform an assessment as to whether the grant is a liability or a contract to perform research and development services for others. If AgeX or a subsidiary receiving the grant is obligated to repay the grant funds to the grantor regardless of the outcome of the research and development activities, then AgeX is required to estimate and recognize that liability. Alternatively, if AgeX or a subsidiary receiving the grant is not required to repay, or if it is required to repay the grant funds only if the research and development activities are successful, then the grant agreement is accounted for as a contract to perform research and development services for others, in which case, grant revenue is recognized when the related research and development expenses are incurred. In applying the provisions of Topic 606, AgeX has determined that government grants are out of the scope of Topic 606 because the government entities do not meet the definition of a “customer”, as defined by Topic 606, as there is not considered to be a transfer of control of good or services to the government entities funding the grant. In the absence of applicable guidance under U.S. GAAP, our policy is to recognize grant revenue when the related costs are incurred, provided that the applicable conditions under the government contracts have been met. Only costs that are allowable under the grant award, certain government regulations and the National Institutes of Health’s supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. Costs incurred are recorded in research and development expenses on the accompanying consolidated statements of operations. In applying the provisions of Topic 606, AgeX has determined that government grants are out of the scope of Topic 606 because the government entities do not meet the definition of a “customer”, as defined by Topic 606, as there is not considered to be a transfer of control of good or services to the government entities funding the grant. In the absence of applicable guidance under U.S. GAAP, our policy is to recognize grant revenue when the related costs are incurred, provided that the applicable conditions under the government contracts have been met. Only costs that are allowable under the grant award, certain government regulations and the National Institutes of Health (“NIH”) supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. Costs incurred are recorded in research and development expenses on the accompanying consolidated statements of operations. AgeX believes the recognition of revenue as costs are incurred and amounts become realizable is analogous to the concept of transfer of control of a service over time under ASC 606. In August 2023, AgeX was awarded a grant of up to approximately $341,000 from the NIH, National Heart, Lung and Blood Institute. The NIH grant will provide funding for continued development of AgeX’s technologies toward treating cardiovascular disease over a one year period starting September 1, 2023. Based on our evaluation under the accounting guidance aforementioned, this grant agreement is accounted for as a contract to perform research and development services for others, in which case, grant revenue is recognized when the related research and development expenses are incurred. Accordingly, grant funds are made available by the NIH as allowable expenses are incurred. For the year ended December 31, 2023, AgeX incurred approximately $77,000 of allowable expenses under the NIH grant and recognized a corresponding amount of grant revenues. ESI BIO research products – AgeX, through its ESI BIO research product division, markets a number of products related to human pluripotent stem cells (“PSC lines”), including research-grade PSC lines and PSC lines produced under current good manufacturing practices or “cGMP.” AgeX offers cells from PSC lines to customers under contracts that permit the customers to utilize PSC lines for the research, development, and commercialization of cell-based therapies or other products in defined fields of application. The compensation to AgeX for providing the PSC line cells under such contracts may include up-front payments, milestone payments related to product development, regulatory matters, and commercialization, and the payment of royalties on sales of products developed from AgeX PSC lines. Revenues from the sale of research products are included in other revenues. Arrangements with multiple performance obligations – AgeX may enter into contracts with customers that include multiple performance obligations. For such arrangements, AgeX will allocate revenue to each performance obligation based on its relative standalone selling price. AgeX will determine or estimate standalone selling prices based on the prices charged, or that would be charged, to customers for that product or service. As of and for the years ended December 31, 2023 and 2022, AgeX did not have significant arrangements with multiple performance obligations. Research and Development Research and development expenses consist primarily of personnel costs and related benefits, including stock-based compensation, amortization of intangible assets, outside consultants and contractors, sponsored research agreements with certain universities, and suppliers, and license fees paid to third parties to acquire patents or licenses to use patents and other technology. Research and development expenses incurred and reimbursed by grants from third parties or governmental agencies if any and as applicable, approximate the respective revenues recognized in the consolidated statements of operations. General and Administrative General and administrative expenses consist primarily of compensation and related benefits, including stock-based compensation, for executive and corporate personnel, and professional and consulting fees. Segments AgeX’s executive management team, as a group, represents the entity’s chief operating decision makers. To date, AgeX’s executive management team has viewed AgeX’s operations as one segment that includes the research and development of regenerative medicine technologies targeting the diseases of aging and metabolic disorders, oncology, and neurological diseases and disorders, blood and vascular system diseases and disorders, and pluripotent cell technologies. As a result, the financial information disclosed materially represents all of the financial information related to AgeX’s sole operating segment. Basic and Diluted Net Loss per Share Attributable to Common Stockholders Basic loss per share is calculated by dividing net loss attributable to AgeX common stockholders by the weighted average number of shares of common stock outstanding, net of unvested restricted stock or restricted stock units, subject to repurchase by AgeX, if any, during the period. Diluted loss per share is calculated by dividing the net income attributable to AgeX common stockholders, if any, by the weighted average number of shares of common stock outstanding, adjusted for the effects of potentially dilutive common stock issuable under outstanding stock options, warrants, and restricted stock units, using the treasury-stock method, and convertible preferred stock, if any, using the if-converted method, and treasury stock held by subsidiaries, if any. For the years ended December 31, 2023 and 2022, because AgeX reported a net loss attributable to common stockholders, all potentially dilutive common stock, comprised of stock options, restricted stock units and warrants, is antidilutive. <p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zzBK40jBzsV2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following weighted-average common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive (in thousands): Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z6MIBX1uZWt7" style="width: 11%; text-align: right" title="Anti-dilutive securities">91</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zXcT4CABv6Ve" style="width: 11%; text-align: right" title="Anti-dilutive securities">94</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.1in; padding-left: 0.1in">Warrants (1)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDEp_zLP9XP3TjF4d" style="text-align: right" title="Anti-dilutive securities">352</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDEp_zbzWuxEj9Yle" style="text-align: right" title="Anti-dilutive securities">272</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Restricted stock units</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zEWfhv4tj4Rj" style="text-align: right" title="Anti-dilutive securities">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zw01Exx1jArh" style="text-align: right" title="Anti-dilutive securities">-</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td id="xdx_F0D_zrsjArEBBQHj" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(1)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As of December 31, 2023 and 2022, warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFudGlkaWx1dGl2ZSBTZWN1cml0aWVzIEV4Y2x1ZGVkIGZyb20gQ29tcHV0YXRpb24gb2YgRWFybmluZ3MgUGVyIFNoYXJlIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementsMember_zEWiif3az2Q4" title="Warrant to purchase shares of common stock">320,115 and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFudGlkaWx1dGl2ZSBTZWN1cml0aWVzIEV4Y2x1ZGVkIGZyb20gQ29tcHV0YXRpb24gb2YgRWFybmluZ3MgUGVyIFNoYXJlIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementsMember_zU8YGmMZzT19" title="Warrant to purchase shares of common stock">344,875 shares, respectively, of AgeX common stock were issued and outstanding and held by Juvenescence as consideration for certain loan agreements discussed in Note 5, Related Party Transactions. Amounts shown in the table are weighted average amounts and reflect the fact that the warrants were issued on various dates during applicable periods presented.</td></tr></table> Recently Adopted Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, and subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04, ASU 2019-05 and ASU 2019-10, which amends the current approach to estimate credit losses on certain financial assets. This ASU requires immediate recognition of management’s estimates of current expected credit losses. Under the prior model, losses were recognized only as they were incurred, which FASB has noted delayed recognition of expected losses that might not yet have met the threshold of being probable. The standard is applicable to all financial assets (and net investment in leases) that are not accounted for at fair value through net income, such as trade receivables, loans, debt securities, and net investment in leases, thereby bringing consistency in accounting treatment across different types of financial instruments and requiring consideration of a broader range of variables when forming loss estimates. Subsequent changes in the valuation allowance are recorded in current earnings and reversal of previous losses are permitted. AgeX adopted this standard as of January 1, 2023, and it did not have a material impact on the consolidated financial statements. In March 2022, the FASB issued ASU 2022-01, Derivatives and Hedging (Topic 815): Fair Value Hedging – Portfolio Layer Method, which clarifies the guidance in ASC 815 on fair value hedge accounting of interest rate risk for portfolios of financial assets. The ASU amends the guidance in ASU 2017-12 (released on August 28, 2017) that, among other things, established the “last-of-layer” method for making the fair value hedge accounting for these portfolios more accessible. ASU 2022-01 renames that method the “portfolio layer” method and addresses feedback from stakeholders regarding its application. AgeX adopted this standard as of January 1, 2023, and it did not have a material impact on the consolidated financial statements. In March 2022, the FASB issued ASU 2022-02, Financial Instruments – Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures, which amends the accounting for credit losses on financial instruments. This amendment eliminates the recognition and measurement guidance on troubled debt restructurings for creditors that have adopted the new credit losses guidance in ASC 326 and requires enhanced disclosures about loan modifications for borrowers experiencing financial difficulty. The new guidance also requires public business entities to present gross write-offs by year of origination in their vintage disclosures. The guidance became effective for AgeX on January 1, 2023 and includes interim periods. Entities can elect to adopt the guidance on troubled debt restructurings using either a prospective or modified retrospective transition. If an entity elects to apply a modified retrospective transition, it will record a cumulative effect adjustment to retained earnings in the period of adoption. This ASU did not have a material impact on the consolidated financial statements. On July 14, 2023, the FASB issued ASU 2023-03, Presentation of Financial Statements (Topic 205), Income Statement – Reporting Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation – Stock Compensation, which amends or supersedes various Securities and Exchange Commission (“SEC”) paragraphs within the codification to conform to past announcements and guidance issued by the SEC. Specifically, the ASU responds to (1) the issuance of SEC Staff Accounting Bulletin (SAB) 120; (2) the SEC staff announcement at the March 24, 2022, EITF meeting; and (3) SAB Topic 6.B, “Accounting Series Release No. 280 — General Revision of Regulation S-X: Income or Loss Applicable to Common Stock.” This ASU is effective immediately and did not have a material impact on AgeX’s consolidated financial statements. Recently Issued Accounting Pronouncements Not Yet Adopted In August 2023, the FASB issued ASU 2023-05, Business Combinations—Joint Venture Formations (Subtopic 805-60): Recognition and Initial Measurement, under which an entity that qualifies as either a joint venture or a corporate joint venture as defined in the FASB ASC master glossary is required to apply a new basis of accounting upon the formation of the joint venture. Specifically, the ASU provides that a joint venture or a corporate joint venture (collectively, “joint ventures”) must initially measure its assets and liabilities at fair value on the formation date. This ASU is effective for AgeX beginning January 1, 2025 and is not expected to have a material impact on the consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to income Tax Disclosures, under which entities must consistently categorize and provide greater disaggregation of information in the rate reconciliation. They must also further disaggregate income taxes paid. ASU 2023-09 enhances annual income tax disclosures to address investor requests for more information about the tax risks and opportunities present in an entity’s worldwide operations. This ASU is effective for AgeX beginning January 1, 2025 and is not expected to have a material impact on the consolidated financial statements.

Going Concern Assessment AgeX assesses going concern uncertainty for its consolidated financial statements to determine if AgeX has sufficient cash and cash equivalents on hand and working capital to operate for a period of at least one year from the date the consolidated financial statements are issued or are available to be issued, which is referred to as the “look-forward period” as defined by Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2014-15. As part of this assessment, based on conditions that are known and reasonably knowable to AgeX, AgeX will consider various scenarios, forecasts, projections, and estimates, and AgeX will make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and its ability to delay or curtail those expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, AgeX makes certain assumptions concerning its ability to curtail or delay research and development programs and expenditures within the look-forward period in accordance with ASU No. 2014-15 (see Note 1, Organization, Basis of Presentation and Liquidity).

Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and (ii) the reported amounts of revenues and expenses during the reporting period with consideration given to materiality. Significant estimates and assumptions which are subject to significant judgment include those related to going concern assessment of consolidated financial statements, allocations and adjustments necessary for carve-out basis of presentation, including the separate return method for income taxes, useful lives associated with long-lived assets, including evaluation of asset impairment, allowances for uncollectible accounts receivables, loss contingencies, deferred income taxes and tax reserves, including valuation allowances related to deferred income taxes, and assumptions used to value stock-based awards or other equity instruments and liability classified warrants. Actual results could differ materially from those estimates. To the extent there are material differences between the estimates and actual results, AgeX’s future results of operations will be affected. See Note 6, Warrant Liability, for discussion on estimated change in fair value of warrant liability. See Note 6, Warrant Liability, for discussion on estimated change in fair value of warrant liability.

Transactions with Noncontrolling Interests of Subsidiaries AgeX accounts for a change in ownership interests in its subsidiaries that does not result in a change of control of the subsidiary under the provisions of ASC 810-10-45-23, Consolidation – Other Presentation Matters, which prescribes the accounting for changes in ownership interest that do not result in a change in control of the subsidiary, as defined by U.S. GAAP, before and after the transaction. Under this guidance, changes in a controlling stockholder’s ownership interest that do not result in a change of control, as defined by U.S. GAAP, in the subsidiary are accounted for as equity transactions. Accordingly, if the controlling stockholder retains control, no gain or loss is recognized in the statements of operations of the controlling stockholder. Similarly, the controlling stockholder will not record any additional acquisition adjustments to reflect its subsequent purchases of additional shares in the subsidiary if there is no change of control. Only a proportional and immediate transfer of carrying value between the controlling and the noncontrolling stockholders occurs based on the respective ownership percentages.

Fair Value Measurements of Financial Instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of the financial statement presentation date. The carrying values of cash equivalents, accounts receivable and accounts payable are carried at, or approximate, fair value as of the reporting date because of their short-term nature. Fair values for AgeX’s warrant liabilities are estimated by utilizing valuation models that consider current and expected stock prices, volatility, dividends, market interest rates, forward yield curves and discount rates. Such amounts and the recognition of such amounts are subject to significant estimates that may change in the future. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value (ASC 820-10-50, Fair Value Measurements and Disclosures): <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 – Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2 – Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets, and inputs that are observable for the assets or liabilities, either directly or indirectly, for substantially the full term of the financial instruments.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3 – Inputs to the valuation methodology are unobservable; that reflect management’s own assumptions about the assumptions market participants would make and significant to the fair value.</td></tr> </table> In determining fair value, AgeX utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. For the periods presented, AgeX has no financial assets recorded at fair value on a recurring basis, except for cash and cash equivalents primarily consisting of money market funds. These assets are measured at fair value using the period-end quoted market prices as a Level 1 input. The carrying amounts of accounts receivable, net, prepaid expenses and other current assets, related party amounts due to affiliates, accounts payable, accrued liabilities and other current liabilities approximate fair values because of the short-term nature of these items. The discounted conversion prices triggered by certain qualified events in the Serina Note and the 2023 Secured Note are Level 3 on the fair value hierarchy and subject to fair valuation at inception and remeasurement at each reporting period. The fair value of the discounted conversion prices under both notes were determined to have an immaterial value at inception and life to date of the notes, as the probability of a future qualifying event is remote. The likelihood of the future qualifying event will be evaluated at the end of each reporting period. For additional information regarding the convertible notes and derivatives, see Notes 4, Convertible Note Receivable, and 5, Related Party Transactions. The accounting guidance establishes a hierarchy which requires an entity to maximize the use of quoted market prices and minimize the use of unobservable inputs. An asset or liability’s level is based on the lowest level of input that is significant to the fair value measurement. Fair value estimates are reviewed at the origination date and again at each applicable measurement date and interim or annual financial reporting dates, as applicable for the financial instrument, and are based upon certain market assumptions and pertinent information available to management at those times. The methods and significant inputs and assumptions utilized in estimating the fair value of the warrant liabilities, as well as the respective hierarchy designations are discussed further in Note 6, Warrant Liability. The warrant liability measurement is considered a Level 3 measurement based on the availability of market data and inputs and the significance of any unobservable inputs as of the measurement date. As of December 31, 2023, AgeX has utilized the full credit subject to warrants, and accordingly, the warrants were fully issued for each of the advances of loan funds under the 2022 Secured Note. See Note 6, Warrant Liability, for additional information on accounting for liability classified warrants and certain Level 3 warrant valuation tables.

Cash and Cash Equivalents AgeX considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of December 31, 2023 and 2022, AgeX’s cash balances totaled $0.3 million and $0.6 million, respectively, and consist entirely of bank account deposits and amounts held in money market funds.

300000

600000

Concentrations of Credit Risk Financial instruments that potentially subject AgeX to significant concentrations of credit risk consist primarily of cash and cash equivalents. AgeX limits the amount of credit exposure of cash balances by maintaining its accounts in high credit quality financial institutions. Cash equivalent deposits with financial institutions may occasionally exceed the limits of insurance on bank deposits; however, AgeX has not experienced any losses on such accounts.

Restricted Cash In accordance with ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, a reconciliation of AgeX’s cash and cash equivalents in the consolidated balance sheets to cash, cash equivalents and restricted cash in the consolidated statements of cash flows for all periods presented is as follows (in thousands): Schedule of Cash, Cash Equivalents and Restricted Cash <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20231231_zJwHuxtUjdW" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20221231_zAdoAAk17wrg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maRCACEzuPR_zD8HvlDjPRSl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Cash and cash equivalents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">345</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">645</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--RestrictedCashEquivalents_iI_pn3n3_maRCACEzuPR_zQzk7OblT8lj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Restricted cash (1)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">50</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">50</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iTI_pn3n3_mtRCACEzuPR_zN69HgOkHkZ1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Cash, cash equivalents, and restricted cash as shown in the consolidated statements of cash flows</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">395</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">695</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(1)</td><td id="xdx_F15_zZI0Kj9Ymc0a" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Restricted cash entirely represents the deposit required to maintain AgeX’s corporate credit card program.</td></tr></table>

In accordance with ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, a reconciliation of AgeX’s cash and cash equivalents in the consolidated balance sheets to cash, cash equivalents and restricted cash in the consolidated statements of cash flows for all periods presented is as follows (in thousands): Schedule of Cash, Cash Equivalents and Restricted Cash <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20231231_zJwHuxtUjdW" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20221231_zAdoAAk17wrg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_maRCACEzuPR_zD8HvlDjPRSl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Cash and cash equivalents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">345</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">645</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--RestrictedCashEquivalents_iI_pn3n3_maRCACEzuPR_zQzk7OblT8lj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Restricted cash (1)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">50</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">50</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iTI_pn3n3_mtRCACEzuPR_zN69HgOkHkZ1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Cash, cash equivalents, and restricted cash as shown in the consolidated statements of cash flows</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">395</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">695</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(1)</td><td id="xdx_F15_zZI0Kj9Ymc0a" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Restricted cash entirely represents the deposit required to maintain AgeX’s corporate credit card program.</td></tr></table>

345000

645000

50000

395000

695000

Accounts Receivable, Net AgeX establishes an allowance for doubtful accounts based on the evaluation of the collectability of its receivables after considering a variety of factors, including the length of time receivables are past due, significant events that may impair the customer’s ability to pay, such as a bankruptcy filing or deterioration in the customer’s operating results or financial position, and historical experience. If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted. There were no amounts reserved for doubtful accounts as of December 31, 2023 and 2022.

Long-Lived Intangible Assets, Net Long-lived intangible assets, consisting primarily of acquired in-process research and development (“IPR&D”) and patents, are stated at acquired cost, less accumulated amortization. Amortization expense is computed using the straight-line method over the estimated useful life of 10 years. See Note 3, Selected Balance Sheet Components.

P10Y

Impairment of Long-Lived Assets AgeX assesses the impairment of long-lived assets whenever events or changes in circumstances indicate that such assets might be impaired and the carrying value may not be recoverable. AgeX’s long-lived assets consist entirely of intangible assets. If events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss, equal to the excess of the carrying value of the asset over its fair value, is recorded. As of December 31, 2023, there has been no impairment of long-lived assets.

Leases AgeX accounts for leases in accordance with ASU 2016-02, Leases (Topic 842) (“ASC 842”), and its subsequent amendments affecting AgeX: (i) ASU 2018-10, Codification Improvements to Topic 842, Leases, and (ii) ASU 2018-11, Leases (Topic 842): Targeted improvements, using the modified retrospective method. AgeX management determines if an arrangement is a lease at inception. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the consolidated statements of operations. When determining whether a lease is a financing lease or an operating lease, ASC 842 does not specifically define criteria to determine “major part of remaining economic life of the underlying asset” and “substantially all of the fair value of the underlying asset.” For lease classification determination, AgeX continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset. Under the available practical expedients, and as applicable, AgeX accounts for the lease and non-lease components as a single lease component. AgeX recognizes right-of-use (“ROU”) assets and lease liabilities for leases with terms greater than twelve months in the consolidated balance sheets. ROU assets represent an entity’s right to use an underlying asset during the lease term and lease liabilities represent an entity’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. If the lease agreement does not provide an implicit rate in the contract, an entity uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the entity will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. AgeX does not capitalize leases that have terms of twelve months or less. AgeX leased office space in Alameda, California. For 2022 base monthly rent was $1,074 and for 2023 base monthly rent is $844 for slightly less space at the same building. AgeX has elected to not apply the recognition requirements under ASC 842 for the lease agreements and instead recognizes the lease payments as lease cost on a straight-line basis over the lease term as lease payments are not deemed material.

(i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset.

1074

844

Accounting for Warrants AgeX determines the accounting classification of warrants it issues, as either liability or equity, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, then in accordance with ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock. Under ASC 480-10, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate AgeX to settle the warrants or the underlying shares by paying cash or other assets, or warrants that must or may require settlement by issuing a variable number of shares. If warrants do not meet liability classification under ASC 480-10, AgeX assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, and in order to conclude equity classification, AgeX also assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable provisions of U.S. GAAP. After all relevant assessments, AgeX concludes whether the warrants are classified as liability or equity. Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance with all changes in fair value after the issuance date recorded in the consolidated statements of operations. Equity classified warrants only require fair value accounting at issuance with no changes recognized subsequent to the issuance date. AgeX has liability classified warrants as of December 31, 2023. See Notes 5, Related Party Transactions, and 6, Warrant Liability, for additional information regarding AgeX warrants.

Stock-Based Compensation AgeX recognizes compensation expense related to employee option grants and restricted stock grants, if any, in accordance with ASC 718, Compensation – Stock Compensation (“ASC 718”). AgeX estimates the fair value of employee stock-based payment awards on the grant-date and recognizes the resulting fair value, net of estimated forfeitures for grants prior to 2017, over the requisite service period. Upon adoption of ASU 2016-09 on January 1, 2017 as further discussed below, forfeitures are accounted for as they occur instead of based on the number of awards that were expected to vest prior to adoption of ASU 2016-09. AgeX uses the Black-Scholes option pricing model for estimating the fair value of options granted under AgeX’s 2017 Equity Incentive Plan (the “Incentive Plan”). The fair value of each restricted stock grant, if any, is determined based on the value of the common stock granted or sold. AgeX has elected to treat stock-based payment awards with time-based service conditions as a single award and recognizes stock-based compensation on a straight-line basis over the requisite service period. Compensation expense for non-employee stock-based awards is recognized in accordance with ASC 718. Stock option awards issued to non-employees, principally consultants or outside contractors, as applicable, are accounted for at fair value using the Black-Scholes option pricing model. Management believes that the fair value of the stock options and restricted stock units can more reliably be measured than the fair value of services received. AgeX records compensation expense based on the then-current fair values of the stock options and restricted stock units at the grant date. Compensation expense for non-employee grants is recorded on a straight-line basis in the consolidated statements of operations. The Black-Scholes option pricing model requires AgeX to make certain assumptions including the fair value of the underlying common stock, the expected term, the expected volatility, the risk-free interest rate and the dividend yield (see Note 8, Stock-Based Awards). The fair value of the shares of common stock underlying the stock options is determined in accordance with the Incentive Plan and is based on prevailing market prices on the NYSE American where AgeX common stock is traded. The expected term of employee stock options represents the weighted-average period that the stock options are expected to remain outstanding. AgeX estimates the expected term of options granted using the “simplified method” provided under Staff Accounting Bulletin Topic 14, or SAB Topic 14. Because AgeX’s common stock has public trading history of fewer than five years, AgeX has estimated the expected volatility using its own stock price volatility to the extent applicable or a combination of its stock price volatility and the stock price volatility of peer companies, for a period equal to the expected term of the options, which may exceed five years. The peer companies used include selected public companies within the biotechnology industry with comparable characteristics to AgeX, including similarity in size, lines of business, market capitalization, revenue and financial leverage. The risk-free interest rate assumption is based upon observed interest rates on the United States government securities appropriate for the expected term of AgeX’s stock options. The dividend yield assumption is based on AgeX’s history and expectation of dividend payouts. AgeX has never declared or paid any cash dividends on its common stock, and AgeX does not anticipate paying any cash dividends in the foreseeable future. All excess tax benefits and tax deficiencies from stock-based compensation awards accounted for under ASC 718 are recognized as an income tax benefit or expense, respectively, in the consolidated statements of operations. An excess income tax benefit arises when the tax deduction of a share-based award for income tax purposes exceeds the compensation cost recognized for financial reporting purposes and, a tax deficiency arises when the compensation cost exceeds the tax deduction. Stock-based compensation expense for the years ended December 31, 2023 and 2022 consists of stock-based compensation under the AgeX Incentive Plan (see Note 8, Stock-Based Awards). Certain of AgeX’s consolidated subsidiaries have had their own share-based compensation plans; however, there are no awards granted and outstanding under those plans as of December 31, 2023 and 2022. For share-based compensation awards granted by privately held consolidated subsidiaries under their respective equity plans, AgeX determines the fair value of the options granted under those plans using similar methodologies and assumptions AgeX used for its stock options discussed above. Although the fair value of stock options and restricted stock units is determined in accordance with FASB guidance, changes in the assumptions and allocations can materially affect the estimated value and therefore the amount of compensation expense recognized in the consolidated financial statements.

Income Taxes AgeX accounts for income taxes in accordance with ASC 740, which prescribes the use of the asset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and enacted rates in effect. Valuation allowances are established when necessary to reduce deferred tax assets when it is more likely than not that a portion or all of the deferred tax assets will not be realized. AgeX’s judgments, estimates and projections regarding future taxable income may change over time due to changes, among other factors, in market conditions, changes in tax laws, and tax planning strategies. If AgeX’s assumptions and consequently its estimates change in the future, the valuation allowance may be increased or decreased, which may have a material impact on AgeX’s consolidated financial statements. The guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities. AgeX recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No unrecognized tax benefits have been recorded and no amounts were accrued for the payment of interest and penalties as of December 31, 2023 and 2022. AgeX does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. AgeX is currently unaware of any tax issues under review.

Revenue Recognition AgeX recognizes revenue in a manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the consideration it expects to receive in exchange for such product or service. In doing so, AgeX follows a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) the customer obtains control of the product or service. AgeX considers the terms of a contract and all relevant facts and circumstances when applying the revenue recognition standard. AgeX applies the revenue recognition standard, including the use of any practical expedients, consistently to contracts with similar characteristics and in similar circumstances. In the applicable paragraphs below, AgeX has summarized its revenue recognition policies for its various revenue sources in accordance with Topic 606. Revenue recognition by source and geography – Revenues are recognized when control of the promised goods or services is transferred to customers, or in the case of governmental entities funding a grant, when allowable expenses are incurred, in an amount that reflects the consideration AgeX or a subsidiary, depending on which company has the customer or the grant, expects to be entitled to in exchange for those goods or services. The following table presents AgeX’s consolidated revenues disaggregated by source for operations (in thousands): Schedule of Disaggregated of Revenues <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">REVENUES:</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20230101__20231231_zS6OVWWDdZsd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20220101__20221231_zaemvQoXIaee" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">REVENUES:</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--GrantRevenuesMember_zXMEKMi9uZAf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Grant revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">77</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--OtherRevenuesMember_zMkFTWBBH1od" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Other revenues</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">65</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">34</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zuW5xB1rwPof" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total revenues</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">142</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">34</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The following table presents consolidated revenues for operations (in thousands), disaggregated by geography, based on the billing addresses of customers: Schedule of Disaggregated Geographical Revenue <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">REVENUES:</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20230101__20231231_zEwqOMG13Jd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20220101__20221231_zUj9cYQ3hdY5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">REVENUES:</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__country--US_zLRF1yU43Nv" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">United States</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">90</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">10</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__custom--ForeignMember_zudc5O7nzrKk" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">52</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">24</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zoqFVmBXwzM9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total revenues</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">142</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">34</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Grant revenues – AgeX accounts for grants received to perform research and development services in accordance with ASC 730-20, Research and Development Arrangements. At the inception of the grant, we perform an assessment as to whether the grant is a liability or a contract to perform research and development services for others. If AgeX or a subsidiary receiving the grant is obligated to repay the grant funds to the grantor regardless of the outcome of the research and development activities, then AgeX is required to estimate and recognize that liability. Alternatively, if AgeX or a subsidiary receiving the grant is not required to repay, or if it is required to repay the grant funds only if the research and development activities are successful, then the grant agreement is accounted for as a contract to perform research and development services for others, in which case, grant revenue is recognized when the related research and development expenses are incurred. In applying the provisions of Topic 606, AgeX has determined that government grants are out of the scope of Topic 606 because the government entities do not meet the definition of a “customer”, as defined by Topic 606, as there is not considered to be a transfer of control of good or services to the government entities funding the grant. In the absence of applicable guidance under U.S. GAAP, our policy is to recognize grant revenue when the related costs are incurred, provided that the applicable conditions under the government contracts have been met. Only costs that are allowable under the grant award, certain government regulations and the National Institutes of Health’s supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. Costs incurred are recorded in research and development expenses on the accompanying consolidated statements of operations. In applying the provisions of Topic 606, AgeX has determined that government grants are out of the scope of Topic 606 because the government entities do not meet the definition of a “customer”, as defined by Topic 606, as there is not considered to be a transfer of control of good or services to the government entities funding the grant. In the absence of applicable guidance under U.S. GAAP, our policy is to recognize grant revenue when the related costs are incurred, provided that the applicable conditions under the government contracts have been met. Only costs that are allowable under the grant award, certain government regulations and the National Institutes of Health (“NIH”) supplemental policy and procedure manual may be claimed for reimbursement, and the reimbursements are subject to routine audits from governmental agencies from time to time. Costs incurred are recorded in research and development expenses on the accompanying consolidated statements of operations. AgeX believes the recognition of revenue as costs are incurred and amounts become realizable is analogous to the concept of transfer of control of a service over time under ASC 606. In August 2023, AgeX was awarded a grant of up to approximately $341,000 from the NIH, National Heart, Lung and Blood Institute. The NIH grant will provide funding for continued development of AgeX’s technologies toward treating cardiovascular disease over a one year period starting September 1, 2023. Based on our evaluation under the accounting guidance aforementioned, this grant agreement is accounted for as a contract to perform research and development services for others, in which case, grant revenue is recognized when the related research and development expenses are incurred. Accordingly, grant funds are made available by the NIH as allowable expenses are incurred. For the year ended December 31, 2023, AgeX incurred approximately $77,000 of allowable expenses under the NIH grant and recognized a corresponding amount of grant revenues. ESI BIO research products – AgeX, through its ESI BIO research product division, markets a number of products related to human pluripotent stem cells (“PSC lines”), including research-grade PSC lines and PSC lines produced under current good manufacturing practices or “cGMP.” AgeX offers cells from PSC lines to customers under contracts that permit the customers to utilize PSC lines for the research, development, and commercialization of cell-based therapies or other products in defined fields of application. The compensation to AgeX for providing the PSC line cells under such contracts may include up-front payments, milestone payments related to product development, regulatory matters, and commercialization, and the payment of royalties on sales of products developed from AgeX PSC lines. Revenues from the sale of research products are included in other revenues. Arrangements with multiple performance obligations – AgeX may enter into contracts with customers that include multiple performance obligations. For such arrangements, AgeX will allocate revenue to each performance obligation based on its relative standalone selling price. AgeX will determine or estimate standalone selling prices based on the prices charged, or that would be charged, to customers for that product or service. As of and for the years ended December 31, 2023 and 2022, AgeX did not have significant arrangements with multiple performance obligations.

The following table presents AgeX’s consolidated revenues disaggregated by source for operations (in thousands): Schedule of Disaggregated of Revenues <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">REVENUES:</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20230101__20231231_zS6OVWWDdZsd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20220101__20221231_zaemvQoXIaee" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">REVENUES:</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--GrantRevenuesMember_zXMEKMi9uZAf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Grant revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">77</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--OtherRevenuesMember_zMkFTWBBH1od" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Other revenues</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">65</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">34</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zuW5xB1rwPof" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total revenues</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">142</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">34</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

77000

65000

34000

142000

34000

The following table presents consolidated revenues for operations (in thousands), disaggregated by geography, based on the billing addresses of customers: Schedule of Disaggregated Geographical Revenue <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">REVENUES:</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20230101__20231231_zEwqOMG13Jd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20220101__20221231_zUj9cYQ3hdY5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">REVENUES:</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__country--US_zLRF1yU43Nv" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">United States</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">90</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">10</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__custom--ForeignMember_zudc5O7nzrKk" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">52</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">24</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zoqFVmBXwzM9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total revenues</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">142</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">34</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

90000

10000

52000

24000

142000

34000

341000

77000

Research and Development Research and development expenses consist primarily of personnel costs and related benefits, including stock-based compensation, amortization of intangible assets, outside consultants and contractors, sponsored research agreements with certain universities, and suppliers, and license fees paid to third parties to acquire patents or licenses to use patents and other technology. Research and development expenses incurred and reimbursed by grants from third parties or governmental agencies if any and as applicable, approximate the respective revenues recognized in the consolidated statements of operations.

General and Administrative General and administrative expenses consist primarily of compensation and related benefits, including stock-based compensation, for executive and corporate personnel, and professional and consulting fees.

Segments AgeX’s executive management team, as a group, represents the entity’s chief operating decision makers. To date, AgeX’s executive management team has viewed AgeX’s operations as one segment that includes the research and development of regenerative medicine technologies targeting the diseases of aging and metabolic disorders, oncology, and neurological diseases and disorders, blood and vascular system diseases and disorders, and pluripotent cell technologies. As a result, the financial information disclosed materially represents all of the financial information related to AgeX’s sole operating segment.

Basic and Diluted Net Loss per Share Attributable to Common Stockholders Basic loss per share is calculated by dividing net loss attributable to AgeX common stockholders by the weighted average number of shares of common stock outstanding, net of unvested restricted stock or restricted stock units, subject to repurchase by AgeX, if any, during the period. Diluted loss per share is calculated by dividing the net income attributable to AgeX common stockholders, if any, by the weighted average number of shares of common stock outstanding, adjusted for the effects of potentially dilutive common stock issuable under outstanding stock options, warrants, and restricted stock units, using the treasury-stock method, and convertible preferred stock, if any, using the if-converted method, and treasury stock held by subsidiaries, if any. For the years ended December 31, 2023 and 2022, because AgeX reported a net loss attributable to common stockholders, all potentially dilutive common stock, comprised of stock options, restricted stock units and warrants, is antidilutive. <p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zzBK40jBzsV2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following weighted-average common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive (in thousands): Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z6MIBX1uZWt7" style="width: 11%; text-align: right" title="Anti-dilutive securities">91</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zXcT4CABv6Ve" style="width: 11%; text-align: right" title="Anti-dilutive securities">94</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.1in; padding-left: 0.1in">Warrants (1)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDEp_zLP9XP3TjF4d" style="text-align: right" title="Anti-dilutive securities">352</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDEp_zbzWuxEj9Yle" style="text-align: right" title="Anti-dilutive securities">272</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Restricted stock units</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zEWfhv4tj4Rj" style="text-align: right" title="Anti-dilutive securities">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zw01Exx1jArh" style="text-align: right" title="Anti-dilutive securities">-</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td id="xdx_F0D_zrsjArEBBQHj" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(1)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As of December 31, 2023 and 2022, warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFudGlkaWx1dGl2ZSBTZWN1cml0aWVzIEV4Y2x1ZGVkIGZyb20gQ29tcHV0YXRpb24gb2YgRWFybmluZ3MgUGVyIFNoYXJlIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementsMember_zEWiif3az2Q4" title="Warrant to purchase shares of common stock">320,115 and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFudGlkaWx1dGl2ZSBTZWN1cml0aWVzIEV4Y2x1ZGVkIGZyb20gQ29tcHV0YXRpb24gb2YgRWFybmluZ3MgUGVyIFNoYXJlIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementsMember_zU8YGmMZzT19" title="Warrant to purchase shares of common stock">344,875 shares, respectively, of AgeX common stock were issued and outstanding and held by Juvenescence as consideration for certain loan agreements discussed in Note 5, Related Party Transactions. Amounts shown in the table are weighted average amounts and reflect the fact that the warrants were issued on various dates during applicable periods presented.</td></tr></table>

<p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zzBK40jBzsV2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following weighted-average common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive (in thousands): Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z6MIBX1uZWt7" style="width: 11%; text-align: right" title="Anti-dilutive securities">91</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zXcT4CABv6Ve" style="width: 11%; text-align: right" title="Anti-dilutive securities">94</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.1in; padding-left: 0.1in">Warrants (1)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDEp_zLP9XP3TjF4d" style="text-align: right" title="Anti-dilutive securities">352</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDEp_zbzWuxEj9Yle" style="text-align: right" title="Anti-dilutive securities">272</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Restricted stock units</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zEWfhv4tj4Rj" style="text-align: right" title="Anti-dilutive securities">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zw01Exx1jArh" style="text-align: right" title="Anti-dilutive securities">-</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td id="xdx_F0D_zrsjArEBBQHj" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(1)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As of December 31, 2023 and 2022, warrants to purchase <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFudGlkaWx1dGl2ZSBTZWN1cml0aWVzIEV4Y2x1ZGVkIGZyb20gQ29tcHV0YXRpb24gb2YgRWFybmluZ3MgUGVyIFNoYXJlIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementsMember_zEWiif3az2Q4" title="Warrant to purchase shares of common stock">320,115 and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEFudGlkaWx1dGl2ZSBTZWN1cml0aWVzIEV4Y2x1ZGVkIGZyb20gQ29tcHV0YXRpb24gb2YgRWFybmluZ3MgUGVyIFNoYXJlIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementsMember_zU8YGmMZzT19" title="Warrant to purchase shares of common stock">344,875 shares, respectively, of AgeX common stock were issued and outstanding and held by Juvenescence as consideration for certain loan agreements discussed in Note 5, Related Party Transactions. Amounts shown in the table are weighted average amounts and reflect the fact that the warrants were issued on various dates during applicable periods presented.</td></tr></table>

91000

94000

352000

272000

320115

344875

Recently Adopted Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, and subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04, ASU 2019-05 and ASU 2019-10, which amends the current approach to estimate credit losses on certain financial assets. This ASU requires immediate recognition of management’s estimates of current expected credit losses. Under the prior model, losses were recognized only as they were incurred, which FASB has noted delayed recognition of expected losses that might not yet have met the threshold of being probable. The standard is applicable to all financial assets (and net investment in leases) that are not accounted for at fair value through net income, such as trade receivables, loans, debt securities, and net investment in leases, thereby bringing consistency in accounting treatment across different types of financial instruments and requiring consideration of a broader range of variables when forming loss estimates. Subsequent changes in the valuation allowance are recorded in current earnings and reversal of previous losses are permitted. AgeX adopted this standard as of January 1, 2023, and it did not have a material impact on the consolidated financial statements. In March 2022, the FASB issued ASU 2022-01, Derivatives and Hedging (Topic 815): Fair Value Hedging – Portfolio Layer Method, which clarifies the guidance in ASC 815 on fair value hedge accounting of interest rate risk for portfolios of financial assets. The ASU amends the guidance in ASU 2017-12 (released on August 28, 2017) that, among other things, established the “last-of-layer” method for making the fair value hedge accounting for these portfolios more accessible. ASU 2022-01 renames that method the “portfolio layer” method and addresses feedback from stakeholders regarding its application. AgeX adopted this standard as of January 1, 2023, and it did not have a material impact on the consolidated financial statements. In March 2022, the FASB issued ASU 2022-02, Financial Instruments – Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures, which amends the accounting for credit losses on financial instruments. This amendment eliminates the recognition and measurement guidance on troubled debt restructurings for creditors that have adopted the new credit losses guidance in ASC 326 and requires enhanced disclosures about loan modifications for borrowers experiencing financial difficulty. The new guidance also requires public business entities to present gross write-offs by year of origination in their vintage disclosures. The guidance became effective for AgeX on January 1, 2023 and includes interim periods. Entities can elect to adopt the guidance on troubled debt restructurings using either a prospective or modified retrospective transition. If an entity elects to apply a modified retrospective transition, it will record a cumulative effect adjustment to retained earnings in the period of adoption. This ASU did not have a material impact on the consolidated financial statements. On July 14, 2023, the FASB issued ASU 2023-03, Presentation of Financial Statements (Topic 205), Income Statement – Reporting Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation – Stock Compensation, which amends or supersedes various Securities and Exchange Commission (“SEC”) paragraphs within the codification to conform to past announcements and guidance issued by the SEC. Specifically, the ASU responds to (1) the issuance of SEC Staff Accounting Bulletin (SAB) 120; (2) the SEC staff announcement at the March 24, 2022, EITF meeting; and (3) SAB Topic 6.B, “Accounting Series Release No. 280 — General Revision of Regulation S-X: Income or Loss Applicable to Common Stock.” This ASU is effective immediately and did not have a material impact on AgeX’s consolidated financial statements.

Recently Issued Accounting Pronouncements Not Yet Adopted In August 2023, the FASB issued ASU 2023-05, Business Combinations—Joint Venture Formations (Subtopic 805-60): Recognition and Initial Measurement, under which an entity that qualifies as either a joint venture or a corporate joint venture as defined in the FASB ASC master glossary is required to apply a new basis of accounting upon the formation of the joint venture. Specifically, the ASU provides that a joint venture or a corporate joint venture (collectively, “joint ventures”) must initially measure its assets and liabilities at fair value on the formation date. This ASU is effective for AgeX beginning January 1, 2025 and is not expected to have a material impact on the consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to income Tax Disclosures, under which entities must consistently categorize and provide greater disaggregation of information in the rate reconciliation. They must also further disaggregate income taxes paid. ASU 2023-09 enhances annual income tax disclosures to address investor requests for more information about the tax risks and opportunities present in an entity’s worldwide operations. This ASU is effective for AgeX beginning January 1, 2025 and is not expected to have a material impact on the consolidated financial statements.

3. Selected Balance Sheet Components Intangible Assets, Net On August 13, 2018, AgeX entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Escape Therapeutics, Inc. (“Escape”) pursuant to which AgeX acquired certain patents and patent applications related primarily to methods of modifying cells and tissues and certain pluripotent stem cell lines so as to reduce their risk of being rejected when transplanted. This technology is called “UniverCyte™.” AgeX paid Escape $1,072,436 in cash and issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20180812__20180813__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_z27g00XctqVc" title="Number of shares issued for acquired, shares">2,274 shares of AgeX common stock, with an approximate value of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_c20180812__20180813__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zj9eXllfRoNl" title="Number of shares issued for aquired">240,000, for aggregate acquisition cost of $<span id="xdx_906_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_pn5n6_c20180812__20180813__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zmavck3N3Abk" title="Aggregate of acquisition cost">1.3 million for the UniverCyte™ assets. The Purchase Agreement was considered an asset acquisition rather than a business combination in accordance with ASC 805-50, Business Combinations. ASC 730-10-25(c), Research and Development – Intangible Assets Purchased from Others, provides guidance for acquisition and capitalization of the cost of intangible assets purchased from others in an asset acquisition that have alternative future uses in other research and development projects. These intangible assets are referred to as acquired IPR&D with alternative future uses and are accounted for as intangible assets and amortized to research and development over their useful life. Acquired IPR&D in an asset acquisition that does not have any alternative future uses is expensed under the same guidance. As an initial focus, AgeX intends to use the UniverCyte™ technology in the development of its two lead products, AGEX-BAT1 and AGEX-VASC1 for the treatment of Type II diabetes and cardiovascular aging, respectively. Accordingly, AgeX recorded the UniverCyte™ technology acquired from Escape as IPR&D intangible assets with alternative future uses in accordance with ASC 730-10-25(c) and is amortizing those assets to research and development expense over their estimated 10-year useful life. In addition to the purchase price, AgeX will pay Escape a royalty of less than 1% on net sales of products, processes and services under the acquired patents if the assets are commercialized. Additional shares of AgeX common stock totaling up to $4.3 million of market value will also be issued to Escape upon the attainment of development and regulatory approval milestones by AgeX for each product covered by the acquired patents. Contingent consideration in an asset acquisition is generally recorded when probable and estimable in accordance with ASC 450, Contingencies. Accordingly, none of the milestone payments have been accrued since the attainment of any milestone in the Purchase Agreement was not probable as of December 31, 2023. AgeX estimated the future undiscounted cash flows expected to be received from the assets developed through the use of the UniverCyte™ technology when commercialized. The estimate of the future undiscounted cash flows considered AgeX’s financial condition and the royalties that may become payable to Escape. At December 31, 2023 and 2022, intangible assets, primarily consisting of acquired IPR&D and patents, and accumulated amortization were as follows (in thousands): Schedule of Intangible Assets, Net <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20231231_zCeXzBW6MNTl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20221231_zpCD9kueIqab" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_maFLIANz8a7_zcdK3KCK3U8i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Intangible assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,312</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,312</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pn3n3_di_msFLIANz8a7_z6Zz5HH7Z7rg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accumulated amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(705</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(574</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iTI_pn3n3_mtFLIANz8a7_zgqioDynClT6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total intangible assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">607</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">738</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> AgeX recognized $131,000 and $132,000 in amortization expense of intangible assets, included in research and development expenses, for the years ended December 31, 2023 and 2022, respectively. <p id="xdx_89B_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zg0QQu8AGWRf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Amortization of intangible assets for periods subsequent to December 31, 2023 is as follows (in thousands): Schedule of Amortization Assets <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Year Ending December 31,</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20221231_zHqK2LCs8rp2" style="border-bottom: Black 1.5pt solid; text-align: center">Amortization Expense</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzFZe_zDS39TwZ2IW4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">131</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzFZe_ziiOQJtCVCl6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">131</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzFZe_zfQSQNB5JPT" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">132</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzFZe_z63ysv3TBYF3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">131</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANzFZe_z8sS4a4hJW6h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">2028</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">82</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzFZe_z918UISRAlRf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">607</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Accounts Payable and Accrued Liabilities At December 31, 2023 and 2022, accounts payable and accrued liabilities were comprised of the following (in thousands): Schedule of Accounts Payable and Accrued Liabilities <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20231231__us-gaap--BalanceSheetLocationAxis__us-gaap--AccountsPayableAndAccruedLiabilitiesMember_zbTPH1ENON64" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20221231__us-gaap--BalanceSheetLocationAxis__us-gaap--AccountsPayableAndAccruedLiabilitiesMember_zh3EYwIt4Utg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--AccountsPayableCurrent_iI_pn3n3_maAPAALzD83_zn11k5GSIGi1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Accounts payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,413</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">568</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AccruedLiabilitiesCurrent_iI_pn3n3_maAPAALzD83_zDkHlLiLseu" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued vendors and other expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">529</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">273</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AccruedBonusesCurrent_iI_pn3n3_maAPAALzD83_zpofhCIs0F0j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Accrued compensation and severance expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">234</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">193</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTI_pn3n3_mtAPAALzD83_zbktQO7wuEZ7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total accounts payable and accrued liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,176</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,034</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1072436

2274

240000

1300000

P10Y

0.01

4300000

At December 31, 2023 and 2022, intangible assets, primarily consisting of acquired IPR&D and patents, and accumulated amortization were as follows (in thousands): Schedule of Intangible Assets, Net <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20231231_zCeXzBW6MNTl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20221231_zpCD9kueIqab" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_maFLIANz8a7_zcdK3KCK3U8i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Intangible assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,312</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,312</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pn3n3_di_msFLIANz8a7_z6Zz5HH7Z7rg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accumulated amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(705</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(574</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iTI_pn3n3_mtFLIANz8a7_zgqioDynClT6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total intangible assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">607</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">738</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1312000

705000

574000

607000

738000

131000

132000

<p id="xdx_89B_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zg0QQu8AGWRf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Amortization of intangible assets for periods subsequent to December 31, 2023 is as follows (in thousands): Schedule of Amortization Assets <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Year Ending December 31,</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20221231_zHqK2LCs8rp2" style="border-bottom: Black 1.5pt solid; text-align: center">Amortization Expense</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzFZe_zDS39TwZ2IW4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">131</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzFZe_ziiOQJtCVCl6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">131</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzFZe_zfQSQNB5JPT" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">132</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzFZe_z63ysv3TBYF3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">131</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANzFZe_z8sS4a4hJW6h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">2028</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">82</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzFZe_z918UISRAlRf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">607</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

131000

132000

131000

82000

607000

At December 31, 2023 and 2022, accounts payable and accrued liabilities were comprised of the following (in thousands): Schedule of Accounts Payable and Accrued Liabilities <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20231231__us-gaap--BalanceSheetLocationAxis__us-gaap--AccountsPayableAndAccruedLiabilitiesMember_zbTPH1ENON64" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20221231__us-gaap--BalanceSheetLocationAxis__us-gaap--AccountsPayableAndAccruedLiabilitiesMember_zh3EYwIt4Utg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--AccountsPayableCurrent_iI_pn3n3_maAPAALzD83_zn11k5GSIGi1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Accounts payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,413</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">568</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AccruedLiabilitiesCurrent_iI_pn3n3_maAPAALzD83_zDkHlLiLseu" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued vendors and other expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">529</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">273</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AccruedBonusesCurrent_iI_pn3n3_maAPAALzD83_zpofhCIs0F0j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Accrued compensation and severance expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">234</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">193</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTI_pn3n3_mtAPAALzD83_zbktQO7wuEZ7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total accounts payable and accrued liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,176</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,034</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1413000

568000

529000

273000

234000

193000

2176000

1034000

4. Convertible Note Receivable On March 15, 2023, AgeX and Serina entered into a Convertible Note Purchase Agreement (the “Serina Note Purchase Agreement”), pursuant to which AgeX lent to Serina an aggregate principal amount of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20230315__dei--LegalEntityAxis__custom--JuvenescenceMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember_znRlbSHDaW6f">10,000,000 as evidenced by the Serina Note on that date. Interest on the principal amount under the Serina Note accrues on the unpaid principal amount at a simple interest rate equal to <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230315__dei--LegalEntityAxis__custom--JuvenescenceMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember_zWYA6rsAaEX1" title="Interest rate">7% per annum, computed on the basis of the 360-day year of twelve 30-day months. The outstanding principal amount and accrued interest of $<span id="xdx_90F_eus-gaap--DepositLiabilitiesAccruedInterest_iI_c20230315__dei--LegalEntityAxis__custom--JuvenescenceMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNotePurchaseAgreementMember_zimtwfsqsQ0c" title="Accrued interest">10,544,000 under the Serina Note will become due and payable on March 15, 2026. In connection with the issuance of the Serina Note, AgeX is entitled to elect one member to the board of directors of Serina and receive certain information and inspection rights as well as participation rights for subsequent equity issuances. The principal balance of the Serina Note with accrued interest will automatically convert into Serina preferred stock if Serina raises at least $25,000,000 through the sale of shares of Serina preferred stock (“qualifying event”). The conversion price per share shall be the lower of (a) <span id="xdx_90E_ecustom--StockholderOutstandingPercentage_iI_pid_dp_uPure_c20230315__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember_zXjQC7nKvZLj" title="Stockholder outstanding percentage">80% of the lowest price at which the shares of preferred stock were sold, and (b) a “capped price” equal to $105,000,000 divided by Serina’s then fully diluted capitalization. AgeX has the option to convert the Serina Note into Serina preferred stock after a sale of Serina preferred stock regardless of the amount sold by Serina. AgeX evaluated the <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230315__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember_zGeKWC7X9sha" title="Discounted conversion price">20% discounted conversion feature of the Serina Note under ASC 815-15, Derivatives and Hedging—Embedded Derivatives, and concluded that it was an embedded derivative which should be bifurcated from the note and accounted for separately. The <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230315__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember_zM51UFrrkLJ4" title="Discounted conversion price">20% discount was determined to have an immaterial value at inception and life to date of the Serina Note, as the probability of a future qualifying event is remote. The likelihood of the future qualifying event will be evaluated at the end of each reporting period and any adjustments will be included in Interest expense, net in the Other expense, net section of the consolidated statements of operations. AgeX may (i) at its election, upon a change of control (as defined in the Serina Note), convert the Serina Note in whole or in part into either (a) cash in an amount equal to <span id="xdx_90C_eus-gaap--LongTermDebtPercentageBearingFixedInterestRate_iI_pid_dp_uPure_c20230315__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_zQammSs2PzU2" title="Outstanding percent">100% of the outstanding principal amount of the Serina Note, plus interest, or (b) into the highest ranking shares of Serina then issued at a conversion price equal to the lowest price per share at which the most senior series of Serina shares has been sold in a single transaction or a series of related transactions through which Serina raised at least $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20230315__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_ztK8zQhtzy7" title="Principal amount">5,000,000 or (ii) if the Serina Note remains outstanding as of the maturity date, AgeX may convert the Serina Note into the most senior shares of Serina issued at the time of conversion at a conversion price equal to the capped price. If the Merger is consummated, the Serina Note will be canceled for no consideration. The outstanding principal balance of the Serina Note with accrued interest may become immediately due and payable prior to the stated maturity date if an Event of Default as defined in the Serina Note occurs. In addition to this and any other remedy, both in equity and in law, upon the occurrence of an Event of Default, an interest rate of 10% per annum and computed on the basis of the 360-day year of twelve 30-day months, shall apply to the Convertible Amount until fully paid. Events of Default under the Serina Note include: (i) the commission of any act of bankruptcy by Serina or any Significant Subsidiary (as such term is defined in Rule 1-02(w) of Regulation S-X), (ii) the execution by Serina of a general assignment for the benefit of creditors, (iii) the filing by or against Serina or any Significant Subsidiary (as such term is defined in Rule 1-02(w) of Regulation S-X) of a petition in bankruptcy or any petition for relief under the federal bankruptcy act (or, in each case, under any similar insolvency law) or the continuation of such petition without dismissal for a period of 60 calendar days or more, (iv) the appointment of a receiver or trustee to take possession of the property or assets of Serina or any Significant Subsidiary (as such term is defined in Rule 1-02(w) of Regulation S-X), (v) failure of Serina to pay any amount due under the Serina Note when due, which failure to pay is not cured by Serina within 5 business days of written notice thereof, (vi) unless waived by AgeX, Serina’s material breach of any representation, warranty or covenant of Serina under the Serina Note Purchase Agreement, Serina Note or other agreements entered in connection therewith, which breach, if curable, is not cured by Serina within 10 business days of written notice by AgeX thereof, (vii) Serina or any subsidiary shall default on any of its obligations under any indebtedness which default causes the indebtedness thereunder to (x) become prematurely due and payable, (y) be placed on demand or (z) become capable of being declared by or on behalf of a creditor thereunder to be prematurely due and payable or being placed on demand, in each case, as a result of such default or any provision having a similar effect (howsoever prescribed), (viii) any monetary judgment, writ or similar final process shall be entered or filed against Serina, any subsidiary or any of their respective property or other assets for more than $250,000, and such judgment, writ or similar final process shall remain unvacated, unbonded or unstayed for a period of 45 calendar days, and (ix) Serina experiences a Material Adverse Effect (as defined in the Serina Note Purchase Agreement). The Serina Note Purchase Agreement and Serina Note each includes certain covenants that among other matters require financial reporting and impose certain restrictions, including (i) restrictions on the incurrence of additional indebtedness by Serina and its subsidiaries; (ii) requiring that Serina use note proceeds and funds that may be raised through certain equity offerings only for research and development work, professional and administrative expenses, and for general working capital; and (iii) prohibiting Serina from entering into any material sale or transfer transactions outside of the ordinary course of business, other than in a merger between AgeX and Serina, without the consent of AgeX. Subordination Agreement In connection with the issuance of the Serina Note, Serina, each other holder of Serina indebtedness (each a “Serina Lender”), and AgeX entered into a Subordination Agreement, dated March 15, 2023, pursuant to which each Serina Lender agreed to subordinate to AgeX’s rights of repayment with respect to the obligations owed under the Serina Note Purchase Agreement and the Serina Note (i) all Serina indebtedness owed to such Serina Lender under certain convertible notes between each Serina Lender and Serina, which aggregate principal amount of all of such convertible notes equals $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230315__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__us-gaap--TypeOfArrangementAxis__custom--SubordinationAgreementMember_zd38jU7zYbGk" title="Principal amount">1,450,000, and (ii) any related security interests.

10000000

0.07

10544000

25000000

0.80

105000000

0.20

5000000

0.10

250000

1450000

5. Related Party Transactions During July 2023, AgeX and Juvenescence entered into an Exchange Agreement pursuant to which AgeX issued shares of Series A Preferred Stock and Series B Preferred Stock to Juvenescence in exchange for the extinguishment of a total of $36 million of indebtedness under the 2020 Loan Agreement, the 2022 Secured Note, and the 2023 Secured Note discussed below. The unused portion of the line of credit under the 2022 Secured Note remains available to AgeX subject to the terms and conditions of the 2022 Secured Note. The Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of AgeX common stock on February 1, 2024. See Notes 7, Stockholders’ Equity/(Deficit), and 11, Subsequent Events. 2019 Loan Agreement On August 13, 2019, AgeX and Juvenescence entered into a Loan Facility Agreement (the “2019 Loan Agreement”) pursuant to which Juvenescence provided to AgeX a $<span id="xdx_907_eus-gaap--LineOfCredit_iI_pn5n6_c20190813__dei--LegalEntityAxis__custom--JuvenescenceMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandNineteenLoanAgreementMember_zfizw4QzGdt4" title="Line of credit facility">2.0 million line of credit for a period of <span id="xdx_908_eus-gaap--LineOfCreditFacilityExpirationPeriod_dtM_c20190812__20190813__dei--LegalEntityAxis__custom--JuvenescenceMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandNineteenLoanAgreementMember_zEs0440DygU" title="Line of credit, term">18 months. On February 10, 2021, AgeX entered into an amendment (the “First Amendment”) to the 2019 Loan Agreement which extended the maturity date of loans under the 2019 Loan Agreement to February 14, 2022, and increased the amount of the loan facility by $<span id="xdx_900_eus-gaap--LineOfCreditFacilityIncreaseDecreaseForPeriodNet_pn5n6_c20210209__20210210__dei--LegalEntityAxis__custom--JuvenescenceMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandNineteenLoanAgreementMember_ziTAaLBpM5oh" title="Increase in line of credit">4.0 million. On November 8, 2021, AgeX entered into Amendment No. 2 to the 2019 Loan Agreement which increased the amount of the loan facility by another $<span id="xdx_903_eus-gaap--LineOfCreditFacilityIncreaseDecreaseForPeriodNet_pn5n6_c20211107__20211108__us-gaap--TypeOfArrangementAxis__custom--TwoThousandNineteenLoanAgreementMember__dei--LegalEntityAxis__custom--JuvenescenceMember_zZsHjQuH59Ca" title="Increase in line of credit">1.0 million. As of December 31, 2021, AgeX had borrowed all of the $<span id="xdx_905_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn5n6_c20211231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandNineteenLoanAgreementMember__dei--LegalEntityAxis__custom--JuvenescenceMember_zFcDvssMqsjk" title="Line of credit facility">7.0 million total line of credit under the 2019 Loan Agreement, as amended. On February 14, 2022, AgeX refinanced the $<span id="xdx_90B_eus-gaap--LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_pn5n6_c20220214__20220214__us-gaap--TypeOfArrangementAxis__custom--TwoThousandNineteenLoanAgreementMember__dei--LegalEntityAxis__custom--JuvenescenceMember_zDEFKeL12fod" title="Line of credit outstanding principal">7.0 million outstanding principal amount of the loans and a $<span id="xdx_90A_eus-gaap--DebtInstrumentFeeAmount_iI_pn3p0_c20220214__us-gaap--TypeOfArrangementAxis__custom--TwoThousandNineteenLoanAgreementMember__dei--LegalEntityAxis__custom--JuvenescenceMember_zsVSA9Qa8XMi" title="Origination fee">160,000 origination fee due under the 2019 Loan Agreement, as amended. See discussion regarding the 2022 Secured Convertible Promissory Note within this Note 5. 2020 Loan Agreement On March 30, 2020, AgeX and Juvenescence entered into a new Secured Convertible Facility Agreement (the “2020 Loan Agreement”) pursuant to which Juvenescence provided to AgeX an $8.0 million line of credit for a period of <span id="xdx_909_eus-gaap--LineOfCreditFacilityExpirationPeriod_dtM_c20200329__20200330__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyLoanAgreementMember_z13hAHRv01Vi" title="Line of credit, term">18 months. Through December 31, 2023, AgeX had drawn the full $<span id="xdx_905_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn5n6_c20231231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyLoanAgreementMember_zCAJhnfP1wTh" title="Line of credit facility, current borrowing capacity">8.0 million line of credit. AgeX issued to Juvenescence <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200329__20200330__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyLoanAgreementMember_zqvJ1fsNdRS9" title="Common stock, shares">810 shares of AgeX common stock as an arrangement fee for the loan facility when AgeX borrowed an aggregate of $<span id="xdx_905_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_pn5n6_c20200330__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyLoanAgreementMember_zMZC6520ZA64" title="Line of credit facility">3.0 million under the 2020 Loan Agreement, and AgeX issued to Juvenescence warrants to purchase a total of <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20200330__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyLoanAgreementMember_zXetE9DPSf4k" title="Total warrants to purchase">104,365 shares of AgeX common stock (“2020 Warrants”) as determined by the warrant formula described below of which 25,628 are outstanding as of December 31, 2023. On March 13, 2023, the 2020 Loan Agreement was amended to extend the maturity date to <span id="xdx_90E_eus-gaap--LineOfCreditFacilityExpirationDate1_c20200329__20200330__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyLoanAgreementMember__us-gaap--LoanRestructuringModificationAxis__us-gaap--ExtendedMaturityMember_zkNr1O0TX0ri" title="Line of credit, extended maturity date">March 30, 2024. During July 2023, the full $8.0 million of 2020 Loan Agreement indebtedness was extinguished in exchange for shares of Series A Preferred Stock pursuant to the Exchange Agreement. 2020 Warrants — Under the terms of the 2020 Loan Agreement, each time AgeX received an advance of funds under the 2020 Loan Agreement, AgeX issued to Juvenescence a number of 2020 Warrants equal to 50% of the number determined by dividing the amount of the advance by the applicable Market Price. The Market Price set for each 2020 Warrant when issued was the closing price per share of AgeX common stock on the NYSE American on the date of the applicable notice from AgeX requesting a draw of funds that triggered the obligation to issue the 2020 Warrant. The 2020 Warrants will expire at 5:00 p.m. New York time three years after the date of issue. AgeX had issued to Juvenescence 2020 Warrants to purchase a total of <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyLoanAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zekerf9TJeDe" title="Sale of warrants purchase of common stock">104,365 shares of AgeX common stock of which <span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyLoanAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhjYfpYwvPEl" title="Common stock, shares, outstanding">25,628 are outstanding as of December 31, 2023. The exercise prices of the 2020 Warrants issued through and that are still outstanding as of December 31, 2023 range from $<span id="xdx_90D_eus-gaap--WarrantExercisePriceDecrease_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--TwentyTwentyWarrantMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyLoanAgreementMember_z93nCqd7lugg" title="Warrants exercise price, minimum">28.49 per share to $<span id="xdx_903_eus-gaap--WarrantExercisePriceIncrease_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--TwentyTwentyWarrantMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyLoanAgreementMember_zX9o9IIVzQz5" title="Warrants exercise price, maximum">66.65 per share representing the market closing price on the NYSE American of AgeX common stock on the one day prior to delivery of the drawdown notices. The number of shares issuable upon exercise of the warrants and the exercise price per share are subject to adjustment upon the occurrence of certain events such as a stock split or reverse split or combination of the common stock, stock dividend, recapitalization or reclassification of the common stock, and similar events, and have been adjusted to give effect to the Reverse Stock Split. 2022 Secured Convertible Promissory Note and Security Agreement On February 14, 2022, AgeX and Juvenescence entered into a Secured Convertible Promissory Note (the “2022 Secured Note”) pursuant to which Juvenescence agreed to provide to AgeX a $<span id="xdx_90F_eus-gaap--LineOfCredit_iI_pn3d_c20220214__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyTwoSecuredConvertiblePromissoryNoteandSecurityAgreementMember_zcgxP5REKe57" title="Line of credit">13,160,000 line of credit for a period of <span id="xdx_907_eus-gaap--LineOfCreditFacilityExpirationPeriod_dtM_c20220214__20220214__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyTwoSecuredConvertiblePromissoryNoteandSecurityAgreementMember_z89SWlDPrPqb" title="Line of credit, term">12 months. AgeX drew an initial $<span id="xdx_90B_eus-gaap--LinesOfCreditCurrent_iI_pn3p0_c20220214__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyTwoSecuredConvertiblePromissoryNoteandSecurityAgreementMember_zrGuzApxiiPi" title="Line of credit facility">8,160,000 of the line of credit and used $<span id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3p0_c20220214__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyTwoSecuredConvertiblePromissoryNoteandSecurityAgreementMember_znqMfCMX94W2" title="Line of credit facility, current borrowing capacity">7,160,000 to refinance the outstanding principal and the loan origination fees under the 2019 Loan Agreement with Juvenescence. On February 9, 2023, AgeX and Juvenescence entered into an Amended and Restated Secured Convertible Promissory Note which amends and restates the 2022 Secured Note and added $<span id="xdx_90D_eus-gaap--LineOfCreditFacilityIncreaseDecreaseForPeriodNet_pn6n6_c20230208__20230209__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyTwoSecuredConvertiblePromissoryNoteandSecurityAgreementMember_z90LPaho2Sah">2 million to the line of credit available to be borrowed by AgeX under the 2022 Secured Note subject to Juvenescence’s discretion to approve each loan draw. On May 9, 2023, AgeX and Juvenescence entered into an Allonge and Second Amendment to Amended and Restated Convertible Promissory Note (the “Second Amendment”) that increased the amount of the line of credit available to AgeX by $<span id="xdx_905_eus-gaap--LineOfCreditFacilityIncreaseDecreaseForPeriodNet_pn3p0_c20230509__20230509__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyTwoSecuredConvertiblePromissoryNoteandSecurityAgreementMember_zPJ8EOF9A27l">4,000,000, subject to the terms of the 2022 Secured Note and Juvenescence’s discretion to approve and fund each of AgeX’s future draws of that additional amount of credit. On June 2, 2023, AgeX and Juvenescence entered into a Third Amendment to Amended and Restated Convertible Promissory Note (the “Third Amendment’), to provide that (i) AgeX may draw on the available portion of the line of credit under the 2022 Secured Note until the earlier of the date a Qualified Offering as defined in the 2022 Secured Note is consummated by AgeX or October 31, 2023 (subject to Juvenescence’s discretion to approve each loan draw as provided in the 2022 Secured Note), (ii) AgeX will not be obligated to issue additional common stock purchase warrants to Juvenescence in connection with the receipt of loan funds made available pursuant to the Second Amendment, and (iii) the definition of Reverse Financing Condition was amended to extend to June 20, 2023 the referenced deadline for fulfillment of the condition to permit borrowing or other incurrence of indebtedness by Reverse Bioengineering, Inc. The date on which the outstanding principal balance of the 2022 Secured Note will become due and payable shall be May 9, 2024. On July 31, 2023, AgeX and Juvenescence entered into a Fourth Amendment (the “Fourth Amendment”) to the 2022 Secured Note to provide that (i) the definition of Reverse Financing Condition is amended to extend to October 31, 2023 the referenced deadline for fulfillment of the condition to permit borrowing or other incurrence of indebtedness by AgeX’s subsidiary Reverse Bio, and (ii) Juvenescence may convert the outstanding amount of the 2022 Secured Note loans or any portion of such loans into AgeX common stock without restriction by the “19.9% Cap” if Juvenescence elects to convert those amounts at a conversion price or prices equal to the “Drawdown Market Prices” applicable to such loan amounts in lieu of a lower conversion price set with reference to the current market price of AgeX common stock at the time of conversion. The 19.9% Cap is a provision of the 2022 Secured Note that limits the amount of common stock that Juvenescence may acquire through the conversion of Secured Note loans in order to comply with NYSE American requirements pertaining to the amount of shares that a listed company, such as AgeX, may sell at a price less than the market prices prevailing at the time the loans were made (the “Drawdown Market Prices”) without shareholder approval. On October 3, 2023, AgeX drew $500,000 of its credit available under the 2022 Secured Note. On October 31, 2023 AgeX drew the final $500,000 of the credit line available under the Fourth Amendment. On November 9, 2023, AgeX and Juvenescence entered into the Allonge and Fifth Amendment to Amended and Restated Convertible Promissory Note (the “Fifth Amendment”) that increases the amount of the line of credit available to AgeX by $4,400,000, subject to the terms of the 2022 Secured Note and Juvenescence’s discretion to approve and fund each of AgeX’s future draws of that additional amount of credit. Concurrently with the execution of the Fifth Amendment, AgeX also entered into an additional Pledge Agreement to add shares of a subsidiary to the collateral under the Security Agreement, and AgeX’s subsidiaries ReCyte, Reverse Bio, and UniverXome each entered into a Guaranty Agreement and Joinder Agreement pursuant to which each of them agreed to guaranty AgeX’s obligations to Juvenescence pursuant to the 2022 Secured Note, as amended by the Fifth Amendment, and to grant Juvenescence a security interest in their respective assets pursuant to the Security Agreement to secure their obligations to Juvenescence. On November 15, 2023, AgeX drew $500,000 of its credit available under the 2022 Secured Note with Juvenescence. On December 5, 2023, AgeX drew $500,000 of its credit available under the 2022 Secured Note with Juvenescence. As of December 31, 2023, AgeX had borrowed a total of $20,160,000 under the 2022 Secured Note, of which $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfSecuredDebt_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember_zdkZensrRoa8" title="Proceeds from issuance of secured debt">7,500,000 was borrowed during the year ended December 31, 2023. During July 2023, $<span id="xdx_90D_eus-gaap--DebtInstrumentDecreaseForgiveness_c20230701__20230731__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember_zdLc8wKWstJh" title="Debt instrument, indebtedness">17,992,800 of 2022 Secured Note indebtedness, comprised of $<span id="xdx_902_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20230731__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember_zIS6PQiXktVd" title="Debt instrument, borrowing">16,660,000 borrowing and $1,332,800 of accrued loan origination fees, was extinguished in exchange for shares of Series A Preferred Stock and Series B Preferred Stock pursuant to the Exchange Agreement. See Note 7, Stockholders’ Equity/(Deficit). As an arrangement fee for the 2022 Secured Note, AgeX will pay Juvenescence an origination fee in an amount equal to 4% of the amount each draw of loan funds, which will accrue as each draw is funded, and an additional 4% of all the total amount of funds drawn that will accrue following the end of the period during which funds may be drawn from the line of credit. The origination fee will become due and payable on the repayment date or in a pro rata amount with any prepayment of in whole or in part of the outstanding principal balance of the 2022 Secured Note. 2022 Warrants – Upon each drawdown of funds under the 2022 Secured Note prior to June 2, 2023 when the Third Amendment went into effect, AgeX issued to Juvenescence warrants to purchase shares of AgeX common stock (“2022 Warrants”). The 2022 Warrants are governed by the terms of a Warrant Agreement between AgeX and Juvenescence. The number of 2022 Warrants issued with respect to each draw of loan funds was equal to 50% of the number determined by dividing the amount of the applicable loan draw by the applicable Market Price. The Market Price was the last closing price per share of AgeX common stock on the NYSE American preceding the delivery of the notice from AgeX requesting the draw of funds that triggered the obligation to issue 2022 Warrants. The exercise price of the 2022 Warrants is the applicable Market Price used to determine the number of Warrants issued. The 2022 Warrants will expire at 5:00 p.m. New York time three years after the date of issue. As of December 31, 2023, AgeX had issued to Juvenescence 2022 Warrants to purchase a total of <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231231__dei--LegalEntityAxis__custom--JuvenescenceMember_z8Av70CBaDW7" title="Warrant to purchase share of common stock">294,482 shares of AgeX common stock, of which 2022 Warrants to purchase 53,980 shares of AgeX common stock were issued during the year ended December 31, 2023. The exercise prices of the 2022 Warrants issued through December 31, 2023 range from $<span id="xdx_90A_eus-gaap--WarrantExercisePriceDecrease_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyTwoWarrantsMember_zWIFsALJJBB7" title="Warrants exercise price, minimum">20.75 per share to $<span id="xdx_908_eus-gaap--WarrantExercisePriceIncrease_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--TwoThousandTwentyTwoWarrantsMember_zvOlVWKDLru" title="Warrants exercise price, maximum">30.94 per share representing the market closing price of AgeX common stock on the NYSE American on the one day prior to delivery of the drawdown notices. The number of shares issuable upon exercise of the warrants and the exercise price per share are subject to adjustment upon the occurrence of certain events such as a stock split or reverse split or combination of the common stock, stock dividend, recapitalization or reclassification of the common stock, and similar events, and have been adjusted to give effect to the Reverse Stock Split.. Conversion of Loan Amounts to Common Stock – In lieu of repayment of funds borrowed, AgeX may convert the loan balance and any accrued but unpaid origination fee into AgeX common stock or “units” if AgeX consummates a sale of common stock (or common stock paired with warrants or other convertible securities in “units”) in which the gross sale proceeds are at least $10,000,000. The conversion price per share or units shall be the lowest price at which shares or units are sold. Juvenescence may convert the loan balance in whole or in part into AgeX common stock at any time at Juvenescence’s election at the closing price per share of AgeX common stock on the NYSE American or other national securities exchange on the date prior to the date Juvenescence gives AgeX notice Juvenescence’s election to convert the loan or a portion thereof into common stock. Default Provisions – The loan balance and origination fees may become immediately due and payable prior to the mandatory repayment date if an Event of Default occurs. Events of Default under the 2022 Secured Note include the following: (a) AgeX fails to pay any principal amount payable by it in the manner and at the time provided under and in accordance with the 2022 Secured Note; (b) AgeX fails to pay any other amount payable by it in the manner and at the time provided under and in accordance with the 2022 Secured Note or the Security Agreement described below or any other agreement executed in connection with the 2022 Secured Note (the “Loan Documents”) and the failure is not remedied within three business days; (c) AgeX fails to perform any of its covenants or obligations or fail to satisfy any of the conditions under the 2022 Secured Note or any other Loan Document and, such failure (if capable of remedy) remains unremedied to the satisfaction of Juvenescence (in its sole discretion) for 10 business days after the earlier of (i) notice requiring its remedy has been given by Juvenescence to AgeX and (ii) actual knowledge of the failure by senior officers of AgeX; (d) if any indebtedness of AgeX in excess of $100,000 becomes due and payable, or a breach or other circumstance arises thereunder such that Juvenescence is entitled to declare such indebtedness due and payable, prior to its due date, or any indebtedness of AgeX in excess of $25,000 is not paid on its due date; (e) AgeX stops payment of its debts generally or ceases or threatens to cease to carry on its business or is unable to pay its debts as they fall due or is deemed by a court of competent jurisdiction to be unable to pay its debts as they fall due, or enters into any arrangements with its creditors generally; (f) if (i) an involuntary proceeding (other than a proceeding instituted by Juvenescence or an affiliate of Juvenescence) shall be commenced or an involuntary petition shall be filed seeking liquidation, reorganization or other relief in respect of AgeX and any subsidiary, or of all or a substantial part of its assets, under any federal, state or foreign bankruptcy, insolvency, receivership or similar law now or hereafter in effect or (ii) an involuntary appointment of a receiver, trustee, custodian, sequestrator, conservator or similar official for AgeX or a subsidiary or for a substantial part of its assets occurs (other than in a proceeding instituted by Juvenescence or an affiliate of Juvenescence), and, in any such case, such proceeding shall continue undismissed and unstayed for sixty (60) consecutive days without having been dismissed, bonded or discharged or an order of relief is entered in any such proceeding; (g) it becomes unlawful for AgeX to perform all or any of its obligations under the 2022 Secured Note or any authorization, approval, consent, license, exemption, filing, registration or other requirement of any governmental, judicial or public body or authority necessary to enable AgeX to comply with its obligations under the 2022 Secured Note or to carry on its business is not obtained or, having been obtained, is modified in a manner that precludes AgeX or its subsidiaries from conducting their business in any material respect, or is revoked, suspended, withdrawn or withheld or fails to remain in full force and effect; (h) the issuance or levy of any judgment, writ, warrant of attachment or execution or similar process against all or any material part of the property or assets of AgeX or a subsidiary if such process is not released, vacated or fully bonded within 60 calendar days after its issue or levy; (i) any injunction, order, judgment or decision of any court is entered or issued which, in the opinion of Juvenescence, materially and adversely affects, or is reasonably likely so to affect, the ability of AgeX or a subsidiary to carry on its business or to pay amounts owed to Juvenescence under the 2022 Secured Note; (j) AgeX, whether in a single transaction or a series of related transactions, sells, leases, licenses, consigns, transfers or otherwise disposes of any material portion of its assets (with any such disposition with respect to any asset or assets with a fair value of at least $250,000 being deemed material), other than (i) certain permitted investments (ii) sales, transfers and dispositions of inventory in the ordinary course of business, (iii) any termination of a lease of real or personal property that is not necessary in the ordinary course of the AgeX’s business, could not reasonably be expected to have a material adverse effect and does not result from AgeX’s default, and (iv) any sale, lease, license, consignment, transfer or other disposition of assets that are no longer necessary in the ordinary course of business or which has been approved in writing by Juvenescence; (k) any of the following shall occur: (i) the security and/or liens created by the Security Agreement or any other Loan Document shall at any time cease to constitute valid and perfected security and/or liens on any material portion of the collateral intended to be covered thereby; (ii) except for expiration in accordance with its terms, the Security Agreement or any other Loan Document pursuant to which a lien is granted by AgeX in favor of Juvenescence shall for whatever reason be terminated or shall cease to be in full force and effect; (iii) the enforceability of the Security Agreement or any other Loan Document pursuant to which a lien is granted by AgeX in favor of Juvenescence shall be contested by AgeX or a subsidiary; (iv) AgeX shall assert that its obligations under the 2022 Secured Note or any other Loan Document shall be invalid or unenforceable; or (v) a loss, theft, damage or destruction occurs with respect to a material portion of the collateral; (l) there is any change in the financial condition of AgeX and its subsidiaries which, in the opinion of Juvenescence, materially and adversely affects, or is reasonably likely so to affect, the ability of AgeX to perform any of its obligations under the 2022 Secured Note; and (m) any representation, warranty or statement made, repeated or deemed made or repeated by AgeX in the 2022 Secured Note, or pursuant to the Loan Documents, is incomplete, untrue, incorrect or misleading in any material respect when made, repeated or deemed made. Restrictive Covenants – The 2022 Secured Note includes certain covenants that among other matters such as financial reporting: (i) impose financial restrictions on AgeX while the 2022 Secured Note remains unpaid, including restrictions on the incurrence of additional indebtedness by AgeX and its subsidiaries, except that AgeX’s subsidiary Reverse Bio will be permitted to incur debt convertible into equity not guaranteed or secured by the assets of AgeX or any other AgeX subsidiary, (ii) require that AgeX use loan proceeds and funds that may be raised through certain equity offerings only for research and development work, professional and administrative expenses, for general working capital, and for repayment of all or a portion of AgeX’s indebtedness to Juvenescence; and (iii) prohibit AgeX from making additional investments in subsidiaries, unless AgeX obtains the written consent of Juvenescence to a transaction that otherwise would be prohibited or restricted. Security Agreement – AgeX has entered into a Security Agreement granting Juvenescence a security interest in substantially all of the assets of AgeX, including a security interest in shares of AgeX subsidiaries that hold certain assets, as collateral for AgeX’s loan obligations. If an Event of Default occurs, Juvenescence will have the right to foreclose on the assets pledged as collateral. $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20231231__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__dei--LegalEntityAxis__custom--JuvenescenceMember_znWQFTjpWoo7" title="Convertiable promissoty note">10 Million Secured Convertible Promissory Note On March 13, 2023, AgeX and Juvenescence entered into a $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20230313__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__dei--LegalEntityAxis__custom--JuvenescenceMember_z91V8tRfQjn7" title="Convertiable promissoty note">10 Million Secured Convertible Promissory Note (the “2023 Secured Note”) pursuant to which Juvenescence has loaned to AgeX $<span id="xdx_90F_eus-gaap--LineOfCreditFacilityCurrentBorrowingCapacity_iI_c20230313__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_z34sBUcDYhV3" title="Line of credit, current borrowing capacity">10,000,000. AgeX used the loan proceeds to finance the $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfLongTermDebt_c20230313__20230313__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_zdyCtJkTSCX7" title="Proceeds from issuance of long term debt">10,000,000 loan to Serina under the Serina Note. See Note 4, Convertible Note Receivable, for further information on the Serina Note and the related Serina Note Purchase Agreement. On July 31, 2023, AgeX and Juvenescence also entered into an amendment to the 2023 Secured Note that mirrors the amendments of the 2022 Secured Note described above, and also creates an earlier time window, ending October 31, 2023, during which Juvenescence may elect to convert any amount outstanding under the 2023 Secured Note into shares of AgeX common stock. After October 31, 2023, Juvenescence may convert outstanding amounts under the 2023 Secured Note into AgeX common stock on any date more than ninety (90) days after the earlier of (a) the occurrence of a Qualified Merger as defined, and (b) March 13, 2024. The outstanding principal balance of the 2023 Secured Note was scheduled to become due and payable on March 13, 2026. <span id="xdx_902_eus-gaap--LineOfCreditFacilityCommitmentFeeDescription_c20230731__20230731__dei--LegalEntityAxis__custom--JuvenescenceMember__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember_zWpPzzOXpVp5" title="Origination fee description">In lieu of accrued interest, AgeX agreed to pay Juvenescence an origination fee in an amount equal to 7% of the loan funds disbursed to AgeX, which will accrue in two installments. The origination fee will become due and payable on the earliest to occur of (i) conversion of the 2023 Secured Note into shares of AgeX common stock, (ii) repayment of the 2023 Secured Note in whole or in part (provided that the origination fee shall be prorated for the amount of any partial repayment), and (iii) the acceleration of the maturity date of the 2023 Secured Note following an Event of Default as defined in the 2023 Secured Note. During July 2023, the 2023 Secured Note indebtedness, plus a portion of the accrued loan origination fees, was exchanged for Series B Preferred Stock pursuant to the Exchange Agreement. The 2023 Secured Note includes a provision allowing AgeX to convert the loan balance and any accrued but unpaid origination fee into AgeX common stock or “units” if AgeX consummates a sale of common stock (or common stock paired with warrants or other convertible securities in “units”) in which the gross sale proceeds are at least $10,000,000. If less than $25,000,000 is raised through the sale of common stock or units, the conversion price per share or units shall be the lowest price at which shares or units are sold. If at least $25,000,000 is raised, the conversion price per share shall be 85% of the “Market Price” of AgeX common stock determined as provided in the 2023 Secured Note. AgeX evaluated the <span id="xdx_903_ecustom--CommonStockOutstandingPercentage_pid_dp_uPure_c20230731__20230731__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember__us-gaap--DebtInstrumentAxis__custom--DerivativesAndHedgingMember_zUFr1csDgxGg" title="Common stock outstanding percentage">15% discounted conversion feature of the 2023 Secured Note under ASC 815-15, Derivatives and Hedging—Embedded Derivatives, and concluded that it was an embedded derivative which should be bifurcated from the 2023 Secured Note and accounted for separately. The <span id="xdx_901_ecustom--CommonStockOutstandingPercentage_pid_dp_uPure_c20230731__20230731__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember__us-gaap--DebtInstrumentAxis__custom--DerivativesAndHedgingMember_zJcNGVzQFbg1" title="Common stock outstanding percentage">15% discount was determined to have an immaterial value at inception and life to date of the 2023 Secured Note, as the probability of a future financing event described above is remote. The likelihood of the future qualifying event will be evaluated at the end of each reporting period and any adjustments will be included in Interest expense, net in the Other expense, net section of the consolidated statements of operations. The 2023 Secured Note includes certain covenants that among other matters require financial reporting and impose certain restrictions on AgeX that are substantially the same as those under the 2022 Secured Note. AgeX has entered into an Amended and Restated Security Agreement that amends the February 14, 2022 Security Agreement between AgeX and Juvenescence and adds the 2023 Secured Note to the obligations secured by the Security Agreement. The Security Agreement grants Juvenescence a security interest in substantially all of the assets of AgeX, including a security interest in shares of AgeX subsidiaries that hold certain assets, as collateral for AgeX’s loan obligations. If an Event of Default as defined in the 2023 Secured Note occurs, Juvenescence will have the right to foreclose on the assets pledged as collateral with respect to any accrued loan origination fees remaining unpaid under the 2023 Secured Note. Registration Rights AgeX entered into certain Registration Rights Agreements, as amended, pursuant to which AgeX has agreed to register for sale under the Securities Act of 1933, as amended (the “Securities Act”) all shares of AgeX common stock presently held by Juvenescence or that may be acquired by Juvenescence through the exercise of common stock purchase warrants that they hold or that they may acquire pursuant to the 2020 Loan Agreement and pursuant to the 2022 Secured Note, and shares that they may acquire through the conversion of those loans into AgeX common stock. <span id="xdx_90C_eus-gaap--LineOfCreditFacilityDescription_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementsMember_zj18Lmi7pJT9" title="Line of credit facility, description">AgeX has filed a registration statement on Form S-3, which has become effective under the Securities Act, for offerings on a delayed or continuous basis covering 467,657 shares of AgeX common stock held by Juvenescence and 92,358 shares of AgeX common stock that may be issued upon the exercise of warrants held by Juvenescence. Juvenescence retains the right to require AgeX to register additional shares of common stock that Juvenescence may acquire through the exercise of warrants or the conversion of loans. AgeX is obligated to pay the fees and expenses of each registered offering under such registration rights agreement except for underwriting discounts and commissions. AgeX and Juvenescence will indemnify each other from certain liabilities in connection the registration, offer, and sale of securities under a registration statement, including liabilities arising under the Securities Act. AgeX and Juvenescence have entered into a second Registration Rights Agreement pursuant to which AgeX has agreed to use commercially reasonable efforts to register the for sale under the Securities Act the shares of common stock issuable upon conversion of Preferred Stock. A registration statement must be filed upon request of Juvenescence if Form S-3 is available to AgeX. Juvenescence will also have “piggyback” registration rights if AgeX files a registration statement for the sale of shares for itself or other stockholders, subject to certain customary exceptions based on the nature of the registration statement. AgeX will bear the expenses of the registration statement but not underwriting or broker’s commissions related to the sale of the common stock. AgeX and Juvenescence will indemnify each other from certain liabilities in connection the registration, offer, and sale of securities under a registration statement, including liabilities arising under the Securities Act. Debt Issuance Costs In accordance with ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs, all debt issuance costs are recorded as a discount on the debt and amortized to interest expense over the term of the applicable loan agreement using the effective interest method. Direct debt issuance costs include but are not limited to legal fees, debt origination fees, estimated fair market value of common stock and warrants issued in connection with the loan agreement, and NYSE American additional listing fees for the underlying shares of warrants issued with each drawdown of funds. The following table summarizes the debt issuance costs and the debt balances net of debt issuance costs by loan agreement as of December 31, 2023 (in thousands): Schedule of Debt Issuance Costs and Debt Balances <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_48E_eus-gaap--LineOfCredit_iI_zfEtfnylBF0f" style="border-bottom: Black 1.5pt solid; text-align: center">Drawdown of Funds</td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_48D_eus-gaap--DebtInstrumentFeeAmount_iI_zoY0pjVTQ8o7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Origination Fee</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_48B_ecustom--DebtExchangedForPreferredStock_iI_zqJrcQ6UaVuk" style="border-bottom: Black 1.5pt solid; text-align: center">Debt Exchanged for Preferred Stock</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_48C_eus-gaap--DebtInstrumentCarryingAmount_iI_zRuF4M0sZvD7" style="border-bottom: Black 1.5pt solid; text-align: center">Total Debt</td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_481_eus-gaap--DeferredFinanceCostsNoncurrentGross_iNI_di_zBY98Iyl5Ii8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Debt Issuance Costs</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_489_eus-gaap--AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts_iI_zOD8QaRNZUE5" style="border-bottom: Black 1.5pt solid; text-align: center">Amortization of Debt Issuance Costs</td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_488_eus-gaap--LongTermDebt_iI_zebwDZQknew5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Debt, Net</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_418_20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyLoanAgreementMember_zmMqQLo9Kel4" style="vertical-align: bottom; background-color: White"> <td style="width: 37%; text-align: left">2020 Loan Agreement</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">8,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(8,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(2,806</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">2,806</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_411_20231231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoSecuredNoteMember_zzkfcrTaCln6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">2022 Secured Note</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,160</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,590</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17,993</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,757</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,197</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,112</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,672</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_41A_20231231__us-gaap--FinancialInstrumentAxis__us-gaap--DebtMember_zUgL1UGb9eRf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total current, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">28,160</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,590</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(25,993</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,757</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(9,003</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,918</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,672</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Non-current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_418_20231231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeSecuredNoteMember_z5kBr3pHVS56" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">2023 Secured Note</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">700</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,007</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">693</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(666</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">666</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">693</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_41F_20231231__us-gaap--FinancialInstrumentAxis__custom--TotalDebtNetMember_zJZtkstaswH2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total debt, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">38,160</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,290</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(36,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,450</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9,669</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,584</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,365</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_41F_20231231__us-gaap--FinancialInstrumentAxis__custom--TotalDebtNetMember_zHdfDjVoCyV1" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total debt, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--LineOfCredit_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--TotalDebtNetMember_z0UtoWSVsAw9" style="border-bottom: Black 2.5pt double; text-align: right" title="Drawdown of Funds">38,160</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtInstrumentFeeAmount_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--TotalDebtNetMember_zh9qcWicLw74" style="border-bottom: Black 2.5pt double; text-align: right" title="Origination Fee">2,290</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--DebtExchangedForPreferredStock_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--TotalDebtNetMember_zqqL645QBd33" style="border-bottom: Black 2.5pt double; text-align: right" title="Debt Exchanged for Preferred Stock">(36,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--DebtInstrumentCarryingAmount_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--TotalDebtNetMember_zUBL3ksOXPSi" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Debt">4,450</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--DeferredFinanceCostsNoncurrentGross_iNI_di_c20231231__us-gaap--FinancialInstrumentAxis__custom--TotalDebtNetMember_z72ezUsQiRa1" style="border-bottom: Black 2.5pt double; text-align: right" title="Debt Issuance Costs">(9,669</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--TotalDebtNetMember_zc3T3Y00KDq6" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortization of Debt Issuance Costs">9,584</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--LongTermDebt_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--TotalDebtNetMember_z6Hwuo3khUbk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Debt, Net">4,365</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Related Party Payables, net From October 2018 through December 2023, AgeX’s Chief Operating Officer, who was also an employee of Juvenescence, was devoting a majority of his time to AgeX’s operations. AgeX reimburses Juvenescence for his services on an agreed-upon fixed annual amount of approximately $280,000. AgeX reimburses Juvenescence for services provided by other Juvenescence employees on a work order basis under a shared services agreement effective January 1, 2023. As of December 31, 2023 and 2022, AgeX had approximately $66,000 and $141,000 payable, respectively, to Juvenescence included in related party payables, net, on the consolidated balance sheets. Indemnification Agreements On March 13, 2023, AgeX executed that certain Letter of Indemnification in Lieu of or Supplemental to a Medallion Signature Guarantee (“Letter of Indemnification”), pursuant to which AgeX agreed to indemnify American Stock Transfer & Trust Company, LLC and its affiliates, successors and assigns (the “AST Indemnity”) from and against any and all claims, damages, liabilities or losses arising out of the transfer of all of the AgeX common stock held by Juvenescence to its wholly-owned subsidiary, Juvenescence US Corp. (the “Share Transfer”). In connection with AgeX’s execution of the Letter of Indemnification, AgeX and Juvenescence entered into that certain Transfer of Shares of AgeX Therapeutics, Inc. Common Stock – Indemnification Agreement, pursuant to which Juvenescence agreed to indemnify AgeX against any and all claims, damages, liabilities or losses arising out of the Share Transfer or AST Indemnity. On December 21, 2023, <span id="xdx_90D_eus-gaap--LineOfCreditFacilityDescription_c20231221__20231221__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementsMember_zNVLSYtqsFJf" title="Line of credit facility, description">AgeX executed that certain Letter of Indemnification in Lieu of or Supplemental to a Medallion Signature Guarantee (the “ETC Letter of Indemnification”), pursuant to which AgeX agreed to indemnify Equiniti Trust Company LLC and its affiliates, successors and assigns (the “ETC Indemnity”) from and against any and all claims, damages, liabilities or losses arising out of the transfer 467,657 shares of AgeX common stock held by Juvenescence US Corp. to JuvVentures (the “JUV US Share Transfer”). In connection with AgeX’s execution of the ETC Letter of Indemnification, AgeX, Juvenescence, the ultimate parent company of Juvenescence US Corp. and JuvVentures, entered into that certain Transfer of Shares of AgeX Therapeutics, Inc. Common Stock – Indemnification Agreement, pursuant to which Juvenescence agreed to indemnify AgeX against any and all claims, damages, liabilities or losses arising out of the JUV US Share Transfer or ETC Indemnity.

36000000

2000000.0

P18M

4000000.0

1000000.0

7000000.0

160000

8000000.0

P18M

8000000.0

810

3000000.0

104365

25628

2024-03-30

8000000.0

104365

25628

28.49

66.65

13160000

P12M

8160000

7160000

2000000

4000000

19.9

500000

4400000

500000

20160000

7500000

17992800

16660000

1332800

294482

53980

20.75

30.94

10000000

if any indebtedness of AgeX in excess of $100,000 becomes due and payable, or a breach or other circumstance arises thereunder such that Juvenescence is entitled to declare such indebtedness due and payable, prior to its due date, or any indebtedness of AgeX in excess of $25,000 is not paid on its due date;

250000

10000000

In lieu of accrued interest, AgeX agreed to pay Juvenescence an origination fee in an amount equal to 7% of the loan funds disbursed to AgeX, which will accrue in two installments. The origination fee will become due and payable on the earliest to occur of (i) conversion of the 2023 Secured Note into shares of AgeX common stock, (ii) repayment of the 2023 Secured Note in whole or in part (provided that the origination fee shall be prorated for the amount of any partial repayment), and (iii) the acceleration of the maturity date of the 2023 Secured Note following an Event of Default as defined in the 2023 Secured Note.

10000000

25000000

0.85 0.15 0.15

AgeX has filed a registration statement on Form S-3, which has become effective under the Securities Act, for offerings on a delayed or continuous basis covering 467,657 shares of AgeX common stock held by Juvenescence and 92,358 shares of AgeX common stock that may be issued upon the exercise of warrants held by Juvenescence.

The following table summarizes the debt issuance costs and the debt balances net of debt issuance costs by loan agreement as of December 31, 2023 (in thousands): Schedule of Debt Issuance Costs and Debt Balances <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_48E_eus-gaap--LineOfCredit_iI_zfEtfnylBF0f" style="border-bottom: Black 1.5pt solid; text-align: center">Drawdown of Funds</td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_48D_eus-gaap--DebtInstrumentFeeAmount_iI_zoY0pjVTQ8o7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Origination Fee</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_48B_ecustom--DebtExchangedForPreferredStock_iI_zqJrcQ6UaVuk" style="border-bottom: Black 1.5pt solid; text-align: center">Debt Exchanged for Preferred Stock</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_48C_eus-gaap--DebtInstrumentCarryingAmount_iI_zRuF4M0sZvD7" style="border-bottom: Black 1.5pt solid; text-align: center">Total Debt</td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_481_eus-gaap--DeferredFinanceCostsNoncurrentGross_iNI_di_zBY98Iyl5Ii8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Debt Issuance Costs</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_489_eus-gaap--AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts_iI_zOD8QaRNZUE5" style="border-bottom: Black 1.5pt solid; text-align: center">Amortization of Debt Issuance Costs</td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_488_eus-gaap--LongTermDebt_iI_zebwDZQknew5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Debt, Net</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_418_20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandAndTwentyLoanAgreementMember_zmMqQLo9Kel4" style="vertical-align: bottom; background-color: White"> <td style="width: 37%; text-align: left">2020 Loan Agreement</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">8,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(8,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(2,806</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">2,806</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_411_20231231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyTwoSecuredNoteMember_zzkfcrTaCln6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">2022 Secured Note</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,160</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,590</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17,993</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,757</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,197</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,112</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,672</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_41A_20231231__us-gaap--FinancialInstrumentAxis__us-gaap--DebtMember_zUgL1UGb9eRf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total current, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">28,160</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,590</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(25,993</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,757</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(9,003</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,918</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,672</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Non-current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_418_20231231__us-gaap--DebtInstrumentAxis__custom--TwentyTwentyThreeSecuredNoteMember_z5kBr3pHVS56" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">2023 Secured Note</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">700</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,007</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">693</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(666</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">666</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">693</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_41F_20231231__us-gaap--FinancialInstrumentAxis__custom--TotalDebtNetMember_zJZtkstaswH2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total debt, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">38,160</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,290</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(36,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,450</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9,669</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,584</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,365</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_41F_20231231__us-gaap--FinancialInstrumentAxis__custom--TotalDebtNetMember_zHdfDjVoCyV1" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total debt, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--LineOfCredit_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--TotalDebtNetMember_z0UtoWSVsAw9" style="border-bottom: Black 2.5pt double; text-align: right" title="Drawdown of Funds">38,160</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--DebtInstrumentFeeAmount_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--TotalDebtNetMember_zh9qcWicLw74" style="border-bottom: Black 2.5pt double; text-align: right" title="Origination Fee">2,290</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--DebtExchangedForPreferredStock_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--TotalDebtNetMember_zqqL645QBd33" style="border-bottom: Black 2.5pt double; text-align: right" title="Debt Exchanged for Preferred Stock">(36,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--DebtInstrumentCarryingAmount_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--TotalDebtNetMember_zUBL3ksOXPSi" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Debt">4,450</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--DeferredFinanceCostsNoncurrentGross_iNI_di_c20231231__us-gaap--FinancialInstrumentAxis__custom--TotalDebtNetMember_z72ezUsQiRa1" style="border-bottom: Black 2.5pt double; text-align: right" title="Debt Issuance Costs">(9,669</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--AccumulatedAmortizationOfNoncurrentDeferredFinanceCosts_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--TotalDebtNetMember_zc3T3Y00KDq6" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortization of Debt Issuance Costs">9,584</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--LongTermDebt_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--TotalDebtNetMember_z6Hwuo3khUbk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Debt, Net">4,365</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

8000000

-8000000

2806000

20160000

1590000

-17993000

3757000

6197000

6112000

3672000

28160000

1590000

-25993000

3757000

9003000

8918000

3672000

10000000

700000

-10007000

693000

666000

693000

38160000

2290000

-36000000

4450000

9669000

9584000

4365000

38160000

2290000

-36000000 -36000000

4450000

9669000

9584000

4365000

280000

66000

141000

AgeX executed that certain Letter of Indemnification in Lieu of or Supplemental to a Medallion Signature Guarantee (the “ETC Letter of Indemnification”), pursuant to which AgeX agreed to indemnify Equiniti Trust Company LLC and its affiliates, successors and assigns (the “ETC Indemnity”) from and against any and all claims, damages, liabilities or losses arising out of the transfer 467,657 shares of AgeX common stock held by Juvenescence US Corp. to JuvVentures (the “JUV US Share Transfer”).

6. Warrant Liability AgeX determines the accounting classification of warrants it issues, as either liability or equity, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, then in accordance with ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock. Under ASC 480, Distinguishing Liabilities from Equity, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate AgeX to settle the warrants or the underlying shares by paying cash or other assets, or warrants that must or may require settlement by issuing a variable number of shares. If warrants do not meet liability classification under ASC 480-10, AgeX assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, and in order to conclude equity classification, AgeX also assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable U.S. GAAP. As a condition of each amount drawn up to $15,160,000 from the 2022 Secured Note, on receipt of each amount drawn AgeX granted to Juvenescence a number of warrants equal to 50% of the gross value of the relevant advance made. The gross value is the quotient of the drawdown amount and the exercise price. The exercise price was based on the market closing price of AgeX’s common stock on the NYSE American on the one day preceding the delivery of the relevant drawdown notice. See Note 5, Related Party Transactions. AgeX has utilized the full credit available under the 2022 Secured Note that is subject to warrants and accordingly the warrants were issued for each of the advances of loan funds under the 2022 Secured Note. After all relevant assessments, AgeX determined that the warrants issued under the 2022 Secured Note require classification as a liability pursuant to ASC 480, Distinguishing Liabilities from Equity. In accordance with the accounting guidance, for each reporting period prior to the full drawdown of the entire $15,160,000 of the 2022 Secured Note line of credit subject to warrants, the amount of warrant liability was determined and recognized on the balance sheet for the applicable reporting period based on the number of warrants that would have been issued if $15,160,000 of the 2022 Secured Note line of credit was drawn. The amount of warrant liability attributed to the expected future issuance of warrants upon subsequent loan draws was subsequently adjusted for the fair value of warrants actually issued upon each loan draw, and the number of warrants that could be issued for the remaining credit available was re-measured for the applicable reporting period with changes being recorded as a component of net other expense in the consolidated statements of operations. Under the Third Amendment, AgeX is not obligated to issue additional warrants to Juvenescence in connection with the receipt of loan funds up to $4 million made available pursuant to the Second Amendment. See Note 5, Related Party Transactions, for further details of the Second Amendment and the Third Amendment. The fair value of the warrant liabilities was measured using a Black-Scholes option pricing model. Significant inputs into the model at the inception date, the date when warrants were issued upon receipt of amounts drawn during the period, and as of the reporting period end remeasurement dates are as follows: Schedule of Warrants Liabilities And Stock Option Awards using a Black-Scholes Option-Pricing Model <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic">Black-Scholes Assumptions</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Exercise Price (1)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Warrant Expiration Date (2)</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Stock Price (3)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Interest Rate (annual) (4)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Volatility (annual) (5)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Time to Maturity (Years)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Calculated Fair Value per Share</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 26%; text-align: left">Inception Date: 2/14/2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDEp_zpUxQsV21Nse" style="width: 7%; text-align: right" title="Exercise Price">27.43</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 7%; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220214__20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDIp_zEprA61NJa7c" title="Warrant Expiration Date">2/13/2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--SharePrice_iI_pid_c20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDMp_zbmyBHRI7gHa" style="width: 7%; text-align: right" title="Stock Price">24.32</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220214__20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDQp_zM334DEd2Wlk" style="width: 7%; text-align: right" title="Interest Rate (annual)">1.80</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220214__20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDUp_zRh51j8KRG29" style="width: 7%; text-align: right" title="Volatility (annual)">122.99</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 6%; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220214__20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_zFs0osS1a3Ig" title="Time to Maturity (Years)">3</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_z5SRt4T3wele" style="width: 7%; text-align: right" title="Calculated fair value per share">17.11</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Issuance Date: 2/14/2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_zDSaY5LaXnWd" style="text-align: right" title="Exercise Price">27.43</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220214__20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zw3istUOO4Wd" title="Warrant Expiration Date">2/13/2025</td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_zL11g5J80fB1" style="text-align: right" title="Stock Price">24.32</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220214__20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_zgWLZHmmVPoj" style="text-align: right" title="Interest Rate (annual)">1.80</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220214__20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zAqxj2bXM0m4" style="text-align: right" title="Volatility (annual)">122.99</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220214__20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_za6UeVHz1qj9" title="Time to Maturity (Years)">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zz3xwNXSMGne" style="text-align: right" title="Calculated fair value per share">17.11</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Issuance Date: 2/15/2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_znmrf8iE8ol2" style="text-align: right" title="Exercise Price">27.43</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220215__20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zvgfBWL0Yw6j" title="Warrant Expiration Date">2/14/2025</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--SharePrice_iI_pid_c20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_zxpObiGvB0qa" style="text-align: right" title="Stock Price">26.28</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220215__20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_z3k26dCoqevb" style="text-align: right" title="Interest Rate (annual)">1.80</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220215__20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zalINsyJ2By1" style="text-align: right" title="Volatility (annual)">123.28</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220215__20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zH9M9dqfnE0b" title="Time to Maturity (Years)">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_z2iazeaWr1f2" style="text-align: right" title="Calculated fair value per share">18.81</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Period Ended 3/31/2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDEp_zScqVXai8rJf" style="text-align: right" title="Exercise Price">33.06</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220331__20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDIp_zlbLfW4MLjmb" title="Warrant Expiration Date">3/30/2025</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--SharePrice_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDMp_zLI1TQCUfnja" style="text-align: right" title="Stock Price">30.04</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220331__20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDQp_zMpqxP7n9h29" style="text-align: right" title="Interest Rate (annual)">2.45</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220331__20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDUp_zpKvpjNj3znc" style="text-align: right" title="Volatility (annual)">123.28</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220331__20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zd5s5fx6cm8l" title="Time to Maturity (Years)">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zuG4paWBnRHf" style="text-align: right" title="Calculated fair value per share">21.36</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Issuance Date: 4/4/2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_zfdfaPO9xt32" style="text-align: right" title="Exercise Price">30.94</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220404__20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zVCCARyX8ip1" title="Warrant Expiration Date">4/3/2025</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--SharePrice_iI_pid_c20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_z6xmpwIsQoOc" style="text-align: right" title="Stock Price">28.79</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220404__20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_zqtZD5yfwsp3" style="text-align: right" title="Interest Rate (annual)">2.61</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220404__20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zG7Ld9gTQPj" style="text-align: right" title="Volatility (annual)">123.31</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220404__20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_ztGbfWopTSma" title="Time to Maturity (Years)">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zZ9R0Z43aacd" style="text-align: right" title="Calculated fair value per share">20.59</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Issuance Date: 6/6/2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_zm0xOQqH3rQb" style="text-align: right" title="Exercise Price">25.01</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220606__20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zkN63n9GP6zc" title="Warrant Expiration Date">6/5/2025</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--SharePrice_iI_pid_c20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_zekhUQmLTyn2" style="text-align: right" title="Stock Price">28.14</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220606__20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_zBn7WntX6ib9" style="text-align: right" title="Interest Rate (annual)">2.94</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220606__20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zaK0EQuIRJLi" style="text-align: right" title="Volatility (annual)">122.62</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220606__20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zAglVXUQvUmc" title="Time to Maturity (Years)">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zH1YEU3Unm56" style="text-align: right" title="Calculated fair value per share">20.84</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Period Ended 6/30/2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDEp_z8Rvmk6TDdn1" style="text-align: right" title="Exercise Price">21.10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220630__20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDIp_zPmntEqobIrc" title="Warrant Expiration Date">6/29/2025</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--SharePrice_iI_pid_c20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDMp_zGAyjykelgS9" style="text-align: right" title="Stock Price">20.27</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220630__20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDQp_zQ1UrZyxKn0e" style="text-align: right" title="Interest Rate (annual)">2.99</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220630__20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDUp_zt8V5G5gepE9" style="text-align: right" title="Volatility (annual)">122.21</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220630__20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zYOi8uKMnIWa" title="Time to Maturity (Years)">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_z0FETVl16cZ7" style="text-align: right" title="Calculated fair value per share">14.53</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Issuance Date: 8/16/2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_zKBP5NGtaA8d" style="text-align: right" title="Exercise Price">23.56</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220815__20220815__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zDcwImQHE028" title="Warrant Expiration Date">8/15/2025</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--SharePrice_iI_pid_c20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_zxMLaO5mjkvb" style="text-align: right" title="Stock Price">22.51</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220815__20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_z3pJ8Lv4wVwj" style="text-align: right" title="Interest Rate (annual)">3.19</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220815__20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zVAQIwItEsb9" style="text-align: right" title="Volatility (annual)">121.37</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220815__20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zqQ7JSAhXp8g" title="Time to Maturity (Years)">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zJjiOMR4ABci" style="text-align: right" title="Calculated fair value per share">16.07</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Period Ended 9/30/2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDEp_z6K42ouEPoZ1" style="text-align: right" title="Exercise Price">21.45</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220929__20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDIp_z5uNzvwNpJ6e" title="Warrant Expiration Date">9/29/2025</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharePrice_iI_pid_c20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDMp_zwwlodlcJa8f" style="text-align: right" title="Stock Price">19.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220929__20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDQp_zJMBRoR1Y2Ra" style="text-align: right" title="Interest Rate (annual)">4.25</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220929__20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDUp_zvLSY2RACTac" style="text-align: right" title="Volatility (annual)">121.49</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220929__20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zaiuxvmI1HXg" title="Time to Maturity (Years)">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zsyDbWYwt0a4" style="text-align: right" title="Calculated fair value per share">14.09</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Issuance Date: 10/21/2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20221021__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_zc9B3gwocFMb" style="text-align: right" title="Exercise Price">24.27</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20221020__20221021__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_ziSg1IEpyAG" title="Warrant Expiration Date">10/20/2025</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--SharePrice_iI_pid_c20221021__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_zyiyOgUIJuqk" style="text-align: right" title="Stock Price">21.81</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20221020__20221021__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_zkXYJTyBj6v3" style="text-align: right" title="Interest Rate (annual)">4.52</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20221020__20221021__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zbiowjQ9wCS8" style="text-align: right" title="Volatility (annual)">120.51</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221020__20221021__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zGInSyg7HP7k" title="Time to Maturity (Years)">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20221021__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zTu3RkGvxtaa" style="text-align: right" title="Calculated fair value per share">15.42</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Issuance Date: 12/14/2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20221214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_zBk0rMKfZGJ2" style="text-align: right" title="Exercise Price">20.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20221213__20221214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zCm5OQSi93fh" title="Warrant Expiration Date">12/13/2025</td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20221214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_zDjZ5PO4jktj" style="text-align: right" title="Stock Price">18.99</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20221213__20221214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_zxGYgAgZRSBh" style="text-align: right" title="Interest Rate (annual)">3.94</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20221213__20221214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zxI0wMcjW7kf" style="text-align: right" title="Volatility (annual)">120.01</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221213__20221214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zaP8hpdOsC6l" title="Time to Maturity (Years)">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20221214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_z6EMaexjFiR4" style="text-align: right" title="Calculated fair value per share">13.40</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Period Ended 12/31/2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDEp_zLdCM44SA5C5" style="text-align: right" title="Exercise Price">19.34</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20221230__20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDIp_zeZxT6yyUrp8" title="Warrant Expiration Date">12/30/2025</td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDMp_zA8Tvec5kxt5" style="text-align: right" title="Stock Price">19.41</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20221230__20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDQp_zdGRgilZ6ARj" style="text-align: right" title="Interest Rate (annual)">4.22</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20221230__20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDUp_z3tWceEtjOw2" style="text-align: right" title="Volatility (annual)">119.31</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221230__20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zOpUiioixHda" title="Time to Maturity (Years)">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zYjhPZi2daD8" style="text-align: right" title="Calculated fair value per share">13.93</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Issuance Date: 1/25/2023</td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20230125__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_zdFBiswdL2O1" style="text-align: right" title="Exercise Price">25.85</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230124__20230125__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zP2SKoB8OB7g" title="Warrant Expiration Date">1/24/2026</td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--SharePrice_iI_pid_c20230125__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_zrOHkTEPXpDj" style="text-align: right" title="Stock Price">26.42</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230124__20230125__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_zJZ1gnH5YTGk" style="text-align: right" title="Interest Rate (annual)">3.84</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230124__20230125__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_z7vwDkPsYyYa" style="text-align: right" title="Volatility (annual)">119.17</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230124__20230125__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zPu46xRCN2ya" title="Time to Maturity (Years)">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20230125__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_z7ZNnKnRzjO3" style="text-align: right" title="Calculated fair value per share">18.98</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Inception Date: 2/9/2023</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20230209__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDEp_zbIozjnOrIAf" style="text-align: right" title="Exercise Price">24.72</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230208__20230209__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDIp_zmGT8vwFXcQ6" title="Warrant Expiration Date">2/8/2026</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--SharePrice_iI_pid_c20230209__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDMp_zL0G98PIqPv2" style="text-align: right" title="Stock Price">23.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230208__20230209__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDQp_zwYOyru8jvX" style="text-align: right" title="Interest Rate (annual)">4.15</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230208__20230209__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDUp_zxDkOS11us77" style="text-align: right" title="Volatility (annual)">118.94</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230208__20230209__us-gaap--AwardTypeAxis__custom--InceptionDateMember_z4fcATSLIHx1" title="Time to Maturity (Years)">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20230209__us-gaap--AwardTypeAxis__custom--InceptionDateMember_zbLcaMErUYB9" style="text-align: right" title="Calculated fair value per share">16.38</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Issuance Date: 2/15/2023</td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20230215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_z7P60F3jJgpg" style="text-align: right" title="Exercise Price">21.93</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230214__20230215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_z0w1MJTq65B2" title="Warrant Expiration Date">2/14/2026</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--SharePrice_iI_pid_c20230215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_zcau7qFj62w6" style="text-align: right" title="Stock Price">21.10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230214__20230215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_z6HuK9nI1tOk" style="text-align: right" title="Interest Rate (annual)">4.35</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230214__20230215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zw97RskwTcTc" style="text-align: right" title="Volatility (annual)">118.93</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230214__20230215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_z1foA0CeQQ6c" title="Time to Maturity (Years)">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20230215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zPHiTcPvDuKc" style="text-align: right" title="Calculated fair value per share">14.99</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Period Ended 3/31/2023</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20230331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDEp_zOylwCfLfQQd" style="text-align: right" title="Exercise Price">23.25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230330__20230331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDIp_zJ0dIld06Oi6" title="Warrant Expiration Date">3/30/2026</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharePrice_iI_pid_c20230331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDMp_zRLkD7ILyLo" style="text-align: right" title="Stock Price">23.32</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230330__20230331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDQp_zdhzlqAQCuE3" style="text-align: right" title="Interest Rate (annual)">3.81</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230330__20230331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDUp_zaBJWyRkWo83" style="text-align: right" title="Volatility (annual)">113.43</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230330__20230331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zE3zd6aEMii" title="Time to Maturity (Years)">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20230331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zmbgRiYgFvMi" style="text-align: right" title="Calculated fair value per share">16.15</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Issuance Date: 4/4/2023</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20230404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_z34mfmxmAAa" style="text-align: right" title="Exercise Price">23.25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230403__20230404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zJX2QgF45ozf" title="Warrant Expiration Date">4/3/2026</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--SharePrice_iI_pid_c20230404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_z1N1LFHSyA31" style="text-align: right" title="Stock Price">23.67</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230403__20230404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_zNSSJyX7PzLl" style="text-align: right" title="Interest Rate (annual)">3.60</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230403__20230404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zWzWbyjh2wa4" style="text-align: right" title="Volatility (annual)">113.01</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230403__20230404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zUpsbudOxA4h" title="Time to Maturity (Years)">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20230404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zTzjbPyZDwMl" style="text-align: right" title="Calculated fair value per share">16.39</td><td style="text-align: left"> </td></tr> </table> <div style="width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(1)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Based on the market closing price of AgeX’s common stock on the NYSE American on the day prior to each debt Inception Date, on each presented period ending date, and one day prior to the delivery of the relevant drawdown notice in accordance with terms of the 2022 Secured Note (with such drawdown notice delivery date being shown as the Issuance Date in the table), and as adjusted to reflect the Reverse Stock Split. For this purpose, the date on which the 2022 Secured Note was amended and restated to increase the line of credit by $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIExpYWJpbGl0aWVzIEFuZCBTdG9jayBPcHRpb24gQXdhcmRzIHVzaW5nIGEgQmxhY2stU2Nob2xlcyBPcHRpb24tUHJpY2luZyBNb2RlbCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--LinesOfCreditCurrent_iI_c20231231_z3VGycq5TJTk" title="Lines of credit current">2,000,000 was treated as a new Inception Date for that portion of the line of credit.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(2)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Warrants are exercisable over a three-year period from each Issuance Date.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(3)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Based on the market price of AgeX’s common stock on the NYSE American as of each date presented.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(4)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Interest rate for U.S. Treasury Bonds, as of each date presented, as published by the U.S. Federal Reserve.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(5)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Based on the historical daily volatility of AgeX common stock as of each date presented.</td></tr></table> The warrants outstanding and fair values at each of the respective valuation dates are summarized below. Schedule of Warrant Outstanding and Fair Values <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Warrant Liability</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Credit Line and Draw Amounts (in thousands)</td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value per Share</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value (in thousands)</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Fair value as of January 1, 2022</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstanding_iS_pn3n3_c20220101__20221231_zo4Nosc5S75b" style="font-weight: bold; text-align: right" title="Credit Line and Draw amounts">-</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pid_c20220101__20221231_zy7R36ZOskij" style="font-weight: bold; text-align: right" title="Fair value, shares">-</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_c20220101__20221231_zobrLdEj2y0e" style="font-weight: bold; text-align: right" title="Fair value, per share">-</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_98A_ecustom--WarrantLiability_iS_pid_c20220101__20221231_zFMWPxyn7wS4" style="font-weight: bold; text-align: right" title="Fair value as of period beginning balance, fair value">-</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 38%; text-align: left">Fair value at initial measurement date of 2/14/2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--InitialMeasurementDateOfFourteenFebruaryTwoThousandAndTwentyTwoMember_fKDEp_ztdBcWxO8Mw6" style="width: 10%; text-align: right" title="Credit Line and Draw amounts">13,160</td><td style="width: 4%; text-align: left">(1)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--InitialMeasurementDateOfFourteenFebruaryTwoThousandAndTwentyTwoMember_fKDIp_zQ1ySe22vIhd" style="width: 10%; text-align: right" title="Fair value, shares">239,860</td><td style="width: 4%; text-align: left">(2)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--InitialMeasurementDateOfFourteenFebruaryTwoThousandAndTwentyTwoMember_zItlIL5hcn35" style="width: 10%; text-align: right" title="Fair value, per share">17,11</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--InitialMeasurementDateOfFourteenFebruaryTwoThousandAndTwentyTwoMember_zNRLBtQ1zrad" style="width: 10%; text-align: right" title="Fair value">4,103</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value of warrants issued on 2/14/2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenFebruaryTwoThousandAndTwentyTwoOneMember_fKDMp_zh6msRessplj" style="text-align: right" title="Credit Line and Draw amounts">(7,160</td><td style="text-align: left">)(3)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenFebruaryTwoThousandAndTwentyTwoOneMember_fKDQp_zeBE77DDokX8" style="text-align: right" title="Fair value, shares">(130,501</td><td style="text-align: left">)(4)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenFebruaryTwoThousandAndTwentyTwoOneMember_zuPYePXfmjLb" style="text-align: right" title="Fair value, per share">17.11</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenFebruaryTwoThousandAndTwentyTwoOneMember_zXRMIf3xLCab" style="text-align: right" title="Fair value">(2,232</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fair value of warrants issued on 2/15/2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyTwoMember_fKDMp_zd151T1F5llh" style="text-align: right" title="Credit Line and Draw amounts">(1,000</td><td style="text-align: left">)(3)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyTwoMember_fKDQp_zq5kjUCPg45i" style="text-align: right" title="Fair value, shares">(18,226</td><td style="text-align: left">)(4)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyTwoMember_zCeA3KYLxVx5" style="text-align: right" title="Fair value, per share">18.81</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyTwoMember_zlsipZWt0Jwj" style="text-align: right" title="Fair value">(343</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value of warrants issued on 4/4/2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourAprilTwentyThousandAndTwentyTwoMember_fKDMp_zRORbxs5nXR6" style="text-align: right" title="Credit Line and Draw amounts">(1,000</td><td style="text-align: left">)(3)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourAprilTwentyThousandAndTwentyTwoMember_fKDQp_zU6R8djnisZ8" style="text-align: right" title="Fair value, shares">(16,162</td><td style="text-align: left">)(4)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourAprilTwentyThousandAndTwentyTwoMember_zG7QiHjrspM2" style="text-align: right" title="Fair value, per share">20.59</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourAprilTwentyThousandAndTwentyTwoMember_zTxCzsFudtK3" style="text-align: right" title="Fair value">(333</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fair value of warrants issued on 6/6/2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixJuneTwentyThousandAndTwentyTwoMember_fKDMp_z3VQNT89Cff3" style="text-align: right" title="Credit Line and Draw amounts">(1,000</td><td style="text-align: left">)(3)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixJuneTwentyThousandAndTwentyTwoMember_fKDQp_zPIsO8lFFp9b" style="text-align: right" title="Fair value, shares">(19,995</td><td style="text-align: left">)(4)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixJuneTwentyThousandAndTwentyTwoMember_zEzjYRMc15Cb" style="text-align: right" title="Fair value, per share">20.84</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixJuneTwentyThousandAndTwentyTwoMember_ze7AFtj2Nj53" style="text-align: right" title="Fair value">(417</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value of warrants issued on 8/16/2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixteenAugustTwentyThousandAndTwentyTwoMember_fKDMp_zv7RfFsx3bff" style="text-align: right" title="Credit Line and Draw amounts">(1,000</td><td style="text-align: left">)(3)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixteenAugustTwentyThousandAndTwentyTwoMember_fKDQp_zxX2jTX10Eva" style="text-align: right" title="Fair value, shares">(21,222</td><td style="text-align: left">)(4)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixteenAugustTwentyThousandAndTwentyTwoMember_zgtEh3Ficigk" style="text-align: right" title="Fair value, per share">16.07</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixteenAugustTwentyThousandAndTwentyTwoMember_zqDWzqn4QTll" style="text-align: right" title="Fair value">(341</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fair value of warrants issued on 10/21/2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--TwentyFirstOctoberTwoThousandAndTwentyTwoMember_fKDMp_zLWUFIKzjKBd" style="text-align: right" title="Credit Line and Draw amounts">(500</td><td style="text-align: left">)(3)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--TwentyFirstOctoberTwoThousandAndTwentyTwoMember_fKDQp_zWKGumI7pWu8" style="text-align: right" title="Fair value, shares">(10,301</td><td style="text-align: left">)(4)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--TwentyFirstOctoberTwoThousandAndTwentyTwoMember_ztdfkBU3zxw4" style="text-align: right" title="Fair value, per share">15.42</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--TwentyFirstOctoberTwoThousandAndTwentyTwoMember_zeQhqmKAn096" style="text-align: right" title="Fair value">(159</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value of warrants issued on 12/14/2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenDecemberTwoThousandAndTwentyTwoMember_fKDMp_zmDfkQdA28sd" style="text-align: right" title="Credit Line and Draw amounts">(1,000</td><td style="text-align: left">)(3)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenDecemberTwoThousandAndTwentyTwoMember_fKDQp_zbgAlOEt3Z5h" style="text-align: right" title="Fair value, shares">(24,096</td><td style="text-align: left">)(4)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenDecemberTwoThousandAndTwentyTwoMember_zCDpK5XW4On6" style="text-align: right" title="Fair value, per share">13.40</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenDecemberTwoThousandAndTwentyTwoMember_z1iE2yubVDOi" style="text-align: right" title="Fair value">(323</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value of warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_ecustom--UnrealizedLossOnChangeInFairValueOfWarrants_pn3n3_c20220101__20221231_fKDIp_zcnbqJoBq0U1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Credit Line and Draw amounts">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98F_ecustom--UnrealizedLossOnChangeOnOtherThanOptions_pid_c20220101__20221231_fKDQp_ztwAQHy0Tz6k" style="padding-bottom: 1.5pt; text-align: right" title="Fair value, shares">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98E_ecustom--UnrealizedLossOnChangeInFairValueOfWarrantsPerShare_pid_c20220101__20221231_z1985yee7ahk" style="padding-bottom: 1.5pt; text-align: right" title="Fair value, per share">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_ecustom--ChangesInFairValue_pn3n3_c20220101__20221231_zQFBu2euVfTl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value">225</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Fair value as of December 31, 2022</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_989_eus-gaap--WarrantsAndRightsOutstanding_iS_pn3n3_c20230101__20231231_fKDEp_zB5hWC6cmOzh" style="font-weight: bold; text-align: right" title="Credit Line and Draw amounts">500</td><td style="font-weight: bold; text-align: left">(1)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pid_c20230101__20231231_fKDIp_zDJjsFOolXgl" style="font-weight: bold; text-align: right" title="Fair value, shares">12,924</td><td style="font-weight: bold; text-align: left">(2)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_c20230101__20231231_zyPQCA4QhAJ6" style="font-weight: bold; text-align: right" title="Fair value, per share">13.93</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_988_ecustom--WarrantLiabilityCurrent_iS_pn3n3_c20230101__20231231_zZ4EpSehlgm7" style="font-weight: bold; text-align: right" title="Fair value">180</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fair value of warrants issued on 1/25/2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230101__20231231__us-gaap--AwardDateAxis__custom--TwentyFiveJanuaryTwoThousandAndTwentyThreeMember_fKDMp_zHMWNw0kOyTg" style="text-align: right" title="Credit Line and Draw amounts">(500</td><td style="text-align: left">)(3)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--FairValueOfOtherThanOptionIssued_pid_c20230101__20231231__us-gaap--AwardDateAxis__custom--TwentyFiveJanuaryTwoThousandAndTwentyThreeMember_fKDQp_z35wf9jrmrUj" style="text-align: right" title="Fair value, shares">(9,671</td><td style="text-align: left">)(4)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--FairValueIssuedPerShare_pid_c20230101__20231231__us-gaap--AwardDateAxis__custom--TwentyFiveJanuaryTwoThousandAndTwentyThreeMember_zTfvOwpkChC1" style="text-align: right" title="Fair value, per share">18.98</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--WarrantsIssuedFairValue_pn3n3_c20230101__20231231__us-gaap--AwardDateAxis__custom--TwentyFiveJanuaryTwoThousandAndTwentyThreeMember_zdsq8yx3iNJg" style="text-align: right" title="Fair value">(184</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value at initial measurement date of 2/9/2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230101__20231231__us-gaap--AwardDateAxis__custom--NineFebruaryTwoThousandAndTwentyThreeMember_fKDEp_z9Ra6thMHs93" style="text-align: right" title="Credit Line and Draw amounts">2,000</td><td style="text-align: left">(1)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--FairValueOfOtherThanOptionIssued_pid_c20230101__20231231__us-gaap--AwardDateAxis__custom--NineFebruaryTwoThousandAndTwentyThreeMember_fKDIp_za6oZFQhGkWk" style="text-align: right" title="Fair value, shares">40,457</td><td style="text-align: left">(2)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--FairValueIssuedPerShare_pid_c20230101__20231231__us-gaap--AwardDateAxis__custom--NineFebruaryTwoThousandAndTwentyThreeMember_zgu0T05zMsue" style="text-align: right" title="Fair value, per share">16.38</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--WarrantsIssuedFairValue_pn3n3_c20230101__20231231__us-gaap--AwardDateAxis__custom--NineFebruaryTwoThousandAndTwentyThreeMember_zrv5Rv7Ya6Y" style="text-align: right" title="Fair value">663</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fair value of warrants issued on 2/15/2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230101__20231231__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyThreeMember_fKDMp_zO3yhozH1laj" style="text-align: right" title="Credit Line and Draw amounts">(1,000</td><td style="text-align: left">)(3)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--FairValueOfOtherThanOptionIssued_pid_c20230101__20231231__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyThreeMember_fKDQp_zJC7F8Fht4v6" style="text-align: right" title="Fair value, shares">(22,801</td><td style="text-align: left">)(4)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--FairValueIssuedPerShare_pid_c20230101__20231231__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyThreeMember_zPd62lk9qLv7" style="text-align: right" title="Fair value, per share">14.99</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--WarrantsIssuedFairValue_pn3n3_c20230101__20231231__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyThreeMember_z7q5POztaIca" style="text-align: right" title="Fair value">(342</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value of warrants issued on 4/4/2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230101__20231231__us-gaap--AwardDateAxis__custom--FourthAprilTwentyThousandAndTwentyThreeMember_fKDMp_zvOXyXOv463l" style="text-align: right" title="Credit Line and Draw amounts">(1,000</td><td style="text-align: left">)(3)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--FairValueOfOtherThanOptionIssued_pid_c20230101__20231231__us-gaap--AwardDateAxis__custom--FourthAprilTwentyThousandAndTwentyThreeMember_fKDQp_zOoE7JRx8wki" style="text-align: right" title="Fair value, shares">(21,507</td><td style="text-align: left">)(4)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--FairValueIssuedPerShare_pid_c20230101__20231231__us-gaap--AwardDateAxis__custom--FourthAprilTwentyThousandAndTwentyThreeMember_zfoyJj8C8uhd" style="text-align: right" title="Fair value, per share">16.39</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--WarrantsIssuedFairValue_pn3n3_c20230101__20231231__us-gaap--AwardDateAxis__custom--FourthAprilTwentyThousandAndTwentyThreeMember_zEMem9Rq7Jl" style="text-align: right" title="Fair value">(352</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value of warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_ecustom--UnrealizedLossOnChangeInFairValueOfWarrants_pn3n3_c20230101__20231231_fKDIp_zQ1tZsFKGEn5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Credit Line and Draw amounts">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_983_ecustom--UnrealizedLossOnChangeOnOtherThanOptions_pid_c20230101__20231231_fKDQp_zJiNpW5Cl5Ii" style="padding-bottom: 1.5pt; text-align: right" title="Fair value, shares">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_986_ecustom--UnrealizedLossOnChangeInFairValueOfWarrantsPerShare_pid_c20230101__20231231_zgEZG3zbzLX4" style="padding-bottom: 1.5pt; text-align: right" title="Fair value, per share">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_ecustom--ChangesInFairValue_pn3n3_c20230101__20231231_zRMgbCR9mBHa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value">35</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 2.5pt">Fair value as of December 31, 2023</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_988_eus-gaap--WarrantsAndRightsOutstanding_iE_pn3n3_c20230101__20231231_fKDEp_zGDGToBswRQj" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Credit Line and Draw amounts">-</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">(1)</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_pid_c20230101__20231231_fKDIp_zjaxB96Eysz5" style="padding-bottom: 2.5pt; font-weight: bold; text-align: right" title="Fair value, shares">-</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">(2)</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_pid_c20230101__20231231_z6R7KnB6HNal" style="padding-bottom: 2.5pt; font-weight: bold; text-align: right" title="Fair value, per share">-</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_982_ecustom--WarrantLiability_iE_pn3n3_c20230101__20231231_zSqoVCk67eQc" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value">-</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td id="xdx_F0F_z80cGMHNKlWd" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(1)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Amount of credit available under the 2022 Secured Note on date of inception and as of each period end date. For this purpose, the date on which the 2022 Secured Note was amended and restated to increase the line of credit by $<span id="xdx_902_eus-gaap--LineOfCreditFacilityIncreaseDecreaseForPeriodNet_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyTwoSecuredNoteMember_zNXrdiT59G44" title="Line of credit increase">2,000,000 was treated as a new Inception Date for that portion of the line of credit.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(2)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Number of warrants issuable, as applicable, (a) if the amount of credit available was drawn for measurement as of the applicable inception date, or (b) subsequently for remeasurement as of each period end date.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(3)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Amount of drawdown as of the date presented.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(4)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Number of warrants issued upon receipt of amounts drawn against the 2022 Secured Note as of the date presented.</td></tr></table> During the years ended December 31, 2023 and 2022, AgeX recorded a loss of $35,000 and $225,000, respectively, on changes in the fair value of warrants. The warrant liabilities are considered Level 3 liabilities on the fair value hierarchy as the determination of fair value includes various assumptions about future activities and AgeX’s stock prices and historical volatility as inputs. None of the warrants issued have been exercised.

15160000

4000000

The fair value of the warrant liabilities was measured using a Black-Scholes option pricing model. Significant inputs into the model at the inception date, the date when warrants were issued upon receipt of amounts drawn during the period, and as of the reporting period end remeasurement dates are as follows: Schedule of Warrants Liabilities And Stock Option Awards using a Black-Scholes Option-Pricing Model <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic">Black-Scholes Assumptions</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Exercise Price (1)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Warrant Expiration Date (2)</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Stock Price (3)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Interest Rate (annual) (4)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Volatility (annual) (5)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Time to Maturity (Years)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Calculated Fair Value per Share</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 26%; text-align: left">Inception Date: 2/14/2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDEp_zpUxQsV21Nse" style="width: 7%; text-align: right" title="Exercise Price">27.43</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 7%; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220214__20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDIp_zEprA61NJa7c" title="Warrant Expiration Date">2/13/2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--SharePrice_iI_pid_c20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDMp_zbmyBHRI7gHa" style="width: 7%; text-align: right" title="Stock Price">24.32</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220214__20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDQp_zM334DEd2Wlk" style="width: 7%; text-align: right" title="Interest Rate (annual)">1.80</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220214__20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDUp_zRh51j8KRG29" style="width: 7%; text-align: right" title="Volatility (annual)">122.99</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 6%; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220214__20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_zFs0osS1a3Ig" title="Time to Maturity (Years)">3</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220214__us-gaap--AwardTypeAxis__custom--InceptionDateMember_z5SRt4T3wele" style="width: 7%; text-align: right" title="Calculated fair value per share">17.11</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Issuance Date: 2/14/2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_zDSaY5LaXnWd" style="text-align: right" title="Exercise Price">27.43</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220214__20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zw3istUOO4Wd" title="Warrant Expiration Date">2/13/2025</td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_zL11g5J80fB1" style="text-align: right" title="Stock Price">24.32</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220214__20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_zgWLZHmmVPoj" style="text-align: right" title="Interest Rate (annual)">1.80</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220214__20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zAqxj2bXM0m4" style="text-align: right" title="Volatility (annual)">122.99</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220214__20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_za6UeVHz1qj9" title="Time to Maturity (Years)">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zz3xwNXSMGne" style="text-align: right" title="Calculated fair value per share">17.11</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Issuance Date: 2/15/2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_znmrf8iE8ol2" style="text-align: right" title="Exercise Price">27.43</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220215__20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zvgfBWL0Yw6j" title="Warrant Expiration Date">2/14/2025</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--SharePrice_iI_pid_c20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_zxpObiGvB0qa" style="text-align: right" title="Stock Price">26.28</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220215__20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_z3k26dCoqevb" style="text-align: right" title="Interest Rate (annual)">1.80</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220215__20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zalINsyJ2By1" style="text-align: right" title="Volatility (annual)">123.28</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220215__20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zH9M9dqfnE0b" title="Time to Maturity (Years)">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_z2iazeaWr1f2" style="text-align: right" title="Calculated fair value per share">18.81</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Period Ended 3/31/2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDEp_zScqVXai8rJf" style="text-align: right" title="Exercise Price">33.06</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220331__20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDIp_zlbLfW4MLjmb" title="Warrant Expiration Date">3/30/2025</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--SharePrice_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDMp_zLI1TQCUfnja" style="text-align: right" title="Stock Price">30.04</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220331__20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDQp_zMpqxP7n9h29" style="text-align: right" title="Interest Rate (annual)">2.45</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220331__20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDUp_zpKvpjNj3znc" style="text-align: right" title="Volatility (annual)">123.28</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220331__20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zd5s5fx6cm8l" title="Time to Maturity (Years)">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zuG4paWBnRHf" style="text-align: right" title="Calculated fair value per share">21.36</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Issuance Date: 4/4/2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_zfdfaPO9xt32" style="text-align: right" title="Exercise Price">30.94</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220404__20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zVCCARyX8ip1" title="Warrant Expiration Date">4/3/2025</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--SharePrice_iI_pid_c20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_z6xmpwIsQoOc" style="text-align: right" title="Stock Price">28.79</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220404__20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_zqtZD5yfwsp3" style="text-align: right" title="Interest Rate (annual)">2.61</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220404__20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zG7Ld9gTQPj" style="text-align: right" title="Volatility (annual)">123.31</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220404__20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_ztGbfWopTSma" title="Time to Maturity (Years)">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zZ9R0Z43aacd" style="text-align: right" title="Calculated fair value per share">20.59</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Issuance Date: 6/6/2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_zm0xOQqH3rQb" style="text-align: right" title="Exercise Price">25.01</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220606__20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zkN63n9GP6zc" title="Warrant Expiration Date">6/5/2025</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--SharePrice_iI_pid_c20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_zekhUQmLTyn2" style="text-align: right" title="Stock Price">28.14</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220606__20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_zBn7WntX6ib9" style="text-align: right" title="Interest Rate (annual)">2.94</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220606__20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zaK0EQuIRJLi" style="text-align: right" title="Volatility (annual)">122.62</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220606__20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zAglVXUQvUmc" title="Time to Maturity (Years)">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220606__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zH1YEU3Unm56" style="text-align: right" title="Calculated fair value per share">20.84</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Period Ended 6/30/2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDEp_z8Rvmk6TDdn1" style="text-align: right" title="Exercise Price">21.10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220630__20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDIp_zPmntEqobIrc" title="Warrant Expiration Date">6/29/2025</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--SharePrice_iI_pid_c20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDMp_zGAyjykelgS9" style="text-align: right" title="Stock Price">20.27</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220630__20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDQp_zQ1UrZyxKn0e" style="text-align: right" title="Interest Rate (annual)">2.99</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220630__20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDUp_zt8V5G5gepE9" style="text-align: right" title="Volatility (annual)">122.21</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220630__20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zYOi8uKMnIWa" title="Time to Maturity (Years)">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220630__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_z0FETVl16cZ7" style="text-align: right" title="Calculated fair value per share">14.53</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Issuance Date: 8/16/2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_zKBP5NGtaA8d" style="text-align: right" title="Exercise Price">23.56</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220815__20220815__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zDcwImQHE028" title="Warrant Expiration Date">8/15/2025</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--SharePrice_iI_pid_c20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_zxMLaO5mjkvb" style="text-align: right" title="Stock Price">22.51</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220815__20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_z3pJ8Lv4wVwj" style="text-align: right" title="Interest Rate (annual)">3.19</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220815__20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zVAQIwItEsb9" style="text-align: right" title="Volatility (annual)">121.37</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220815__20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zqQ7JSAhXp8g" title="Time to Maturity (Years)">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220816__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zJjiOMR4ABci" style="text-align: right" title="Calculated fair value per share">16.07</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Period Ended 9/30/2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDEp_z6K42ouEPoZ1" style="text-align: right" title="Exercise Price">21.45</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220929__20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDIp_z5uNzvwNpJ6e" title="Warrant Expiration Date">9/29/2025</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharePrice_iI_pid_c20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDMp_zwwlodlcJa8f" style="text-align: right" title="Stock Price">19.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220929__20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDQp_zJMBRoR1Y2Ra" style="text-align: right" title="Interest Rate (annual)">4.25</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220929__20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDUp_zvLSY2RACTac" style="text-align: right" title="Volatility (annual)">121.49</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220929__20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zaiuxvmI1HXg" title="Time to Maturity (Years)">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20220930__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zsyDbWYwt0a4" style="text-align: right" title="Calculated fair value per share">14.09</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Issuance Date: 10/21/2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20221021__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_zc9B3gwocFMb" style="text-align: right" title="Exercise Price">24.27</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20221020__20221021__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_ziSg1IEpyAG" title="Warrant Expiration Date">10/20/2025</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--SharePrice_iI_pid_c20221021__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_zyiyOgUIJuqk" style="text-align: right" title="Stock Price">21.81</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20221020__20221021__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_zkXYJTyBj6v3" style="text-align: right" title="Interest Rate (annual)">4.52</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20221020__20221021__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zbiowjQ9wCS8" style="text-align: right" title="Volatility (annual)">120.51</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221020__20221021__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zGInSyg7HP7k" title="Time to Maturity (Years)">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20221021__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zTu3RkGvxtaa" style="text-align: right" title="Calculated fair value per share">15.42</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Issuance Date: 12/14/2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20221214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_zBk0rMKfZGJ2" style="text-align: right" title="Exercise Price">20.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20221213__20221214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zCm5OQSi93fh" title="Warrant Expiration Date">12/13/2025</td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20221214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_zDjZ5PO4jktj" style="text-align: right" title="Stock Price">18.99</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20221213__20221214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_zxGYgAgZRSBh" style="text-align: right" title="Interest Rate (annual)">3.94</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20221213__20221214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zxI0wMcjW7kf" style="text-align: right" title="Volatility (annual)">120.01</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221213__20221214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zaP8hpdOsC6l" title="Time to Maturity (Years)">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20221214__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_z6EMaexjFiR4" style="text-align: right" title="Calculated fair value per share">13.40</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Period Ended 12/31/2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDEp_zLdCM44SA5C5" style="text-align: right" title="Exercise Price">19.34</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20221230__20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDIp_zeZxT6yyUrp8" title="Warrant Expiration Date">12/30/2025</td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDMp_zA8Tvec5kxt5" style="text-align: right" title="Stock Price">19.41</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20221230__20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDQp_zdGRgilZ6ARj" style="text-align: right" title="Interest Rate (annual)">4.22</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20221230__20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDUp_z3tWceEtjOw2" style="text-align: right" title="Volatility (annual)">119.31</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20221230__20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zOpUiioixHda" title="Time to Maturity (Years)">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20221231__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zYjhPZi2daD8" style="text-align: right" title="Calculated fair value per share">13.93</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Issuance Date: 1/25/2023</td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20230125__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_zdFBiswdL2O1" style="text-align: right" title="Exercise Price">25.85</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230124__20230125__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zP2SKoB8OB7g" title="Warrant Expiration Date">1/24/2026</td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--SharePrice_iI_pid_c20230125__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_zrOHkTEPXpDj" style="text-align: right" title="Stock Price">26.42</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230124__20230125__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_zJZ1gnH5YTGk" style="text-align: right" title="Interest Rate (annual)">3.84</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230124__20230125__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_z7vwDkPsYyYa" style="text-align: right" title="Volatility (annual)">119.17</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230124__20230125__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zPu46xRCN2ya" title="Time to Maturity (Years)">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20230125__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_z7ZNnKnRzjO3" style="text-align: right" title="Calculated fair value per share">18.98</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Inception Date: 2/9/2023</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20230209__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDEp_zbIozjnOrIAf" style="text-align: right" title="Exercise Price">24.72</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230208__20230209__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDIp_zmGT8vwFXcQ6" title="Warrant Expiration Date">2/8/2026</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--SharePrice_iI_pid_c20230209__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDMp_zL0G98PIqPv2" style="text-align: right" title="Stock Price">23.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230208__20230209__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDQp_zwYOyru8jvX" style="text-align: right" title="Interest Rate (annual)">4.15</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230208__20230209__us-gaap--AwardTypeAxis__custom--InceptionDateMember_fKDUp_zxDkOS11us77" style="text-align: right" title="Volatility (annual)">118.94</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230208__20230209__us-gaap--AwardTypeAxis__custom--InceptionDateMember_z4fcATSLIHx1" title="Time to Maturity (Years)">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20230209__us-gaap--AwardTypeAxis__custom--InceptionDateMember_zbLcaMErUYB9" style="text-align: right" title="Calculated fair value per share">16.38</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Issuance Date: 2/15/2023</td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20230215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_z7P60F3jJgpg" style="text-align: right" title="Exercise Price">21.93</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230214__20230215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_z0w1MJTq65B2" title="Warrant Expiration Date">2/14/2026</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--SharePrice_iI_pid_c20230215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_zcau7qFj62w6" style="text-align: right" title="Stock Price">21.10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230214__20230215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_z6HuK9nI1tOk" style="text-align: right" title="Interest Rate (annual)">4.35</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230214__20230215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zw97RskwTcTc" style="text-align: right" title="Volatility (annual)">118.93</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230214__20230215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_z1foA0CeQQ6c" title="Time to Maturity (Years)">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20230215__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zPHiTcPvDuKc" style="text-align: right" title="Calculated fair value per share">14.99</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Period Ended 3/31/2023</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20230331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDEp_zOylwCfLfQQd" style="text-align: right" title="Exercise Price">23.25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230330__20230331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDIp_zJ0dIld06Oi6" title="Warrant Expiration Date">3/30/2026</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharePrice_iI_pid_c20230331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDMp_zRLkD7ILyLo" style="text-align: right" title="Stock Price">23.32</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230330__20230331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDQp_zdhzlqAQCuE3" style="text-align: right" title="Interest Rate (annual)">3.81</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230330__20230331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_fKDUp_zaBJWyRkWo83" style="text-align: right" title="Volatility (annual)">113.43</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230330__20230331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zE3zd6aEMii" title="Time to Maturity (Years)">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20230331__us-gaap--AwardTypeAxis__custom--PeriodEndingMember_zmbgRiYgFvMi" style="text-align: right" title="Calculated fair value per share">16.15</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Issuance Date: 4/4/2023</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20230404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDEp_z34mfmxmAAa" style="text-align: right" title="Exercise Price">23.25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230403__20230404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDIp_zJX2QgF45ozf" title="Warrant Expiration Date">4/3/2026</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--SharePrice_iI_pid_c20230404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDMp_z1N1LFHSyA31" style="text-align: right" title="Stock Price">23.67</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230403__20230404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDQp_zNSSJyX7PzLl" style="text-align: right" title="Interest Rate (annual)">3.60</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230403__20230404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_fKDUp_zWzWbyjh2wa4" style="text-align: right" title="Volatility (annual)">113.01</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230403__20230404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zUpsbudOxA4h" title="Time to Maturity (Years)">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20230404__us-gaap--AwardTypeAxis__custom--IssuanceDateMember_zTzjbPyZDwMl" style="text-align: right" title="Calculated fair value per share">16.39</td><td style="text-align: left"> </td></tr> </table> <div style="width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(1)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Based on the market closing price of AgeX’s common stock on the NYSE American on the day prior to each debt Inception Date, on each presented period ending date, and one day prior to the delivery of the relevant drawdown notice in accordance with terms of the 2022 Secured Note (with such drawdown notice delivery date being shown as the Issuance Date in the table), and as adjusted to reflect the Reverse Stock Split. For this purpose, the date on which the 2022 Secured Note was amended and restated to increase the line of credit by $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIExpYWJpbGl0aWVzIEFuZCBTdG9jayBPcHRpb24gQXdhcmRzIHVzaW5nIGEgQmxhY2stU2Nob2xlcyBPcHRpb24tUHJpY2luZyBNb2RlbCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--LinesOfCreditCurrent_iI_c20231231_z3VGycq5TJTk" title="Lines of credit current">2,000,000 was treated as a new Inception Date for that portion of the line of credit.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(2)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Warrants are exercisable over a three-year period from each Issuance Date.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(3)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Based on the market price of AgeX’s common stock on the NYSE American as of each date presented.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(4)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Interest rate for U.S. Treasury Bonds, as of each date presented, as published by the U.S. Federal Reserve.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(5)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Based on the historical daily volatility of AgeX common stock as of each date presented.</td></tr></table>

27.43

2025-02-13

24.32

0.0180

1.2299

P3Y

17.11

27.43

2025-02-13

24.32

0.0180

1.2299

P3Y

17.11

27.43

2025-02-14

26.28

0.0180

1.2328

P3Y

18.81

33.06

2025-03-30

30.04

0.0245

1.2328

P3Y

21.36

30.94

2025-04-03

28.79

0.0261

1.2331

P3Y

20.59

25.01

2025-06-05

28.14

0.0294

1.2262

P3Y

20.84

21.10

2025-06-29

20.27

0.0299

1.2221

P3Y

14.53

23.56

2025-08-15

22.51

0.0319

1.2137

P3Y

16.07

21.45

2025-09-29

19.75

0.0425

1.2149

P3Y

14.09

24.27

2025-10-20

21.81

0.0452

1.2051

P3Y

15.42

20.75

2025-12-13

18.99

0.0394

1.2001

P3Y

13.40

19.34

2025-12-30

19.41

0.0422

1.1931

P3Y

13.93

25.85

2026-01-24

26.42

0.0384

1.1917

P3Y

18.98

24.72

2026-02-08

23.20

0.0415

1.1894

P3Y

16.38

21.93

2026-02-14

21.10

0.0435

1.1893

P3Y

14.99

23.25

2026-03-30

23.32

0.0381

1.1343

P3Y

16.15

23.25

2026-04-03

23.67

0.0360

1.1301

P3Y

16.39

2000000000

The warrants outstanding and fair values at each of the respective valuation dates are summarized below. Schedule of Warrant Outstanding and Fair Values <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Warrant Liability</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Credit Line and Draw Amounts (in thousands)</td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value per Share</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value (in thousands)</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Fair value as of January 1, 2022</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstanding_iS_pn3n3_c20220101__20221231_zo4Nosc5S75b" style="font-weight: bold; text-align: right" title="Credit Line and Draw amounts">-</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pid_c20220101__20221231_zy7R36ZOskij" style="font-weight: bold; text-align: right" title="Fair value, shares">-</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_c20220101__20221231_zobrLdEj2y0e" style="font-weight: bold; text-align: right" title="Fair value, per share">-</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_98A_ecustom--WarrantLiability_iS_pid_c20220101__20221231_zFMWPxyn7wS4" style="font-weight: bold; text-align: right" title="Fair value as of period beginning balance, fair value">-</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 38%; text-align: left">Fair value at initial measurement date of 2/14/2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--InitialMeasurementDateOfFourteenFebruaryTwoThousandAndTwentyTwoMember_fKDEp_ztdBcWxO8Mw6" style="width: 10%; text-align: right" title="Credit Line and Draw amounts">13,160</td><td style="width: 4%; text-align: left">(1)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--InitialMeasurementDateOfFourteenFebruaryTwoThousandAndTwentyTwoMember_fKDIp_zQ1ySe22vIhd" style="width: 10%; text-align: right" title="Fair value, shares">239,860</td><td style="width: 4%; text-align: left">(2)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--InitialMeasurementDateOfFourteenFebruaryTwoThousandAndTwentyTwoMember_zItlIL5hcn35" style="width: 10%; text-align: right" title="Fair value, per share">17,11</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--InitialMeasurementDateOfFourteenFebruaryTwoThousandAndTwentyTwoMember_zNRLBtQ1zrad" style="width: 10%; text-align: right" title="Fair value">4,103</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value of warrants issued on 2/14/2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenFebruaryTwoThousandAndTwentyTwoOneMember_fKDMp_zh6msRessplj" style="text-align: right" title="Credit Line and Draw amounts">(7,160</td><td style="text-align: left">)(3)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenFebruaryTwoThousandAndTwentyTwoOneMember_fKDQp_zeBE77DDokX8" style="text-align: right" title="Fair value, shares">(130,501</td><td style="text-align: left">)(4)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenFebruaryTwoThousandAndTwentyTwoOneMember_zuPYePXfmjLb" style="text-align: right" title="Fair value, per share">17.11</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenFebruaryTwoThousandAndTwentyTwoOneMember_zXRMIf3xLCab" style="text-align: right" title="Fair value">(2,232</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fair value of warrants issued on 2/15/2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyTwoMember_fKDMp_zd151T1F5llh" style="text-align: right" title="Credit Line and Draw amounts">(1,000</td><td style="text-align: left">)(3)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyTwoMember_fKDQp_zq5kjUCPg45i" style="text-align: right" title="Fair value, shares">(18,226</td><td style="text-align: left">)(4)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyTwoMember_zCeA3KYLxVx5" style="text-align: right" title="Fair value, per share">18.81</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyTwoMember_zlsipZWt0Jwj" style="text-align: right" title="Fair value">(343</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value of warrants issued on 4/4/2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourAprilTwentyThousandAndTwentyTwoMember_fKDMp_zRORbxs5nXR6" style="text-align: right" title="Credit Line and Draw amounts">(1,000</td><td style="text-align: left">)(3)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourAprilTwentyThousandAndTwentyTwoMember_fKDQp_zU6R8djnisZ8" style="text-align: right" title="Fair value, shares">(16,162</td><td style="text-align: left">)(4)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourAprilTwentyThousandAndTwentyTwoMember_zG7QiHjrspM2" style="text-align: right" title="Fair value, per share">20.59</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourAprilTwentyThousandAndTwentyTwoMember_zTxCzsFudtK3" style="text-align: right" title="Fair value">(333</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fair value of warrants issued on 6/6/2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixJuneTwentyThousandAndTwentyTwoMember_fKDMp_z3VQNT89Cff3" style="text-align: right" title="Credit Line and Draw amounts">(1,000</td><td style="text-align: left">)(3)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixJuneTwentyThousandAndTwentyTwoMember_fKDQp_zPIsO8lFFp9b" style="text-align: right" title="Fair value, shares">(19,995</td><td style="text-align: left">)(4)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixJuneTwentyThousandAndTwentyTwoMember_zEzjYRMc15Cb" style="text-align: right" title="Fair value, per share">20.84</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixJuneTwentyThousandAndTwentyTwoMember_ze7AFtj2Nj53" style="text-align: right" title="Fair value">(417</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value of warrants issued on 8/16/2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixteenAugustTwentyThousandAndTwentyTwoMember_fKDMp_zv7RfFsx3bff" style="text-align: right" title="Credit Line and Draw amounts">(1,000</td><td style="text-align: left">)(3)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixteenAugustTwentyThousandAndTwentyTwoMember_fKDQp_zxX2jTX10Eva" style="text-align: right" title="Fair value, shares">(21,222</td><td style="text-align: left">)(4)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixteenAugustTwentyThousandAndTwentyTwoMember_zgtEh3Ficigk" style="text-align: right" title="Fair value, per share">16.07</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--SixteenAugustTwentyThousandAndTwentyTwoMember_zqDWzqn4QTll" style="text-align: right" title="Fair value">(341</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fair value of warrants issued on 10/21/2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--TwentyFirstOctoberTwoThousandAndTwentyTwoMember_fKDMp_zLWUFIKzjKBd" style="text-align: right" title="Credit Line and Draw amounts">(500</td><td style="text-align: left">)(3)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--TwentyFirstOctoberTwoThousandAndTwentyTwoMember_fKDQp_zWKGumI7pWu8" style="text-align: right" title="Fair value, shares">(10,301</td><td style="text-align: left">)(4)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--TwentyFirstOctoberTwoThousandAndTwentyTwoMember_ztdfkBU3zxw4" style="text-align: right" title="Fair value, per share">15.42</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--TwentyFirstOctoberTwoThousandAndTwentyTwoMember_zeQhqmKAn096" style="text-align: right" title="Fair value">(159</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value of warrants issued on 12/14/2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenDecemberTwoThousandAndTwentyTwoMember_fKDMp_zmDfkQdA28sd" style="text-align: right" title="Credit Line and Draw amounts">(1,000</td><td style="text-align: left">)(3)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--FairValueOfOtherThanOptionIssued_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenDecemberTwoThousandAndTwentyTwoMember_fKDQp_zbgAlOEt3Z5h" style="text-align: right" title="Fair value, shares">(24,096</td><td style="text-align: left">)(4)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--FairValueIssuedPerShare_pid_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenDecemberTwoThousandAndTwentyTwoMember_zCDpK5XW4On6" style="text-align: right" title="Fair value, per share">13.40</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--WarrantsIssuedFairValue_pn3n3_c20220101__20221231__us-gaap--AwardDateAxis__custom--FourteenDecemberTwoThousandAndTwentyTwoMember_z1iE2yubVDOi" style="text-align: right" title="Fair value">(323</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value of warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_ecustom--UnrealizedLossOnChangeInFairValueOfWarrants_pn3n3_c20220101__20221231_fKDIp_zcnbqJoBq0U1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Credit Line and Draw amounts">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98F_ecustom--UnrealizedLossOnChangeOnOtherThanOptions_pid_c20220101__20221231_fKDQp_ztwAQHy0Tz6k" style="padding-bottom: 1.5pt; text-align: right" title="Fair value, shares">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98E_ecustom--UnrealizedLossOnChangeInFairValueOfWarrantsPerShare_pid_c20220101__20221231_z1985yee7ahk" style="padding-bottom: 1.5pt; text-align: right" title="Fair value, per share">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_ecustom--ChangesInFairValue_pn3n3_c20220101__20221231_zQFBu2euVfTl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value">225</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Fair value as of December 31, 2022</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_989_eus-gaap--WarrantsAndRightsOutstanding_iS_pn3n3_c20230101__20231231_fKDEp_zB5hWC6cmOzh" style="font-weight: bold; text-align: right" title="Credit Line and Draw amounts">500</td><td style="font-weight: bold; text-align: left">(1)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pid_c20230101__20231231_fKDIp_zDJjsFOolXgl" style="font-weight: bold; text-align: right" title="Fair value, shares">12,924</td><td style="font-weight: bold; text-align: left">(2)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_c20230101__20231231_zyPQCA4QhAJ6" style="font-weight: bold; text-align: right" title="Fair value, per share">13.93</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_988_ecustom--WarrantLiabilityCurrent_iS_pn3n3_c20230101__20231231_zZ4EpSehlgm7" style="font-weight: bold; text-align: right" title="Fair value">180</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fair value of warrants issued on 1/25/2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230101__20231231__us-gaap--AwardDateAxis__custom--TwentyFiveJanuaryTwoThousandAndTwentyThreeMember_fKDMp_zHMWNw0kOyTg" style="text-align: right" title="Credit Line and Draw amounts">(500</td><td style="text-align: left">)(3)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--FairValueOfOtherThanOptionIssued_pid_c20230101__20231231__us-gaap--AwardDateAxis__custom--TwentyFiveJanuaryTwoThousandAndTwentyThreeMember_fKDQp_z35wf9jrmrUj" style="text-align: right" title="Fair value, shares">(9,671</td><td style="text-align: left">)(4)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--FairValueIssuedPerShare_pid_c20230101__20231231__us-gaap--AwardDateAxis__custom--TwentyFiveJanuaryTwoThousandAndTwentyThreeMember_zTfvOwpkChC1" style="text-align: right" title="Fair value, per share">18.98</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--WarrantsIssuedFairValue_pn3n3_c20230101__20231231__us-gaap--AwardDateAxis__custom--TwentyFiveJanuaryTwoThousandAndTwentyThreeMember_zdsq8yx3iNJg" style="text-align: right" title="Fair value">(184</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value at initial measurement date of 2/9/2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230101__20231231__us-gaap--AwardDateAxis__custom--NineFebruaryTwoThousandAndTwentyThreeMember_fKDEp_z9Ra6thMHs93" style="text-align: right" title="Credit Line and Draw amounts">2,000</td><td style="text-align: left">(1)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--FairValueOfOtherThanOptionIssued_pid_c20230101__20231231__us-gaap--AwardDateAxis__custom--NineFebruaryTwoThousandAndTwentyThreeMember_fKDIp_za6oZFQhGkWk" style="text-align: right" title="Fair value, shares">40,457</td><td style="text-align: left">(2)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--FairValueIssuedPerShare_pid_c20230101__20231231__us-gaap--AwardDateAxis__custom--NineFebruaryTwoThousandAndTwentyThreeMember_zgu0T05zMsue" style="text-align: right" title="Fair value, per share">16.38</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--WarrantsIssuedFairValue_pn3n3_c20230101__20231231__us-gaap--AwardDateAxis__custom--NineFebruaryTwoThousandAndTwentyThreeMember_zrv5Rv7Ya6Y" style="text-align: right" title="Fair value">663</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fair value of warrants issued on 2/15/2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230101__20231231__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyThreeMember_fKDMp_zO3yhozH1laj" style="text-align: right" title="Credit Line and Draw amounts">(1,000</td><td style="text-align: left">)(3)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--FairValueOfOtherThanOptionIssued_pid_c20230101__20231231__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyThreeMember_fKDQp_zJC7F8Fht4v6" style="text-align: right" title="Fair value, shares">(22,801</td><td style="text-align: left">)(4)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--FairValueIssuedPerShare_pid_c20230101__20231231__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyThreeMember_zPd62lk9qLv7" style="text-align: right" title="Fair value, per share">14.99</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--WarrantsIssuedFairValue_pn3n3_c20230101__20231231__us-gaap--AwardDateAxis__custom--FifteenFebruaryTwentyThousandAndTwentyThreeMember_z7q5POztaIca" style="text-align: right" title="Fair value">(342</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value of warrants issued on 4/4/2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230101__20231231__us-gaap--AwardDateAxis__custom--FourthAprilTwentyThousandAndTwentyThreeMember_fKDMp_zvOXyXOv463l" style="text-align: right" title="Credit Line and Draw amounts">(1,000</td><td style="text-align: left">)(3)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--FairValueOfOtherThanOptionIssued_pid_c20230101__20231231__us-gaap--AwardDateAxis__custom--FourthAprilTwentyThousandAndTwentyThreeMember_fKDQp_zOoE7JRx8wki" style="text-align: right" title="Fair value, shares">(21,507</td><td style="text-align: left">)(4)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--FairValueIssuedPerShare_pid_c20230101__20231231__us-gaap--AwardDateAxis__custom--FourthAprilTwentyThousandAndTwentyThreeMember_zfoyJj8C8uhd" style="text-align: right" title="Fair value, per share">16.39</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--WarrantsIssuedFairValue_pn3n3_c20230101__20231231__us-gaap--AwardDateAxis__custom--FourthAprilTwentyThousandAndTwentyThreeMember_zEMem9Rq7Jl" style="text-align: right" title="Fair value">(352</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value of warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_ecustom--UnrealizedLossOnChangeInFairValueOfWarrants_pn3n3_c20230101__20231231_fKDIp_zQ1tZsFKGEn5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Credit Line and Draw amounts">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_983_ecustom--UnrealizedLossOnChangeOnOtherThanOptions_pid_c20230101__20231231_fKDQp_zJiNpW5Cl5Ii" style="padding-bottom: 1.5pt; text-align: right" title="Fair value, shares">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_986_ecustom--UnrealizedLossOnChangeInFairValueOfWarrantsPerShare_pid_c20230101__20231231_zgEZG3zbzLX4" style="padding-bottom: 1.5pt; text-align: right" title="Fair value, per share">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_ecustom--ChangesInFairValue_pn3n3_c20230101__20231231_zRMgbCR9mBHa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value">35</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 2.5pt">Fair value as of December 31, 2023</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_988_eus-gaap--WarrantsAndRightsOutstanding_iE_pn3n3_c20230101__20231231_fKDEp_zGDGToBswRQj" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Credit Line and Draw amounts">-</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">(1)</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_pid_c20230101__20231231_fKDIp_zjaxB96Eysz5" style="padding-bottom: 2.5pt; font-weight: bold; text-align: right" title="Fair value, shares">-</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">(2)</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_pid_c20230101__20231231_z6R7KnB6HNal" style="padding-bottom: 2.5pt; font-weight: bold; text-align: right" title="Fair value, per share">-</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_982_ecustom--WarrantLiability_iE_pn3n3_c20230101__20231231_zSqoVCk67eQc" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Fair value">-</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td id="xdx_F0F_z80cGMHNKlWd" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(1)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Amount of credit available under the 2022 Secured Note on date of inception and as of each period end date. For this purpose, the date on which the 2022 Secured Note was amended and restated to increase the line of credit by $<span id="xdx_902_eus-gaap--LineOfCreditFacilityIncreaseDecreaseForPeriodNet_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyTwoSecuredNoteMember_zNXrdiT59G44" title="Line of credit increase">2,000,000 was treated as a new Inception Date for that portion of the line of credit.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(2)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Number of warrants issuable, as applicable, (a) if the amount of credit available was drawn for measurement as of the applicable inception date, or (b) subsequently for remeasurement as of each period end date.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(3)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Amount of drawdown as of the date presented.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(4)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Number of warrants issued upon receipt of amounts drawn against the 2022 Secured Note as of the date presented.</td></tr></table>

13160000

239860 17.11 4103000

-7160000

-130501 17.11 -2232000

-1000000

-18226 18.81 -343000

-1000000

-16162 20.59 -333000

-1000000

-19995 20.84 -417000

-1000000

-21222 16.07 -341000

-500000

-10301 15.42 -159000

-1000000

-24096 13.40 -323000 225000

500000

12924

13.93

180000

-500000

-9671 18.98 -184000

2000000

40457 16.38 663000

-1000000

-22801 14.99 -342000

-1000000

-21507 16.39 -352000 35000

2000000000

35000

225000

7. Stockholders’ Equity/(Deficit) Preferred Stock On July 24, 2023, AgeX issued to Juvenescence <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230724__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zLdOLUztPMuh" title="Preferred stock, shares authorized">211,600 shares of a newly authorized Series A Preferred Stock and <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230724__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z9y4FGmrqCKf" title="Preferred stock, shares authorized">148,400 shares of a newly authorized Series B Preferred Stock in exchange for the cancellation of a total of $36 million of indebtedness consisting of the outstanding principal amount of loans then outstanding under the 2020 Loan Agreement, the 2022 Secured Note, and the 2023 Secured Note, plus the loan origination fees accrued with respect to the 2022 Secured Note and a portion of the loan origination fees accrued pursuant to the 2023 Secured Note. The cancellation of indebtedness in exchange for the Series A Preferred Stock and Series B Preferred Stock (collectively referred to as the “Preferred Stock”) was conducted pursuant to the Exchange Agreement between AgeX and Juvenescence. All of the shares of Preferred Stock were automatically converted into a total of <span id="xdx_902_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_pid_c20240201__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_z9MWRs9tx06l" title="Conversion of stock, shares converted">1,421,666 shares of AgeX common stock on February 1, 2024 in accordance with the terms of the Preferred Stock. See Note 11, Subsequent Events. Classification of Preferred Stock On November 7, 2023, certain terms of the Series A Preferred Stock and Series B Preferred Stock was amended (i) to clarify that certain change of control or disposition of asset transactions would be treated as adeemed liquidation if the applicable transaction is approved by the Board of Directors or stockholders of AgeX, and (ii) to provide that in case of such a deemed liquidation transaction holders of Preferred Stock would receive the same type of consideration as that distributed or paid to holders of AgeX common stock. This amendment permits the classification of the Series A Preferred Stock and Series B Preferred Stock as permanent equity effective November 7, 2023. The redemption rights of the Series A Preferred Stock and Series B Preferred Stock in case of a “deemed liquidation” provide that the holders of AgeX preferred stock would always be entitled to receive the same form of consideration as the holders of AgeX common stock. Accordingly, the preferred stock has been presented in permanent equity section of the consolidated balance sheet. The following is a description of certain terms of the Preferred Stock that were applicable to the shares of Preferred Stock outstanding as of December 31, 2023. However, all of the Preferred Stock was converted into shares of common stock on February 1, 2024. See Note 11, Subsequent Events. Dividends – The Preferred Stock is not entitled to receive any payment or distribution of cash or other dividends. Liquidation Preference – In the event of any voluntary or involuntary liquidation, dissolution or other winding up of the affairs of AgeX, subject to the preferences and other rights of any senior stock, before any assets of AgeX shall be distributed to holders of common stock or other junior stock, all of the assets of AgeX available for distribution to stockholders shall be distributed among the holders of Series A Preferred Stock and Series B Preferred Stock and any other “parity stock” that may be issued ranking parri passu with those series of Preferred Stock with respect to liquidation rights, in proportion to the number of shares of Series B Preferred Stock and parity stock held by each such holder as of the record date for the determination of holders of Series A Preferred Stock, Series B Preferred Stock, and parity stock entitled to receive such distribution, until AgeX shall have distributed to the holders of those shares an amount of assets having a value equal to the subscription price per share. If the assets of AgeX shall be insufficient to pay in full such amounts, then the entire assets to be distributed to the holders of Series A Preferred Stock, Series B Preferred Stock and parity stock shall be ratably distributed among such holders. The (i) acquisition of AgeX by another entity by means of any transaction or series of transactions (including, without limitation, any reorganization, merger or consolidation) in which the stockholders of AgeX immediately before such transaction or series of transactions do not own a majority of the outstanding stock of the surviving or acquiring corporation upon completion of such transaction or series of transactions or (ii) a sale of all or substantially all of the assets of AgeX in a single transaction or series of related transactions, shall be deemed a liquidation. On November 7, 2023, certain terms of the liquidation preference were amended. Conversion of Preferred Stock into Common Stock – Each share of Preferred Stock shall be convertible into a number of shares of AgeX common stock determined by dividing (x) a number equal to the number of dollars and cents comprising the subscription price, by (y) a number equal to the number of dollars and cents comprising the conversion price. The subscription price per share of Preferred Stock is $<span id="xdx_901_eus-gaap--CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_iI_pn3n3_c20230724__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zymIaoG3Hy52" title="Subscriptions price">100 which was paid through the exchange of indebtedness for shares of Preferred Stock. The conversion price per share of Series A Preferred Stock or Series B Preferred Stock is $<span id="xdx_908_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20230724__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zYl4fDbLqXwl" title="Preferred stock closing price">0.72 which was the closing price of AgeX common stock on the NYSE American on the last trading day immediately preceding the execution of the Exchange Agreement and prior to adjustment to give effect to the Reverse Stock Split. Optional Conversion – Preferred Stock shall be convertible into common stock at the election of the holder of shares of Preferred Stock at any time and from time to time subject to the limitations on conversion of Series B Preferred Stock discussed below. Automatic Conversion – The outstanding shares of Series A Preferred Stock and Series B Preferred Stock shall automatically be converted into common stock without any further act of AgeX or its stockholders (“Automatic Conversion”) upon the earliest of: (x) the date on which AgeX or a subsidiary shall have consummated a merger with Serina, or a subsidiary thereof; and (y) February 1, 2024. Further, if the holders of at least a majority of the outstanding shares of Series A Preferred Stock or Series B Preferred Stock approve or consent to the Automatic Conversion of the shares of that series, then the outstanding shares of Series A Preferred Stock or Series B Preferred Stock, as applicable, shall be converted into common stock upon such approval or consent. The outstanding shares of Series B Preferred Stock shall automatically be converted into common stock without any further act of AgeX or its stockholders upon the earliest of: (x) the date on which AgeX or a subsidiary shall have consummated a merger with Serina or a subsidiary thereof; and (y) February 1, 2024. Adjustment of conversion price and subscription price – If AgeX shall (a) declare a dividend or make a distribution on its common stock in shares of common stock, (b) subdivide or reclassify the outstanding common stock into a greater number of shares, or (c) combine or reclassify the outstanding common stock into a smaller number of shares, the conversion price in effect at the time of the record date for such dividend or distribution or the effective date of such subdivision, combination or reclassification shall be proportionately adjusted. If AgeX shall (i) declare a dividend or make a distribution on a series of Preferred Stock in shares of Preferred Stock, (ii) subdivide or reclassify the outstanding shares of a series of Preferred Stock into a greater number of shares, or (iii) combine or reclassify the outstanding shares of a series of Preferred Stock into a smaller number of shares, the subscription price in effect at the time of the record date for such dividend or distribution or the effective date of such subdivision, combination or reclassification shall be proportionately adjusted. Successive adjustments in the conversion price or subscription price, as applicable, shall be made whenever any event specified above shall occur. No Fractional Shares – No fractional share of common stock or scrip shall be issued upon conversion of Preferred Stock. Instead of any fractional share of common stock which would otherwise be issuable upon conversion of any Preferred Stock, AgeX will pay a cash adjustment in respect of such fractional interest in an amount equal to that fractional interest at the then fair value determined in accordance with the terms of the Preferred Stock. Voting Rights – The following matters shall require the approval of the holders of a majority of the shares of a series of Preferred Stock then outstanding, voting as a separate class: (i) creation of any Preferred Stock ranking as senior stock to the series with respect to liquidation preferences; (ii) repurchase of any shares of common stock or other junior stock except shares issued pursuant to or in connection with a compensation or incentive plan or agreement approved by the Board of Directors for any officers, directors, employees or consultants of AgeX; (iii) any sale, conveyance, or other disposition of all or substantially all AgeX’s property or business, or any liquidation or dissolution of AgeX, or a merger into or consolidation with any other corporation (other than a wholly-owned subsidiary corporation) but only to the extent that the Delaware General Corporation Law requires that such transaction be approved by each class or series of Preferred Stock; (iv) any adverse change in the powers, preferences and rights of, and the qualifications, limitations or restrictions on, the series of Preferred Stock; or (v) any amendment of AgeX’s Certificate of Incorporation or Bylaws that results in any adverse change in the powers, preferences and rights of, and the qualifications, limitations or restrictions on, the series of Preferred Stock. However, the terms of the Preferred Stock do not restrict or limit the rights and powers of the Board of Directors to fix by resolution the rights, preferences, and privileges of, and restrictions and limitations on, stock ranking as parity stock or junior stock to a series of Preferred Stock. Except as may otherwise be required by the Delaware General Corporation Law, as the same may be amended from time to time, the Preferred Stock will have no other voting rights. Governing Law – The powers, designations, preferences, rights, qualifications, limitations, and restrictions of either series of Preferred Stock, the validity, authorization and issuance of such Preferred Stock, and the conversion of such Preferred Stock into common stock shall be governed by and construed and enforced in accordance with the internal laws of the State of Delaware, without regard to the principles of conflict of laws thereof, and all legal proceedings pursuant or with respect to or concerning such matters (a “Proceeding”), whether brought by or against a holder of Preferred Stock or AgeX or any of their respective directors, officers, stockholders, employees or agents, shall be commenced in the state and federal courts sitting in the State of Delaware (the “Delaware Courts”). The Preferred Stock provides that (a) AgeX and each holder of Preferred Stock irrevocably submits to the exclusive jurisdiction of the Delaware Courts for the adjudication of any Proceeding, and irrevocably waives, and agrees not to assert in any Proceeding any claim that they are not personally subject to the jurisdiction of such Delaware Courts, or such Delaware Courts are an improper or inconvenient venue for such Proceeding, and (b) AgeX and each holder of Preferred Stock irrevocably waives personal service of process and consents to process being served in any such Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to such party and agrees that such service shall constitute good and sufficient service of process and notice. Common Stock AgeX has 200,000,000 shares of common stock, $0.0001 par value per share, authorized. The holders of AgeX’s common stock are entitled to receive ratably dividends when, as, and if declared by the Board of Directors out of funds legally available. Upon liquidation, dissolution, or winding up, the holders of AgeX common stock are entitled to receive ratably the net assets available after the payment of all debts and other liabilities and subject to the prior rights of AgeX outstanding preferred shares, if any. The holders of common stock are entitled to one vote for each share held on all matters submitted to a vote of AgeX stockholders. The holders of common stock have no preemptive, subscription, or redemption rights. The outstanding shares of common stock are fully paid and non-assessable. As of December 31, 2023 and 2022, there were 1,079,080 and 1,079,022 shares of AgeX common stock issued and outstanding, respectively. Issuance and Sale of Warrants by AgeX In connection with the $2,500,000 of drawdowns of loan funds from Juvenescence under the 2022 Secured Note during the year ended December 31, 2023, AgeX issued to Juvenescence 2022 Warrants to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231231__dei--LegalEntityAxis__custom--JuvenescenceMember__us-gaap--DebtInstrumentAxis__custom--IssuanceAndSaleOfWarrantsMember_zzLHNMaOdNQb" title="Warrant to purchase share of common stock">53,980 shares of AgeX common stock. See Note 6, Warrant Liability.

211600

148400

36000000

1421666

100000

0.72

(i) creation of any Preferred Stock ranking as senior stock to the series with respect to liquidation preferences; (ii) repurchase of any shares of common stock or other junior stock except shares issued pursuant to or in connection with a compensation or incentive plan or agreement approved by the Board of Directors for any officers, directors, employees or consultants of AgeX; (iii) any sale, conveyance, or other disposition of all or substantially all AgeX’s property or business, or any liquidation or dissolution of AgeX, or a merger into or consolidation with any other corporation (other than a wholly-owned subsidiary corporation) but only to the extent that the Delaware General Corporation Law requires that such transaction be approved by each class or series of Preferred Stock; (iv) any adverse change in the powers, preferences and rights of, and the qualifications, limitations or restrictions on, the series of Preferred Stock; or (v) any amendment of AgeX’s Certificate of Incorporation or Bylaws that results in any adverse change in the powers, preferences and rights of, and the qualifications, limitations or restrictions on, the series of Preferred Stock. However, the terms of the Preferred Stock do not restrict or limit the rights and powers of the Board of Directors to fix by resolution the rights, preferences, and privileges of, and restrictions and limitations on, stock ranking as parity stock or junior stock to a series of Preferred Stock.

200000000

0.0001

1079080

1079022

2500000

53980

8. Stock-Based Awards Equity Incentive Plan Under the 2017 Equity Incentive Plan, as amended (the “Incentive Plan”), AgeX has reserved<span id="xdx_90C_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zCyKG7HYu7P" title="Number of common stock reserved"> 241,683 shares of common stock for the grant of stock options or the sale of restricted stock (“Restricted Stock”) or for the settlement of restricted stock units which are hypothetical units issued with reference to common stock (“Restricted Stock Units” or “RSUs”). AgeX may also grant stock appreciation rights (“SARs”) under the Incentive Plan. The Plan also permits AgeX to issue such other securities as its Board of Directors (the “Board”) or the Compensation Committee (the “Committee”) administering the Incentive Plan may determine. Awards of stock options, Restricted Stock, SARs, and RSUs (“Awards”) may be granted under the Incentive Plan to AgeX employees, directors, and consultants. Awards may vest and thereby become exercisable or have restrictions on forfeiture lapse on the date of grant or in periodic installments or upon the attainment of performance goals, or upon the occurrence of specified events. <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zToxkc0RjoBk" title="Granted options description">No person shall be granted, during any one year period, options to purchase, or SARs with respect to, more than <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zvL3mZos0lek" title="Options to purchase shares">28,433 shares in the aggregate, or any Awards of Restricted Stock or RSUs with respect to more than <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--RangeAxis__srt--MaximumMember_znUkowS18dhi" title="Options to purchase shares">14,216 shares in the aggregate. If an Award is to be settled in cash, the number of shares on which the Award is based shall not count toward the individual share limit. No Awards may be granted under the Incentive Plan more than ten years after the date upon which the Incentive Plan was adopted by the Board, and no options or SARS granted under the Incentive Plan may be exercised after the expiration of ten years from the date of grant. Stock Options Options granted under the Incentive Plan may be either “incentive stock options” within the meaning of Section 422(b) of the Internal Revenue Code of 1986, as amended (“IRC” or the “Code”), or “non-qualified” stock options that do not qualify incentive stock options. Incentive stock options may be granted only to AgeX employees and employees of subsidiaries. The exercise price of stock options granted under the Incentive Plan must be equal to the fair market of AgeX common stock on the date the option is granted. <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zF558CPlXCN2" title="Granted options description">In the case of an optionee who, at the time of grant, owns more than 10% of the combined voting power of all classes of AgeX stock, the exercise price of any incentive stock option must be at least 110% of the fair market value of the common stock on the grant date, and the term of the option may be no longer than five years. The aggregate fair market value of common stock (determined as of the grant date of the option) with respect to which incentive stock options become exercisable for the first time by an optionee in any calendar year may not exceed $<span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember__srt--RangeAxis__srt--MaximumMember_zwq578ytvrdj" title="Options exercisable">100,000. The exercise price of an option may be payable in cash or in common stock having a fair market value equal to the exercise price, or in a combination of cash and common stock, or other legal consideration for the issuance of stock as the Board or Committee may approve. Generally, options will be exercisable only while the optionee remains an employee, director or consultant, or during a specific period thereafter, but in the case of the termination of an employee, director, or consultant’s services due to death or disability, the period for exercising a vested option shall be extended to the earlier of 12 months after termination or the expiration date of the option. Restricted Stock and RSUs In lieu of granting options, AgeX may enter into purchase agreements with employees under which <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20230101__20231231__us-gaap--AwardTypeAxis__custom--RestrictedStockAndRestrictedStockUnitsMember__srt--RangeAxis__srt--MaximumMember_z5KcuNdoI358" title="Granted options description">they may purchase or otherwise acquire Restricted Stock or RSUs subject to such vesting, transfer, and repurchase terms, and other restrictions. The price at which Restricted Stock may be issued or sold will be not less than 100% of fair market value. Employees or consultants, but not executive officers or directors, who purchase Restricted Stock may be permitted to pay for their shares by delivering a promissory note or an installment payment agreement that may be secured by a pledge of their Restricted Stock. Restricted Stock may also be issued for services actually performed by the recipient prior to the issuance of the Restricted Stock. Unvested Restricted Stock for which AgeX has not received payment may be forfeited, or AgeX may have the right to repurchase unvested shares upon the occurrence of specified events, such as termination of employment. Subject to the restrictions set with respect to the particular Award, a recipient of Restricted Stock generally shall have the rights and privileges of a stockholder, including the right to vote the Restricted Stock and the right to receive dividends; provided that, any cash dividends and stock dividends with respect to the Restricted Stock shall be withheld for the recipient’s account, and interest may be credited on the amount of the cash dividends withheld. The cash dividends or stock dividends so withheld and attributable to any particular share of Restricted Stock (and earnings thereon, if applicable) shall be distributed to the recipient in cash or, at the discretion of the Board or Committee, in shares of common stock having a fair market value equal to the amount of such dividends, if applicable, upon the release of restrictions on the Restricted Stock and, if the Restricted Stock is forfeited, the recipient shall have no right to the dividends. The terms and conditions of a grant of RSUs shall be determined by the Board or Committee. No shares of common stock shall be issued at the time a RSU is granted. A recipient of RSUs shall have no voting rights with respect to the RSUs. Upon the expiration of the restrictions applicable to a RSU, AgeX will either issue to the recipient, without charge, one share of common stock per RSU or cash in an amount equal to the fair market value of one share of common stock. At the discretion of the Board or Committee, each RSU (representing one share of common stock) may be credited with cash and stock dividends paid in respect of one share (“Dividend Equivalents”). Dividend Equivalents shall be withheld for the recipient’s account, and interest may be credited on the amount of cash Dividend Equivalents withheld. Dividend Equivalents credited to a recipient’s account and attributable to any particular RSU (and earnings thereon, if applicable) shall be distributed in cash or in shares of common stock having a fair market value equal to the amount of the Dividend Equivalents and earnings, if applicable, upon settlement of the RSU. If a RSU is forfeited, the recipient shall have no right to the related Dividend Equivalents. Stock Appreciation Rights (“SARs”) A SAR is the right to receive, upon exercise, an amount payable in cash or shares, or a combination of shares and cash, equal to the number of shares subject to the SAR that is being exercised, multiplied by the excess of (a) the fair market value of a common stock on the date the SAR is exercised, over (b) the exercise price specified in the SAR Award agreement. SARs may be granted either as free standing SARs or in tandem with options. No SAR may be exercised later than <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockAppreciationRightsSARSMember_z5etXWDFe4q1">10 years after the date of grant. The exercise price of a SAR shall not be less than <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockAppreciationRightsSARSMember_zQw9m5jQxXUe" title="Fair market value of common stock">100% of the fair market value of one share of common stock on the date of grant. A SAR granted in conjunction with an option shall have the same exercise price as the related option, shall be transferable only upon the same terms and conditions as the related option, and shall be exercisable only to the same extent as the related option; provided, however, that the SAR by its terms shall be exercisable only when the fair market value per share exceeds the exercise price per share of the SAR or related option. Upon any exercise of a SAR granted in tandem with an option, the number of shares for which the related option shall be exercisable shall be reduced by the number of shares for which the SAR has been exercised. The number of shares for which a SAR issued in tandem with an option shall be exercisable shall be reduced by the number of shares for which the related option has been exercised. Equity Incentive Plan Awards A summary of the Incentive Plan activity and related information follows (in thousands except weighted-average exercise price): Summary of Stock Option Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares Available for Grant</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Options Outstanding</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of RSUs Outstanding</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted- Average Exercise Price</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%">Balance at January 1, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_z2yihsXABczj" style="width: 10%; text-align: right" title="Shares available for grant, beginning balance">29</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_z3HV5YYrUcJ7" style="width: 10%; text-align: right" title="Number of options outstanding, beginning balance">96</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_z5sRVyz6kBzj" style="width: 10%; text-align: right" title="Number of RSUs outstanding, beginning balance"> -</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zmkU668Pxjnb" style="width: 10%; text-align: right" title="Weighted average exercise price, outstanding, beginning balance">81.62</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Increase option pool</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zj3IVYFOz2H3" style="text-align: right" title="Shares available for grant increase option pool">114</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zyuZPRGuCQIa" style="text-align: right" title="Options grants increase option pool">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zYYllEL96qEl" style="text-align: right" title="Number of shares outstanding increase option pool">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zhwQ2sOA2LNk" style="text-align: right" title="Weighted average exercise price increase option pool">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--SharesAvailableForGrantOptionsGranted_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zttXZVEvdOg1" style="text-align: right" title="Shares available for grant, options granted">(3</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zTIsqWfB401d" style="text-align: right" title="Number of options outstanding, options granted">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zpt5nFKftNI4" style="text-align: right" title="Number of RSUs outstanding, options granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_z4Pf4cOeUbIg" style="text-align: right" title="Weighted average exercise price, options granted">27.76</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options forfeited, cancelled or expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--SharesAvailableForGrantOptionsForfeitedCancelledOrExpired_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zoIJwN3ivD9" style="text-align: right" title="Shares available for grant, options forfeited, cancelled or expired">6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pn3n3_di_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zN2g5LZIz6Ae" style="text-align: right" title="Number of options outstanding, options forfeited, cancelled or expired">(6</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zMNLOrAvE7zk" style="text-align: right" title="Number of RSUs outstanding, options forfeited, cancelled or expired">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zWPPyIWLSiH3" style="text-align: right" title="Weighted average exercise price, options forfeited, cancelled or expired">99.12</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Restricted stock units vested</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--SharesAvailableForGrantRestrictedStockUnitsVested_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zcKCvLjz7Ejg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares available for grant, restricted stock units vested">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRestrictedStockUnitGrantsInPeriodGross_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zsQlEg20IJTl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options outstanding, restricted stock units vested">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pn3n3_di_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zGNKHZMgUsX7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs outstanding, restricted stock units vested">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRestrictedStockUnitGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_z7OeeScVen89" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, restricted stock units vested">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Balance at December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_pn3n3_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zCKju6d4VNQ9" style="text-align: right" title="Shares available for grant, beginning balance">146</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zSxhCreMHCo1" style="text-align: right" title="Number of options outstanding, beginning balance">93</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pn3n3_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zWZGhRvnA6Zd" style="text-align: right" title="Number of RSUs outstanding, beginning balance">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zgYkOMkleGj6" style="text-align: right" title="Weighted average exercise price, outstanding, beginning balance">79.07</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--SharesAvailableForGrantOptionsGranted_pn3n3_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zU9kgE9ovCQ1" style="text-align: right" title="Shares available for grant, options granted">(1</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zSanPu11KS54" style="text-align: right" title="Number of options outstanding, options granted">1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn3n3_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zGfvEJUOIcph" style="text-align: right" title="Number of RSUs outstanding, options granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zoFFoT4el0X6" style="text-align: right" title="Weighted average exercise price, options granted">26.73</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options forfeited, cancelled or expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--SharesAvailableForGrantOptionsForfeitedCancelledOrExpired_pn3n3_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zIEDYFqdUbFc" style="text-align: right" title="Shares available for grant, options forfeited, cancelled or expired">11</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pn3n3_di_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zfNhhHxv3kpl" style="text-align: right" title="Number of options outstanding, options forfeited, cancelled or expired">(11</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pn3n3_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zydES6DPGqfd" style="text-align: right" title="Number of RSUs outstanding, options forfeited, cancelled or expired">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zjTH0c5w5bQ6" style="text-align: right" title="Weighted average exercise price, options forfeited, cancelled or expired">67.30</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Restricted stock units vested</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_ecustom--SharesAvailableForGrantRestrictedStockUnitsVested_pn3n3_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zrHultgwS3jg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares available for grant, restricted stock units vested">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRestrictedStockUnitGrantsInPeriodGross_pn3n3_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zndIJvYK7Fp5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options outstanding, restricted stock units vested">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pn3n3_di_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zbuKvnUeUEAj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs outstanding, restricted stock units vested">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRestrictedStockUnitGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zccOZIsKEx51" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, restricted stock units vested">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pn3n3_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_z9qIHoDzRTBd" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares available for grant, ending balance">156</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zlcunbGyauE3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, ending balance">83</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pn3n3_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zUo1vqnLI852" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of RSUs outstanding, ending balance">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zArmB1eWPEw2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, outstanding, ending balance">80.28</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Options exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pn3n3_c20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zo4zGU6sS8jh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, exercisable, ending balance">80</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zWdhPICZiQnc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable, ending balance">81.70</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> There were <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_do_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1bxpjmUCFh3" title="Number of options exercised"><span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_do_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPuvVyUzx8B9" title="Number of options exercised">no exercises of stock options during the years ended December 31, 2023 and 2022. Total proceeds, if all options granted and outstanding as of December 31, 2023 were exercised, would be approximately $<span id="xdx_903_eus-gaap--ProceedsFromStockOptionsExercised_pn5n6_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUOtVe6wt8q3" title="Options granted and outstanding exercised">6.6 million. At December 31, 2023, AgeX had approximately $68,000 of total unrecognized compensation costs related to the stock options and unvested RSUs under the Incentive Plan that will be recognized as expense over a weighted-average period of approximately<span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231_zEYGiKIi3zR6" title="Recognized over weighted average period"> 1.36 years. The aggregate intrinsic value of options outstanding and options exercisable were nil as of December 31, 2023. Stock-Based Compensation Expense <p id="xdx_892_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zrjWKBtsXlgj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">AgeX recorded stock-based compensation expense in the following categories on the accompanying consolidated statements of operations for the years ended December 31, 2023 and 2022 (in thousands): Schedule of Stock Based Compensation Expense <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20230101__20231231_zv60RFY83RPi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20220101__20221231_zpfkxhiv9Wck" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zgOSAUislxN8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; text-align: left">Research and development</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">9</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">32</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zFdJdRP59O44" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">639</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">728</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_z32q1pjhdtCf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">648</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">760</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The weighted-average estimated fair value of stock options granted during the years ended December 31, 2023 and 2022 was $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20231231_zdvsg3btn9Y" title="Weighted-average estimated fair value of stock options granted">22.41 per share and $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_iI_pid_c20221231_zabek9d0hcJg" title="Weighted-average estimated fair value of stock options granted">24.48 per share, respectively, using the Black-Scholes option pricing model with the following weighted-average assumptions: Schedule of Weighted Average Assumptions to Calculate Fair Value of Stock Options <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%">Grant Price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zqXy39lAIXLf" style="width: 12%; text-align: right" title="Grant Price">26.73</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231_zUpGadO6IcP9" style="width: 12%; text-align: right" title="Grant Price">27.76</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected life (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.15</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.58</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rates</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.12</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.74</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">118.12</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">130.71</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231_zVYPDVo9AkKg" style="text-align: right" title="Dividend yield">-</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231_zvijrEI14Slf" style="text-align: right" title="Dividend yield">-</td><td style="text-align: left">%</td></tr> </table> The determination of stock-based compensation is inherently uncertain and subjective and involves the application of valuation models and assumptions requiring the use of judgment. If AgeX had made different assumptions, its stock-based compensation expense and net loss for the years ended December 31, 2023 and 2022 may have been significantly different. See Note 2, Summary of Significant Accounting Policies, for a discussion of the factors used in determining these assumptions. AgeX does not recognize deferred income taxes for incentive stock option compensation expense and records a tax deduction only when a disqualified disposition has occurred.

241683

No person shall be granted, during any one year period, options to purchase, or SARs with respect to, more than 28,433 shares in the aggregate, or any Awards of Restricted Stock or RSUs with respect to more than 14,216 shares in the aggregate. If an Award is to be settled in cash, the number of shares on which the Award is based shall not count toward the individual share limit.

28433

14216

In the case of an optionee who, at the time of grant, owns more than 10% of the combined voting power of all classes of AgeX stock, the exercise price of any incentive stock option must be at least 110% of the fair market value of the common stock on the grant date, and the term of the option may be no longer than five years.

100000

they may purchase or otherwise acquire Restricted Stock or RSUs subject to such vesting, transfer, and repurchase terms, and other restrictions. The price at which Restricted Stock may be issued or sold will be not less than 100% of fair market value.

P10Y

A summary of the Incentive Plan activity and related information follows (in thousands except weighted-average exercise price): Summary of Stock Option Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares Available for Grant</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Options Outstanding</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of RSUs Outstanding</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted- Average Exercise Price</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%">Balance at January 1, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_z2yihsXABczj" style="width: 10%; text-align: right" title="Shares available for grant, beginning balance">29</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_z3HV5YYrUcJ7" style="width: 10%; text-align: right" title="Number of options outstanding, beginning balance">96</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_z5sRVyz6kBzj" style="width: 10%; text-align: right" title="Number of RSUs outstanding, beginning balance"> -</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zmkU668Pxjnb" style="width: 10%; text-align: right" title="Weighted average exercise price, outstanding, beginning balance">81.62</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Increase option pool</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zj3IVYFOz2H3" style="text-align: right" title="Shares available for grant increase option pool">114</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zyuZPRGuCQIa" style="text-align: right" title="Options grants increase option pool">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zYYllEL96qEl" style="text-align: right" title="Number of shares outstanding increase option pool">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zhwQ2sOA2LNk" style="text-align: right" title="Weighted average exercise price increase option pool">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--SharesAvailableForGrantOptionsGranted_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zttXZVEvdOg1" style="text-align: right" title="Shares available for grant, options granted">(3</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zTIsqWfB401d" style="text-align: right" title="Number of options outstanding, options granted">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zpt5nFKftNI4" style="text-align: right" title="Number of RSUs outstanding, options granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_z4Pf4cOeUbIg" style="text-align: right" title="Weighted average exercise price, options granted">27.76</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options forfeited, cancelled or expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--SharesAvailableForGrantOptionsForfeitedCancelledOrExpired_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zoIJwN3ivD9" style="text-align: right" title="Shares available for grant, options forfeited, cancelled or expired">6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pn3n3_di_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zN2g5LZIz6Ae" style="text-align: right" title="Number of options outstanding, options forfeited, cancelled or expired">(6</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zMNLOrAvE7zk" style="text-align: right" title="Number of RSUs outstanding, options forfeited, cancelled or expired">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zWPPyIWLSiH3" style="text-align: right" title="Weighted average exercise price, options forfeited, cancelled or expired">99.12</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Restricted stock units vested</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--SharesAvailableForGrantRestrictedStockUnitsVested_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zcKCvLjz7Ejg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares available for grant, restricted stock units vested">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRestrictedStockUnitGrantsInPeriodGross_pn3n3_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zsQlEg20IJTl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options outstanding, restricted stock units vested">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pn3n3_di_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zGNKHZMgUsX7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs outstanding, restricted stock units vested">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRestrictedStockUnitGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_z7OeeScVen89" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, restricted stock units vested">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Balance at December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_pn3n3_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zCKju6d4VNQ9" style="text-align: right" title="Shares available for grant, beginning balance">146</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zSxhCreMHCo1" style="text-align: right" title="Number of options outstanding, beginning balance">93</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pn3n3_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zWZGhRvnA6Zd" style="text-align: right" title="Number of RSUs outstanding, beginning balance">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zgYkOMkleGj6" style="text-align: right" title="Weighted average exercise price, outstanding, beginning balance">79.07</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--SharesAvailableForGrantOptionsGranted_pn3n3_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zU9kgE9ovCQ1" style="text-align: right" title="Shares available for grant, options granted">(1</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zSanPu11KS54" style="text-align: right" title="Number of options outstanding, options granted">1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn3n3_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zGfvEJUOIcph" style="text-align: right" title="Number of RSUs outstanding, options granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zoFFoT4el0X6" style="text-align: right" title="Weighted average exercise price, options granted">26.73</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options forfeited, cancelled or expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--SharesAvailableForGrantOptionsForfeitedCancelledOrExpired_pn3n3_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zIEDYFqdUbFc" style="text-align: right" title="Shares available for grant, options forfeited, cancelled or expired">11</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pn3n3_di_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zfNhhHxv3kpl" style="text-align: right" title="Number of options outstanding, options forfeited, cancelled or expired">(11</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pn3n3_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zydES6DPGqfd" style="text-align: right" title="Number of RSUs outstanding, options forfeited, cancelled or expired">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zjTH0c5w5bQ6" style="text-align: right" title="Weighted average exercise price, options forfeited, cancelled or expired">67.30</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Restricted stock units vested</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_ecustom--SharesAvailableForGrantRestrictedStockUnitsVested_pn3n3_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zrHultgwS3jg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares available for grant, restricted stock units vested">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRestrictedStockUnitGrantsInPeriodGross_pn3n3_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zndIJvYK7Fp5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options outstanding, restricted stock units vested">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pn3n3_di_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zbuKvnUeUEAj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs outstanding, restricted stock units vested">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRestrictedStockUnitGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zccOZIsKEx51" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, restricted stock units vested">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_pn3n3_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_z9qIHoDzRTBd" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares available for grant, ending balance">156</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zlcunbGyauE3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, ending balance">83</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pn3n3_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zUo1vqnLI852" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of RSUs outstanding, ending balance">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zArmB1eWPEw2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, outstanding, ending balance">80.28</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Options exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pn3n3_c20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zo4zGU6sS8jh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, exercisable, ending balance">80</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zWdhPICZiQnc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable, ending balance">81.70</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

29000

96000

81.62

114000

-3000

3000

27.76

6000

99.12

146000

93000

79.07

-1000

1000

26.73

11000

67.30

156000

83000

80.28

80000

81.70

6600000

68000

P1Y4M9D

<p id="xdx_892_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zrjWKBtsXlgj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">AgeX recorded stock-based compensation expense in the following categories on the accompanying consolidated statements of operations for the years ended December 31, 2023 and 2022 (in thousands): Schedule of Stock Based Compensation Expense <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20230101__20231231_zv60RFY83RPi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20220101__20221231_zpfkxhiv9Wck" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zgOSAUislxN8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; text-align: left">Research and development</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">9</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">32</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zFdJdRP59O44" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">639</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">728</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_z32q1pjhdtCf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">648</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">760</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

9000

32000

639000

728000

648000

760000

22.41

24.48

Schedule of Weighted Average Assumptions to Calculate Fair Value of Stock Options <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%">Grant Price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zqXy39lAIXLf" style="width: 12%; text-align: right" title="Grant Price">26.73</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231_zUpGadO6IcP9" style="width: 12%; text-align: right" title="Grant Price">27.76</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected life (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.15</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.58</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rates</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.12</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.74</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">118.12</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">130.71</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231_zVYPDVo9AkKg" style="text-align: right" title="Dividend yield">-</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231_zvijrEI14Slf" style="text-align: right" title="Dividend yield">-</td><td style="text-align: left">%</td></tr> </table>

26.73

27.76

P5Y1M24D

P5Y6M29D

0.0412

0.0174

1.1812

1.3071

9. Income Taxes Net loss from operations before income taxes for the years ended December 31, 2023 and 2022 was approximately $14.8 million and $10.5 million, respectively. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The primary components of the net deferred tax assets and liabilities as of December 31, 2023 and 2022 were as follows (in thousands): Schedule of Components of Deferred Tax Assets and Liabilities <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20231231_zaDLG92vMgl8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20221231_zD9yX9jYCOt6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid">Deferred tax assets/(liabilities):</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTANzon4_z73sZ173PAo3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">14,278</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">12,408</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_pn3n3_maDTANzon4_zZYYiFwihCUi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Capital loss carryforwards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,120</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,120</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_maDTANzon4_z2MZqjSW9zB1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Research and development credit carryforwards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,178</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,138</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--DeferredTaxAssetsPatentsAndFixedAssets_iI_pn3n3_maDTANzon4_zRxkcwijYjJf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Patents and fixed assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">975</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">879</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTANzon4_zivJb2KowV63" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Stock-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">676</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">643</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--DeferredTaxAssetsCapitalizedResearchExpenses_iI_pn3n3_maDTANzon4_zXC1mTKGfAx8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Capitalized research expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">414</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">211</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_iI_pn3n3_maDTANzon4_zQj38n7L7Km8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">175</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">62</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzon4_zV4ZvttNOW4h" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(20,816)</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(18,461</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzon4_zFNvqnhKRZ8e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total net deferred tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> A valuation allowance is provided when it is more likely than not that all or some portion of the deferred tax assets will not be realized. AgeX established a full valuation allowance for all periods presented due to the uncertainty of realizing future tax benefits from its net operating loss (“NOL”) carryforwards and other deferred tax assets. Income taxes differed from the amounts computed by applying the U.S. federal income tax rate indicated to pretax losses from operations as a result of the following: Schedule of Income Tax Rate Reconciliation <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20230101__20231231_zbmk9KJutDe4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20220101__20221231_zjn4KLm3Ou28" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maAM_zUttQbFTXs21" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Computed tax benefit at federal statutory rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">21</td><td style="width: 3%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">21</td><td style="width: 3%; text-align: left">%</td></tr> <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_msAM_zcpQFETM6BYa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development and other credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1</td><td style="text-align: left">%</td></tr> <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maAM_zeClT7stj5y4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">State tax benefit, net of effect on federal income taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(7</td><td style="text-align: left">)%</td></tr> <tr id="xdx_40A_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferences_pid_dp_uPure_maAM_zJ4m1lewHM5b" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Permanent differences</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left">%</td></tr> <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_maAM_zk4zZR5OHIyb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Stock-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2</td><td style="text-align: left">)%</td></tr> <tr id="xdx_40A_ecustom--EffectiveIncomeTaxRateReconciliationDebtFinanceEquityCosts_pid_dp_uPure_maAM_zi5m7nvLJTaf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Debt finance equity costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6</td><td style="text-align: left">)%</td></tr> <tr id="xdx_408_ecustom--EffectiveIncomeTaxRateReconciliationReturnToProvisionOtherAdjustments_pid_dp_uPure_maAM_zJQwMVvq4zIi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Return to provision and other adjustments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5</td><td style="text-align: left">)%</td></tr> <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maAM_zM7Ykkpde9mg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(15</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_mtAM_zeti1IdA43P" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Income tax rate</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> AgeX has established an accrual for uncertain tax positions related to its U.S. research and development credits. As of December 31, 2023 and 2022, there was no accrued interest related to uncertain tax positions. AgeX does not believe it is reasonably possible that its unrecognized tax benefits will significantly change in the next twelve months. A reconciliation of beginning and ending balances for unrecognized tax benefits is as follows (in thousands): Schedule of Unrecognized Tax Benefits <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20230101__20231231_zTXM5QQmNzt7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20220101__20221231_zyXqr6fXXsT1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--UnrecognizedTaxBenefits_iS_zcODuRmIHN0k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%">Balance at January 1</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">379</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_zOrq2r0gKNu7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Additions for tax positions related to the current year</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_z4sSfDZ2e8qa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Additions for tax positions related to prior years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">356</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_zCHLAoAf8KHh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Reductions for tax positions related to prior years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_zPIBPzAdC74" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Reductions related to settlements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_z3ATlicHaiC1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Reductions related to a lapse of statute</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--UnrecognizedTaxBenefits_iE_ziOGLFOcNLSh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at December 31</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">393</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">379</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> AgeX monitors proposed and issued tax law, regulations, and cases to determine the potential impact of uncertain income tax positions. At December 31, 2023, AgeX had not identified any potential subsequent events that would have a material impact on unrecognized income tax benefits within the next twelve months. As of December 31, 2023, AgeX has net operating loss carryforwards of approximately $59.7 million for U.S. federal income tax purposes. In general, NOLs and other tax credit carryforwards generated by legal entities in a consolidated federal tax group are available to other members of the tax group depending on the nature of the transaction that a member may enter into while still in the consolidated federal tax group. As of December 31, 2023, AgeX has net operating losses of approximately $19.8 million for California purposes. In general, NOLs and other tax credit carryforwards generated by legal entities in a combined state tax group are available to other members of the tax group depending on the nature of the transaction that a member may enter into while still in the combined state tax group. Federal net operating losses generated on or prior to December 31, 2017, expire in varying amounts between 2028 and 2037, while federal net operating losses generated after December 31, 2017, carryforward indefinitely. The state net operating losses expire in varying amounts between 2028 and 2043. As of December 31, 2023, AgeX has research and development tax credit carryforwards for federal and state tax purposes $0.7 million and $0.5 million, respectively. The federal tax credits expire between 2028 and 2043, while the state tax credits have no expiration date. As of December 31, 2023, AgeX has capital loss carryforwards for federal and state tax purposes of $<span id="xdx_902_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zpXoGdnLxK03" title="Deferred tax assets capital loss carry forwards">12.4 million and $<span id="xdx_90D_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zufJBMns2kl2" title="Deferred tax assets capital loss carry forwards">5.9 million, respectively. The federal and California capital loss carryforwards will expire in 2026. Effective for tax years beginning after December 31, 2021, taxpayers are required to capitalize any expenses incurred that are considered incidental to research and experimentation (“R&E”) activities under IRC Section 174. While taxpayers historically had the option of deducting these expenses under IRC Section 174, the December 2017 Tax Cuts and Jobs Act mandates capitalization and amortization of R&E expenses for tax years beginning after December 31, 2021. Expenses incurred in connection with R&E activities in the US must be amortized over a <span id="xdx_90B_ecustom--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentInYears_dtY_c20230101__20231231__srt--StatementGeographicalAxis__country--US_zly68CcOS55j" title="Amortized over Period">5-year period if incurred, and R&E expenses incurred outside the US must be amortized over a 15-year period. R&E activities are broader in scope than qualified research activities considered under IRC Section 41 (relating to the research tax credit). For the year ended December 31, 2023, the Company performed an analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization and amortization of its R&E expenses. We will continue to monitor this issue for future developments, but we do not expect R&E capitalization and amortization to require us to pay cash taxes now or in the near future. For the year ended December 31, 2023, we experienced a loss; therefore, no income tax provision was recorded for the year ended December 31, 2023. Other Income Tax Matters Code Section 382 places a limitation (“Section 382 Limitation”) on the amount of taxable income that can be offset by NOL carryforwards after a change in control (generally greater than 50% change in ownership within a three-year period) of a loss corporation. California has similar rules. Generally, after a control change, a loss corporation cannot deduct NOL carryforwards in excess of the Section 382 Limitation. Due to these “change in ownership” provisions, utilization of the NOL and tax credit carryforwards may be subject to an annual limitation regarding their utilization against taxable income in future periods. AgeX and its subsidiaries may be subject to potential income tax examination by U.S. federal or states authorities. These potential examinations may include inquiries regarding the timing and amount of deductions, and compliance with U.S. federal and state tax laws. AgeX filed its first consolidated federal tax return in 2018. AgeX and its current subsidiaries are not subject to tax examination by federal tax authorities for tax years beginning before 2020 and for state tax authorities beginning before 2019. However, the tax authorities may still make adjustments to the net operating loss and credit carryforwards used in open years by AgeX or any of its subsidiaries. Any potential examinations may include inquiries regarding the timing and amount of deductions, and compliance with U.S. federal and state tax laws.

14800000

10500000

The primary components of the net deferred tax assets and liabilities as of December 31, 2023 and 2022 were as follows (in thousands): Schedule of Components of Deferred Tax Assets and Liabilities <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20231231_zaDLG92vMgl8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20221231_zD9yX9jYCOt6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid">Deferred tax assets/(liabilities):</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTANzon4_z73sZ173PAo3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">14,278</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">12,408</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_pn3n3_maDTANzon4_zZYYiFwihCUi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Capital loss carryforwards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,120</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,120</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_maDTANzon4_z2MZqjSW9zB1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Research and development credit carryforwards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,178</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,138</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--DeferredTaxAssetsPatentsAndFixedAssets_iI_pn3n3_maDTANzon4_zRxkcwijYjJf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Patents and fixed assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">975</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">879</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTANzon4_zivJb2KowV63" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Stock-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">676</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">643</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--DeferredTaxAssetsCapitalizedResearchExpenses_iI_pn3n3_maDTANzon4_zXC1mTKGfAx8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Capitalized research expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">414</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">211</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_iI_pn3n3_maDTANzon4_zQj38n7L7Km8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">175</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">62</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzon4_zV4ZvttNOW4h" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(20,816)</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(18,461</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzon4_zFNvqnhKRZ8e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total net deferred tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

14278000

12408000

3120000

1178000

1138000

975000 879000

676000

643000

414000 211000

175000

62000

20816000

18461000

Income taxes differed from the amounts computed by applying the U.S. federal income tax rate indicated to pretax losses from operations as a result of the following: Schedule of Income Tax Rate Reconciliation <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20230101__20231231_zbmk9KJutDe4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20220101__20221231_zjn4KLm3Ou28" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: left; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maAM_zUttQbFTXs21" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Computed tax benefit at federal statutory rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">21</td><td style="width: 3%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">21</td><td style="width: 3%; text-align: left">%</td></tr> <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_msAM_zcpQFETM6BYa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development and other credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1</td><td style="text-align: left">%</td></tr> <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maAM_zeClT7stj5y4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">State tax benefit, net of effect on federal income taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(7</td><td style="text-align: left">)%</td></tr> <tr id="xdx_40A_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferences_pid_dp_uPure_maAM_zJ4m1lewHM5b" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Permanent differences</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left">%</td></tr> <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_uPure_maAM_zk4zZR5OHIyb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Stock-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2</td><td style="text-align: left">)%</td></tr> <tr id="xdx_40A_ecustom--EffectiveIncomeTaxRateReconciliationDebtFinanceEquityCosts_pid_dp_uPure_maAM_zi5m7nvLJTaf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Debt finance equity costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6</td><td style="text-align: left">)%</td></tr> <tr id="xdx_408_ecustom--EffectiveIncomeTaxRateReconciliationReturnToProvisionOtherAdjustments_pid_dp_uPure_maAM_zJQwMVvq4zIi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Return to provision and other adjustments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5</td><td style="text-align: left">)%</td></tr> <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maAM_zM7Ykkpde9mg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(15</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_mtAM_zeti1IdA43P" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Income tax rate</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table>

0.21

0.01

0.04

-0.07

-0.04

-0.01

-0.02

-0.05 -0.06 -0.05

-0.15

-0.02

Schedule of Unrecognized Tax Benefits <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20230101__20231231_zTXM5QQmNzt7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20220101__20221231_zyXqr6fXXsT1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--UnrecognizedTaxBenefits_iS_zcODuRmIHN0k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%">Balance at January 1</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">379</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_zOrq2r0gKNu7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Additions for tax positions related to the current year</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_z4sSfDZ2e8qa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Additions for tax positions related to prior years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">356</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_zCHLAoAf8KHh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Reductions for tax positions related to prior years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_zPIBPzAdC74" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Reductions related to settlements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_z3ATlicHaiC1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Reductions related to a lapse of statute</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--UnrecognizedTaxBenefits_iE_ziOGLFOcNLSh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at December 31</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">393</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">379</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

379000

14000

23000

356000

393000

379000

59700000

19800000

Federal net operating losses generated on or prior to December 31, 2017, expire in varying amounts between 2028 and 2037, while federal net operating losses generated after December 31, 2017, carryforward indefinitely. The state net operating losses expire in varying amounts between 2028 and 2043.

700000

500000

The federal tax credits expire between 2028 and 2043, while the state tax credits have no expiration date.

12400000

5900000

P5Y

Code Section 382 places a limitation (“Section 382 Limitation”) on the amount of taxable income that can be offset by NOL carryforwards after a change in control (generally greater than 50% change in ownership within a three-year period) of a loss corporation. California has similar rules

10. Commitments and Contingencies Office Lease Agreement AgeX leased office space in Alameda, California. For 2022, base monthly rent was $1,074 and for 2023, base monthly rent is $844 for slightly less space at the same building. The lease also includes office furniture rental, janitorial services, utilities, and internet service. ASC 842 For the office lease, AgeX has elected to not apply the recognition requirements under ASC 842 and instead recognized the lease payments as lease costs on a straight-line basis over the lease term, as the amount of the lease payments is not deemed material. There were no future minimum lease commitments as of December 31, 2023. Litigation – General AgeX is subject to various claims and contingencies in the ordinary course of its business, including those related to litigation, business transactions, employee-related matters, and others. When AgeX is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, AgeX will record a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated, AgeX discloses the claim if the likelihood of a potential loss is reasonably possible and the amount involved could be material. AgeX is not aware of any claim for which a liability has not been accrued and which is likely to have a material adverse effect on its financial condition or results of operations. Tax Filings AgeX tax filings are subject to audit by taxing authorities in jurisdictions where it conducts business. These audits may result in assessments of additional taxes that are subsequently resolved with the authorities or potentially through the courts. Management believes AgeX has adequately provided for any ultimate amounts that are likely to result from these audits; however, final assessments, if any, could be significantly different than the amounts recorded in the consolidated financial statements. Employment Contracts AgeX has entered into employment contracts with certain executive officers. Under the provisions of the contracts, AgeX may be required to incur severance obligations for matters relating to changes in control, as defined, and involuntary terminations. Indemnifications In the normal course of business, AgeX may provide indemnifications of varying scope under AgeX’s agreements with other companies or consultants, typically for AgeX’s research and development programs. Pursuant to these agreements, AgeX will generally agree to indemnify, hold harmless, and reimburse the indemnified parties for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties in connection with AgeX’s research and development. Indemnification provisions could also cover third-party infringement claims with respect to patent rights, copyrights, or other intellectual property licensed from AgeX to third parties. Office and laboratory leases will also generally indemnify the lessor with respect to certain matters that may arise during the term of the lease. A sales agreement between AgeX and Chardan Capital Markets, LLC also included indemnification provisions pursuant to which the parties agreed to indemnify each other from certain liabilities that could arise from the offer and sale of AgeX common stock, including liabilities under the Securities Act. Similarly, the Registration Rights Agreement between Juvenescence and AgeX includes indemnification provisions pursuant to which the parties will indemnify each other from certain liabilities in connection with the registration, offer, and sale of securities under a registration statement, including liabilities arising under the Securities Act. AgeX has also agreed to provide the AST Indemnity and ETC Indemnity pursuant to the Letter of Indemnification and ETC Letter of Indemnity described in Note 5, Related Party Transactions. The term of these indemnification obligations will generally continue in effect after the termination or expiration of the particular license, lease, or agreement to which they relate. The potential future payments AgeX could be required to make under these indemnification agreements will generally not be subject to any specified maximum amount. Historically, AgeX has not been subject to any claims or demands for indemnification. AgeX also maintains various liability insurance policies that limit AgeX’s financial exposure and in the case of the AST Indemnity and ETC Indemnity AgeX has received cross-indemnities from Juvenescence against all claims, damages, liabilities or losses arising out of the AST Indemnity and ETC Indemnity. As a result, AgeX believes the fair value of these indemnification agreements is minimal. Accordingly, AgeX has not recorded any liabilities for these agreements as of December 31, 2023 and 2022. Notice of Delisting On April 20, 2023, AgeX received a letter (the “2023 Deficiency Letter”) from the staff of the Exchange indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Sections 1003(a)(i), (ii), and (iii) of the Exchange Company Guide in that AgeX has stockholders equity of less than (A) $2,000,000 and has incurred losses from continuing operations and/or net losses during its two most recent fiscal years, (B) $4,000,000 and has incurred losses from continuing operations and/or net losses during three out of four of its most recent fiscal years, and (C) $6,000,000 or more and has reported losses from continuing operations and/or net losses in its five most recent fiscal years. The 2023 Deficiency Letter states that as AgeX remains subject to the conditions set forth in prior letters from the Exchange with respect to AgeX’s deficiencies in stockholders equity, and if AgeX is not in compliance with all of the Exchange’s stockholders equity standards, or does not make progress consistent with AgeX’s Exchange approved plan to come into compliance with the Exchange’s continued listing standards, by May 17, 2023, the Exchange will initiate delisting proceedings as appropriate. On May 17, 2023 AgeX received a notice from the staff of the Exchange indicating that they intend to commence proceedings to delist AgeX common stock from the Exchange based upon AgeX’s non-compliance with the stockholders’ equity requirements set forth in Sections 1003(a)(i), (ii) and (iii) of the Exchange’s Company Guide by the end of a compliance plan period that expired on May 17, 2023. Specifically, AgeX did not meet the continued listing standards because it had stockholders equity of less than (A) $2,000,000 and has incurred losses from continuing operations and/or net losses during its two most recent fiscal years, (B) $4,000,000 and has incurred losses from continuing operations and/or net losses during three out of four of its most recent fiscal years, and (C) $6,000,000 or more and has reported losses from continuing operations and/or net losses in its five most recent fiscal years. On May 24, 2023, AgeX filed a request for a review of the delisting determination by a Committee of the Board of Directors of the Exchange. On May 31, 2023, AgeX received a notice from the staff of the Exchange which scheduled a hearing for July 25, 2023. On July 24, 2023, AgeX issued shares of preferred stock to Juvenescence in exchange for the extinguishment of $36 million of indebtedness owed to Juvenescence for the purpose of remediating the deficiency in stockholders equity, and the hearing at the Exchange scheduled for July 25 was cancelled. See Note 7, Stockholders’ Equity/(Deficit), for further discussion on the classification of preferred stock and amendment to Section 3(b) of the terms of the Series A Preferred Stock and Series B Preferred Stock.

1074

844

2000000

4000000

6000000

2000000

4000000

6000000

36000000

11. Subsequent Events On February 9, 2024, AgeX and Juvenescence executed a Sixth Amendment to Amended and Restated Convertible Promissory Note (the “Sixth Amendment”) that extends to May 9, 2024 the “Repayment Date” on which the outstanding principal balance and accrued loan origination fees will become due and payable pursuant to the 2022 Secured Note. From January 1 through March 20, 2024, AgeX drew in the aggregate $<span id="xdx_901_eus-gaap--ProceedsFromLinesOfCredit_c20240101__20240320__us-gaap--TypeOfArrangementAxis__custom--TwentyTwentyTwoSecuredNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zi4F4R9PHRs1" title="Proceeds from line of credit">5,800,000 of its credit available under the 2022 Secured Note with Juvenescence. On February 1, 2024, all outstanding shares of Series A Preferred Stock and Series B Preferred Stock automatically converted into a total of <span id="xdx_90C_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_pid_c20240201__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_zATQ8qbFxdl1">1,421,666 shares of AgeX common stock in accordance with their terms and after that conversion no shares of AgeX Preferred Stock remained outstanding. Those shares of common stock issued to Juvenescence increased Juvenescence’s direct and indirect holding of outstanding shares of AgeX common stock to 1,889,323 shares, or approximately <span id="xdx_902_ecustom--CommonStockOutstandingPercentage_pid_dp_c20240314__20240314__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--JuvenescenceLimitedMember_zkJhbY9wgGh2">75.6% of the shares of common stock outstanding on March 14, 2024, including shares of AgeX common stock held by Juvenescence’s subsidiaries but not taking into account any additional shares of AgeX common stock that Juvenescence may acquire through the conversion of loan balances and the exercise of AgeX common stock purchase warrants or Post-Merger Warrants that were distributed on March 19, 2024. At the Special Meeting of stockholders on March 14, 2024, AgeX stockholders approved certain matters required for the Merger to be consummated in accordance with the terms of the Merger Agreement. On February 16, 2024, holders of outstanding Serina voting securities approved certain matters required for the Merger to be consummated in accordance with the terms of the Merger Agreement. On March 14, 2024, AgeX implemented the 1 for 35.17 Reverse Stock Split of its common stock. See Note 1, Organization, Basis of Presentation and Liquidity. On March 19, 2024, AgeX issued the Post-Merger Warrants to each holder of AgeX common stock as of the dividend record date, March 18, 2024.

5800000

1421666

1889323

0.756

1 for 35.17

Restricted cash entirely represents the deposit required to maintain AgeX’s corporate credit card program. As of December 31, 2023 and 2022, warrants to purchase 320,115 and 344,875 shares, respectively, of AgeX common stock were issued and outstanding and held by Juvenescence as consideration for certain loan agreements discussed in Note 5, Related Party Transactions. Amounts shown in the table are weighted average amounts and reflect the fact that the warrants were issued on various dates during applicable periods presented. Based on the market closing price of AgeX’s common stock on the NYSE American on the day prior to each debt Inception Date, on each presented period ending date, and one day prior to the delivery of the relevant drawdown notice in accordance with terms of the 2022 Secured Note (with such drawdown notice delivery date being shown as the Issuance Date in the table), and as adjusted to reflect the Reverse Stock Split. For this purpose, the date on which the 2022 Secured Note was amended and restated to increase the line of credit by $2,000,000 was treated as a new Inception Date for that portion of the line of credit. Warrants are exercisable over a three-year period from each Issuance Date. Based on the market price of AgeX’s common stock on the NYSE American as of each date presented. Interest rate for U.S. Treasury Bonds, as of each date presented, as published by the U.S. Federal Reserve.